UNIVERSITÉ DU QUÉBEC À MONTRÉAL

INVESTIGATING THE METABOLOME AND PROTEOME OF COLON AND FECAL SAMPLES FROM HEALTHY MICE BY LC-MS/MS

MASTER'S THESIS

PRESENTED

AS PARTIAL FULFILLMENT

OF THE MASTER'S IN BIOCHEMISTRY

ΒY

ORIANA ZAMBITO

UNIVERSITÉ DU QUÉBEC À MONTRÉAL

ÉTUDE DU MÉTABOLOME ET DU PROTÉOME DES ÉCHANTILLONS DE CÔLON ET DE FÈCES DE SOURIS SAINES PAR LC-MS/MS

MÉMOIRE

PRÉSENTÉE

COMME EXIGENCE PARTIELLE

À LA MAÎTRISE EN BIOCHIMIE

PAR

ORIANA ZAMBITO

UNIVERSITÉ DU QUÉBEC À MONTRÉAL Service des bibliothèques

<u>Avertissement</u>

La diffusion de ce mémoire se fait dans le respect des droits de son auteur, qui a signé le formulaire *Autorisation de reproduire et de diffuser un travail de recherche de cycles supérieurs* (SDU-522 – Rév.12-2023). Cette autorisation stipule que «conformément à l'article 11 du Règlement no 8 des études de cycles supérieurs, [l'auteur] concède à l'Université du Québec à Montréal une licence non exclusive d'utilisation et de publication de la totalité ou d'une partie importante de [son] travail de recherche pour des fins pédagogiques et non commerciales. Plus précisément, [l'auteur] autorise l'Université du Québec à Montréal à reproduire, diffuser, prêter, distribuer ou vendre des copies de [son] travail de recherche à des fins non commerciales sur quelque support que ce soit, y compris l'Internet. Cette licence et cette autorisation n'entraînent pas une renonciation de [la] part [de l'auteur] à [ses] droits moraux ni à [ses] droits de propriété intellectuelle. Sauf entente contraire, [l'auteur] conserve la liberté de diffuser et de commercialiser ou non ce travail dont [il] possède un exemplaire.»

REMERCIEMENTS

I am deeply grateful to Prof. Lekha Sleno for generously welcoming me into her academic realm and providing me with the invaluable opportunity to learn under her guidance. Her support, patience, and dedication have been pivotal throughout my studies and research, inspiring me to persist on this academic path. Special thanks extend to the members of Prof. Lekha Sleno's lab, including Maggy Lépine, Kahina Chabi, Nathan Ghafari, Ikram Benhadji, Myriam Mireault, Carina Lima, Kathrina Mae Kumaresan, Ons Ousji and Said Matar, along with a notable mention of Leanne Ohlund.

I would also like to say a big thank you to our collaborators Prof. Nicolas Pilon, Nejia Lassoued, and Rodolphe Soret for their crucial contributions to this project. This project would not have been realised without their vital contribution.

I extend my gratitude to my family and my partner, without whom this academic journey would not have been possible. Their consistent support, unwavering presence, and unconditional love have never gone unnoticed. Through the highs and lows of these past two years, they have been a source of joy, laughter, and support as a constant, grounding force that has enabled me to overcome challenges and continue my academic path.

TABLE DES MATIÈRES

| REMERCIEMENTS | iii |
|---|----------|
| LISTE DES FIGURES | vi |
| LISTE DES TABLEAUX | viii |
| LISTE DES ABRÉVIATIONS, DES SIGLES ET DES ACRONYMES | ix |
| LISTE DES SYMBOLES ET DES UNITÉS | xii |
| RÉSUMÉ | xiii |
| ABSTRACT | xiv |
| CHAPITRE 1 INTRODUCTION | 1 |
| 1.1 Gastrointestinal Tract | 1 |
| 1.2 Anatomy of The Large Intestine 1.2.1 Variability in the Large Intestine | 3 4 |
| 1.3 Liquid Chromatography Coupled to High Resolution Tandem Mass Spectrometry (LC- HRMS/MS) | 5 |
| 1.3.1 High Performance Liquid Chromatography 1.3.2 High Resolution Tandem Mass Spectrometry | 5 7 |
| 1.4 Metabolomic Analysis | 12 |
| 1.5 Proteomic Analysis | 15 |
| 1.5.1 Metaproteomic Analysis of Microbial Species | 17 |
| 1.6 Literature on Metabolomics and Proteomics in the Colon | 18 |
| 1.7 Mouse Model System | 18 |
| 1.8 Objectives | 20 |
| CHAPITRE 2 SCIENTIFIC ARTICLE: PROTEOMIC AND METABOLOMIC ANALYSIS OF COLON AND FECES FROM PROXIMAL AND DISTAL REGIONS IN HEALTHY MICE | 21 |
| 2.1 Résumé | 23 |
| 2.2 Abstract | 24 |
| 2.3 Introduction | 24 |
| 2.4 Experimental Methods | 26 |
| 2.4.1 Chemicals | 26 |
| 2.4.2 Sample Collection | 26 27 |
| 2.4.3.1 Metabolite extraction | 27 |

| 2.4.3.2 Protein solubilisation and digestion | 27 |
|--|-----------|
| 2.4.4 LC-HRMS/MS Analysis | |
| 2.4.4.1 Metabolomics | |
| 2.4.4.2 Proteomics | 29 |
| 2.4.5 Data Processing | 29 |
| 2.4.5.1 Metabolomics | 29 |
| 2.4.5.2 Proteomics | 30 |
| 2.5 Results and Discussion | 31 |
| 2.5.1 Untargeted Metabolomics | |
| 2.5.1.1 Metabolite Differences Between Distal and Proximal Regions | 35 |
| 2.5.2 Untargeted Quantitative Proteomics | |
| 2.5.2.1 Protein Level Differences Between Distal and Proximal Regions in Colon | Tissue 45 |
| 2.5.3 Combining Metabolomic and Proteomic Analyses | 49 |
| 2.5.4 Metaproteomics of Fecal Samples | 52 |
| 2.6 Conclusion | 60 |
| 2.7 Supplemental Tables | 60 |
| CHAPITRE 3 GENERAL DISCUSSION | 158 |
| | |
| 3.1 Metabolomic Analysis of Colon and Fecal Samples | 158 |
| 3.2 Proteomic Analysis of Colon Samples | 162 |
| 3.3 Metaproteomics of Fecal Samples | 166 |
| CONCLUSION | 170 |
| BIBLIOGRAPHIE | |

LISTE DES FIGURES

| Figure 1.1 Diagram of organs of the gastrointestinal tract (upper GI organs shown in black, lower GI organs shown in blue) |
|--|
| Figure 1.2 Anatomy of colon and its distinct regions when separated at the splenic flexure 4 |
| Figure 1.3 General overview of the components of a mass spectrometer7 |
| Figure 1.4 Simplified diagram demonstrating the steps for compound ionization via electrospray ionization (ESI) |
| Figure 1.5 Diagram of a quadrupole time-of-flight mass analyzer in MS/MS mode (QqTOF) 10 |
| Figure 1.6 Structural elucidation of succinic acid by accurate mass measurements and MS/MS fragmentation |
| Figure 1.7 Comparison of information dependent acquisition (IDA) and data-independent acquisition (DIA, SWATH) |
| Figure 1.8 Different "omic" technologies and their applications 13 |
| Figure 1.9 Untargeted LC-HRMS/MS metabolomics workflow 14 |
| Figure 1.10 Simplified bottom-up proteomics workflow |
| Figure 2.1 Untargeted metabolomics workflow of colon and fecal samples from sample preparation to data processing, with an example of spectral matching for succinic acid |
| Figure 2.2 Venn diagrams representing unique and common metabolites with putative identifications by MS/MS spectral matching, from combined positive and negative ion modes, using Scherzo and PFP columns for colon (a) and fecal (b) samples |
| Figure 2.3 Classification of metabolite superclasses from combined putative identifications from Scherzo and PFP datasets in positive and negative modes from colon (a) and fecal (b) samples |
| Figure 2.4 Unsupervised PCA plots of all identified and statistically significant metabolite IDs from Scherzo and PFP columns of a) colon, and b) fecal samples |
| Figure 2.5 a) Heatmap of 153 statistically significant colon metabolites; b) Heatmap of 23 statistically significant fecal metabolites; c) Enrichment analysis using MetaboAnalyst 5.0 of statistically significant metabolites that are increased in distal and proximal colon |
| Figure 2.6 a) Tryptophan metabolism via serotonin and kynurenine pathways with metabolites identified (kynurenine, xanthurenic acid, serotonin, and 5-hydroxyindole-acetic acid) shown to be increased in the proximal region of the colon (decreased in distal colon). Other metabolites in the respective pathways were not identified in any datasets. b) Relative peak intensities between distal and proximal colon of identified metabolites are shown as extracted ion chromatograms for representative samples |

| Figure 2.9 a) Heatmap with hierarchical clustering of 158 statistically significant mouse proteins from proximal and distal colon tissue, and b) the number of these proteins increased in each region involved in different pathways |
|---|
| Figure 2.10 Joint pathway analysis of 153 metabolites and 158 proteins significantly changing between distal and proximal colon |
| Figure 2.11 Diagram of Pyrimidine Pathway with Significant Proteins and Metabolites from Colon |
| Figure 2.12 Distribution of peptides from bacterial species between distal and proximal fecal samples from SWATH quantitative analysis |
| Figure 3.1 Overlap of colon and fecal metabolites identified |

LISTE DES TABLEAUX

| Table 2.1 Metabolites Increased in Proximal Colon Involved in Tryptophan Metabolism 37 |
|---|
| Table 2.2 All Identified Prostaglandin Metabolites in Colon from All Metabolite Datasets 41 |
| Table 2.3 All Identified Acylcarnitines in Colon Samples from All Metabolomic Datasets |
| Table 2.4 Protein Pathways in Distal and Proximal Colon Regions pertaining to Immune System,Metabolism, Developmental Biology, and Muscle Contraction |
| Table 2.5 Metabolites and Proteins Mapped to Each Pathway from Joint Pathway Analysis 50 |
| Table 2.6 Significant Colon Proteins and Metabolites from Pyrimidine Metabolism 51 |
| Table 2.7 Bacterial Species and their Unique Peptides Identified in Distal and Proximal fecal Samples from IDA data |
| Table 2.8 Putative Colon Metabolite Identifications Compiled from Four Untargeted Metabolomic Datasets 61 |
| Table 2.9 Putative Fecal Metabolite Identifications Compiled from Four Untargeted Metabolomic Datasets 84 |
| Table 2.10 Statistically Significant Colon Metabolites 116 |
| Table 2.11 Statistically Significant Fecal Metabolites |
| Table 2.12 Complete List of Quantified Mouse Proteins in Colon Samples |
| Table 2.13 Complete List of Quantified Mouse Proteins in Feces 150 |
| Table 2.14 Species Identified Across Distal and Proximal Fecal Samples and their Characteristics |
| Table 3.1 Proteins with Higher Levels in Distal Colon Involved in A) Cytoskeletal Regulation, B)Integrin Signalling Pathway, and C) Glycolysis164 |

LISTE DES ABRÉVIATIONS, DES SIGLES ET DES ACRONYMES

| ABC | Ammonium bicarbonate buffer |
|------|--|
| ACN | Acetonitrile |
| APCI | Atmospheric pressure chemical ionization |
| Arg | Arginine |
| BMI | Body mass index |
| CE | Collision energy |
| CI | Chemical ionization |
| CID | Collision induced dissociation |
| CNS | Central nervous system |
| СОХ | Cyclooxygenase |
| CRC | Colorectal cancer |
| DC | Direct current |
| DIA | Data independent acquisition |
| DTT | Dithiothreitol |
| ECM | Extracellular matrix |
| EI | Electronic ionization |
| ENS | Enteric nervous system |
| ESI | Electrospray ionization |
| EtOH | Ethanol |
| FA | Formic acid |

| FDR | False discovery rate |
|----------|---|
| GC | Gas chromatography |
| GI | Gastrointestinal tract |
| HLB | Hydrophilic-lipophilic balance |
| HPLC | High resolution liquid chromatography |
| HRMS | High resolution mass spectrometry |
| IAM | Iodoacetamide |
| IBD | Irritable bowel disease |
| IBS | Irritable bowel syndrome |
| IDA | Information dependent acquisition |
| IMA | Inferior mesenteric artery |
| K8 | Keratin type II cytoskeletal 8 |
| K18 | Keratin type II cytoskeletal 18 |
| K19 | Keratin type II cytoskeletal 19 |
| K20 | Keratin type II cytoskeletal 20 |
| LC-MS/MS | Liquid chromatography coupled to tandem mass spectrometry |
| Lys | Lysine |
| MeOH | Methanol |
| MRM | Multiple reaction monitoring |
| MS | Mass spectrometry |
| MS/MS | Tandem mass spectrometry |

| NMR | Nuclear magnetic resonance |
|-------------|---|
| PCA | Principal component analysis |
| PCR | Polymerase chain reaction |
| PFP | Pentafluorophenyl |
| PGA1 | Prostaglandin A1 |
| PGA2 | Prostaglandin A2 |
| PGB1 | Prostaglandin B1 |
| PGD1 | Prostaglandin D1 |
| PGE1 | Prostaglandin E1 |
| PGE2 | Prostaglandin E2 |
| PGF2a | Prostaglandin F2alpha |
| PGH2 | Prostaglandin H2 |
| PGI2 | Prostaglandin I2 |
| 15deltaPGJ2 | 15-deoxy-DELTA 12,14-prostaglandin J2 |
| QqTOF | Quadrupole time-of-flight mass analyzer |
| RF | Radio frequency |
| RPLC | Reverse-phase liquid chromatography |
| SPE | Solid phase extraction |
| SSRI | Selective serotonin reuptake inhibitor |
| TLC | Thin layer chromatography |
| TOF | Time-of-Flight |

LISTE DES SYMBOLES ET DES UNITÉS

| m/z | Mass-to-charge ratio |
|-----|-----------------------------|
| rpm | Revolutions per minute |
| ppm | Parts per million |
| % | Percent |
| °C | Degrees Celsius |
| mg | Milligram |
| g | Gram |
| ml | Millilitre |
| L | Litre |
| Q | Quadrupole |
| RT | Retention time |
| Psi | Pound-force per square inch |
| V | Voltage |
| Min | Minute |
| cm | Centimetre |
| pН | Potential of hydrogen |

RÉSUMÉ

Les perturbations du microbiome intestinal suscitent un intérêt croissant, car elles peuvent être reliées à plusieurs maladies intestinales et constituer des marqueurs de la santé intestinale globale. Compte tenu de la présence de divers micro-organismes dans le côlon et dans les matières fécales, ces types d'échantillons sont idéaux pour étudier le microbiome intestinal, ce qui les rend d'un grand intérêt à étudier. De plus, les régions proximaux et distaux de ces types d'échantillons peuvent également fournir une compréhension supplémentaire des voies biologiques se produisant dans différentes parties de l'intestin. Dans cette étude, des analyses LC-MS/MS non ciblées ont été effectuées sur des échantillons de selles et de côlon proximaux et distaux provenant de souris saines pour le profilage métabolomique et protéomique. Lors d'une étape d'homogéneisation suivi par la précipitation de protéines, les surnageants résultants ont été utilisés pour l'analyse métabolomique non ciblée et les culots protéigues ont servi pour l'analyse protéomique ascendante quantitative. Les protéines ont été solubilisées et leurs quantités normalisées avant la digestion trypsique et l'extraction en phase solide des peptides résultants. Les analyses métabolomiques et protéomiques ont été effectuées sur une plate-forme quadripôle temps de vol. Pour l'analyse métabolomique, les échantillons ont été injectés sur une colonne à mode mixte à phase inverse d'échange d'ions ainsi que sur une colonne pentafluorophényle avec une séparation optimisée pour l'analyse de métabolites polaires. Les deux colonnes ont fourni des résultats complémentaires, augmentant la couverture des métabolites détectés. Le logiciel Sciex OS a été utilisé pour la recherche de pics non ciblés et leur correspondance spectral à l'aide de base de données pour l'identification de métabolites putatifs. Suivant une analyse statistique, 153 métabolites du côlon et 23 métabolites fécaux ont été filtrés selon leurs différences quantitatives entre les régions proximales et distales du côlon. Pour l'analyse protéomique, les peptides ont été séparés à l'aide d'une colonne C18 en phase inverse. À partir de ces données, 1103 protéines de souris ont été quantifiés dans les échantillons du côlon, dont 158 se sont révélées significativement changeantes entre les régions distales et proximales. Pour les échantillons fécaux, une analyse métaprotéomique a été réalisée pour identifier des espèces bactériennes uniques provenant des différentes régions de l'intestin et pour déterminer qu'il n'y avait pas des différences significatives au niveau de ces espèces dans les différentes régions du côlon. Ce mémoire explique la méthodologie détaillée utilisée, y compris les étapes de traitement des données, ainsi que les résultats élucidés grâce à cette étude.

Mots clés : Intestin, Côlon, Microbiome, Fèces, Métabolomique, Protéomique, LC-MS/MS

ABSTRACT

There is a growing interest in gut microbiome perturbations as they can be related to several intestinal diseases and be markers of overall gut health. Fecal and colon samples can mirror or reflect gut health, including changes at the microbiome level, and are therefore of great interest to study. Proximal and distal locations of these sample types can also provide additional understanding of the biological pathways occurring in different parts of the gut. In this study, untargeted LC-MS/MS analyses were performed on proximal and distal fecal and colon samples from healthy mice for metabolomic and proteomic profiling. Proximal and distal fecal and colon samples were collected from healthy mice prior to sample homogenisation and protein precipitation. Resulting supernatants were used for untargeted metabolomics, and protein pellets were used for quantitative proteomics. Proteins were solubilized and amounts normalized prior to trypsin digestion and solid-phase extraction of resulting peptides. Metabolomic and proteomic analyses were performed on a guadrupole time-of-flight platform. For the untargeted metabolomics, samples were separated on ion exchange-reverse phase mixed-mode and pentafluorophenyl columns using optimized solvent gradients for the analysis of polar metabolites. The two columns provided complementary results, increasing the coverage of detected metabolites. Sciex OS software was employed for untargeted peak finding and searching small molecule spectral libraries for putative metabolite identification, in which 966 colon metabolites and 1183 fecal metabolites were putatively identified. Performing statistical analyses demonstrated that 153 colon and 23 fecal metabolites were changing quantitively between proximal and distal regions. For proteomics analyses, peptides were separated using a reversephase C18 column with quantitative SWATH analysis. From the resulting data, 1103 mouse proteins were quantified in the colon samples, 158 of which were significantly changing between distal and proximal regions. Identification and guantification of several bacterial species was possible through metaproteomics analysis of the fecal samples, although no differentially expressed species were determined between the distal and proximal regions. The methodology, results and data processing pipelines used in this study are outlined in this Master's thesis.

Keywords : Gut, Microbiome, Feces, Colon, Metabolomics, Proteomics, LC-MS/MS

CHAPITRE 1 INTRODUCTION

With intestinal diseases on the rise, it is critical to understand the biological implications and variability occurring within the gut. This chapter includes an introduction on the gastrointestinal system and the analytical technique (LC-HRMS/MS) used in the context of this thesis to study the gut. Metabolomics and proteomics were performed to provide insight into the proteomic and metabolic profiles occurring in colon tissue and fecal samples. Before diving into the results and methodologies used in of this project, it is important to introduce the anatomy, previous research, and analytical methods used to understand the results in later chapters.

1.1 Gastrointestinal Tract

The gastrointestinal (GI) system includes some of the most complex organs in the human body, responsible for digestive, absorptive, and excretive processes, all of which are essential for human health (Cheng et al., 2010; Ogobuiro et al., 2023). The gastrointestinal (GI) tract which is the largest component of the gastrointestinal system is composed of two large sections: the upper GI tract and the lower GI tract. The upper GI tract is composed of the mouth, esophagus, stomach, and part of the small intestine (duodenum, jujenum and ileum) with the lower GI tract being composed of the colon, rectum, and anus (Greenwood-Van Meerveld et al., 2017). The oral cavity is responsible for processing/breaking down ingested food in a manner that can be efficiently moved down the esophagus by peristalsis to the stomach for efficient nutrient absorption through the action of various digestive enzymes present (Greenwood-Van Meerveld et al., 2017; Livovsky et al., 2020; Ogobuiro et al., 2023). The processed material in the stomach (chyme) is then passed into the small intestine where the digestion procedures continue, in which the majority of nutrient absorption occurs notably in the jejunum (Ogobuiro et al., 2023). Any ingested material that hasn't been digested or absorbed throughout the GI tract is directed to the large intestine, or colon, where water from undigested food will be absorbed, leading to the formation of fecal matter that is designated for excretion (Greenwood-Van Meerveld et al., 2017; Livovsky et al., 2020; Ogobuiro et al., 2023). Accessory organs that are not directly part of the GI tract such as the liver and pancreas are responsible for releasing essential digestive enzymes, bile acids and lipases that are key contributors to the digestive process (Ogobuiro et al., 2023). In addition to water absorption in the colon, undigested materials act as a source of nutrition for the various microbiome species present in the large intestine (Thursby et Juge, 2017).



Figure 1.1 Diagram of organs of the gastrointestinal tract (upper GI organs shown in black, lower GI organs shown in blue)

The GI tract plays a large role in the human body's overall immunity and immune response, as it acts as a barrier between the external environment and the body's internal homeostasis (Di Tommaso *et al.*, 2021; Dieterich *et al.*, 2018; Monteiro et Batterham, 2017; Thursby et Juge, 2017). The GI tract can protect the body against invading pathogens and antigens by distinguishing harmful from beneficial microorganisms and sending signals based on ingested/exposed matter to the brain (Dieterich *et al.*, 2018). Changes in microbiome composition along the GI tract can have a large effect on signals conveyed to the brain and can thus alter immune responses and the performance of absorptive, digestive, and excretive processes, highlighting its importance in health and disease. (Di Tommaso *et al.*, 2021; Hillman *et al.*, 2017; Viggiano *et al.*, 2015). Although the GI tract harbors up to trillions of different microorganisms, not all organs have the same species or relative amount of different organisms (Rinninella *et al.*, 2019; Thursby et Juge, 2017). For example, the stomach has a very small amount of microorganisms present (10¹ bacteria/gram) due to its acidic environment, whereas large intestine presents much higher amounts (10¹²

bacteria/gram) as the environment is ideal for microorganism survival (Dieterich et al., 2018; Hillman et al., 2017; Rinninella et al., 2019). The type of microorganisms that reside in the GI tract vary from bacteria, fungi, and viruses (Hou et al., 2022). It was shown that 75% of all human encoding genes were expressed at the intestinal level (Gremel et al., 2015). Due to factors such as age, genetics, diet, lifestyle habits and environmental exposures that can alter microbiome composition, the GI tract and notably the colon is highly heterogeneous from one individual to another. The gut-brain axis which enables the communication between the GI tract and the brain, can occur through signals from the enteric nervous system (ENS) and the central nervous system (CNS) (Geng et al., 2022). The ENS has been shown to be heavily involved within the gut in which millions of ganglia and neural cells are rooted (Holland et al., 2021). The colon harbours the largest population of microorganisms in the GI tract. Over the last several decades, there has been a large rise in gastrointestinal diseases with many of these diseases being expressed in the colon, including Crohn's, Ulcerative Colitis, Irritable Bowel Syndrome, and Colorectal Cancer (Cosnes et al., 2011; Dieterich et al., 2018; Huang, Z. et al., 2022; Kuipers et al., 2015). These intestinal diseases and conditions often involve microbial dysbiosis occurring in the colon (Thursby et Juge, 2017).

1.2 Anatomy of The Large Intestine

The large intestine also named the colon, is very large and presents significant heterogeneity between one individual from another. The colon can be separated into several different parts notably the proximal region (right-sided colon) and the distal region (left-sided colon). The proximal region is made up of the cecum, ascending and transverse colon, whereas the distal portion of the colon is made up of the descending colon, sigmoid colon, and the rectum. Separation at the splenic flexure is the boundary between the two distinct portions of the colon (Figure 1.2) (Kahai *et al.*, 2023). The superior mesenteric artery (SMA) provides blood and nutrients for the cecum, ascending colon and two thirds of the transverse colon, all of which are formed by the midgut (Kahai *et al.*, 2023; Malone *et al.*, 2023). On the distal side, the remaining third of the transverse colon, the descending colon, sigmoid colon, and the rectum are formed from the hindgut and are supplied blood by the inferior mesenteric artery (IMA) (Kahai *et al.*, 2023; Malone *et al.*, 2023).



Figure 1.2 Anatomy of colon and its distinct regions when separated at the splenic flexure

In the colon, fecal formation occurs predominantly in the proximal region of the colon where remaining water and other nutrients are absorbed. The formed feces will then move towards the distal region of the colon where they are mainly stored and awaiting excretion out of the rectum (Azzouz et Sharma, 2023).

1.2.1 Variability in the Large Intestine

The colon is a very large organ with high heterogeneity between individuals due to the differences in genetics and exposures. As previously mentioned, intestinal diseases that are expressed in the colon such as ucerative colitis, Crohn's, irritable bowel syndrome (IBS), and colorectal cancer (CRC) have been on the rise for the past few decades and more research has been dedicated for diagnostic and prognostic purposes of these diseases. Expression of intestinal diseases as well as prognosis has been shown to differ between the two distinct regions (Koutroubakis, 2010; Lotfollahzadeh *et al.*, 2023; Loupakis *et al.*, 2015; Petrelli *et al.*, 2017; Soret *et al.*, 2020).

Many studies on CRC have been published showing that prognosis differs greatly on tumor location in the colon. Overall, the outcome is far worse for patients with tumors residing in the proximal region as opposed to the distal region (Arnold *et al.*, 2017; Duraes *et al.*, 2022; Loupakis *et al.*, 2015; Petrelli *et al.*, 2017). *Arnold et al.* performed a study on 2159 patients with location specific CRC (515 patients with tumors in proximal region and 1644 patients with tumors in the distal region) to observe how the survival rates and response rates of varying therapies, differed

between patients with tumours located in the two regions. They were able to conclude that overall and progression-free survival rates were significantly worse for patients with tumors located in the proximal region of the colon. Additionally, they tested the effects of treatment on tumors from both regions, and found that overall treatment was the most successful only on distal tumors (Arnold *et al.*, 2017).

Hirschsprung's disease, which affects 1/5000 newborns is characterized by the absence of neural ganglionic cells of the ENS which prevents peristalsis in the colon, leading to a major blockage (Klein et Varga, 2020; Lotfollahzadeh *et al.*, 2023; Soret *et al.*, 2020). In most cases (\approx 80%), this disease is mainly expressed in the distal region of the colon, mainly in the recto sigmoidal region or the sigmoidal region. It is only in very rare cases that the entire colon is affected by this absence of neural ganglion cells, also touching the proximal region (Kessmann, 2006; Lotfollahzadeh *et al.*, 2023). Ulcerative colitis which is a type of irritable bowel disease (IBD) is characterized by chronic inflammation in the colon causing symptoms such as bloody diarrhea, stomach pain and fecal incontinence, shows an increased prevalence in the distal region (recto sigmoidal) (Koutroubakis, 2010). The proximal region can be affected in much rarer cases of ulcerative colitis (Feuerstein *et al.*, 2019; Koutroubakis, 2010). These examples demonstrate the variability occurring within the colon notably when diseases are involved.

1.3 Liquid Chromatography Coupled to High Resolution Tandem Mass Spectrometry (LC-HRMS/MS)

1.3.1 High Performance Liquid Chromatography

Chromatography is a powerful separation technique that utilizes a stationary phase and a flowing mobile phase to separate compounds in a complex matrix. There are various types of chromatography that can be employed depending on the nature of the sample and compounds to be separated. Four of the most commonly used types of chromatography include liquid chromatography (LC), gas chromatography (GC), and thin-layer chromatography (TLC) (Coskun, 2016). In the scope of this project, liquid chromatography was employed and will therefore be the type of chromatography further explained.

High performance liquid chromatography (HPLC) implies the use of liquid chromatography at high pressures with the use of high performance pumps. This technique is widely used for non-volatile and thermolabile compounds. Separation occurs on the basis that some molecules present in the sample will interact more with the stationary phase and be more highly retained, while other

molecules will be eluted more quickly. Properties such as polarity, charge, and molecular size of a molecule will affect its affinity to adhere to the stationary phase and will dictate its elution time (time retained on the column). Although there are many types of liquid chromatography, normal phase, reverse phase (RPLC), and ion-exchange chromatography are some examples of very widely used types (Bird, 1989; Snyder et al., 2010). Normal phase employs a polar stationary phase and non-polar mobile phases resulting in polar compounds having more retention and thus longer retention times. The opposite can be said for RPLC where a rather non-polar stationary phase is used, and rather polar mobile phases are used. In RPLC, polar compounds will elute much earlier as their interaction with the polar mobile phase is favoured, whereas non-polar compounds will adhere to the non-polar stationary phase resulting in their later elution. Reversephase liquid chromatography was employed in the scope of this project and will therefore be further discussed. RPLC is the most common type of liquid chromatography employed since the solvents required for normal phase are generally incompatible with LC-MS/MS analysis. RPLC yields an efficient separation of a broad range of metabolites and if specific types of metabolites are targeted for separation, the stationary phase can always be changed to tailor the analysis. Non-polar stationary phases used in RPLC are often packed with silica-based particles. There are columns that vary in the amount of carbon atoms that are bound to the silica particles from C_4 , C_8 , and C₁₈. The larger carbon chain will result in a more hydrophobic stationary phase (Snyder et al., 2010). Three different chromatographic columns were used in the context of this project, an Aeris Peptide C₁₈ column, a Scherzo SM-C18 column and a Luna PFP column. Each of these columns separate compounds differently, with the Aeris column being a classic C₁₈ column used for RPLC with solid core particles. Although the Scherzo SM-C18 (mixed-mode) utilizes some of the same concepts as a traditional C₁₈, it also offers the advantage of anion/cation exchange interactions resulting in the separation of basic/acidic compounds as well. The Luna PFP column employs a pentafluorophenyl phase resulting in good retention for aromatic and conjugated molecules. The Scherzo mixed-mode and Luna PFP columns were employed for metabolomic analyses to maximize metabolite coverage from complex samples, as metabolite structures, their polarities, and acid/base properties can vary greatly.

Mobile phases used in RPLC are composed of water and an organic solvent such as acetonitrile (ACN) or methanol (MeOH). The mobile phases can be passed through the stationary phase either with a constant percentage of organic solvent (isocratic elution), or with increasing percentages of organic solvent over time (gradient elution) allowing very hydrophobic molecules to be able to elute out of the column. As the analytes elute from the column, a retention time and peak intensity

6

is recorded, representative to each eluted molecule used for qualitative and quantitative purposes respectively (Snyder *et al.*, 2010).

1.3.2 High Resolution Tandem Mass Spectrometry

Mass spectrometry is a very powerful analytical tool that separates ionized molecules based on their respective mass to charge ratio (m/z). Tandem mass spectrometry when coupled to liquid chromatography (LC-MS/MS) yields important information about compounds as it allows for the identification, quantification and structural elucidation of the molecules present in a complex sample matrix (Ho *et al.*, 2003). Mass spectrometry is a powerful tool due to its potential for high resolving power and sensitivity allowing for the detection of exact masses. This allows for the differentiation of molecules that have the same nominal masses, but not the same exact mass, making it an ideal tool for the study of metabolites and proteins (Sleno, 2012).

When molecules separated by liquid chromatography elute, an ionization step is essential to bring them to gaseous phase and give them a positive or negative charge to these compounds. Once all compounds are ionized, they are then able to pass through the mass analyzer which can differ from one instrument to another and a mass spectrum will be produced as shown in Figure 1.3. The mass spectrum displays peaks respective to the m/z of ions (*x*-axis) and their abundance (peak intensity) (*y*-axis).





There are several different ionization sources that can be employed where soft ionization sources are most appropriate when tandem mass spectrometry is employed, in order to limit in-source

fragmentation. Hard ionization sources will fragment the molecular ion using electron bombardment, but this can often lead to the fragmentation and loss of the molecular ion from being detected. Soft ionization sources will ionise particularly thermally labile and non-volatile molecules in a gentler way resulting in the majority of cases, the molecular ion intact and able to be detected (Garg et Zubair, 2023).

Electrospray ionization (ESI) is one of the most utilized ionization techniques in modern mass spectrometry and was used in this project. Although ESI is useful for metabolomics studies, it is also perfectly suited to proteomic studies (Banerjee et Mazumdar, 2012). Molecules incoming from liquid chromatography separation travel through a fine capillary or needle-like tube where an energy potential is applied, resulting in charged droplets when these molecules exit the capillary almost in the form of an aerosol. As there is still solvent surrounding these charged droplets, nitrogen gas is used to help with the solvent evaporation process. The droplets will continuously decrease in size as the solvent continues to evaporate with a large charge accumulation occurring in the droplet. This results in a coulombic explosion releasing all the gaseous phase ions out of the droplet. These ions are then directed into the mass analyzer for separation and sorting based on their respective m/z (Banerjee et Mazumdar, 2012; Ho *et al.*, 2003; Hoffmann et Stroobant, 2007). This overall process is demonstrated in a simplified manner in Figure 1.4.





Many mass analyzers exist such as quadrupole, time-of-flight (TOF), and Orbitrap analyzers to name a few, and each type has their own set of features (mass range, resolving power, mass

accuracy) making them suitable for different types of analyses (Haag, 2016). One feature that is highly important when considering mass analyzers is the mass accuracy which essentially describes how accurate the m/z detected for a given compound is when compared to the theoretical m/z value of that given compound This goes hand in hand with the resolving power of the mass analyzer, as a higher resolving power will be able to distinguish exact masses that are very close in value to each other, also leading to more accurate m/z values detected when adequate mass calibration is performed (Hoffmann et Stroobant, 2007).

The combination of different mass analyzers is often employed to exploit their different features. In this project, a hybrid quadrupole-time of flight (QqTOF) system was used. Although quadrupole analyzers operate at unit resolution, they are great for isolating ions of interest that are within a defined range of m/z (Haag, 2016). Quadrupole analyzers are composed of four parallel circular rods (with opposite charges) that have alternating radiofrequency (RF) and direct current (DC) voltages applied. At these applied voltages, ions that possess a m/z that is within the defined range will be able to oscillate through the field without encountering the charged rods. Ions that have a m/z outside the defined range, will oscillate into the rods neutralizing their charge, and expelling them from the analyzer. A second quadrupole (q2) acts as a collision cell (only RF applied) where precursor ions that were able to pass through the first quadrupole (Q1) will get fragmented producing product ions yielding tandem mass spectrometry (MS/MS) data (Haag, 2016; Ho et al., 2003). Triple quadrupole mass analyzers also exist and are widely used for targeted analyses in which selectivity is extremely high when performing multiple reaction monitoring (MRM) (Ho et al., 2003). TOF mass analyzers differentiate ions based on the speed at which they travel in a field free flight tube (Figure 1.5). Prior to entry into the flight tube, all ions acquire the same kinetic energy as they are accelerated into the field free flight tube in which the ions are then separated based on the speed at which they travel to the detector. Ions with smaller m/z will travel much quicker than ions with larger m/z (Gross, 2010; Hoffmann et Stroobant, 2007). The combination of both the quadrupole (Qq) and TOF analyzers is widely used in metabolomic and proteomic studies due to the high sensitivity, resolving power, and robustness (Hoffmann et Stroobant, 2007). With the combination of both these mass analyzers, both MS and MS/MS spectra can be acquired. In TOF-MS mode, the quadrupole does not filter any ions and simply passes all ions into the TOF for separation of precursor ions formed in the source. In MS/MS mode, the first quadrupole (Q1) will act as a mass filter selecting precursor ions to enter into the second quadrupole (q2) for fragmentation by collision-induced dissociation (CID), where residual precursor ions and fragment ions will enter the TOF analyzer for separation (Gross, 2010; Hoffmann et Stroobant, 2007).



Figure 1.5 Diagram of a quadrupole time-of-flight mass analyzer in MS/MS mode (QqTOF)

In untargeted acquisitions such as global metabolomics and proteomics as performed in the scope of this project, tandem MS is crucial as it generates MS/MS spectra of compounds in which each spectrum can help elucidate the structure of a compound or peptide sequence. Many molecules can have the same exact mass, if not very close ones meaning that there's no way to distinguish these molecules from the MS1 spectrum obtained, even with high resolution instruments as the one used in this study. One way to confirm the identity of a compound is through structural elucidation which can be done with MS/MS spectra as it shows how each compound fragments based on their structure. An example is shown of structural elucidation in Figure 1.6 with succinic acid.



Figure 1.6 Structural elucidation of succinic acid by accurate mass measurements and MS/MS fragmentation

MS/MS spectra can be produced via two types of acquisition modes when doing untargeted analyses. Samples can be run in information-dependent (IDA) or in data-independent acquisition (DIA, SWATH) modes. In IDA, the mass spectrometer will select only certain precursor ions to get fragmented in the collision cell. This selection is based on parameters set within the method in which the user will specify that in one cycle, for example, only the ten highest intensity ions will be selected for fragmentation. This parameter can change to any given number depending on what the user is interested in. This usually leads to good quality MS/MS spectra as it avoids interference from other ions outside of the narrow selection window (usually around 0.7 Da) that could potentially be in the same m/z window. In contrast, DIA acquisition will select a wider window of precursor ions (as specified by the user) to get fragmented in the collision cell to produce MS/MS spectra. This is beneficial in some cases as it can lead to a higher coverage of compounds having MS/MS spectra, but it can also lead to more complicated spectra to analyze (Zhu *et al.*, 2014). The difference between these two acquisition types is shown in Figure 1.7.



Figure 1.7 Comparison of information dependent acquisition (IDA) and data-independent acquisition (DIA, SWATH)

1.4 Metabolomic Analysis

Metabolomics comprises the study of metabolites, also known as small molecules from biological matrices that are end products of compounds originating from the host (endogenous metabolites) or compounds originating from the external environment such as food, contaminants, drugs, and pollution (exogenous metabolites) (Johnson *et al.*, 2016). There are several "omic" studies: genomics, transcriptomics, proteomics and metabolomics which are generally described in Figure 1.8 (Dettmer *et al.*, 2007). Studying metabolites is of high interest as the variation of certain metabolites can often be the result of a perturbation occurring from genomic or proteomic changes, in which these metabolites allow a different view of what the effects of these perturbations are.

This makes metabolomics ideal for use in precision medicine, drug development/monitoring and biomarker discovery for a plethora of diseases.



Figure 1.8 Different "omic" technologies and their applications

Moreover, because metabolites are essentially the endpoint from the other "omics", metabolites are the key to understand phenotypes and phenotypical changes that often times cannot be understood from genomics as metabolomics is the closest link to phenotype (Clish, 2015; Dettmer *et al.*, 2007; Guijas *et al.*, 2018). Metabolites can also predict certain phenotypes as their change in abundance or even presence can occur prior to phenotypic changes occurring, which is essential for prevention in the context of health and disease (Wang, Z. et Yu, 2019).

Metabolomics, in the scope of this project, is done so using liquid chromatography coupled to high resolution tandem mass spectrometry (LC-HRMS/MS) due to its robustness, sensitivity and versatility, but other analytical techniques such as nuclear magnetic resonance (NMR) can also be utilized (Johnson *et al.*, 2016; Wishart, 2008). The overall metabolomics processing workflow when using LC-HRMS/MS as the analytical technique of choice is composed of several steps (Figure 1.9): *1*) sample preparation for metabolite extraction, *2*) injection of samples into LC-MS/MS for separation and characterization, *3*) putative metabolite identification by spectral matching between experimental MS/MS spectra with MS/MS spectra from various databases, *4*) statistical analysis to find changing metabolites for biomarker discovery with pathway analysis (mainly in the context of disease) (Wishart, 2008). Sample preparation in metabolomics is quite simple including a step to homogenize the samples using buffer and then precipitate proteins with organic solvents such as methanol (MeOH), ethanol (EtOH) or acetonitrile (ACN), to name a few. Following a centrifugation step, the supernatant is evaporated and reconstituted for metabolomic analysis. Method development is often required to optimize the chromatographic separation a given set of samples as well as the optimization of mass spectrometer parameters.



Figure 1.9 Untargeted LC-HRMS/MS metabolomics workflow

A key goal when performing untargeted metabolomics is to identify as many metabolites as possible in a given sample set. The initial goal is to maximize the metabolite coverage in order to try an understand the overall profile of what can be detected within a given sample type. This also leads to the ability to compile an in-house database of a variety of metabolites which can be extremely useful for later metabolomic studies. Metabolite identification is putatively done when matching MS/MS spectra from experimental samples with those available from various databases such as NIST, HMDB and Metlin, to name a few (Scalbert et al., 2009). When identifications are made this way, they are known as putative because they are not a direct comparison between experimental spectra and spectra from authentic standards. This is a limitation in metabolomics notably when performing untargeted metabolomics. The datasets obtained in untargeted metabolomics are often very large and authentic standards can be very costly. Therefore, the goal is to characterize as many metabolites as possible and to create in-house databases for future work of metabolite characterization on different sample types. With databases that have very high metabolite coverage identified from varying chromatography columns and mass spectrometry methods, it allows the possibility to perform targeted metabolomic analyses with higher reproducibility and quantitative measurements, as well as limited data size. Another advantage of is the fact that the contents of the database will be based off of results originating from same instrumentation and methods being run for actual samples, allowing for a more accurate metabolite identification. This is a way to work around the large limitation of very large datasets, by putatively identifying as many metabolites as possible in the untargeted acquisition and then focusing in on a group of metabolites of interest in subsequent sample sets. For example, performing statistical analysis to find a smaller subset of metabolites of interest or metabolites of a pathway of interest that can then be studied in a targeted manner, and confirmed with metabolite standards for accurate metabolite confirmation. The use of authentic standards also aids greatly in establishing the correct retention times of metabolites, a factor in which can be a source of error in metabolite databases and spectral libraries due to differing separation methods being used which can lead to different retention times reported for the same metabolite (Scalbert *et al.*, 2009).

The metabolome constitutes a very large number of metabolites in which there is a large variability in their structures and properties. Metabolites can range from lipids of varying chain lengths, amino acids, small peptides, to name only a few (Gonzalez-Covarrubias *et al.*, 2022). Evidently this makes a large subset of molecules to study when performing untargeted metabolomics, as the goal is to identify as many metabolites as possible. Due to the vast variability in properties that all these metabolites possess, it is impossible to use only one chromatographic separation method or column to identify all these metabolites with varying properties. To account for the differing properties of metabolites, different separation columns are often used with the aim at observing complementary separation to identify a larger range of metabolites as employed in the scope of this project (Scalbert *et al.*, 2009).

Although metabolomics poses several technical challenges and limitations, it remains an essential technique to study how metabolites vary within various tissues and biofluids to discover new biomarkers of disease, development of new drugs and new treatments for the ever-evolving world, as well as play a large role in precision medicine. In the scope of this project, metabolomics was performed to study the variations within the respective regions of the colon of healthy subjects, for further understanding of the baseline metabolic variations before the introduction of disease as well as compile an in-house database of which metabolites can be detected in these sample types, for subsequent studies to come.

1.5 Proteomic Analysis

Contrary to metabolomics, proteomics involves the study of proteins which unlike metabolites, are very large molecules in which their composition can range from 50 to over 2000 amino acids. When using LC-HRMS/MS to perform proteomic analysis, protein identification, quantification as well as the study of post-translational modifications is possible (Matthiesen et Bunkenborg, 2013).

Much like metabolomics, changes or perturbations occurring in the body (Figure 1.9) can reflect altered protein expression levels giving rise to the identification of potential biomarkers and pathways involved in various diseases. Additionally, proteomics offers great complementarity to transcriptomic analysis since reported mRNA abundance levels of genes does not necessarily mean these same levels are expressed at the protein level. Proteins carry out key functions and biological processes in the body (such as enzymes), therefore it is advantageous to study changes in the levels of expressed proteins allowing for a more comprehensive understanding of what types of biological processes are occurring (Karpievitch *et al.*, 2010; Macklin *et al.*, 2020).

Due to the large size of proteins, the sample preparation workflow for optimal protein identification, quantification and characterization in complex sample matrices is quite different to the one for metabolomic analysis. For proteomic analysis by LC-HRMS/MS two main types of LC-MS/MS proteomics can be employed: top-down proteomics and bottom-up proteomics where the latter was performed in the scope of this project. Top-down proteomics involves studying intact proteins, whereas bottom-up proteomics involves digesting the proteins into peptides and studying the resulting peptides (Figure 1.10). Bottom-up proteomics will be the focus of this section. Peptides can be studied through digestion of proteins which involves a protease that will cleave proteins at known sites, such as trypsin that cleaves proteins at C-terminal arginine (Arg) and lysine residues (Lys) and is the most common protease used for this task (Matthiesen et Bunkenborg, 2013).



Figure 1.10 Simplified bottom-up proteomics workflow

Following sample preparation, samples are injected into the LC-HRMS/MS system for peptide separation and characterization. The separated peptides can be sequenced through MS/MS spectra obtained, in which the m/z fragments correspond to the differences in mass of linked amino acids of the peptide sequences (Matthiesen et Bunkenborg, 2013). When peptides are

selected for fragmentation in the mass spectrometer, the peptide bond linking amino acids is broken, resulting most commonly in a series of *y* and *b* ions, when collision-induced dissociation is employed, as in most MS/MS experiments. The *y* ions denote the charge remaining with the Cterminal end peptide sequence and *b* ions have the charge remaining on the N-terminal end, allowing the direction of the peptide sequence to be deduced when sequencing peptides from the MS/MS spectra (Cleveland et Rose, 2013; Dupree *et al.*, 2020). Proteins are then able to be identified by matching these sequenced peptides using several databases and softwares such as UniProt and ProteinPilot. The databases will identify these proteins based on unique peptide sequences with some peptides mapping to multiple proteins and therefore showing a protein group instead of a unique protein being identified in some instances (Tuli et Ressom, 2009).

1.5.1 Metaproteomic Analysis of Microbial Species

The term metaproteomics is used for many applications and is defined as the identification and quantification of proteins from microbial species, in which it can be done using LC-HRMS/MS (Kleiner, 2019). Although major breakthroughs in microbiome studies have been achieved using 16S rRNA technology for assessing microbial taxonomy, metaproteomics has shown extreme potential for being able to touch on certain aspects regarding the microbiome that are challenging by 16S rRNA. For example, metaproteomics offers strain specific information through the proteins expressed, which is challenged when using 16S rRNA (Cortes et al., 2019). Another challenge that has been reported with 16S rRNA is the innacurate taxonomic classification for certain bacterial species such as Enterobacter and Klebsiella for example, which have a very high 16S rRNA gene similarity. In cases like these where there is high similarity in 16S rRNA gene sequences between genera, complimentary metaproteomic analysis could be beneficial (Cortes et al., 2019; Zwittink et al., 2017). Abundance levels of expressed proteins mapping to unique microbial species can also be measured with metaproteomics, allowing for a better picture of the abundance and activities of species. This adds a more comprehensive view of the microbial species (Kleiner, 2019). Although metaproteomics shows promise for advancing the scientific community into further understand the microbiome and its dynamic nature for the understanding of diseases, there are many challenges associated. These challenges include characterization of low abundance microbial proteins, the high heterogeneity between samples (notably in feces), the lack of developed metaproteomic databases, and the data processing time needed (Armengaud, 2023; Lai, L. A. et al., 2019). Despite these challenges, metaproteomics still acts as an important complimentary analysis to 16S rRNA for comprehensive microbiome research.

17

1.6 Literature on Metabolomics and Proteomics in the Colon

Although many studies have been conducted on the colon and the microbiome by LC-MS/MS, to our knowledge no studies have combined the metabolomic, proteomic, and metaproteomic variations between the different regions of the colon using whole colon tissue and fecal samples from the distal and proximal regions in healthy mice. To date, many studies that involve metabolomic or proteomic analyses studying the colon have been in human patients with an intestinal disease such as colorectal cancer, ulcerative colitis, and IBD, with very few combining multiple analyses (Ang *et al.*, 2010; Busi *et al.*, 2023; Folz *et al.*, 2023; Marshall *et al.*, 2021; Su *et al.*, 2022). Additionally, some studies do not study explicitly the proximal and distal regions of the colon, but rather parts of the small intestine compared to the proximal region of the large intestine such as in the study performed by *Folz et al (Folz et al., 2023)*.

A study performed by *van der Post et al.* studied membrane protein profiles of the distinct regions of the colon by LC-MS/MS in which they were able to find distinct proteomic patterns distinct to each region of the colon in humans. They also studied the transverse and sigmoid colon regions separately along with the ascending and descending colon. Although, this study has some similarities to the one performed in this project, there are important differences. In the study presented by *van der Post et al.* they mainly focus on membrane proteins in the four differing regions of the colon as opposed to studying the whole proteome, as well as the metabolome (van der Post et Hansson, 2014).

Additionally, a study by *Baxter et al.* included untargeted metabolomics to explore differences among individuals undergoing colonoscopy procedures. This involved colon biopsies from both proximal and distal regions, along with self-collected stool samples. The study observed considerable diversity among individuals, particularly related to BMI, and identified distinct metabolites associated with different colon regions (Baxter *et al.*, 2020)

1.7 Mouse Model System

Murine models have been used extensively in research due to their genetic, anatomic, and physiological similarities to humans and their ability to be serve as models to study various diseases. Murine models are essential to study biological perturbations since human samples are often not available (Meier *et al.*, 2023).

18

In this project, a murine model was used to study the metabolic and proteomic variations between the proximal and distal colon. Increasingly, murine models are being used for research into host-microbiome interactions and disease driven by microbiome dysbiosis, as it is possible to control the diet and treatments (Hugenholtz et de Vos, 2018; Nguyen *et al.*, 2015). Although murine models do present many similarities to humans as previously mentioned, there are some limitations when applying knowledge obtained from murine models to humans.

As this project focused on the gut, it is important to outline some differences between the murine and human gut. The size of the murine GI is much smaller than the human GI, and although anatomically they are quite similar, some differences are presented lower in the GI tract. Firstly, humans don't possess a non-glandular forestomach like mice do, although the glandular stomach in mice is like the one in humans. Another difference is at the cecum. In mice, the cecum is large relative to the size of the GI tract, whereas in humans the cecum is quite small. This also leads to differences where principal fermentation occurs between mice and humans. In mice, seeing as the cecum is quite large, a big portion of fermentation is occurring in the cecum, whereas in humans this is not the case (Hugenholtz et de Vos, 2018; Nguyen *et al.*, 2015).

Along with anatomical differences in the GI tract, microbiome composition also differs between mice and humans. Although, 79 genera are found in common to both mouse and human gut, their abundances differ greatly, where it was reported that *Prevotella, Faecalibacterium, Succinivibrio, Dialister, and Ruminococcus* genera were shown to be highly abundant in human microbiota whereas in mice they were shown to be much less abundant. *Lactobacillus,* on the other hand, is highly abundant in mice compared to humans, presenting a limitation when bridging the gap between gut microbiome studies in mice to humans (Hugenholtz et de Vos, 2018; Nguyen *et al.,* 2015).

In this project, FVB/N mice strains (from Charles River Laboratories) were used as they are very suitable for transgenic experiments. The mice were sacrificed at 20 days post-natal pre-weaning for sample collection to avoid changes in diet or microbiome composition when they wean at 21 days. Sex was not considered in most of this study, although a small analysis was done to compare the fecal metabolomic variations between female and male mice.

1.8 Objectives

As previously noted, the prevalence of intestinal diseases like colorectal cancer, IBS, Crohn's, and ulcerative colitis has increased in recent decades. While numerous studies have explored their prevalence, diagnostics, and potential treatments, there is a notable gap in understanding the internal heterogeneity within distinct regions of the colon in healthy individuals.

Prognosis and expression of disease can differ greatly between the proximal and distal regions of the colon. Therefore, it is crucial to comprehend the baseline differences present in a healthy colon before diseases manifest. A baseline understanding of how heterogeneous a healthy colon is could potentially help accelerate understanding of the perturbations being seen in the colon when intestinal diseases are introduced. The objective of this project is to investigate the metabolome and proteome of colon and fecal samples from the proximal and distal regions in healthy mice using untargeted LC-MS/MS. This involves examining the overall detectable metabolome and proteome coverage across all colon and fecal samples, alongside conducting statistical analyses to identify the predominant metabolites and proteins in the distinct regions of the colon. This comprehensive approach will shed light on unique pathways and biological processes in these different regions of the colon.

The project also delves into the gut microbiome, aiming to perform metaproteomics to identify unique microbial species and observe their dominance in respective colon regions. Given that factors like diet, environmental exposure, medication use, age, and stress can influence metabolic, proteomic, and microbiome profiles in subjects, this study is conducted on mice where these variables were kept constant to ensure more reliable results. These studies in healthy mice could be employed for future work on mouse models of human diseases or environmental exposures. Few studies have integrated metabolomics and proteomics for this purpose, making this project a valuable contribution to an important area of research. The results and methodology will be detailed in Chapter 2.

CHAPITRE 2

SCIENTIFIC ARTICLE: PROTEOMIC AND METABOLOMIC ANALYSIS OF COLON AND FECES FROM PROXIMAL AND DISTAL REGIONS IN HEALTHY MICE

Oriana Zambito, Nejia Lassoued, Rodolphe Soret, Nicolas Pilon, Lekha Sleno
Proteomic and Metabolomic Analysis of Colon and Feces from Proximal and Distal Regions in Healthy Mice

Oriana Zambito^{1,3}, Nejia Lassoued^{2,3}, Rodolphe Soret^{2,3}, Nicolas Pilon^{2,3}, Lekha Sleno^{1,3}

- 1) University of Quebec in Montreal (UQAM), Chemistry Department, PO Box 8888 Downtown Station, Montreal, H3C 3P8, Canada, <u>sleno.lekha@uqam.ca</u>
- 2) University of Quebec in Montreal (UQAM), Biology Department, PO Box 8888 Downtown Station, Montreal, H3C 3P8, Canada
- 3) *CERMO-FC*, Centre d'Excellence de Recherches sur les Maladies Orphelines-Fondation Courtois

Oriana Zambito is the principal author of this article. She carried out all bibliographical research, laboratory manipulations, preparation of figures and tables as well as the writing of the article. Nejia Lassoued, Rodolphe Soret and Nicolas Pilon were all implicated in providing the samples required for this article as it is the result of a collaboration between Prof. Pilon's and Prof. Sleno's research groups. Prof. Lekha Sleno guided and supervised the project, as well as revised the manuscript.

2.1 Résumé

Le système gastro-intestinal fait partie des systèmes les plus complexes du corps humain, avec une grande hétérogénéité entre les individus en raison des expositions environnementales et de la génétique. Une forte hétérogénéité est observée au sein des régions distinctes du côlon, notamment avec l'introduction de maladies avec des pronostics et des options de traitement différents. Dans cette étude, la chromatographie liquide couplée à la spectrométrie de masse en tandem haute résolution (LC-HRMS/MS) a été utilisée pour étudier la couverture globale du métabolome et du protéome dans une analyse non ciblée de tissus du côlon et d'échantillons fécaux chez des souris en bonne santé, ainsi que pour étudier l'homogénéité des régions distales et proximales du côlon pour étudier les profils de base dans l'intestin sain. Des échantillons de selles et de côlon ont été prélevés sur dix souris saines avant la précipitation des protéines. Les surnageants résultants ont été utilisés pour la métabolomique non ciblée, et les culots de protéines ont été utilisées pour la protéomique quantitative. Des analyses métabolomiques et protéomiques ont été effectuées sur une plateforme quadripolaire de temps de vol. La métabolomique a été réalisée avec deux méthodes chromatographiques complémentaires, en modes d'ionisation par électrospray négatif et positif, suivies d'une correspondance spectrale et d'une analyse statistique. TOF-MS/MS a été collecté en mode dépendant des données et en mode SWATH ciblé. Plus de 900 métabolites putatifs ont été identifiés, dans lesquels une distinction claire entre les régions proximales et distales a été démontrée pour 153 métabolites du tissu du côlon. Une tendance similaire a été observée à partir d'une analyse protéomique quantitative, avec 1103 protéines du côlon de souris quantifiées, dont 158 présentaient des niveaux significativement différents entre les deux régions. Bien qu'une couverture élevée du métabolome a été obtenue à partir d'échantillons fécaux, avec plus de 1100 métabolites putatifs mesurés, un degré d'hétérogénéité beaucoup plus faible a été observé dans les métabolites fécaux. La métaprotéomique des échantillons fécaux a révélé la capacité d'identifier les espèces au-delà de la taxonomie et a permis de résoudre les informations sur les espèces et de quantifier leurs peptides uniques. D'après les résultats quantitatifs de SWATH, aucune distinction dans les profils du microbiome n'a été observée entre les selles proximales et distales de souris saines.

23

2.2 Abstract

The GI tract is amongst the most complex systems in the human body with high heterogeneity between individuals due to environmental exposures and genetics. High heterogeneity is observed within the distinctive regions of the colon notably with the introduction of disease with different prognoses and treatment options. In this study, liquid chromatography coupled to high resolution tandem mass spectrometry (LC-HRMS/MS) was employed to study the overall metabolome and proteome coverage in an untargeted analysis of colon tissue and fecal samples in healthy mice, as well as to investigate the homogeneity of the distal and proximal colon regions to study baseline profiles within a healthy gut. Fecal and colon samples were collected from ten healthy mice prior to protein precipitation. Resulting supernatants were used for untargeted metabolomics, and the protein pellets were used for quantitative proteomics. Both metabolomic and proteomic analyses were performed on a quadrupole time-of-flight platform. Metabolomics was performed with two complementary chromatographic methods, in both negative and positive electrospray ionisation modes, followed by spectral matching and statistical analysis. TOF-MS/MS was collected in data-dependent mode, and targeted SWATH mode. Over 900 putative metabolites were identified in which a clear distinction between proximal and distal regions was shown for 153 colon tissue metabolites. A similar trend was observed from quantitative proteomic analysis, with 1103 mouse colon proteins guantified, 158 of which had significantly different levels between the two regions. Although high metabolome coverage was obtained from fecal samples, with over 1100 putative metabolites measured, a much lower degree of heterogeneity was seen in the fecal metabolites. Metaproteomics of fecal samples revealed the ability to identify species beyond taxonomy and was able to resolve species information and quantify unique peptides from each of these species. From the quantitative SWATH results, no distinction in microbiome profiles was seen between proximal and distal feces from healthy mice.

2.3 Introduction

The gastrointestinal (GI) tract is composed of many complex organs, having specific functions in digestion, absorption, and elimination, acting as a critical connection between the external environment and the body (Cheng *et al.*, 2010; Monteiro et Batterham, 2017; Thursby et Juge, 2017). Along with these functions, the GI tract is essential in various immune responses for protecting against pathogens and antigens, and its microbiome composition exhibits a significant role in intestinal homeostasis (Mason *et al.*, 2008; Wu et Wu, 2012). Due to the complexity of the

GI tract and factors such as diet, age, genetics, lifestyle and other environmental exposures that can affect its microbial communities, it is highly heterogenous being different individuals, and even within the same individuals over time (Hou *et al.*, 2022; Thursby et Juge, 2017; Weiss et Hennet, 2017). The upper GI tract is composed of the mouth, esophagus, stomach, and the first part of the small intestine, while the lower GI tract runs from the small intestine to the colon, rectum, and anus (Greenwood-Van Meerveld *et al.*, 2017). The colon is home to the largest microbiome population in the GI tract and its dysbiosis is the source of many inflammatory intestinal diseases, such as Crohn's, ulcerative colitis and colorectal cancer, all of which have been on the rise over the last several decades (Agrawal et Jess, 2022; Cosnes *et al.*, 2011; Dieterich *et al.*, 2018; Huang, Z. *et al.*, 2022; Kuipers *et al.*, 2015; Thursby et Juge, 2017). Untargeted metabolomic and proteomics analyses using liquid chromatography coupled to high resolution tandem mass spectrometry was performed on colon and fecal samples with the objectives of characterizing which proteins and metabolites can be detected through untargeted approaches in these two sample types, as well as looking specifically at the differences within two regions of the colon.

The colon, also known as the large intestine is composed of six major segments; the cecum, ascending colon, transverse colon, descending colon, sigmoid colon and the rectum (Vadlamudi et al., 2012). The first three segments make up the proximal colon (ascending colon), and the latter three portions make up the distal colon (descending colon) (Vadlamudi et al., 2012). Fecal samples can also originate from both these regions of the colon as their formation starts in the late proximal region and is then stored and excreted further down the distal region (Azzouz et Sharma, 2023). Certain diseases such as Hirschsprung's disease, a rare disorder characterized by an underdeveloped enteric nervous system in the gut leading to impaired peristalsis, and ulcerative colitis affect more commonly the distal region of the colon(Koutroubakis, 2010; Soret et al., 2020). Severity of disease can also be distinct between locations as seen in colorectal cancer, where different prognostic rates are recorded between the two regions for reasons that are not yet fully understood (Deng, K. et al., 2018; Duraes et al., 2022; Huang, Y. et al., 2021; Lee et al., 2017; Petrelli et al., 2017; Su et al., 2022). Investigating the differences between metabolomic and proteomic profiles in healthy mice can serve as a foundation to better understand the biological pathways involved and highlight the importance of region specificity within the colon, notably when intestinal diseases are present.

To date, many metabolomic or proteomic studies have been performed to study these perturbations in different regions of the colon by studying fecal, and colon samples from individuals

possessing a disease, such as colorectal cancer, and irritable bowel disease, but very few studies have involved healthy subjects to investigate variations within the colon without the presence of disease (Deng, K. et al., 2018; Su et al., 2022). A recent study used untargeted metabolomics to investigate differences in individuals undergoing colonoscopy procedures, by collecting colon biopsies from the proximal and distal regions, as well as self-collected stool samples, noting high interindividual diversity especially based on BMI, as well as specific characteristic metabolites correlating with different regions (Baxter et al., 2020). By performing the analysis on healthy wildtype mice, otherwise confounding factors such as diet, environmental stress, age, and medications are limited. There is extensive literature combining various "omics" studies, such as proteogenomics and metagenomics, comparing proximal and distal colon regions, however the majority of studies compare profiles in disease vs. healthy tissue. Imperial et al. conducted proteogenomics to investigate differing gene mutations and proteins between proximal, distal, and rectal colorectal cancers (Imperial et al., 2018). Huang et al. compared proximal and distal colon profiles in patients with colorectal cancer by studying transcriptomic and gene mutational differences (Huang, Y. et al., 2021). Parigi et al. performed transcriptomic analysis using quantitative PCR on healthy and colitis-induced mice to understand transcriptomic differences across different regions of the colon and how this profile changes upon introduction of disease (Parigi et al., 2022). A large portion of studies investigate the differences between regions in the context of disease, but not in healthy subjects, highlighting the importance of understanding baseline variations. Very few have employed a combination of proteomics and metabolomics for this purpose (Busi et al., 2023; Huang, Y. et al., 2021; Marshall et al., 2021; Xu et al., 2022).

2.4 Experimental Methods

2.4.1 Chemicals

Sequencing-grade, TPCK-treated trypsin (from bovine pancreas), iodoacetamide (IAM) and dithiothreitol (DTT), as well as HPLC grade acetonitrile (ACN), methanol (MeOH), ethanol (EtOH), ammonium bicarbonate (ABC), and formic acid (FA), were obtained from Sigma-Aldrich (Oakville, ON, Canada). Ultrapure water was obtained from a Millipore Synergy UV system (Billerica, MA, USA).

2.4.2 Sample Collection

Colon and fecal samples from proximal and distal regions were collected from five female healthy FVB/N mice (Taketo *et al.*, 1991). Additional fecal samples were collected for simultaneous

preparation of metabolite extracts and peptide digests from six FVB/N mice (3 male, 3 female). These latter samples were necessary, since we noted that protein pellets from feces stored in the freezer following metabolite extraction for several days prior to digestion into peptides did not yield satisfactory proteome coverage. Before dissection, all mice were euthanized using carbon dioxide. Regarding colon samples, mesenteric fat was first removed and then the colon was divided into the proximal and distal regions, each 1.5 cm in length. Each region of the colon was opened longitudinally for feces collection. All mice were obtained from Charles River Laboratories (Senneville, QC, Canada) and fed standard rodent chow diet #5075 (Charles River). Mice were maintained at the animal facility at *Université du Québec à Montréal* (UQAM), and sample collection was performed at 20 days postnatal (pre-weaning). All samples were collected into pre-weighed 1.5 mL Safe-Lock polypropylene tubes (Eppendorf, Mississauga, ON, Canada) and stored at -80°C. Distal and proximal colon samples weighed an average of 93 ± 19 mg and 128 ± 26 mg, respectively. Distal and proximal fecal samples weighed an average of 50 ± 25 mg and 55 ±17 mg, respectively.

2.4.3 Sample Preparation

2.4.3.1 Metabolite extraction

An initial volume of 100 mM ammonium bicarbonate (ABC) buffer (pH 8.5) was added to tissues collected, corresponding to half the weight of tissue collected (0.5 µl per mg) for colon samples and 1 µl per mg weight for fecal samples, followed by vortex mixing (5 s) and bath sonication for 15 minutes. Proteins were then precipitated using 3 times the volume of buffer with 100% MeOH. All colon samples were probe sonicated using a QSonica XL-2000 CML-4 sonicator (5 cycles, 5s each) for further tissue homogenization. All samples (colon and fecal) were centrifuged (8 minutes, 4°C, 14000 rpm) where the supernatant was kept for metabolomic analysis, and the resulting protein pellet used for proteomic analysis. Supernatants were dried with a universal vacuum concentrator (Fisher Scientific, Mississauga, ON, Canada) and reconstituted in 25% MeOH with reconstitution volume either matching or doubling the supernatant volume taken for colon and fecal samples, respectively. Prepared sample extracts were stored at -30°C prior to analysis.

2.4.3.2 Protein solubilisation and digestion

A solution of 7 M urea and 2 M thiourea (100 μ l) was added to each dried protein pellet followed by vortex mixing (10 s) and sonication in a water bath for 15 minutes. ABC buffer (300 μ l) was then added to each sample followed by probe sonication for five 5 s cycles. Quantitation of protein in resulting extracts was performed by the Bradford protein assay, with appropriate dilutions to cover the dynamic range from 20-140 μ g/ml protein. A normalized sample size of 100 μ g protein was then aliquoted into a new tube and volumes completed to 400 μ l with ABC buffer, followed by 15 μ l of 100 mM DTT (15 min at 37°C), and 20 μ l of 100 mM IAM (30 min at 37°C in the dark) for reductive alkylation. Digestion was initiated with the addition of 20 μ l trypsin solubilized in 50 mM acetic acid with overnight incubation at 37°C and continual mixing at 650 rpm on an Eppendorf thermomixer. Following digestion, samples were diluted with water to 1 mL followed by solid phase extraction (SPE) on OASIS HLB cartridges (30 mg/mL) from Waters Limited (Mississauga, ON, Canada). Cartridges were conditioned with 1 mL each of 100% MeOH and nanopure water, followed by sample loading. Cartridges were washed with 1 mL of nanopure water and eluted with 2 volumes of 500 μ l of 100% MeOH. Samples were dried (SpeedVac) and reconstituted in 120 μ l of 10% ACN, 0.2% formic acid (FA), and stored at -30°C prior to LC-MS/MS analysis.

2.4.4 LC-HRMS/MS Analysis

2.4.4.1 Metabolomics

Metabolite extracts (10 µl) were analyzed on a Nexera UHPLC (Shimadzu, Columbia, MD, USA) coupled to a quadrupole time-of flight (TripleTOF 5600) mass spectrometer (Sciex, Concord, ON, Canada) equipped with a DuoSpray ion source in both ionization electrospray modes. Chromatographic separation of metabolites employed an Imtakt Scherzo SM-C18 column (100 x 3 mm, 3 µm) with a flow rate of 0.3 mL/min, column temperature of 40°C, and gradient elution with water (A) and ACN (B), both containing 0.1% FA. Complementary chromatographic separation was performed using a Phenomenex Luna Reverse-Phase PFP column (150 x 2.1 mm, 3 µm) at a flow rate of 0.25 mL/min and gradient elution with water containing 0.1% FA (A) and 100% MeOH (B). The gradient elution for both columns was initiated at 3% B at 2.0 min, increased linearly to 65% at 15 min followed by an increase to 95% within 0.5 min, then held for 2.5 min, followed by column re-equilibration at starting conditions.

Ion source parameters were set at 450°C for source temperature, 5000 (or -4500) V for ionspray voltage and 80 V for declustering potential (DP), 35 psi for curtain gas, 50 psi for nebulizer gas (nitrogen) and drying gases. Information dependent acquisition (IDA) was employed with TOF-MS data for m/z 80-980 (200 ms accumulation time) followed by MS/MS acquisition for m/z 40-800 for the 8 most intense ions (100 ms accumulation time) with a cycle time of 1.1 s, with collision offset voltage set to 30 ± 10 V. An in-house standard mix (from m/z 120-922) was injected every four samples for auto-calibration in MS and MS/MS mode.

2.4.4.2 Proteomics

Samples (20 µI) were analyzed on a Nexera UHPLC (Shimadzu, Columbia, MD, USA) coupled to a quadrupole time-of flight (TripleTOF 5600) mass spectrometer (Sciex, Concord, ON, Canada) equipped with a DuoSpray ion source in positive electrospray mode. Gradient elution of water and acetonitrile with 0.1% FA were used as mobile phases A and B respectively, on a Phenomenex Aeris PEPTIDE XB-C18 column (100 x 2.1mm, 1.7µm) with a SecurityGuard ULTRA C18 peptide guard (2.1 x 2mm) (Phenomenex, Torrance, CA, USA) at a flow rate of 0.30 mL/min and column temperature of 40°C. Gradient elution was initiated at 5% B at 2.5 min, increased to 30% at 40 min followed by an increase to 50% at 42 min, increase to 90% at 44 min and held for 3 min, followed by decrease to 5% at 47 min for column re-equilibration for 8 min.

Ion source parameters were set at 500°C for source temperature, 5000 V for ionspray voltage and 80V for declustering potential (DP), 35 psi for curtain gas, 50 psi for nebulizer gas (nitrogen) and drying gases. An in-house standard mix was injected every four samples for auto-calibration in MS and MS/MS mode. Information-dependent acquisition (IDA) and data-independent acquisition (SWATH) were both employed for high resolution mass spectrometry analysis. TOF-MS data for IDA acquisition was acquired from *m*/*z* 140-1250 with an accumulation time of 250 ms, followed by MS/MS acquisition from *m*/*z* 80-1300 of the 15 most intense ions. Collision-offset voltage was set to 30 \pm 10 V. Pooled samples were prepared for distal and proximal colon and fecal samples for ion library creation from IDA analyses. For SWATH acquisition, TOF-MS scan from *m*/*z* 140-1250 with an accumulation time of 150 ms, followed by MS/MS experiments (100) with variable Q1 windows from *m*/*z* 80-1500 for a total cycle time of 2.7 s. Collision-offset voltage was set to 30 \pm 5 V.

2.4.5 Data Processing

2.4.5.1 Metabolomics

Data was acquired using Sciex Analyst TF (v1.7.1) software and data visualization used PeakView (v2.2) with MasterView 1.1 from Sciex. For untargeted data processing, MarkerView (v1.2.1, Sciex) software was used for peak picking to find unique features (m/z, RT) and for normalization. Putative identification of metabolites was performed by importing feature lists and data into Sciex OS-Q for spectral matching using several databases (Sciex *all-in-one* HR-MS metabolite library, NIST and an in-house library of standard metabolites). Putative metabolite identifications used mass error cutoff within \pm 10 ppm for protonated or deprotonated precursor ions and a library

score of 80% for MS/MS spectral matching. Peak verification was performed for each putative metabolite to ensure adequate signal/noise and proper integration using MultiQuant software (Sciex), and results were then imported into MarkerView for MLR (most likely ratio) normalization prior to statistical analysis using a Welch corrected *t*-test and Principal Component Analysis (PCA).

For further coverage of metabolite features that did not yield a putative metabolite hit by spectral matching of IDA data, a different approach was taken by first using MarkerView (v1.2.1, Sciex) software to process raw data to find statistically significant peaks (using thresholds of p < 0.01, fold change $\geq |2|$ following t-test). Peak verification was then performed on these features using Multiquant. The remaining features (m/z, RT pairs) that did not have previous putative metabolite assignments were targeted using SWATH acquisition with 1 Da windows, for subsequent spectral matching within Sciex OS-Q as previously described.

Heat maps were constructed using NG-CHM Builder from MD Anderson Cancer Centre (Houston, TX, USA) (Ryan *et al.*, 2019). An excel file was uploaded with defined peak areas of each compound for each sample. Peak areas were annotated as percentage relative to the highest peak area for a given compound. Hierarchical clustering was applied to row ordering options specifying Euclidean distance metric and Ward agglomeration with original order specified for column ordering options. No covariates were assigned.

Enrichment analysis of metabolites was performed using MetaboAnalyst 5.0 (Montreal, Canada) (Pang *et al.*, 2021). The Human Metabolome Database (HMDB) numbers corresponding to metabolites were inputted for analysis with Small Molecule Pathway Database (SMPDB) based pathways selected and using metabolite sets containing at least 2 entries.

2.4.5.2 Proteomics

Raw data visualization was performed with PeakView 2.2 with MasterView 1.1 from Sciex. OneOmics Suite 3.1 cloud-based program was used for protein identifications from IDA data with UniprotKB database released February 2022. Criteria specified for protein identification for colon samples was as follows: mouse species, iodoacetamide cysteine alkylation, trypsin digestion, 1% global protein and peptide false discovery rate with up to 4 peptides per protein and 3 transitions per peptide. For fecal samples, the same parameters were employed for protein identification, except no species were specified, and results were filtered to identify proteins from bacterial

30

species as well as mouse. Heat maps were constructed using the same process as previously mentioned.

2.5 Results and Discussion

2.5.1 Untargeted Metabolomics

Colon and fecal samples from five healthy mice were analyzed by LC-MS/MS to characterize the coverage of our untargeted metabolomics workflows as well as to study the variations between two distinct regions of the colon. Raw LC-HRMS/MS data were first processed to find unique features (*m/z*, retention time) present in the samples. These features were then searched against HRMS/MS spectral databases for putative metabolite identification (Figure 2.1). Due to the limitations in proper peak integration with automated peak picking, each metabolite peak was verified to ensure adequate signal-to-noise and consistent integrations throughout the dataset. This step was essential for subsequent statistical analyses. Overall, 307, 215, 272, and 217 colon metabolites, as well as 416, 208, 386, and 225 fecal metabolites identified in Scherzo (+), Scherzo (-), PFP (+) and PFP (-) datasets, respectively. These results are summarized in Supplemental Tables 2.8 and 2.9, listing each metabolite name, library score, mass error, and formula, and which dataset they were from. It is important to note that these tables list metabolite IDs from four datasets in which overlapping metabolites can be present.



Figure 2.1 Untargeted metabolomics workflow of colon and fecal samples from sample preparation to data processing, with an example of spectral matching for succinic acid

Separation of metabolites was performed using two chromatographic columns for complementary separation. Both columns serve different roles as the Scherzo mixed-mode column exhibits good retention of polar compounds having either acidic or basic groups, due its ion exchange and reverse phase characteristics, whereas the PFP column separates based on polarity with preferential retention of aromatic and conjugated compounds. As seen in Figure 2.2a, there are 162 putative colon metabolites uniquely identified with the Scherzo column, 140 identified metabolites unique to the PFP column, and 212 identified metabolites common to both columns. The same complementarity was seen from fecal samples (Figure 2.2b), where 179 and 163 metabolites are unique to the Scherzo and PFP columns, respectively, with 282 metabolites in common. When comparing putative metabolite identifications between the two chromatographic columns, retention times were not considered explaining the discrepancy of total number of metabolites.



Figure 2.2 Venn diagrams representing unique and common metabolites with putative identifications by MS/MS spectral matching, from combined positive and negative ion modes, using Scherzo and PFP columns for colon (a) and fecal (b) samples

When all metabolites were compiled, the highest proportion represent organic acids and derivatives (HDMB metabolite superclass), more specifically, carboxylic acids and derivatives (class), and amino acids and peptides (subclass). This dataset also covered many organoheterocyclic compounds and lipid-like molecules as seen in Figure 2.3. Regarding lipid molecules in colon and fecal samples, fatty acyls, such as eicosanoids and fatty acids, were the major sub-classes. Glycerophospholipids and steroids were seen to have better coverage with the

Scherzo column whereas organic acids notably in fecal samples has better cover from the PFP column but not in colon samples.



Figure 2.3 Classification of metabolite superclasses from combined putative identifications from Scherzo and PFP datasets in positive and negative modes from colon (a) and fecal (b) samples

Principal Component Analysis (PCA) was performed on the quantitative data to determine if there was any clustering of proximal and distal samples. For colon, there is already a clustering of samples from the two regions based on using all metabolites, whereas for feces, no distinction was seen (Figure 2.4). This indicates that at the tissue level, certain metabolites are differing between the two regions causing the groups to cluster into their respective areas of the PCA plot, whereas in the fecal samples, less clustering between groups is observed overall. Although PCA plots greatly help to visualize the clustering pattern of large data sets, it is used in this case as a visual aid to get a generalized view of the data obtained.



Figure 2.4 Unsupervised PCA plots of all identified and statistically significant metabolite IDs from Scherzo and PFP columns of a) colon, and b) fecal samples

2.5.1.1 Metabolite Differences Between Distal and Proximal Regions

Statistical analysis was performed to observe which metabolites are shown to increase or decrease in the distal portion of the colon compared to proximal samples. In Figure 2.4, we are able to observe the difference in the generated PCA plots when only the statistically significant metabolites are used in the analysis. When a threshold of *p*-value < 0.05 and fold change greater than \pm 50% was set, 153 colon and 23 fecal metabolites were found to be significantly changing between the two regions. Regarding colon samples, 100 metabolites were increased and 53 were decreased in the distal region. Of the 23 fecal metabolites, 9 increased and 14 decreased. These results are summarized in Supplemental Tables 2.10 and 2.11. Heatmaps with hierarchical clustering were used to visualize the changes in levels in the individual samples. The Welch *t*-test allows inter-individual variation to be considered when finding significant differences between groups. The Welch *t*-test will consider inter-individual variation and compare two given groups of samples (West, 2021).



Figure 2.5 a) Heatmap of 153 statistically significant colon metabolites; b) Heatmap of 23 statistically significant fecal metabolites; c) Enrichment analysis using MetaboAnalyst 5.0 of statistically significant metabolites that are increased in distal and proximal colon

As shown in Figure 2.5a, there is a shift in abundance in the colon tissue for many metabolites. The same extent of variability is not seen in fecal samples as shown in Figure 2.5b, both in terms of number of statistically significant metabolites but also in the variation within the same region of these metabolites. This lack of significant variability between regions from fecal samples can be potentially explained by how fecal formation occurs in the colon. Fecal formation starts in the proximal portion of the colon, where the proximal colon will absorb nutrients and water from matter incoming from the small intestine, forming feces that are then stored in the distal portion of the colon waiting to be expelled (Azzouz et Sharma, 2023). There should not, in fact, be much variation of the level of metabolites in the feces in the absence of disease. This finding can also be due to the large complexity of fecal metabolome (most of which is not even contained in metabolite databases, and therefore not a subject of this study). With such highly complex samples, it is increasingly difficult to detect differences in low abundance metabolites.

Performing an enrichment analysis revealed certain specific pathways that were affected as seen in Figure 2.5. For example, methionine metabolism is a highly enriched pathway in the distal colon, whereas metabolites involved in tryptophan metabolism have higher levels in the proximal region. Tryptophan is metabolised through the serotonin, kynurenine, and indole pathways. Metabolites involved in the serotonin and kynurenine pathways were increased in the proximal region as shown in Figure 2.6 and Table 2.1 (Wang, S. *et al.*, 2023). Figure 2.6 and Table 2.1 also show the overlap and complementarity between the four datasets. For example, 5-hydroxyindoleacetic acid and kynurenine are well detected (and identified through spectral matching) in three of four datasets with similar results between proximal and distal regions. However, serotonin was only idenfied in Scherzo (+) dataset, and xanthurenic acid was seen uniquely in PFP (-) dataset.



Figure 2.6 a) Tryptophan metabolism via serotonin and kynurenine pathways with metabolites identified (kynurenine, xanthurenic acid, serotonin, and 5-hydroxyindole-acetic acid) shown to be increased in the proximal region of the colon (decreased in distal colon). Other metabolites in the respective pathways were not identified in any datasets. b) Relative peak intensities between distal and proximal colon of identified metabolites are shown as extracted ion chromatograms for representative samples.

| Metabolite ID | Chemical Formula | Retention Time (min) | Fold Change DC/PC | <i>p</i> -value | Column (+/-) |
|----------------------------|----------------------|-------------------------|----------------------|----------------------|--------------|
| Serotonin | $C_{10}H_{12}N_2O$ | 4.1 | -23.8 | 1.6x10 ⁻² | Scherzo (+) |
| | | 9.6 | -3.5 | 1.1x10 ⁻² | Scherzo (+) |
| 5-hydroxyindoleacetic acid | $C_{10}H_9NO_3$ | 10.6 | -3.3 | 5.2x10 ⁻³ | PFP (+) |
| | | 10.7 | -3.7 | 1.0x10 ⁻³ | PFP (-) |
| | | 5.9 | -3.9 | 3.2x10 ⁻² | Scherzo (+) |
| Kynurenine | $C_{10}H_{12}N_2O_3$ | 5.7 | -3.8 | 2.5x10 ⁻² | PFP (+) |
| | | 5.7 | -3.3 | 2.6x10 ⁻² | PFP (-) |
| Xanthurenic acid | $C_{10}H_7NO_4$ | 10.7 | -4.5 | 5.4x10 ⁻³ | PFP (-) |

Table 2.1 Metabolites Increased in Proximal Colon Involved in Tryptophan Metabolism

Specific metabolites, such as serotonin, 5-hydroxyindoleacetic acid, kynurenine and xanthurenic acid, were shown to have higher levels in the proximal colon. Kynurenine is implicated in the inflammatory response, as well as being a crucial player in the gut-brain axis (Deng, Y. et al., 2021). Tryptophan is converted into kynurenine by the enzyme indolearnine 2,3-dioxygenase. which has been shown to be an oncogenic protein as its levels are elevated in colorectal cancer, leading to depleted tryptophan and elevated kynurenine levels (Bishnupuri et al., 2019; Venkateswaran et al., 2019; Zhang, X. et al., 2021). Kynurenine is capable of modulating immune responses during tumour growth by inactivating immune cells such as T-cells allowing cancerous cells to continuously proliferate (Bishnupuri et al., 2019; Venkateswaran et Conacci-Sorrell, 2020; Zhang, X. et al., 2021). Due to kynurenine's role in the gut-brain axis, altered tryptophan metabolism and kynurenine via intestinal microbiota dysbiosis has also been shown to lead to neurological diseases (Deng, Y. et al., 2021). Tryptophan can also be metabolized into serotonin, with implications in both neurological and gastrointestinal signaling, where serotonin in the gut surprisingly accounts for over 90% of the serotonin produced in the body (Fouquet et al., 2019; Gershon et Tack, 2007; Reigstad et al., 2015; Roth et al., 2021). Although all of these metabolites exhibited at least over 300% increase in peak area, serotonin was seen to have the highest fold change with peak areas in proximal colon 24-fold higher than in distal colon samples. Serotonin is produced from enterochromaffin cells (EC) in the intestinal mucosa in the gut and plays a large role in colonic motility, secretion, signalling, sensation, and immune activity (Gao et al., 2022; Mawe et Hoffman, 2013; Roth et al., 2021). Atypical levels of serotonin are a growing area of research due to their implications in various intestinal diseases, such as colorectal cancer, ulcerative colitis, and irritable bowel syndrome (IBS) (Manocha et Khan, 2012). IBS symptoms can be expressed either through constipation or diarrhea, two symptoms of different extremities (Bonetto et al., 2021; Manocha et Khan, 2012; Saha, 2014). Serotonin levels associated with symptoms of constipation IBS are shown to decrease, whereas serotonin is increased in IBS patients with diarrhea symptoms (Bonetto et al., 2021; Manocha et Khan, 2012; Saha, 2014; Spiller, 2008). Metabolites resulting from tryptophan degradation are thus largely implicated in intestinal diseases and are a group of molecules that are continuously studied to further understand their implication in pathogenesis and treatment of these intestinal diseases. This study has shown that these metabolites are increased in the proximal region of the colon. A study by Wei et al., demonstrated similar results that elevated levels of EC cells and serotonin are found in the proximal colon and that their altered levels led to significant differences in colon motility and contractions resulting in delayed gastric excretions from the proximal region (Wei et al., 2021).

Prostaglandins are another group of metabolites that showed significant changes between the two regions. Five prostaglandin molecules (PGA1, PGA2, PGD1, PGE1, and PGH2 respectively, at several different retention times) were shown to be higher in the distal colon (prostaglandin E1, A1, A2, and H2) (Figure 2.7, Table 2.2). Prostaglandins can be synthesized from arachidonic acid or dihomo-gamma linolenic acid through cyclooxygenase (COX) enzymes. Prostaglandin A2 (PGA2) and H2 (PGH2) are products of arachidonic acid metabolism, whereas prostaglandin A1 (PGA1), and prostaglandin E1 (PGE1) are products of dihomo-gamma linolenic acid metabolism, the direct precursor of arachidonic acid (Figure 2.7a) (Schröder, R. et al., 2012; Straus et Glass, 2001; Wang, W. et al., 2021). Interestingly, prostaglandins can either be pro or anti-inflammatory depending on the type of prostaglandin (Ricciotti et FitzGerald, 2011; Wang, D. et DuBois, 2008). For example, prostaglandin E2 (PGE2) is pro-inflammatory and can contribute to chronic inflammation and can be pro-tumorigenic in certain cases, whereas prostaglandin E1 (PGE1) has been shown to have beneficial effects on tissue injury (Hao et al., 2018; Levin et al., 2002; Ricciotti et FitzGerald, 2011; Wang, D. et DuBois, 2008). Unlike PGE2, prostaglandin A2 (PGA2) can have anti-tumorigenic and anti-inflammatory effects. Elevated levels of prostaglandin E synthases have been reported in colorectal cancer, in which PGA2 was shown to cause a decrease in prostaglandin E synthase enzyme levels (Gorospe et al., 1996; Sasaki et Fukushima, 1994; Schröder, O. et al., 2006). Like PGA2, PGE1 and PGA1 also have anti-inflammatory properties in cases of colorectal cancer and irritable bowel syndrome (Kunkel et al., 1979; Mandal et al., 2005; Rossi et al., 2000; Sasaki et Fukushima, 1994). These anti-inflammatory prostaglandins (PGA2, PGE1, PGA1) that are increased in the distal colon could potentially play a role as to why morbidity rates and tumor progression for colorectal cancer in the distal colon have more favourable outcomes compared to those affecting the proximal colon. This highlights once more the heterogeneity between the two distinct regions and that prostaglandin metabolites are molecules of interest when studying diseases affecting the gut. As shown in Figure 2.7a, PGH2 is also a precursor for many prostaglandins, such as PGI2, PGF2, PGE2, PGD2, 15APGJ2, as well as various thromboxanes (TXA2) (not shown). PGH2 being increased in distal colon can lead to a potential cascade of formation of other prostaglandins leading to potential cases of pro or anti inflammatory action in the distal colon (Jara-Gutiérrez et Baladrón, 2021; Rajakariar et al., 2007; Simon, 1999).



Figure 2.7 a) Arachidonic acid metabolism (Adapted from (Surh et al., 2011)). Prostaglandins in red have increased levels in the distal colon and other bolded prostaglandins were identified in the dataset but did not show statistical significance between the two regions b) Relative peak intensities between distal and proximal colon of identified metabolites are shown as extracted ion chromatograms for representative samples.

| Metabolite ID | Retention Time (min) | Chemical Formula | Fold Change DC/PC | <i>p</i> -value | Column (+/-) |
|--|-------------------------|--|----------------------|----------------------|--------------|
| .DELTA.17-6-Ketoprostaglandin F1.alpha. | 12.3 | C ₂₀ H ₃₂ O ₆ | 1.0 | 8.5x10 ⁻¹ | Scherzo (-) |
| 13,14-Dihydro-15-ketoprostaglandin A2 | 16.8 | | 1.1 | 6.0x10 ⁻¹ | Scherzo (+) |
| 13,14-Dihydro-15-ketoprostaglandin A2 | 16.8 | $C_{20}H_{30}O_4$ | 1.0 | 7.8x10 ⁻¹ | Scherzo (-) |
| 13,14-Dihydro-15-ketoprostaglandin A2 | 15.4 | | -1.2 | 3.1x10 ⁻¹ | Scherzo (-) |
| 15-DeoxyDELTA.12,14-prostaglandin J2 (in-source fragment) | 17.8 | | 2.5 | 2.2x10 ⁻² | PFP (-) |
| 15-DeoxyDELTA.12,14-prostaglandin J2 | 17.1 | CHO. | 1.6 | 1.1x10 ⁻¹ | Scherzo (-) |
| 15-DeoxyDELTA.12,14-prostaglandin J2 (in-source fragment) | 16.1 | 020112803 | 2.7 | 9.2x10-6 | Scherzo (-) |
| 15-DeoxyDELTA.12,14-prostaglandin J2 (in-source fragment) | 14.6 | | 2.3 | 6.7x10 ⁻⁴ | Scherzo (-) |
| 5-Isoprostaglandin-F2.alphaVI | 14.4 | | 1.4 | 3.3x10 ⁻³ | Scherzo (-) |
| 5-Isoprostaglandin-F2.alphaVI | 17.1 | $C_{20}H_{34}O_5$ | 1.2 | 1.2x10 ⁻¹ | PFP (-) |
| 5-Isoprostaglandin-F2.alphaVI | 13.9 | | 1.2 | 2.6x10 ⁻¹ | Scherzo (-) |
| 8-iso-Prostaglandin A1 (in-source fragment) | 14.8 | $C_{20}H_{32}O_4$ | 1.8 | 1.6x10 ⁻³ | Scherzo (-) |
| 9-Oxoprosta-5Z,10,12Z,14E-tetraenoic acid (in-source fragment) | 17.8 | C.,H.O. | 2.0 | 4.0x10 ⁻⁴ | PFP (+) |
| 9-Oxoprosta-5Z,10,12Z,14E-tetraenoic acid (in-source fragment) | 16.1 | 020112803 | 2.8 | 5.9x10 ⁻³ | Scherzo (+) |
| Bicyclo-prostaglandin E2 | 15.3 | C ₂₀ H ₃₀ O ₄ | -1.2 | 2.4x10 ⁻¹ | Scherzo (+) |
| Prostaglandin A1 | 16.4 | $C_{20}H_{32}O_4$ | 1.6 | 1.1x10 ⁻² | Scherzo (-) |
| Prostaglandin A2 | 16.1 | | 2.7 | 2.1x10⁻⁵ | Scherzo (-) |
| Prostaglandin A2 | 17.8 | $C_{20}H_{30}O_4$ | 2.1 | 3.9x10 ⁻⁴ | PFP (-) |
| Prostaglandin A2 (in-source fragment) | 14.6 | | 2.3 | 7.6x10-4 | Scherzo (-) |
| Prostaglandin B1 | 15.6 | $C_{20}H_{32}O_4$ | 1.2 | 3.1x10 ⁻¹ | Scherzo (-) |
| Prostaglandin D1 | 17.7 | $C_{20}H_{34}O_5$ | 1.5 | 1.4x10 ⁻³ | PFP (-) |
| Prostaglandin E1 | 14.8 | C ₂₀ H ₃₄ O ₅ | 1.5 | 2.8x10 ⁻² | Scherzo (-) |
| Prostaglandin H2 | 14.6 | C. H. O. | 2.2 | 5.9x10 ⁻⁴ | Scherzo (-) |
| Prostaglandin H2 | 17.6 | 020113205 | 1.8 | 1.3x10 ⁻³ | PFP (-) |
| Prostaglandin I2 | 13.0 | | 1.1 | 3.3x10 ⁻¹ | Scherzo (+) |
| Prostaglandin I2 | 12.8 | CH.O. | 1.1 | 3.3x10 ⁻¹ | Scherzo (+) |
| Prostaglandin I2 | 13.8 | C ₂₀ , 1 ₃₂ C ₅ | -1.1 | 5.0x10 ⁻¹ | Scherzo (+) |
| Prostaglandin I2 | 17.4 | | 1.3 | 3.6x10 ⁻² | PFP (+) |

Table 2.2 All Identified Prostaglandin Metabolites in Colon from All Metabolite Datasets

Unlike the prostaglandins that are increased in the distal colon, shown in Table 2.2, other prostaglandins were putatively identified but not found to be changing between the regions. These prostaglandins, namely prostaglandin I2 (PGI2), 13,14-dihydro-15-ketoprostaglandin A2, prostaglandin B1 (PGB1), isoprostaglandin F2 alpha (PGF2a), prostaglandin D1 (PGD1), Ketoprostaglandin F1 alpha, and bicyclo-prostaglandin E2 did not have sufficiently low *p*-values and high enough fold changes to be considered as significantly different as shown in Table 2.2. PGI2 and PGF2a are shown to be products of arachidonic metabolism (Figure 2.7) (Wang, B. *et al.*, 2021; Zhang, Y. *et al.*, 2023). PGH2 acts as a precursor for various prostaglandins, such as PGI2, PGA2, and PGF2a (Wang, B. *et al.*, 2021; Zhang, Y. *et al.*, 2023). The lack of significance in this dataset of these other prostaglandins could potentially be due to lower signal-to-noise and therefore higher variabilities in these measured peaks within samples from the same region. An

additional prostaglandin molecule initially found as statistically significant was putatively identified as 15-deoxy- Δ 12,14-prostaglandin J2 (15 Δ PGJ2). This prostaglandin was identified at the same retention times as PGA2 on both Scherzo (-) (shown in Figure 2.8) and PFP (-) and results from an in-source loss of water from PGA2, and thus did not correspond to a separate metabolite. This highlights the need to verify final lists of statistically significant metabolites, for artifacts stemming from in-source fragmentation. A similar in-source dehydration was seen in the case of PGA2 and PGH2 and with 8-iso PGA1 and PGE1 from Scherzo (-), where they co-elute at 14.6 minutes and 14.8 minutes, respectively.



Figure 2.8 Extracted ion chromatograms demonstrating 15delta-PGJ2 as in-source fragment of PGA2 isomers in Scherzo (-) at retention times of 14.6 and 16.1 minutes.

Carnitines are a group of metabolites that have also been shown to be largely implicated in the colon, in which they are have roles in the transport of long-chain fatty acids into the mitochondria for their oxidation (Roscilli *et al.*, 2013; Srinivas *et al.*, 2007). Acylcarnitines are the result of the conjugation of carnitine with fatty acids and linked to energy production required for cell activity. Acylcarnitines are an important group of metabolites to study as they are known biomarkers for metabolic, diabetic, cardiovascular, and neurodegenerative disorders (Dambrova *et al.*, 2022). They have also been shown to play a role in various cancers in which Roscilli *et al.* found that a mixture of three acylcarnitines (carnitine, acetyl-carnitine, and propionyl-carnitine) were found to halt formation of lesions throughout all steps of tumour progession in an induced colon cancer mouse model indicating their promise in cancer therapeutics (Roscilli *et al.*, 2013). As shown in Table 2.3, 34 acylcarnitines have been identified in colon samples with 16 having significantly

higher levels in the distal colon.. Zhao *et* al. also found that various acylcarntines had beneficial actions agains colorectal cancer, but no distinction between proximal or distal colorectal cancer was made (Zhao *et al.*, 2023). The significance of many acylcarnitines being increased in the distal colon could be a potential reason as to why there are better outcomes reported with tumours residing in the distal colon as opposed to the proximal colon.

| Metabolite ID | Retention Time (min) | Chemical Formula | Fold Change DC/PC | <i>p</i> -value | Column (+/-) |
|--------------------------------|-------------------------|---|----------------------|----------------------|--------------|
| Carnitine | 2.0 | | 1.4 | 2.6x10 ⁻² | PFP (+) |
| Carnitine | 2.4 | C7H15INO3 | 1.3 | 1.6x10 ⁻² | Scherzo (+) |
| Acetylcarnitine | 2.5 | | 1.6 | 4.6x10 ⁻² | Scherzo (+) |
| Acetylcarnitine | 2.9 | C ₉ H ₁₇ NO ₄ | 1.2 | 5.1x10 ⁻¹ | PFP (+) |
| Acetylcarnitine | 3.8 | | 1.1 | 5.0x10 ⁻¹ | PFP (+) |
| Propionylcarnitine | 2.9 | | 1.8 | 1.1x10 ⁻¹ | Scherzo (+) |
| Propionylcarnitine | 3.5 | $C_{10}H_{19}NO_4$ | 1.6 | 6.2x10 ⁻² | Scherzo (+) |
| Propionylcarnitine | 6.4 | | 1.5 | 7.9x10 ⁻² | PFP (+) |
| Butyrylcarnitine | 4.5 | | 1.9 | 2.4x10 ⁻³ | Scherzo (+) |
| Butyrylcarnitine | 5.0 | C ₁₁ H ₂₁ NO ₄ | 1.4 | 1.7x10 ⁻¹ | Scherzo (+) |
| Butyrylcarnitine | 8.5 | | 1.6 | 2.3x10 ⁻² | PFP (+) |
| 3-Hydroxybutyrylcarnitine | 2.6 | | 1.5 | 2.2x10 ⁻² | Scherzo (+) |
| 3-Hydroxybutyrylcarnitine | 4.2 | C11H21NO5 | 1.2 | 9.0x10 ⁻² | PFP (+) |
| 2-Methylbutyrylcarnitine | 7.3 | | 1.4 | 2.3x10 ⁻¹ | Scherzo (+) |
| 2-Methylbutyrylcarnitine | 10.3 | C12H23INO4 | 1.8 | 1.6x10 ⁻² | PFP (+) |
| 3-Hydroxyisovaleroylcarnitine | 2.9 | | 1.3 | 9.1x10 ⁻³ | Scherzo (+) |
| 3-Hydroxyisovaleroylcarnitine | 3.5 | $C_{12}H_{23}NO_5$ | 1.0 | 7.9x10 ⁻¹ | Scherzo (+) |
| 3-Hydroxyisovaleroylcarnitine | 6.4 | | 1.1 | 5.6x10 ⁻¹ | PFP (+) |
| Hexanoylcarnitine | 8.9 | | 2.4 | 2.4x10 ⁻² | Scherzo (+) |
| Hexanoylcarnitine | 12.6 | 01311251104 | 2.0 | 3.4x10 ⁻² | PFP (+) |
| Octanoylcarnitine | 11.0 | | 2.7 | 1.5x10 ⁻² | Scherzo (+) |
| Octanoylcarnitine | 15.9 | 01511291004 | 2.3 | 1.1x10 ⁻² | PFP (+) |
| Lauroylcarnitine | 17.7 | | 1.9 | 1.9x10 ⁻² | PFP (+) |
| Lauroylcarnitine | 13.6 | 019113/1104 | 1.7 | 2.2x10 ⁻¹ | Scherzo (+) |
| Palmitoylcarnitine | 16.6 | | 3.5 | 1.0x10 ⁻¹ | Scherzo (+) |
| Palmitoylcarnitine | 17.9 | 0231 1451 104 | 4.8 | 7.3x10 ⁻² | PFP (+) |
| 3-Hydroxyhexadecanoylcarnitine | 15.3 | | 2.5 | 1.6x10 ⁻² | Scherzo (+) |
| 3-Hydroxyhexadecanoylcarnitine | 17.8 | C23H45INO5 | 3.0 | 1.9x10 ⁻² | PFP (+) |
| Linoleoyl carnitine | 17.8 | C ₂₅ H ₄₅ NO ₄ | 2.0 | 1.2x10 ⁻² | PFP (+) |
| Oleoylcarnitine | 16.8 | | 3.1 | 3.1x10 ⁻² | Scherzo (+) |
| Oleoylcarnitine | 17.9 | C25H47NO4 | 2.1 | 2.2x10 ⁻² | PFP (+) |
| 3-Hydroxyoleylcarnitine | 15.7 | C ₂₅ H ₄₇ NO ₅ | 2.9 | 2.5x10 ⁻³ | Scherzo (+) |
| Stearoylcarnitine | 17.9 | | 5.0 | 3.0x10 ⁻¹ | Scherzo (+) |
| Stearoylcarnitine | 17.9 | U201 1491 NU4 | 3.5 | 2.0x10 ⁻¹ | PFP (+) |

Table 2.3 All Identified Acylcarnitines in Colon Samples from All Metabolomic Datasets

To help maximize the coverage of identified colon metabolites, a method based on targeted SWATH acquisition was employed. From the initial peak list generated from raw data, a list of statistically significant features was generated, using *p*-value < 0.01 and fold change > |2| as threshold, yielding 981 peaks of interest. This list was filtered after peaks were verified to ensure adequate peak shape and signal/noise ratio. The remaining 713 features were targeted for SWATH acquisitions to potentially gain more putative metabolite IDs with spectral searching of SWATH data. Using this approach, only four new putative metabolites of interest were found, in which 50 metabolites were previously identified from the IDA data. Metabolites involved in tryptophan and arachidonic metabolism pathways that were not previously identified from the original methods used were searched in the set of significantly changing features by exact mass with the purpose of potentially identifying more putative metabolites. Unfortunately, this strategy did not lead to any new identifications of metabolites from these pathways. N-formyl kynurenine, 3-hydroxy-kynurenine, 3-hydroxy-anthranilate, guinolinic acid, picolinic acid, 5-hydroxytryptophan, N-acetylserotonin, 5-hydroxyindole-acetaldehyde, melatonin, 5-hydroxyindoleacetylglycine and 6-methoxy-indoleacetate are molecules that are part of the tryptophan metabolism pathway but were not identified these datasets. Prostaglandin G2, D2, E2, J2, arachidonic acid, and linolenic acid were metabolites from arachidonic metabolism pathway were searched by exact mass as well but not found in these data either.

2.5.2 Untargeted Quantitative Proteomics

Protein digests from colon and fecal samples were used to assess proteome coverage and verify any region-specific differences on the protein level. Pooled samples, one from each sample group (proximal colon, distal colon, proximal feces, distal feces), were first analysed with data-dependent acquisition (IDA) for protein identification purposes and served as an *"ion library"* (database) for quantitative analysis. Individual samples were injected using data-independent acquisition (SWATH) for peptide quantitation. A total of 1103 and 75 **mouse** proteins were quantified in colon and fecal samples, respectively, as shown in supplemental tables 2.12 and 2.13. The number of quantified mouse proteins in feces were much lower than colon, but this was expected due to the main composition of fecal matter being from microorganisms (Cortes *et al.*, 2019). From these results, metaproteomics was performed and the results and challenges are described following the discussion of proteins from colon tissue samples.

2.5.2.1 Protein Level Differences Between Distal and Proximal Regions in Colon Tissue

Proteins quantified in colon samples with *p*-values below 0.01 and fold changes of 100% were considered as significant between the distal and proximal regions. Of 1103 quantified proteins, 158 proteins were statistically significant, in which 80 and 78 proteins were shown to be increased in the distal and proximal colon, respectively. A heatmap of these proteins can be seen in Figure 2.9a, showing their relative abundances, and distinct patterns between both portions of the colon. Figure 2.9b also shows the difference in number of proteins that are increased in the distal and proximal colon that are implicated in different biological processes in which "Muscle Contraction" was shown to only be mapped from proteins that are increased in distal colon.



Figure 2.9 a) Heatmap with hierarchical clustering of 158 statistically significant mouse proteins from proximal and distal colon tissue, and b) the number of these proteins increased in each region involved in different pathways.

The online software Reactome was used to perform pathway analysis on these changing proteins (Fabregat *et al.*, 2017). When proteins increased in the distal region were considered, pathways involved in the immune response were enriched. As seen in Table 2.4, sixteen of these proteins are directly implicated in the innate immune system and more specifically, eleven of these are implicated in neutrophil degranulation. Neutrophils, which are a type of leukocyte, are important cells for the elimination of pathogens and invading microbes, although their activation can often

cause extensive inflammation (Lehman et Segal, 2020). These proteins could play a role in chronic inflammation found particularly in intestinal diseases that are localized in the distal colon, such as ulcerative colitis and Hirschsprung's disease (James et al., 2008; Koutroubakis, 2010; Soret et al., 2020). They could also be of interest for inflammatory bowel diseases that are expressed mainly in one region of the colon, using the unaffected region as a potential control. Although proteins involved in axon guidance are found in both regions (Table 2.4), this pathway has more proteins elevated in the distal region, with ten proteins compared to only five in the proximal region. Axon guidance involves an array of different cytoskeletal proteins, such as microtubules and actin filaments that make up the axon growth cone, the area at the tip of an axon that is responsible for detecting environmental cues, demonstrating that neuronal signalling in the gut could be region specific (Dent et al., 2011; Russell et Bashaw, 2018). Proteins involved in keratinization were increased in the proximal colon. This is a pertinent finding as keratins tend to play an important role in the intestine even though their exact mechanisms are not clearly defined. Of the 8 keratin proteins quantified, cytoskeletal keratin type II 8, 18, 19, and 20 (K8, K18, K19, and K20) have been reported to be expressed in the intestines (Corfe et al., 2015; Majumdar et al., 2012; Mun et al., 2022). Keratins are important filament proteins that make up the cytoskeleton allowing the cell to maintain its integrity during stress (Majumdar et al., 2012; Mun et al., 2022). There is growing evidence that keratins and their expression levels, as well as their mutations, correlate with several intestinal diseases such as Crohn's, ulcerative colitis and colorectal cancer, demonstrated by studies showing how mice deficient in K8 develop colonic inflammation similar to IBD (Baribault et al., 1994; Habtezion et al., 2005; Mun et al., 2022). These results demonstrate that keratin proteins are expressed differently within the colon.

Table 2.4 Protein Pathways in Distal and Proximal Colon Regions pertaining to Immune System, Metabolism, Developmental Biology, and Muscle Contraction

| | Pathway | Accession # | Protein Name | Fold Change DC/PC |
|------------------|---|--|--|---|
| | Innate: Neutrophil Degranulation | Q61598 P97430 Q91V92 Q9CQI6 Q8BG32 O08709 P13020 P07356 Q60854 Q9D154 Q9Z0L8 | Rab GDP dissociation inhibitor beta Antileukoproteinase ATP-citrate synthase Coactosin-like protein 26S proteasome non-ATPase regulatory Peroxiredoxin-6 Gelsolin Annexin A2 Serpin B6 Leukocyte elastase inhibitor A Gamma-olutamyl hydrolase | DC/PC 3.2* 4.8** 3.9* 2.1** 3.1* 3** 2.8* 2.8* 2.8* 3* 2.8* 3* 2.8* 4.4** |
| Immune System | Cytokine Signalling: | P15379 P09528 P11983 P10107/P07356 | CD44 antigen Ferritin heavy chain T-complex protein 1 subunit alpha Annexin A1/A2 | -2.4** -7.4** 2.3** 2.2** |
| | Signalling by Interleukins | Q8BG32 | 26S proteasome non-ATPase regulatory | 3.1* |
| | Adaptive: TCR | P62838 | Ubiguitin-conjugating enzyme E2 D2 | 2.1* |
| | Signalling/Class I MHC Mediated Antigen Processing | | | 3.1* |
| | and Presentation | Q8BG32 | 26S proteasome non-ATPase regulatory | |
| | Cytokine Signalling: | Q6NZJ6 | Eukaryotic translation initiation factor 4 gamma 1 | -2.2** |
| | Interforon Signalling | P62960 | Nuclease-sensitive element-binding protein 1 | -2.1** |
| | Interieron Signalling | P15379 | CD44 antigen | -2.4** |
| | | P21550 | Beta-enolase | 7.2* |
| | | P45376 | Aldose reductase | 3.2** |
| | | P16858 | Glyceraldehyde-3-phosphate dehydrogenase | 2 4** |
| | | | Prolargin | 2.1** |
| | Metabolism of Carbohydrates | 062000 | Mimecan | 0.1 2 7* |
| | | | | 2.1 |
| | | Q0K009 | ODP-glucose 4-epimerase | Z.Z |
| | | P61022 | Calcineurin B nomologous protein 1 | -2.3** |
| | | P15379 | CD44 antigen | -2.4** |
| | | P45376 | Aldose reductase | 3.2** |
| | | Q91V92 | ATP-citrate synthase | 3.9* |
| | | Q9D0K2 | Succinyl-CoA:3-ketoacid coenzyme A transferase | 2.3** |
| | Metabolism of Lipids | Q91V12 | Cytosolic acyl coenzyme A thioester hydrolase | 2.5* |
| Metabolism | | Q9DBG5 | Perilipin-3 | -2.5** |
| | | P55050 | Fatty acid-binding protein intestinal | -11 3** |
| | | P62245 | 40S ribosomal protein S15a | 2* |
| | | P27650/P62018 | 60S ribosomal protein L 3/L 8 | 2 1** |
| | Metabolism of Amino Acids | 08BC32 | 26S protessome pon-ATPase regulatory | 2.1 |
| | and derivatives | 000032 | Creating kingge II type mitaghandrial | 3 2 0* |
| | | F 30273 | | 2.3 |
| | | | | <u>-2.3</u> |
| | | PU015/P10125 | | 2.3 |
| | | Q00932 | voltage-dependent anion-selective channel | 2.4 |
| | Citric Acid Cycle (TCA) | P19536/P56391 | Cytochrome c oxidase subunit 5B/6B1 | -2.2** |
| | | P99028 | Cytochrome b-C1 complex subunit 6 | -2.3"" |
| | | P52503 | INAUH denyarogenase iron-sulfur protein 6 | -∠.3 ^{``^} |
| | | Q922F4 | I UDUIIN DETA-6 CNAIN | 2.3 |
| | | Q02788 | Collagen alpha-2(VI) chain | 4.1* |
| | | P62245 | 40S ribosomal protein S15a | 2* |
| Developmental | Axon Guidance | Q9CVB6/P59999 | Actin-related protein 2/3 complex subunit 2/ 4 | 2.1** |
| Biology | | P62962 | Profilin-1 | 3.3** |
| 2.0.097 | | P27659/P62918 | 60S ribosomal protein L3/L8 | 2.1** |
| | | Q8BG32 | 26S proteasome non-ATPase regulatory | 3* |
| | | Q99JY9 | Actin-related protein 3 | 2.6* |

| | | Q6NZJ6 Q6IRU5 Q62261 Q9ES28 Q6URW6 | Eukaryotic translation initiation factor 4 gamma 1 Clathrin light chain B Spectrin beta chain, non-erythrocytic 1 Rho guanine nucleotide exchange factor 7 Myosin-14 | -2.2** -2.4** -2.2** -5.1* -4.1* |
|-------------|-----------------------------|--|--|--|
| | Keratinization | P11679 Q9DCV7 P19001 Q9D312 P05784 | Keratin, type II cytoskeletal 8 Keratin, type II cytoskeletal 7 Keratin, type I cytoskeletal 19 Keratin, type I cytoskeletal 20 Keratin, type I cytoskeletal 18 | -2* -2.7** -2.1** -7.5** -2.9** |
| Muscle | Smooth Muscle Contraction | P63268 P47738 P10107/P07356 | Actin, gamma-enteric smooth muscle Aldehyde dehydrogenase, mitochondrial Annexin A1/A2 | 2.9* 3.2** 2.2** |
| Contraction | Striated Muscle Contraction | P68134 P20801 | Actin, alpha skeletal muscle Troponin C, skeletal muscle | 3.8** 58.2* |

p < 0.01*, *p* < 0.001**

2.5.3 Combining Metabolomic and Proteomic Analyses

Although individual metabolomic and proteomic analyses revealed lots of information regarding metabolites and proteins having regional specificity and clinical significance in colon tissue, a joint pathway analysis combining both types of analyses was performed as well to observe the pathways triggered from a combination of the significant proteins and metabolites. To perform this joint pathway analysis, MetaboAnalyst was used by inputting the 153 and 158 statistically significant metabolites and proteins, respectively. As shown in Figure 2.10, pathways such as pyrimidine metabolism, glycolysis/gluconeogenesis, central carbon metabolism in cancer, and bacterial evasion in epithelial cells were shown to be enriched. Amongst these pathways, pyrimidine metabolism, central carbon metabolism in cancer, cysteine/methionine metabolism, and arginine/proline metabolism were mapped from a combination of metabolites and proteins, whereas glycolysis/gluconeogenesis and bacterial evasion in epithelial cells were shown to be enriched. Amongst these pathways, pyrimidine metabolism, central carbon metabolism in cancer, cysteine/methionine metabolism, and arginine/proline metabolism were mapped from a combination of metabolites and proteins, whereas glycolysis/gluconeogenesis and bacterial evasion in epithelial cells were only mapped from proteins. A diagram showing the proteins and metabolites involved in pyrimidine metabolism are outlined in Figure 2.11, demonstrating that the metabolites and proteins that are involved are being mapped to each node/branch of the overall pathway.



Figure 2.10 Joint pathway analysis of 153 metabolites and 158 proteins significantly changing between distal and proximal colon

| Pathway | Hits | Metabolites | Proteins |
|---------------------------------------|------|---|--|
| Arginine/Proline Metabolism | 6 | S-Adenosyl-L-methionine* Creatine Creatinine Sarcosine | (Accession #) P47738* P30275 |
| Cysteine/Methionine Metabolism | 6 | 5'-Methylthioadenosine; S-Adenosyl-L-methionine L-Methionine S-oxide O-phospho-l-serine | P06151* P16125* |
| ABC Transporters | 8 | I-Glutamine* I-Histidine* sn-glycerol 3 phosphate I-Phenylalanine* Adenosine Uridine* Deoxyuridine* Deoxyadenosine | |
| Bacterial Evasion in Epithelial Cells | 6 | No metabolites | Q80UG5 Q60598 P59999 Q9CVB6 Q9JLQ0 Q6IRU5 |
| Central Carbon Metabolism in Cancer | 7 | I-Glutamine* Citric Acid I-Phenylalanine* I-Histidine* | P06151* P16125* P17710* |
| Glycolysis/Gluconeogenesis | 7 | No metabolites | P17710* P16858 P21550 P16125* P00329 P47738* P06151* |
| Pyrimidine Metabolism | 8 | I-Glutamine* Uridine* Thymine Beta-alanine Deoxyuridine* Orotic Acid | Q8VCE6 P23492 |

Table 2.5 Metabolites and Proteins Mapped to Each Pathway from Joint Pathway Analysis

Within these mapped pathways, several metabolites and proteins were shown to be overlapping across almost all pathways. Although this is the case with metabolites such as glutamine, histidine, and uridine, each pathway contains some metabolites that are unique to each pathway as seen in Table 2.5. Several proteins also show the same patterns of being mapped to several pathways but when observing bacterial evasion in epithelial cells pathway, it is observed that all proteins in this pathway are unique. Regarding the *bacterial evasion in epithelial cells* pathway, the six

proteins that were mapped back to this pathway interestingly don't overlap much with pathways found from the Reactome protein pathway analysis. The only overlap observed is from the subunit 4 of actin related protein 2/3 complex, which mapped to axon guidance from the Reactome pathway analysis, seen in Table 2.4. Additionally, the proteins that mapped to glycolysis/gluconeogenesis correlate with other pathways found from the Reactome pathway analysis. Proteins such as glyceraldehyde-3-dehydrogenase, enolase. and *lactate* dehydrogenase also involved the metabolism of carbohydrates and the TCA cycle from the Reactome pathway analysis (Table 2.4). This crossover between glycolysis/gluconeogenesis. metabolism of carbohydrates and TCA cycle is due to the fact that glycolysis/gluconeogenesis involves the combination of metabolism of carbohydrates and the TCA cycle (Chandel, 2021). This demonstrates the benefits of using various pathway analysis tools to exploit the different results obtained. As opposed to separating proteins and metabolites based on their different expression levels in the distal/proximal colon as previously performed for the earlier pathway analyses, all statistically significant metabolites and proteins were considered when performing this analysis, as it was shown that proteins and metabolites don't necessarily always follow the same trends in expression. For example, a higher amount of a given metabolite could be the result of a low amount of a given protein and vice versa. This is shown for pyrimidine metabolism in which the metabolites are overall lower in the distal colon region, whereas the proteins quantified in this pathway are overall higher in the distal colon region as shown in Table 2.6. Separating the compounds based on their expression levels would likely lead to skewed results as well as the potential loss of information.

| Compound Type | Compound ID | <i>p</i> -value | Fold Change DC/PC | Column (+/-) |
|---------------|---------------------------------|----------------------|----------------------|--------------|
| | Glutamine | 9.0x10 ⁻³ | 1.6 | Scherzo (-) |
| | Uridine | 4.0x10 ⁻³ | -2.1 | Scherzo (-) |
| Matabalita | Thymine | 9.0x10 ⁻³ | -2.4 | Scherzo (+) |
| wietabolite | Beta-alanine | 1.0x10 ⁻⁴ | 1.7 | PFP (-) |
| | Deoxyuridine | 2.6x10 ⁻² | -2.5 | PFP (-) |
| | Orotic acid | 1.3x10 ⁻² | -2.5 | PFP (-) |
| Drotoin | 5'(3')-deoxyribonucleotidase | 2.0x10 ⁻⁷ | 3.2 | Aeris (+) |
| Frotein | Purine nucleoside phosphorylase | 3.0x10 ⁻³ | 2.1 | Aeris (+) |

| Table 2.6 Significant Colo | Proteins and Metabolites | from Pvrimidine Metabolism |
|----------------------------|--------------------------|----------------------------|
| | | |



Figure 2.11 Diagram of Pyrimidine Pathway with Significant Proteins and Metabolites from Colon

2.5.4 Metaproteomics of Fecal Samples

As previously mentioned, quantifying mouse proteins in fecal samples was not very successful, due to fecal proteins originating mainly from microorganisms in the gut (Cortes *et al.*, 2019). Therefore, metaproteomics was performed to further study the microbial proteins and the species from which they originated. There are considerable challenges with performing metaproteomics, due to the high complexity of databases including all possible species. The main goal was to find which peptide signals were able to identify unique bacterial species, and thus assess the differences in these species from the two regions of the colon. Being able to identify unique bacterial species present in the respective fecal samples was only possible on the peptide level rather than the protein level. On the protein level, the same protein quantified would often come from multiple bacterial species, complicating any possible conclusions that could be made for the

distribution of bacterial species. This indicates that these bacterial species can only be distinguished by the specific unique peptide sequence of a given protein being quantified. Table 2.7 summarizes the bacterial species being identified with the associated protein and peptides from IDA acquisition. This table exemplifies how many quantified proteins are common across various bacterial species, but the peptides that were used to identify these proteins are unique.

Once peptides of interest were selected and associated to specific bacterial species (Table 2.7), individual samples analysed with SWATH acquisition were used for quantitation purposes. The fact that a peptide was uniquely identified by IDA in the sample from distal feces and not the proximal sample, does not mean that the species was found uniquely in that region, as the SWATH data confirms. From these results, it is evident that these peptides did not show regional specificity. In fact, looking at the heatmap of the resulting peptide intensities throughout the sample set (Figure 2.12), it clearly shows that there are no species clearly distinguishing distal and proximal fecal samples, which is not surprising in the context of a healthy colon without the presence of disease in a specific region.



Figure 2.12 Distribution of peptides from bacterial species between distal and proximal fecal samples from SWATH quantitative analysis

The data-dependent approach selects precursors of the highest intensity for MS/MS acquisition, whereas the SWATH approach utilizes varying mass windows and all precursors within the given mass window will get fragmented for MS/MS (Li *et al.*, 2021), therefore SWATH ensures that if a peptide is detectable over a minimal signal-to-noise threshold, it can be quantified in all samples in the dataset. These results stress the fact that IDA data is not quantitative if relying of peptide identification by acquired MS/MS (Barkovits *et al.*, 2020).

| Species Code | Species | Protein | Peptide | ID from: |
|---------------|---|--|-------------------|-------------|
| AGARV | Agathobacter rectalis | 30S ribosomal protein S10 | NGSQVSGPVPLPTK | DF/PF |
| | | 30S ribosomal protein S9 | DIDEYLGLETLK | DF |
| | | 50S ribosomal protein L5 | IVVNMGVGEAK | DF |
| | | Chaperonin GroEL | DLVEGMQFDR | DF |
| | | | TELDLVEGMQFDR | DF |
| | | 30S ribosomal protein S19 | KGPFADESLLK | PF |
| | | | STIFPSFVGH | PF |
| | | 30S ribosomal protein S3 | ADIDYGFAEADTTYGK | PF |
| | | 50S ribosomal protein L15 | SGAPRPGFEGGQMPL | PF |
| | | Elongation factor Tu | CDMVDDPELI | PF |
| | | | CMPGDNVEMTI | PF |
| | | | TVVTGIEMFR | PF |
| ACET2 | Acetivibrio thermocellus | 50S ribosomal protein L1 | IQNENWFEFDVV | PF |
| ALISL | Aliivibrio salmonicida | Multifunctional CCA protein | DLTINAIAQSDK | DF |
| ANAPI | Anaerotignum propionicum | Acryloyl-CoA reductase electron transfer subunit gamma | QAIDGDTAQVGPQIAEK | DF/PF |
| | | | VAVNPDGTLNR | PF |
| BACME | Bacillus megaterium | Sirohydrochlorin ferrochelatase | DLNEIAQLLK | DF/PF |
| CLOSY | Clostridium symbiosum | Pyruvate, phosphate dikinase | LAVTYPEIAK | DF/PF |
| | | | NAQGEDVVAGVR | DF/PF |
| | | | SLDQLLHPT | DF/PF |
| | | | ASMPGMMDTIL | PF |
| COREF*/CORGL* | Corynebacterium efficiens*/glutamicum* | NADP-specific glutamate dehydrogenase | NSLTGLPIGGGK | DF |
| BACLD | Bacillus licheniformis | Elongation factor Tu | LLDYAEAGDNIGALLR | PF |
| CYTH3 | Cytophaga hutchinsonii | 50S ribosomal protein L11 | SFDFVVK | DF |
| | | 50S ribosomal protein L7/L12 | DLVDGAPK | PF |
| | | | QLEEAGAEVEIK | PF |

Table 2.7 Bacterial Species and their Unique Peptides Identified in Distal and Proximal fecal Samples from IDA data

| | CLOB8 | Clostridium beijerinckii | 50S ribosomal protein L5 | EQLIFPEIEYDKIDKV | DF/PF |
|--|--|----------------------------|---|---------------------|-------|
| | | | | IVINMGVGEAK | DF/PF |
| | GEOUR | Geobacter uraniireducens | Glycogen synthase | TGGLADVTAALPK | DF/PF |
| | LACE2 | Lachnospira eligens | Chaperonin GroEL | IIAEDVEGEALT | DF/PF |
| | | | | LLIIAEDVEGEAL | PF |
| | | | | SALQNATSVASTLL | PF |
| | | | Elongation factor Tu | ALEDPNSEWGDK | DF/PF |
| | LACP7 Lachnoclostridium phytofermentans | 30S ribosomal protein S10 | LIDIIAPTQK | DF/PF | |
| | | | 50S ribosomal protein L23 | YYDVILKPIVTEK | DF/PF |
| | | | ATP synthase subunit alpha | MNLRPEEISSVIK | DF/PF |
| | | | | AIDSMVPIGR | PF |
| | | | | SVDTPLQTGIK | PF |
| | | | 30S ribosomal protein S10 | LIDIIAPTQK | DF/PF |
| | | | 30S ribosomal protein S11 | ALQACGIEVTSIK | PF |
| | | | 50S ribosomal protein L23 | YYDVILKPIVTEK | DF/PF |
| | | | ATP synthase subunit beta | SIVELGIYPAVDPLESTSR | PF |
| | | | | VVDLLCPYQK | PF |
| | | | Chaperonin GroEL | AAVEEGIIAGGGSAY | PF |
| | | | | IIAEDIEGEAL | PF |
| | | | | SFGAPLITNDGVTIAK | PF |
| | | | | TMQTELDLVEGMQFDR | PF |
| | | | Elongation factor Tu | LLDEAQAGDNIGALLR | PF |
| | | | | NKPHCNIGTI | PF |
| | OCEIH | Oceanobacillus iheyensis | 30S ribosomal protein S7 | LANEILDASNNTGAAVK | DF/PF |
| | | | Ribonuclease HIII | AKTNNAVITAYQSGK | PF |
| | PARD8 | Parabacteroides distasonis | 50S ribosomal protein L11 | GGAANPSPPVGPALGSK | PF |
| | | | 50S ribosomal protein L7/L12 | QLEEAGAEVELK | DF/PF |
| | | | Phosphoenolpyruvate carboxykinase (ATP) | VINLDKESEPDIY | DF/PF |
| | | | | ALVAAGPQL | DF |

| | | Elongation factor Tu | KLLDQGEAGDNVGL | DF |
|--|---|--|---|--|
| | | | LLDQGEAGDNVGLLL | DF |
| | | | SFDSIDNAPEEK | DF |
| | | 50S ribosomal protein L2 | GVVMNPVDHPMGGGEGR | DF |
| RUMCH | Ruminiclostridium cellulolyticum | 30S ribosomal protein S9 | GGGFTGQAGAIR | DF/PF |
| | - | | SLDDYFGLETLK | DF/PF |
| | | Elongation factor G | ANPVLLEPIMK | PF |
| BACFR | Bacteroides fragilis | Phosphoenolpyruvate carboxykinase (ATP) | FDFVVPTELPGVDPK | PF |
| | | 50S ribosomal protein L7/L12 | DMVDGAPSVVK/TLEEAGAEVELK | DF |
| CLOPE/CLOP1/CLOPS | Clostridium perfringens | 50S ribosomal protein L5 | EQLIFPEIEYDKVDKV | DF/PF |
| | | | VVINMGVGEAK | DF/PF |
| | | Phosphoglycerate kinase | CDFNVPLK | DF/PF |
| | | | MSHISTGGGASLEFLEGK | DF/PF |
| | | | STGGGASLEFLEGK | DF/PF |
| | | | SLEFLEGK | DF |
| CLOTE | Clostridium tetani | Triosephosphate isomerase | LVIAYEPIWAIGTGK | DF/PF |
| | | | | DE |
| CORGL | Corynebacterium glutamicum | NADP-specific glutamate dehydrogenase | FLGFEQIFK | PF |
| CORGL | Corynebacterium glutamicum | NADP-specific glutamate dehydrogenase | FLGFEQIFK NSLTGLPIGGGK | DF |
| CORGL | Corynebacterium glutamicum Escherichia coli | NADP-specific glutamate dehydrogenase Uncharacterized ABC transporter ATP- binding protein YcjV | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV | DF PF |
| CORGL | Corynebacterium glutamicum Escherichia coli | NADP-specific glutamate dehydrogenase Uncharacterized ABC transporter ATP- binding protein YcjV | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV DFNLEIADK | DF PF DF/PF |
| CORGL | Corynebacterium glutamicum Escherichia coli | NADP-specific glutamate dehydrogenase Uncharacterized ABC transporter ATP- binding protein YcjV | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV DFNLEIADK MDEPLSNLDAK | DF PF DF/PF DF/PF |
| CORGL | Corynebacterium glutamicum Escherichia coli | NADP-specific glutamate dehydrogenase Uncharacterized ABC transporter ATP- binding protein YcjV | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV DFNLEIADK MDEPLSNLDAK FVGPSGCGK | DF PF DF/PF DF/PF DF/PF |
| CORGL ECOLI PORGI*/PORG3* | Corynebacterium glutamicum Escherichia coli Porphyromonas gingivalis | NADP-specific glutamate dehydrogenase Uncharacterized ABC transporter ATP- binding protein YcjV Phosphoenolpyruvate carboxykinase (ATP) | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV DFNLEIADK MDEPLSNLDAK FVGPSGCGK SADAFGVLPPVSILTPEQTK | DF PF DF/PF DF/PF DF PF |
| CORGL ECOLI PORGI*/PORG3* | Corynebacterium glutamicum Escherichia coli Porphyromonas gingivalis | NADP-specific glutamate dehydrogenase Uncharacterized ABC transporter ATP-binding protein YcjV Phosphoenolpyruvate carboxykinase (ATP) 30S ribosomal protein S14 | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV DFNLEIADK MDEPLSNLDAK FVGPSGCGK SADAFGVLPPVSILTPEQTK EMASAGLIPGVK | DF PF DF/PF DF/PF DF PF DF |
| CORGL ECOLI PORGI*/PORG3* STRP6/STRP8/STRPQ | Corynebacterium glutamicum Escherichia coli Porphyromonas gingivalis Streptococcus pyogenes | NADP-specific glutamate dehydrogenase Uncharacterized ABC transporter ATP- binding protein YcjV Phosphoenolpyruvate carboxykinase (ATP) 30S ribosomal protein S14 Glyceraldehyde-3-phosphate dehydrogenase | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV DFNLEIADK MDEPLSNLDAK FVGPSGCGK SADAFGVLPPVSILTPEQTK EMASAGLIPGVK AGAANIVPNSTGAAK | PF DF PF DF/PF DF/PF DF PF DF/PF |
| CORGL ECOLI PORGI*/PORG3* STRP6/STRP8/STRPQ | Corynebacterium glutamicum Escherichia coli Porphyromonas gingivalis Streptococcus pyogenes | NADP-specific glutamate dehydrogenaseUncharacterized ABC transporter ATP- binding protein YcjVPhosphoenolpyruvate carboxykinase (ATP)30S ribosomal protein S14Glyceraldehyde-3-phosphate dehydrogenase | FLGFEQIFK NSLTGLPIGGGK ALYPHMTV DFNLEIADK MDEPLSNLDAK FVGPSGCGK SADAFGVLPPVSILTPEQTK EMASAGLIPGVK AGAANIVPNSTGAAK AIGLVIPELNGK | PF DF PF DF/PF DF/PF DF PF DF DF/PF DF/PF |
| | | | TGDQMILDGPHR | DF |
|---------------|--|--|-----------------|----|
| SPITD | Spirochaeta thermophila | Pyrophosphatefructose 6-phosphate 1- phosphotransferase | NTGGFDIIGSGR | DF |
| BACTN | Bacteroides thetaiotaomicron | 30S ribosomal protein S7 | ALDNVTPQVEVK | DF |
| | | Phosphoenolpyruvate carboxykinase ATP | ALVAAGPK | DF |
| | | | DFVVPTELPGVDPK | DF |
| | | | GIIDAILDGSIDK | DF |
| | | | VINLDKESEPDI | DF |
| PROM4 | Prochlorococcus marinus | Enolase | VNQIGSLTETL | DF |
| SELRU | Selenomonas ruminantium | Phosphoenolpyruvate carboxykinase ATP | GVLPPVSILTPEQTK | DF |
| SHEAM*/SHELP* | Shewanella amazonensis/loihica | 50S ribosomal protein L7/L12 | ELEEAGAQVEIK | DF |
| SYNJB | Synechococcus sp. | 50S ribosomal protein L3 | LGGGRVTTRK | DF |
| SYNS3 | Synechococcus sp. | Ketol-acid reductoisomerase NADP+ | ILSDIQDGTFAK | DF |
| THEP3 | Thermoanaerobacter pseudethanolicus | 50S ribosomal protein L17 | LFDEIAPK | DF |
| LACDB | Lactobacillus delbrueckii | Phosphoglycerate kinase | IVAALPTIK | DF |
| FLAJ1 | Flavobacterium johnsoniae | 30S ribosomal protein S8 | VVEIPASNLK | DF |
| PSEAE | Pseudomonas aeruginosa | 30S ribosomal protein S8 | SMQDPLADMLTR | PF |
| FUSNN | Fusobacterium nucleatum subsp. nucleatum | Chaperonin GroEL | EIELEDPFENMGA | PF |
| | | | VGAATEVEMK | PF |
| CORDI | Corynebacterium diphtheriae | 50S ribosomal protein L14 | IVSLAPEVI | PF |
| CLOBB | Clostridium botulinum | Chaperone protein DnaK | GIPQIEVTF | PF |
| | | | IIGIDLGTTN | PF |
| | | | LGGDDFDQK | PF |
| SYNY3 | Synechocystis sp. | Putative nickel insertion protein | VGLGAGSK | PF |
| LEPBP | Leptospira biflexa serovar Patoc | Elongation factor Tu | AYDQIDNAPEEK | PF |
| | | | SVVTGIEMFR | PF |

| LEUMM*/LEUCK* | Leuconostoc mesenteroides/citreum | Phosphoglycerate kinase | TVVWNGPMGV | PF |
|---------------|---------------------------------------|--------------------------------|-----------------------|----|
| LISIN*/LISMO* | Listeria innocua/monocytogenes | 30S ribosomal protein S9 | GGGYTGQAGAIR | PF |
| LACLM | Lactococcus lactis subsp. Cremoris | Chaperonin GroEL | TELDVVEGMQFDR | PF |
| | | | VGSDGVITIEESK | PF |
| DEHMC | Dehalococcoides mccartyi | 30S ribosomal protein S12 | GTLDTAGVANR | PF |
| DICTD | Dictyoglomus turgidum | Chaperonin GroEL | EIDLEDPFENMGAQLVK | PF |
| CARHZ | Carboxydothermus hydrogenoformans | Formatetetrahydrofolate ligase | AINPTPAGEGK | PF |
| | | | GGAAGGGYAQVVPMEDINLH | PF |
| | | | LILVTAINPTPAGEGK | PF |
| CELJU | Cellvibrio japonicus | 50S ribosomal protein L3 | VTVQNLEIVR | PF |
| CLOAB | Clostridium acetobutylicum | 50S ribosomal protein L11 | ATPAPPVGPALGQHGV | PF |
| | | | MPDLNAASLEAAMSMIAGTAR | PF |
| | | | TPPAAVLIK | PF |

*Peptide quantified sourced back to two species of the same family

Fecal samples represent a very complex matrix, where there is the potential of high background signal being produced and consequently these background signals could get mistakenly integrated if not properly verified, and therefore this should be considered for future studies. Manual peptide verification can be employed to ensure proper peak integration and more accurate statistical analysis. Although, no major differences in bacterial species were seen when the two regions were compared in these healthy mice, the results from this metaproteomics analysis were able to provide unique peptides for 47 different bacterial species, useful for quantitative analyses in the context of microbiome dysbiosis in subsequent studies.

2.6 Conclusion

Untargeted analyses allowed for extensive metabolome and proteome coverage in colon and fecal samples from healthy mice. Statistical analysis revealed high metabolite and protein differences between the distal and proximal colon regions, and less so on the fecal level, highlighting baseline differences that can be seen between the two regions in healthy subjects. By compiling the metabolites and proteins showing regional specificity within the colon highlights certain molecular pathways of interest in future studies involving various diseases affecting the gut and can help thus further understand mechanisms involved and if distinctive regions are implicated.

Metaproteomics was performed on fecal samples with the goal of characterizing which species can be quantified using this data as well as to verify if certain bacterial species were localized preferentially in one region. Although this proved to be a great challenge, partly due to the complexity of fecal samples, bacterial identification was achieved for 47 species.

Despite the limitations and challenges presented, this study demonstrated the high heterogeneity present within the gut of healthy mice offering a better understanding of the baseline changes expected within the colon prior to the introduction of diseases. This analysis also yielded extensive characterization of the metabolome and proteome in colon and feces that will be useful for subsequent studies involving perturbations in the gut in the context of disease or nutrition.

2.7 Supplemental Tables

Table 2.8 Putative Colon Metabolite Identifications Compiled from Four Untargeted Metabolomic Datasets

| Putative ID | Retention | Chemical | Found at | Exact | Mass | Column (+/-) |
|--|------------|------------|---------------------|----------------|-------|--------------|
| | Time (min) | Formula | Mass (<i>m/z</i>) | Mass | Error | |
| | () | | () | (<i>m/z</i>) | (ppm) | |
| (-)-Homoeriodictyol | 14.2 | C16H14O6 | 303.0865 | 303.0863 | -0.6 | Scherzo (+) |
| (-)-N-Acetylneuraminic acid | 2.1 | C11H19NO9 | 308.0992 | 308.0987 | -1.6 | PFP (-) |
| (-)-N-Acetylneuraminic acid | 5.5 | C11H19NO9 | 310.1147 | 310.1133 | -4.6 | Scherzo (+) |
| (-)-N-Acetylneuraminic acid | 5.6 | C11H19NO9 | 308.0995 | 308.0987 | -2.6 | Scherzo (-) |
| (-)-N-Acetylneuraminic acid | 1.9 | C11H19NO9 | 310.1136 | 310.1133 | -1.1 | PFP (+) |
| (-)-N-Acetylneuraminic acid | 2.1 | C11H19NO9 | 310.1141 | 310.1133 | -2.7 | PFP (+) |
| (-)-Quinic acid | 3.4 | C7H12O6 | 191.0561 | 191.0561 | 0.1 | Scherzo (-) |
| (-)-Quinic acid | 3.6 | C7H12O6 | 191.0567 | 191.0561 | -3.1 | Scherzo (-) |
| (+-)-2-Hydroxyisocaproic acid | 9.4 | C6H12O3 | 131.0712 | 131.0714 | 1.3 | PFP (-) |
| (+-)-2-Hydroxyisocaproic acid | 9.9 | C6H12O3 | 131.0710 | 131.0714 | 2.8 | PFP (-) |
| (+-)-2-Hydroxyisocaproic acid | 10.1 | C6H12O3 | 131.0714 | 131.0714 | -0.2 | Scherzo (-) |
| (+-)7-epi-Jasmonic acid | 9.6 | C12H18O3 | 211.1326 | 211.1329 | 1.3 | Scherzo (+) |
| (+-)7-epi-Jasmonic acid | 12.3 | C12H18O3 | 211.1328 | 211.1329 | 0.3 | PFP (+) `´ |
| (+)2Hydroxy3methylbutyric acid | 5.7 | C5H10O3 | 117.0557 | 117.0557 | 0.2 | PFP (-) |
| 1-(1Z-Hexadecenyl)-sn-glycero-3-phosphocholine | 14.4 | C24H50NO6P | 480.3438 | 480.3449 | 2.2 | Scherzo (+) |
| 1-beta-D-Arabinofuranosyluracil 5'-monophosphate | 2.8 | C9H13N2O9P | 323.0301 | 323.0286 | -4.7 | PFP (-) |
| 1-beta-D-Arabinofuranosyluracil 5'-monophosphate | 13.0 | C9H13N2O9P | 323.0297 | 323.0286 | -3.4 | Scherzo (-) |
| 1-beta-D-Arabinofuranosyluracil 5'-monophosphate | 2.8 | C9H13N2O9P | 325.0424 | 325.0432 | 2.3 | PFP (+) |
| 1-Ethyl-3-piperidinamine | 2.0 | C7H16N2 | 129.1385 | 129.1386 | 1.0 | Scherzo (+) |
| 1-Ethyl-3-piperidinamine | 3.3 | C7H16N2 | 129.1386 | 129.1386 | 0.2 | PFP (+) |
| 1-Methyl-L-histidine | 1.9 | C7H11N3O2 | 170.0922 | 170.0924 | 1.2 | PFP (+) |
| 1-Methyladenosine | 2.6 | C11H15N5O4 | 282.1202 | 282.1197 | -1.8 | Scherzo (+) |
| 1-Methyladenosine | 2.7 | C11H15N5O4 | 282.1199 | 282.1197 | -0.8 | PFP (+) `´ |
| 1-Methyladenosine | 6.7 | C11H15N5O4 | 282.1206 | 282.1197 | -3.3 | Scherzo (+) |
| 1-Methyladenosine | 6.8 | C11H15N5O4 | 282.1199 | 282.1197 | -0.8 | PFP (+) `´ |
| 1-Methylhistamine | 2.3 | C6H11N3 | 126.1021 | 126.1026 | 3.7 | Scherzo (+) |
| 1-Methyluric acid | 7.0 | C6H6N4O3 | 181.0369 | 181.0367 | -1.0 | Scherzo (-) |
| 1-Methylxanthine | 7.4 | C6H6N4O2 | 167.0563 | 167.0564 | 0.3 | Scherzo (+) |
| 1-Methylxanthine | 7.1 | C6H6N4O2 | 167.0563 | 167.0564 | 0.3 | PFP (+) `´ |
| 1-Myristoyl-2-hydroxy-sn-glycero-3- | 16.1 | C19H40NO7P | 426.2623 | 426.2615 | -1.8 | Scherzo (+) |
| phosphoethanolamine | | | | | | |
| 1-Myristoyl-2-hydroxy-sn-glycero-3- | 16.2 | C19H40NO7P | 424.2472 | 424.2470 | -0.5 | Scherzo (-) |
| phosphoethanolamine | | | | | | |
| 1-Myristoyl-sn-glycero-3-phosphocholine | 16.6 | C22H46NO7P | 468.3093 | 468.3085 | -1.8 | Scherzo (+) |
| 1-Naphthalenamine | 7.8 | C10H9N | 144.0802 | 144.0808 | 4.0 | Scherzo (+) |
| 1-Naphthalenamine | 9.4 | C10H9N | 144.0805 | 144.0808 | 1.9 | PFP (+) `´ |
| 1-Oleoyl-sn-glycero-3-phosphocholine | 14.9 | C26H52NO7P | 522.3562 | 522.3554 | -1.5 | Scherzo (+) |
| 1-Oleoyl-sn-glycero-3-phosphoethanolamine | 16.3 | C23H46NO7P | 478.2942 | 478.2939 | -0.6 | Scherzo (-) |
| 1-Palmitoyl-2-hydroxy-sn-glycero-3- | 15.0 | C21H44NO7P | 454.2932 | 454.2928 | -0.8 | Scherzo (+) |
| phosphoethanolamine | | | | | | ~ / |

| 1-Palmitoyl-2-hydroxy-sn-glycero-3- | 15.2 | C21H44NO7P | 452.2779 | 452.2783 | 0.8 | Scherzo (-) |
|--|------|--------------|----------|----------|------|-------------|
| 1 Polmitoul 2 hydroxy on glygoro 2 | 17 / | | 452 2770 | 150 0700 | 0.0 | Soborzo () |
| phosphoethanolamine | 17.4 | 62 IN44N07 F | 452.2779 | 452.2705 | 0.0 | Scherzo (-) |
| 1-Pentadecanoyl-sn-glycero-3-phosphocholine | 17.6 | C23H48NO7P | 482.3248 | 482.3241 | -1.4 | PFP (+) |
| 1,11-Undecanedicarboxylic acid | 15.9 | C13H24O4 | 243.1609 | 243.1602 | -3.0 | Scherzo (-) |
| 1,11-Undecanedicarboxylic acid | 17.8 | C13H24O4 | 243.1604 | 243.1602 | -0.9 | PFP (-) |
| 1,2-Dimethylimidazole | 2.7 | C5H8N2 | 97.0760 | 97.0760 | 0.2 | PFP (+) |
| 1,3-Cyclohexanedicarboxylic acid | 9.5 | C8H12O4 | 171.0662 | 171.0663 | 0.5 | PFP (-) |
| 1,3-Cyclohexanedicarboxylic acid | 12.4 | C8H12O4 | 171.0665 | 171.0663 | -1.3 | PFP (-) |
| 1,3-Dicyclohexylurea | 16.4 | C13H24N2O | 225.1962 | 225.1961 | -0.3 | Scherzo (+) |
| 1,3,5-Benzenetriol | 8.5 | C6H6O3 | 127.0386 | 127.0390 | 2.9 | Scherzo (+) |
| 1,5-Diaminonaphthalene | 7.8 | C10H10N2 | 159.0916 | 159.0917 | 0.4 | Scherzo (+) |
| 1,5-Diaminonaphthalene | 9.4 | C10H10N2 | 159.0919 | 159.0917 | -1.4 | PFP (+) `´ |
| 1,5-Isoquinolinediol | 9.4 | C9H7NO2 | 162.0549 | 162.0550 | 0.4 | Scherzo (+) |
| 1,5-Isoquinolinediol | 10.2 | C9H7NO2 | 162.0551 | 162.0550 | -0.9 | PFP (+) |
| 1,5-Isoquinolinediol | 12.5 | C9H7NO2 | 162.0549 | 162.0550 | 0.4 | PFP (+) |
| 10-Formyl-7,8-dihydrofolic acid | 9.3 | C20H21N7O7 | 472.1578 | 472.1575 | -0.6 | Scherzo (+) |
| 10-Formyl-7,8-dihydrofolic acid | 9.4 | C20H21N7O7 | 470.1444 | 470.1430 | -3.0 | Scherzo (-) |
| 10-Formyl-7,8-dihydrofolic acid | 10.1 | C20H21N7O7 | 470.1453 | 470.1430 | -5.0 | PFP (-) |
| 10-Formyl-7,8-dihydrofolic acid | 10.1 | C20H21N7O7 | 472.1587 | 472.1575 | -2.5 | PFP (+) |
| 10E,12Z-octadecadienoic acid | 16.6 | C18H32O2 | 281.2474 | 281.2475 | 0.4 | Scherzo (+) |
| 11(12)-Epoxy-5Z,8Z,14Z-eicosatrienoic acid | 18.0 | C20H32O3 | 319.2282 | 319.2279 | -1.0 | PFP (-) |
| 12,13-Dihydroxy-9Z-octadecenoic acid | 14.3 | C18H34O4 | 315.2526 | 315.2530 | 1.2 | Scherzo (+) |
| 12,13-Dihydroxy-9Z-octadecenoic acid | 17.1 | C18H34O4 | 315.2534 | 315.2530 | -1.3 | Scherzo (+) |
| 12,13-Dihydroxy-9Z-octadecenoic acid | 17.9 | C18H34O4 | 313.2380 | 313.2384 | 1.4 | PFP (-) |
| 12,13-Dihydroxy-9Z-octadecenoic acid | 17.9 | C18H34O4 | 315.2522 | 315.2530 | 2.5 | PFP (+) |
| 12(13)-Epoxy-9Z-octadecenoic acid | 17.9 | C18H32O3 | 295.2291 | 295.2279 | -4.2 | PFP (-) |
| 12S-Hydroxy-5Z,8E,10E-heptadecatrienoic acid | 17.8 | C17H28O3 | 279.1973 | 279.1966 | -2.6 | Scherzo (-) |
| 12S-Hydroxy-5Z,8E,10E-heptadecatrienoic acid | 17.9 | C17H28O3 | 279.1979 | 279.1966 | -4.8 | PFP (-) |
| 13,14-Dihydro-15-ketoprostaglandin A2 | 15.4 | C20H30O4 | 333.2076 | 333.2071 | -1.4 | Scherzo (-) |
| 13,14-Dihydro-15-ketoprostaglandin A2 | 16.8 | C20H30O4 | 335.2223 | 335.2217 | -1.8 | Scherzo (+) |
| 13,14-Dihydro-15-ketoprostaglandin A2 | 16.8 | C20H30O4 | 333.2080 | 333.2071 | -2.6 | Scherzo (-) |
| 15-Deoxy-DELTA12,14-prostaglandin J2 | 17.1 | C20H28O3 | 315.1969 | 315.1966 | -1.0 | Scherzo (-) |
| 17alpha-Nandrolone | 17.5 | C18H26O2 | 275.2008 | 275.2006 | -0.9 | PFP (+) |
| 1H-Indole-3-propanoic acid | 13.6 | C11H11NO2 | 190.0865 | 190.0863 | -1.3 | Scherzo (+) |
| 1H-Indole-3-propanoic acid | 15.8 | C11H11NO2 | 188.0726 | 188.0717 | -4.8 | PFP (-) |
| 1H-Indole-3-propanoic acid | 15.8 | C11H11NO2 | 190.0866 | 190.0863 | -1.8 | PFP (+) |
| 1H-Indole-3-propanoic acid | 16.5 | C11H11NO2 | 190.0858 | 190.0863 | 2.4 | PFP (+) |
| 1H-Indole-4-carboxaldehyde | 7.8 | C9H7NO | 146.0598 | 146.0600 | 1.6 | Scherzo (+) |
| 1H-Indole-4-carboxaldehyde | 9.6 | C9H7NO | 146.0598 | 146.0600 | 1.6 | Scherzo (+) |
| 1H-Indole-4-carboxaldehyde | 12.3 | C9H7NO | 146.0596 | 146.0600 | 3.0 | Scherzo (+) |
| 1H-Indole-4-carboxaldehyde | 10.6 | C9H7NO | 146.0601 | 146.0600 | -0.4 | PFP (+) |
| 2-Amino-1-naphthol | 3.9 | C10H9NO | 160.0747 | 160.0757 | 6.2 | Scherzo (+) |
| 2-Amino-1-naphthol | 9.2 | C10H9NO | 160.0757 | 160.0757 | -0.1 | Scherzo (+) |

| 2-Amino-1-naphthol | 6.1 | C10H9NO | 160.0757 | 160.0757 | -0.1 | PFP (+) |
|---|------|-------------|----------|----------|------|-------------|
| 2-Amino-1-naphthol | 9.9 | C10H9NO | 160.0758 | 160.0757 | -0.7 | PFP (+) |
| 2-Aminoadipic acid | 2.6 | C6H11NO4 | 160.0620 | 160.0615 | -2.9 | Scherzo (-) |
| 2-Aminocaprylic acid | 10.5 | C8H17NO2 | 160.1328 | 160.1332 | 2.6 | PFP (+) |
| 2-Deoxyguanosine 5-monophosphate | 11.4 | C10H14N5O7P | 346.0564 | 346.0558 | -1.7 | Scherzo (-) |
| 2-Deoxyribose 5-phosphate | 9.5 | C5H11O7P | 213.0169 | 213.0170 | 0.3 | Scherzo (-) |
| 2-Dimethylamino-6-hydroxypurine | 5.0 | C7H9N5O | 180.0874 | 180.0880 | 3.3 | Scherzo (+) |
| 2-Dimethylamino-6-hydroxypurine | 7.4 | C7H9N5O | 180.0879 | 180.0880 | 0.5 | Scherzo (+) |
| 2-Dimethylamino-6-hydroxypurine | 5.9 | C7H9N5O | 180.0881 | 180.0880 | -0.6 | PFP (+) |
| 2-Dimethylamino-6-hydroxypurine | 8.3 | C7H9N5O | 180.0884 | 180.0880 | -2.3 | PFP (+) |
| 2-Hydroxy-3-methoxybenzoic acid | 10.0 | C8H8O4 | 167.0356 | 167.0350 | -3.7 | Scherzo (-) |
| 2-Hydroxy-3-methoxybenzoic acid | 11.6 | C8H8O4 | 167.0348 | 167.0350 | 1.1 | PFP (-) |
| 2-Hydroxyglutaric acid | 4.4 | C5H8O5 | 147.0307 | 147.0299 | -5.4 | Scherzo (-) |
| 2-Hydroxyibuprofen | 17.3 | C13H18O3 | 221.1187 | 221.1183 | -1.7 | PFP (-) |
| 2-Hydroxyoctanoic acid | 15.5 | C8H16O3 | 159.1026 | 159.1027 | 0.4 | PFP (-) |
| 2-Isopropylmalic acid | 8.4 | C7H12O5 | 175.0611 | 175.0612 | 0.6 | PFP (-) |
| 2-Ketohexanoic acid | 9.2 | C6H10O3 | 129.0558 | 129.0557 | -0.6 | PFP (-) |
| 2-Methoxybenzoic acid | 10.1 | C8H8O3 | 151.0401 | 151.0401 | -0.2 | PFP (-) |
| 2-Methyl-3-ketovaleric acid | 8.3 | C6H10O3 | 129.0558 | 129.0557 | -0.6 | PFP (-) |
| 2-Methylbutyryl-L-carnitine | 7.3 | C12H23NO4 | 246.1706 | 246.1700 | -2.5 | Scherzo (+) |
| 2-Methylbutyryl-L-carnitine | 10.3 | C12H23NO4 | 246.1708 | 246.1700 | -3.3 | PFP (+) |
| 2-Nitrophenol | 13.0 | C6H5NO3 | 138.0201 | 138.0197 | -3.1 | Scherzo (-) |
| 2-Phenylacetamide | 3.8 | C8H9NO | 136.0757 | 136.0757 | -0.1 | Scherzo (+) |
| 2-Phenylacetamide | 3.0 | C8H9NO | 136.0759 | 136.0757 | -1.5 | PFP (+) |
| 2-Piperidinone | 6.6 | C5H9NO | 100.0758 | 100.0757 | -1.1 | PFP (+) |
| 2-tert-Butyl-p-quinone | 17.1 | C10H12O2 | 165.0909 | 165.0910 | 0.7 | Scherzo (+) |
| 2,2-Dimethylglutaric acid | 10.4 | C7H12O4 | 159.0667 | 159.0663 | -2.6 | Scherzo (-) |
| 2,2-Dimethylglutaric acid | 11.2 | C7H12O4 | 159.0663 | 159.0663 | -0.1 | PFP (-) |
| 2,3-Dihydroxybenzoic acid | 8.6 | C7H6O4 | 153.0196 | 153.0193 | -1.8 | Scherzo (-) |
| 2,4(3H,5H)-Furandione | 2.9 | C4H4O3 | 101.0231 | 101.0233 | 2.2 | PFP (+) |
| 2,6-Di-tert-butylphenol | 18.0 | C14H22O | 205.1597 | 205.1598 | 0.4 | PFP (-) |
| 2,6-Dihydroxybenzoic acid | 14.1 | C7H6O4 | 153.0195 | 153.0193 | -1.1 | PFP (-) |
| 2,7,8-Trimethyl-2-(betacarboxyethyl)-6- | 17.4 | C15H20O4 | 263.1293 | 263.1289 | -1.6 | PFP (-) |
| hydroxychroman | | | | | | |
| 2'-Deoxyadenosine 5'-monophosphate | 6.5 | C10H14N5O6P | 332.0753 | 332.0755 | 0.5 | Scherzo (+) |
| 2'-Deoxyadenosine 5'-monophosphate | 6.5 | C10H14N5O6P | 330.0608 | 330.0609 | 0.3 | Scherzo (-) |
| 2'-Deoxycytidine 5'-monophosphate | 3.5 | C9H14N3O7P | 306.0503 | 306.0497 | -2.1 | Scherzo (-) |
| 2'-Deoxyinosine | 6.2 | C10H12N4O4 | 253.0932 | 253.0931 | -0.3 | PFP (+) |
| 2'-O-Methyladenosine | 6.2 | C11H15N5O4 | 282.1194 | 282.1197 | 1.0 | Scherzo (+) |
| 21-Hydroxy-5 beta-pregnane-3,11,20-trione | 11.6 | C21H30O4 | 347.2226 | 347.2217 | -2.6 | Scherzo (+) |
| 2S-Amino-4E-octadecene-1,3S-diol | 14.8 | C18H37NO2 | 300.2906 | 300.2897 | -3.0 | Scherzo (+) |
| 2S-Amino-4E-octadecene-1,3S-diol | 17.8 | C18H37NO2 | 300.2901 | 300.2897 | -1.3 | PFP (+) |
| 3-(2-Ethylhexoxy)propan-1-amine | 11.2 | C11H25NO | 188.2012 | 188.2009 | -1.6 | Scherzo (+) |
| 3-(2-Ethylhexoxy)propan-1-amine | 17.1 | C11H25NO | 188.2011 | 188.2009 | -1.1 | PFP (+) |
| 3-(2-Hydroxyphenyl)propionic acid | 11.0 | C9H10O3 | 165.0564 | 165.0557 | -4.1 | Scherzo (-) |

| 3-(2-Hydroxyphenyl)propionic acid | 12.4 | C9H10O3 | 165.0561 | 165.0557 | -2.3 | PFP (-) |
|---|------|-----------|----------|----------|------|-------------|
| 3-Acetamidophenol | 9.5 | C8H9NO2 | 152.0705 | 152.0706 | 0.7 | Scherzo (+) |
| 3-Acetamidophenol | 9.7 | C8H9NO2 | 150.0557 | 150.0561 | 2.3 | PFP (-) |
| 3-Acetamidophenol | 9.7 | C8H9NO2 | 152.0705 | 152.0706 | 0.7 | PFP (+) |
| 3-Acetyl-11-keto-beta-boswellic acid | 17.9 | C32H48O5 | 513.3552 | 513.3575 | 4.4 | PFP (+) |
| 3-alpha-Hydroxy-7-oxo-5beta-cholanic acid | 16.4 | C24H38O4 | 391.2844 | 391.2843 | -0.3 | Scherzo (+) |
| 3-Cyclohexyl-1,1-dimethylurea | 12.8 | C9H18N2O | 171.1479 | 171.1492 | 7.5 | Scherzo (+) |
| 3-Cyclohexyl-1,1-dimethylurea | 13.9 | C9H18N2O | 171.1492 | 171.1492 | -0.1 | PFP (+) |
| 3-Deoxy-D-glycero-D-galacto-2-nonulosonic acid | 5.1 | C9H16O9 | 267.0736 | 267.0722 | -5.4 | Scherzo (-) |
| 3-Ethylphenol | 11.0 | C8H10O | 121.0663 | 121.0659 | -3.4 | Scherzo (-) |
| 3-Ethylphenol | 12.4 | C8H10O | 121.0657 | 121.0659 | 1.6 | PFP (-) |
| 3-Furancarboxylic acid, tetrahydro-4-methylene-2- | 17.6 | C14H22O4 | 253.1452 | 253.1445 | -2.6 | PFP (-) |
| octyl-5-oxo-, (2R,3S)- | | | | | | |
| 3-Furancarboxylic acid, tetrahydro-4-methylene-2- | 15.6 | C14H22O4 | 253.1444 | 253.1445 | 0.5 | Scherzo (-) |
| octyl-5-oxo-, (2R,3S)-rel- | | | | | | |
| 3-Hydroxy-3-methylglutaric acid | 3.0 | C6H10O5 | 161.0458 | 161.0456 | -1.6 | PFP (-) |
| 3-Hydroxy-3-methylglutaric acid | 3.5 | C6H10O5 | 161.0456 | 161.0456 | -0.3 | PFP (-) |
| 3-Hydroxy-3-methylglutaric acid | 5.2 | C6H10O5 | 161.0459 | 161.0456 | -2.2 | Scherzo (-) |
| 3-Hydroxy-4-methoxybenzoic acid | 10.0 | C8H8O4 | 169.0495 | 169.0495 | 0.2 | Scherzo (+) |
| 3-Hydroxy-4-methoxybenzoic acid | 11.6 | C8H8O4 | 169.0496 | 169.0495 | -0.4 | PFP (+) |
| 3-Hydroxy-4-methoxycinnamic acid | 11.5 | C10H10O4 | 195.0652 | 195.0652 | -0.1 | Scherzo (+) |
| 3-Hydroxy-4-methoxycinnamic acid | 13.9 | C10H10O4 | 193.0509 | 193.0506 | -1.4 | PFP (-) |
| 3-Hydroxy-4-methoxycinnamic acid | 13.8 | C10H10O4 | 195.0653 | 195.0652 | -0.6 | PFP (+) |
| 3-Hydroxybenzaldehyde | 10.4 | C7H6O2 | 121.0300 | 121.0295 | -4.1 | Scherzo (-) |
| 3-Hydroxybenzaldehyde | 11.2 | C7H6O2 | 121.0291 | 121.0295 | 3.3 | PFP (-) |
| 3-Hydroxybenzoic acid | 9.6 | C7H6O3 | 139.0389 | 139.0390 | 0.5 | Scherzo (+) |
| 3-Hydroxybutyrylcarnitine | 2.6 | C11H21NO5 | 248.1499 | 248.1493 | -2.6 | Scherzo (+) |
| 3-Hydroxybutyrylcarnitine | 4.2 | C11H21NO5 | 248.1497 | 248.1493 | -1.8 | PFP (+) |
| 3-Hydroxydodecanoic acid | 17.8 | C12H24O3 | 215.1655 | 215.1653 | -1.1 | Scherzo (-) |
| 3-Hydroxyglutaric acid | 3.9 | C5H8O5 | 147.0301 | 147.0299 | -1.4 | Scherzo (-) |
| 3-Hydroxyhexadecanoylcarnitine | 15.3 | C23H45NO5 | 416.3379 | 416.3371 | -2.0 | Scherzo (+) |
| 3-Hydroxyhexadecanoylcarnitine | 17.8 | C23H45NO5 | 416.3374 | 416.3371 | -0.8 | PFP (+) |
| 3-Hydroxyisovaleroylcarnitine | 2.9 | C12H23NO5 | 262.1646 | 262.1649 | 1.1 | Scherzo (+) |
| 3-Hydroxyisovaleroylcarnitine | 3.5 | C12H23NO5 | 262.1658 | 262.1649 | -3.4 | Scherzo (+) |
| 3-Hydroxyisovaleroylcarnitine | 6.4 | C12H23NO5 | 262.1653 | 262.1649 | -1.5 | PFP (+) |
| 3-Hydroxyoctanoic acid | 14.6 | C8H16O3 | 159.1027 | 159.1027 | -0.2 | PFP (-) |
| 3-Hydroxyoleylcarnitine | 15.7 | C25H47NO5 | 442.3537 | 442.3527 | -2.3 | Scherzo (+) |
| 3-Indoleacetic acid | 12.5 | C10H9NO2 | 176.0706 | 176.0706 | 0.1 | Scherzo (+) |
| 3-Indoleacetic acid | 14.4 | C10H9NO2 | 176.0711 | 176.0706 | -2.8 | PFP (+) |
| 3-Indoleacetic acid | 14.4 | C10H9NO2 | 174.0558 | 174.0561 | 1.4 | PFP (-) |
| 3-Indoleacetic acid | 8.4 | C10H9NO2 | 176.0704 | 176.0706 | 1.2 | PFP (+) |
| 3-Indoleacrylic acid | 7.8 | C11H9NO2 | 188.0712 | 188.0706 | -3.1 | Scherzo (+) |
| 3-Indoleacrylic acid | 12.2 | C11H9NO2 | 188.0706 | 188.0706 | 0.1 | Scherzo (+) |
| 3-Indoleacrylic acid | 9.4 | C11H9NO2 | 188.0710 | 188.0706 | -2.1 | PFP (+) |
| 3-Methylindole | 7.9 | C9H9N | 132.0802 | 132.0808 | 4.4 | Scherzo (+) |

| 3-Methylindole | 9.4 | C9H9N | 132.0804 | 132.0808 | 2.9 | PFP (+) |
|--|------|-------------|----------|----------|------|-------------|
| 3-O-Methylgallic acid | 8.8 | C8H8O5 | 183.0300 | 183.0299 | -0.5 | Scherzo (-) |
| 3-Oxocholic acid | 15.1 | C24H38O5 | 405.2644 | 405.2647 | 0.6 | Scherzo (-) |
| 3-Oxocholic acid | 16.1 | C24H38O5 | 405.2648 | 405.2647 | -0.4 | Scherzo (-) |
| 3-Oxocholic acid | 17.7 | C24H38O5 | 405.2656 | 405.2647 | -2.3 | PFP (-) |
| 3-Phenyllactic acid | 11.6 | C9H10O3 | 165.0562 | 165.0557 | -2.9 | PFP (-) |
| 3-Phenyllactic acid | 11.8 | C9H10O3 | 165.0562 | 165.0557 | -2.9 | Scherzo (-) |
| 3,3-Dimethylacrylic acid | 1.9 | C5H8O2 | 101.0595 | 101.0597 | 2.1 | PFP (+) |
| 3,4-Dihydrocoumarin | 5.7 | C9H8O2 | 149.0592 | 149.0597 | 3.4 | Scherzo (+) |
| 3,4-Dihydrocoumarin | 11.0 | C9H8O2 | 149.0599 | 149.0597 | -1.3 | Scherzo (+) |
| 3,4-Dihydrocoumarin | 12.4 | C9H8O2 | 149.0599 | 149.0597 | -1.3 | PFP (+) |
| 3,4-Dihydrocoumarin | 15.0 | C9H8O2 | 149.0600 | 149.0597 | -1.9 | PFP (+) |
| 3,4-Dihydroxy-L-phenylalanine | 3.9 | C9H11NO4 | 196.0619 | 196.0615 | -1.9 | Scherzo (-) |
| 3,4-Dimethylbenzoic acid | 17.1 | C9H10O2 | 151.0750 | 151.0754 | 2.4 | PFP (+) |
| 3,4,2',4',6'-Pentahydroxychalcone | 16.7 | C15H12O6 | 287.0568 | 287.0561 | -2.4 | PFP (-) |
| 3,4,2',4',6'-Pentahydroxychalcone | 16.6 | C15H12O6 | 289.0706 | 289.0707 | 0.2 | PFP (+) |
| 3,4'-Dimethoxy-5,7,3'-trihydroxyflavone | 14.6 | C17H14O7 | 329.0662 | 329.0667 | 1.5 | Scherzo (-) |
| 3,4'-Dimethoxy-5,7,3'-trihydroxyflavone | 17.9 | C17H14O7 | 329.0668 | 329.0667 | -0.4 | PFP (-) |
| 3,5-Dihydroxybenzoic acid | 8.6 | C7H6O4 | 153.0196 | 153.0193 | -1.8 | PFP (-) |
| 3,5-Dihydroxybenzoic acid | 8.5 | C7H6O4 | 155.0337 | 155.0339 | 1.2 | PFP (+) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 11.4 | C11H12O5 | 225.0761 | 225.0758 | -1.6 | Scherzo (+) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 11.4 | C11H12O5 | 223.0622 | 223.0612 | -4.5 | Scherzo (-) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 14.2 | C11H12O5 | 223.0617 | 223.0612 | -2.2 | PFP (-) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 14.2 | C11H12O5 | 225.0758 | 225.0758 | -0.2 | PFP (+) |
| 3,7,3'-Trihydroxyflavone | 12.3 | C15H10O5 | 269.0459 | 269.0456 | -1.3 | Scherzo (-) |
| 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid | 3.0 | C8H18N2O4S | 237.0925 | 237.0915 | -4.4 | PFP (-) |
| 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid | 3.5 | C8H18N2O4S | 237.0912 | 237.0915 | 1.1 | PFP (-) |
| 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid | 4.4 | C8H18N2O4S | 237.0920 | 237.0915 | -2.3 | Scherzo (-) |
| 4-Ethoxybenzoic acid | 14.1 | C9H10O3 | 167.0700 | 167.0703 | 1.6 | Scherzo (+) |
| 4-Ethoxybenzoic acid | 17.6 | C9H10O3 | 167.0704 | 167.0703 | -0.8 | Scherzo (+) |
| 4-Ethoxybenzoic acid | 16.2 | C9H10O3 | 167.0702 | 167.0703 | 0.4 | PFP (+) |
| 4-Hydroxy-L-glutamic acid | 3.2 | C5H9NO5 | 164.0549 | 164.0554 | 2.7 | Scherzo (+) |
| 4-Hydroxybenzaldehyde | 4.0 | C7H6O2 | 123.0442 | 123.0441 | -1.1 | Scherzo (+) |
| 4-Hydroxybenzaldehyde | 2.8 | C7H6O2 | 123.0441 | 123.0441 | -0.3 | PFP (+) |
| 4-Hydroxybenzaldehyde | 3.0 | C7H6O2 | 123.0440 | 123.0441 | 0.5 | PFP (+) |
| 4-Hydroxybenzaldehyde | 10.1 | C7H6O2 | 123.0438 | 123.0441 | 2.1 | PFP (+) |
| 4-Hydroxybenzoic acid | 9.7 | C7H6O3 | 137.0253 | 137.0244 | -6.4 | Scherzo (-) |
| 4-Hydroxybenzoic acid | 10.2 | C7H6O3 | 139.0388 | 139.0390 | 1.2 | PFP (+) |
| 4-Hydroxybenzoic acid | 10.3 | C7H6O3 | 137.0245 | 137.0244 | -0.6 | PFP (-) |
| 4-Hydroxybenzoic acid | 14.8 | C7H6O3 | 137.0245 | 137.0244 | -0.6 | PFP (-) |
| 4-Hydroxynonenal glutathione | 10.7 | C19H33N3O8S | 464.2076 | 464.2061 | -3.2 | Scherzo (+) |
| 4-Hydroxynonenal glutathione | 12.8 | C19H33N3O8S | 464.2065 | 464.2061 | -0.8 | PFP (+) |
| 4-Imidazoleacrylic acid | 2.4 | C6H6N2O2 | 137.0355 | 137.0357 | 1.1 | PFP (-) |
| 4-Imidazoleacrylic acid | 2.4 | C6H6N2O2 | 139.0500 | 139.0502 | 1.4 | PFP (+) |
| 4-Pyridoxic acid | 4.3 | C8H9NO4 | 182.0464 | 182.0459 | -2.9 | Scherzo (-) |

| 4-Pyridoxic acid | 6.0 | C8H9NO4 | 182.0461 | 182.0459 | -1.2 | PFP (-) |
|--|------|-------------|----------|----------|------|-------------|
| 4-Pyridoxic acid | 6.6 | C8H9NO4 | 184.0606 | 184.0604 | -0.9 | Scherzo (+) |
| 4-Pyridoxic acid | 6.7 | C8H9NO4 | 182.0466 | 182.0459 | -4.0 | Scherzo (-) |
| 4-Pyridoxic acid | 6.0 | C8H9NO4 | 184.0603 | 184.0604 | 0.7 | PFP (+) |
| 5-(2-Hydroxyethyl)-4-methylthiazole | 4.5 | C6H9NOS | 144.0473 | 144.0478 | 3.2 | Scherzo (+) |
| 5-(2-Hydroxyethyl)-4-methylthiazole | 4.6 | C6H9NOS | 144.0474 | 144.0478 | 2.5 | PFP (+) |
| 5-alpha-Pregnan-3alpha-ol-11,20-dione | 12.3 | C21H32O3 | 333.2429 | 333.2424 | -1.4 | Scherzo (+) |
| 5-Amino-1-beta-D-ribofuranosyl-1H-imidazole-4- | 3.6 | C9H14N4O5 | 259.1041 | 259.1037 | -1.5 | Scherzo (+) |
| carboxamide | | | | | | |
| 5-Aminovaleric acid | 1.9 | C5H11NO2 | 118.0863 | 118.0863 | -0.3 | PFP (+) |
| 5-Hydroxy-6E,8Z,11Z,14Z-eicosatetraenoic acid, | 17.9 | C20H30O2 | 303.2324 | 303.2319 | -1.8 | PFP (+) |
| 1,5-lactone | | | | | | |
| 5-Hydroxyindole-3-acetic acid | 10.5 | C10H9NO3 | 192.0657 | 192.0655 | -0.9 | Scherzo (+) |
| 5-Hydroxyindole-3-acetic acid | 10.5 | C10H9NO3 | 190.0518 | 190.0510 | -4.4 | Scherzo (-) |
| 5-Hydroxyindole-3-acetic acid | 10.7 | C10H9NO3 | 190.0515 | 190.0510 | -2.8 | PFP (-) |
| 5-Hydroxyindole-3-acetic acid | 11.3 | C10H9NO3 | 190.0516 | 190.0510 | -3.3 | PFP (-) |
| 5-Hydroxyindole-3-acetic acid | 11.3 | C10H9NO3 | 192.0660 | 192.0655 | -2.5 | PFP (+) |
| 5-Hydroxyindole-3-acetic acid | 11.7 | C10H9NO3 | 192.0657 | 192.0655 | -0.9 | PFP (+) |
| 5-Hydroxyindoleacetic acid | 9.6 | C10H9NO3 | 192.0655 | 192.0655 | 0.1 | Scherzo (+) |
| 5-Hydroxyindoleacetic acid | 10.6 | C10H9NO3 | 192.0660 | 192.0655 | -2.5 | PFP (+) |
| 5-Hydroxyisovanillic acid | 9.8 | C8H8O5 | 183.0303 | 183.0299 | -2.2 | PFP (-) |
| 5-Hydroxylysine | 1.9 | C6H14N2O3 | 163.1074 | 163.1077 | 2.0 | Scherzo (+) |
| 5-Hydroxytryptophol | 9.2 | C10H11NO2 | 178.0860 | 178.0863 | 1.5 | Scherzo (+) |
| 5-Hydroxytryptophol | 9.9 | C10H11NO2 | 178.0865 | 178.0863 | -1.3 | PFP (+) |
| 5-Isoprostaglandin-F2 alpha VI | 13.9 | C20H34O5 | 353.2329 | 353.2334 | 1.3 | Scherzo (-) |
| 5-Isoprostaglandin-F2 alpha VI | 14.4 | C20H34O5 | 353.2336 | 353.2334 | -0.7 | Scherzo (-) |
| 5-Isoprostaglandin-F2 alpha VI | 17.1 | C20H34O5 | 353.2333 | 353.2334 | 0.1 | PFP (-) |
| 5-Keto-D-gluconic acid | 4.0 | C6H10O7 | 193.0363 | 193.0354 | -4.8 | Scherzo (-) |
| 5-Methyltetrahydrofolic acid | 7.1 | C20H25N7O6 | 460.1951 | 460.1939 | -2.6 | Scherzo (+) |
| 5-Methyltetrahydrofolic acid | 7.2 | C20H25N7O6 | 458.1801 | 458.1794 | -1.6 | Scherzo (-) |
| 5-Methyltetrahydrofolic acid | 8.6 | C20H25N7O6 | 458.1811 | 458.1794 | -3.8 | PFP (-) |
| 5-Methyltetrahydrofolic acid | 8.6 | C20H25N7O6 | 460.1947 | 460.1939 | -1.7 | PFP (+) |
| 5-Thymidylic acid | 4.0 | C10H15N2O8P | 321.0496 | 321.0493 | -0.8 | PFP (-) |
| 5'-S-Methyl-5'-thioadenosine | 7.5 | C11H15N5O3S | 298.0972 | 298.0968 | -1.2 | Scherzo (+) |
| 5'-S-Methyl-5'-thioadenosine | 2.4 | C11H15N5O3S | 298.0969 | 298.0968 | -0.2 | PFP (+) |
| 5'-S-Methyl-5'-thioadenosine | 8.7 | C11H15N5O3S | 298.0974 | 298.0968 | -1.9 | PFP (+) |
| 6,7,4'-Trihydroxyisoflavone | 15.5 | C15H10O5 | 271.0602 | 271.0601 | -0.4 | PFP (+) |
| 7-Keto-3-alpha,12-alpha-dihydroxycholanic acid | 13.3 | C24H38O5 | 407.2790 | 407.2792 | 0.5 | Scherzo (+) |
| 7-Keto-3-alpha,12-alpha-dihydroxycholanic acid | 14.6 | C24H38O5 | 407.2788 | 407.2792 | 1.0 | Scherzo (+) |
| 7-Methylguanine | 2.9 | C6H7N5O | 166.0714 | 166.0723 | 5.7 | PFP (+) |
| 7-Methylguanine | 3.5 | C6H7N5O | 166.0725 | 166.0723 | -1.0 | Scherzo (+) |
| 7-Methylguanosine | 7.0 | C11H15N5O5 | 298.1157 | 298.1146 | -3.7 | Scherzo (+) |
| 7-Methylguanosine | 7.1 | C11H15N5O5 | 298.1151 | 298.1146 | -1.7 | PFP (+) |
| 7,8-Dehydropregnenolone | 12.3 | C21H30O2 | 315.2326 | 315.2319 | -2.3 | Scherzo (+) |
| 7,8-Dihydro-L-Biopterin | 3.0 | C9H13N5O3 | 240.1085 | 240.1091 | 2.6 | PFP (+) |

| 7,8-Dimethoxycoumarin | 11.4 | C11H10O4 | 207.0652 | 207.0652 | 0.0 | Scherzo (+) |
|---|------|--------------|----------|----------|------|-------------|
| 7,8-Dimethoxycoumarin | 14.2 | C11H10O4 | 207.0655 | 207.0652 | -1.5 | PFP (+) |
| 8-Hydroxyquinoline-5-carboxylic acid | 10.6 | C10H7NO3 | 188.0357 | 188.0353 | -2.0 | PFP (-) |
| 8-Hydroxyquinoline-5-carboxylic acid | 11.8 | C10H7NO3 | 188.0361 | 188.0353 | -4.1 | PFP (-) |
| 8-Hydroxyquinoline-5-carboxylic acid | 17.1 | C10H7NO3 | 188.0356 | 188.0353 | -1.5 | Scherzo (-) |
| 8-iso-Prostaglandin A1 | 14.8 | C20H32O4 | 335.2229 | 335.2228 | -0.4 | Scherzo (-) |
| 9-Oxoprosta-5Z,10,12Z,14E-tetraenoic acid | 16.1 | C20H28O3 | 317.2119 | 317.2111 | -2.5 | Scherzo (+) |
| 9-Oxoprosta-5Z,10,12Z,14E-tetraenoic acid | 17.8 | C20H28O3 | 317.2118 | 317.2111 | -2.1 | PFP (+) |
| 9,10-Dihydroxy-12Z-octadecenoic acid | 16.9 | C18H34O4 | 315.2521 | 315.2530 | 2.8 | Scherzo (+) |
| 9(10)-Epoxy-12Z-octadecenoic acid | 16.9 | C18H32O3 | 297.2429 | 297.2424 | -1.6 | Scherzo (+) |
| Acetyl-L-carnitine | 2.5 | C9H17NO4 | 204.1234 | 204.1230 | -1.8 | Scherzo (+) |
| Acetyl-L-carnitine | 2.9 | C9H17NO4 | 204.1233 | 204.1230 | -1.3 | PFP (+) `´ |
| Acetyl-L-carnitine | 3.8 | C9H17NO4 | 204.1234 | 204.1230 | -1.8 | PFP (+) |
| Acetyl-L-Threonine | 2.5 | C6H11NO4 | 160.0619 | 160.0615 | -2.3 | PFP (-) |
| Acetyl-L-Threonine | 4.6 | C6H11NO4 | 160.0623 | 160.0615 | -4.8 | Scherzo (-) |
| Acetyl-L-Threonine | 4.7 | C6H11NO4 | 162.0759 | 162.0761 | 1.1 | Scherzo (+) |
| Acetylcysteine | 17.7 | C5H9NO3S | 162.0227 | 162.0230 | 2.1 | PFP (-) |
| Adenine | 2.3 | C5H5N5 | 136.0618 | 136.0618 | -0.2 | PFP (+) |
| Adenine | 2.5 | C5H5N5 | 136.0613 | 136.0618 | 3.5 | Scherzo (+) |
| Adenine | 4.0 | C5H5N5 | 136.0618 | 136.0618 | -0.2 | PFP (+) |
| Adenine | 4.0 | C5H5N5 | 134.0471 | 134.0472 | 0.9 | PFP (-) |
| Adenine | 7.1 | C5H5N5 | 136.0620 | 136.0618 | -1.7 | PFP (+) |
| Adenine | 7.4 | C5H5N5 | 136.0614 | 136.0618 | 2.7 | Scherzo (+) |
| Adenine | 7.9 | C5H5N5 | 136.0618 | 136.0618 | -0.2 | PFP (+) |
| Adenosine | 4.0 | C10H13N5O4 | 268.1051 | 268.1040 | -4.0 | PFP (+) |
| Adenosine | 4.0 | C10H13N5O4 | 266.0906 | 266.0895 | -4.2 | PFP (-) |
| Adenosine | 4.1 | C10H13N5O4 | 268.1044 | 268.1040 | -1.4 | Scherzo (+) |
| Adenosine | 7.4 | C10H13N5O4 | 268.1037 | 268.1040 | 1.2 | Scherzo (+) |
| Adenosine | 7.8 | C10H13N5O4 | 268.1041 | 268.1040 | -0.3 | PFP (+) |
| Adenosine 2'-monophosphate | 7.4 | C10H14N5O7P | 348.0702 | 348.0704 | 0.5 | Scherzo (+) |
| Adenosine 2'-monophosphate | 7.9 | C10H14N5O7P | 348.0718 | 348.0704 | -4.1 | Scherzo (+) |
| Adenosine 2'-monophosphate | 4.9 | C10H14N5O7P | 348.0706 | 348.0704 | -0.7 | PFP (+) |
| Adenosine 3'-monophosphate | 3.4 | C10H14N5O7P | 346.0569 | 346.0558 | -3.1 | PFP (-) |
| Adenosine 3'-monophosphate | 7.5 | C10H14N5O7P | 346.0563 | 346.0558 | -1.4 | Scherzo (-) |
| Adenosine 3'-monophosphate | 3.5 | C10H14N5O7P | 348.0703 | 348.0704 | 0.2 | PFP (+) |
| Adenosine 5-monophosphate | 2.4 | C10H14N5O7P | 346.0571 | 346.0558 | -3.7 | PFP (-) |
| Adenosine 5-monophosphate | 2.5 | C10H14N5O7P | 348.0708 | 348.0704 | -1.3 | PFP (+) |
| Adenosine 5-monophosphate | 3.0 | C10H14N5O7P | 348.0705 | 348.0704 | -0.4 | PFP (+) |
| Adenosine 5-monophosphate | 5.1 | C10H14N5O7P | 348.0711 | 348.0704 | -2.1 | Scherzo (+) |
| Adenosine 5-monophosphate | 5.2 | C10H14N5O7P | 346.0566 | 346.0558 | -2.3 | Scherzo (-) |
| Adenosine 5-monophosphate | 7.9 | C10H14N5O7P | 348.0695 | 348.0704 | 2.5 | PFP (+) |
| Adenosine 5-monophosphate | 12.8 | C10H14N5O7P | 348.0710 | 348.0704 | -1.8 | PFP (+) |
| Adenylosuccinic acid | 6.8 | C14H18N5O11P | 462.0687 | 462.0668 | -4.2 | PFP (-) |
| Adenylosuccinic acid | 7.4 | C14H18N5O11P | 462.0683 | 462.0668 | -3.3 | PFP (-) |
| Adenylyl (3'-5')cytidine | 6.7 | C19H25N8O11P | 573.1470 | 573.1453 | -2.9 | Scherzo (+) |

| Adenylyl (3'-5')cytidine | 6.8 | C19H25N8O11P | 571.1317 | 571.1308 | -1.6 | Scherzo (-) |
|----------------------------------|------|--------------|----------|----------|------|-------------|
| Adenylyl (3'-5')cytidine | 7.1 | C19H25N8O11P | 571.1343 | 571.1308 | -6.2 | PFP (-) |
| Adenylyl (3'-5')cytidine | 7.1 | C19H25N8O11P | 573.1462 | 573.1453 | -1.5 | PFP (+) |
| Adipic acid | 7.5 | C6H10O4 | 145.0512 | 145.0506 | -3.9 | PFP (-) |
| Alanine | 2.9 | C3H7NO2 | 88.0405 | 88.0404 | -1.1 | PFP (-) |
| Allantoin | 2.8 | C4H6N4O3 | 157.0366 | 157.0367 | 0.7 | Scherzo (-) |
| Allose | 2.6 | C6H12O6 | 179.0564 | 179.0561 | -1.6 | Scherzo (-) |
| alpha-D-Galactose 1-phosphate | 2.2 | C6H13O9P | 259.0235 | 259.0224 | -4.1 | PFP (-) |
| alpha-D-Glucose 1,6-bisphosphate | 2.6 | C6H14O12P2 | 338.9887 | 338.9888 | 0.2 | PFP (-) |
| alpha-L-Glu-L-Tyr | 7.6 | C14H18N2O6 | 311.1248 | 311.1238 | -3.3 | Scherzo (+) |
| alpha-L-Glu-L-Tyr | 7.3 | C14H18N2O6 | 311.1246 | 311.1238 | -2.7 | PFP (+) |
| Alpha-Linolenic acid | 17.9 | C18H30O2 | 279.2324 | 279.2319 | -1.9 | PFP (+) |
| Amino caproic acid | 8.3 | C6H13NO2 | 132.1013 | 132.1019 | 4.6 | PFP (+) |
| Apigenin 7-glucoside | 14.5 | C21H20O10 | 433.1124 | 433.1129 | 1.2 | PFP (+) |
| Arabinonic acid | 1.9 | C5H10O6 | 165.0408 | 165.0405 | -2.1 | PFP (-) |
| Arabinonic acid | 2.8 | C5H10O6 | 165.0409 | 165.0405 | -2.7 | Scherzo (-) |
| Arabinonic acid | 3.3 | C5H10O6 | 165.0413 | 165.0405 | -5.1 | Scherzo (-) |
| Arabitol | 2.7 | C5H12O5 | 151.0624 | 151.0612 | -7.9 | Scherzo (-) |
| Arginine | 2.2 | C6H14N4O2 | 173.1052 | 173.1044 | -4.6 | Scherzo (-) |
| Arginine | 2.5 | C6H14N4O2 | 175.1191 | 175.1190 | -0.9 | Scherzo (+) |
| Arginine | 1.9 | C6H14N4O2 | 175.1189 | 175.1190 | 0.3 | PFP (+) |
| Argininosuccinic acid | 1.9 | C10H18N4O6 | 291.1302 | 291.1299 | -1.0 | PFP (+) |
| Argininosuccinic acid | 2.4 | C10H18N4O6 | 289.1160 | 289.1154 | -2.2 | Scherzo (-) |
| Argininosuccinic acid | 2.5 | C10H18N4O6 | 291.1306 | 291.1299 | -2.4 | Scherzo (+) |
| Arsenic acid | 7.1 | AsH3O4 | 140.9175 | 140.9175 | -0.4 | Scherzo (-) |
| Asiatic acid | 17.9 | C30H48O5 | 487.3440 | 487.3429 | -2.3 | PFP (-) |
| Asp-Pro | 3.1 | C9H14N2O5 | 231.0981 | 231.0976 | -2.4 | Scherzo (+) |
| Asparagine | 2.4 | C4H8N2O3 | 131.0468 | 131.0462 | -4.4 | Scherzo (-) |
| Aspartic acid | 1.9 | C4H7NO4 | 132.0303 | 132.0302 | -0.5 | PFP (-) |
| Aspartic acid | 2.7 | C4H7NO4 | 134.0445 | 134.0448 | 2.1 | Scherzo (+) |
| Aspartic acid | 2.8 | C4H7NO4 | 132.0310 | 132.0302 | -5.8 | Scherzo (-) |
| Aspartic acid | 3.2 | C4H7NO4 | 134.0449 | 134.0448 | -0.9 | Scherzo (+) |
| Azelaic acid | 11.9 | C9H16O4 | 189.1125 | 189.1121 | -1.9 | Scherzo (+) |
| Azelaic acid | 11.9 | C9H16O4 | 187.0986 | 187.0976 | -5.5 | Scherzo (-) |
| Azelaic acid | 14.3 | C9H16O4 | 189.1123 | 189.1121 | -0.8 | PFP (+) |
| Azelaic acid | 14.3 | C9H16O4 | 187.0982 | 187.0976 | -3.3 | PFP (-) |
| Baicalin | 13.8 | C21H18O11 | 445.0770 | 445.0776 | 1.4 | Scherzo (-) |
| Baicalin | 13.9 | C21H18O11 | 447.0922 | 447.0922 | 0.0 | Scherzo (+) |
| Baicalin | 14.7 | C21H18O11 | 445.0783 | 445.0776 | -1.5 | PFP (-) |
| Benzanilide | 15.4 | C13H11NO | 198.0915 | 198.0913 | -0.8 | Scherzo (+) |
| Benzoic acid ethyl ester | 15.0 | C9H10O2 | 151.0752 | 151.0754 | 1.1 | Scherzo (+) |
| Benzophenone | 17.3 | C13H10O | 183.0807 | 183.0804 | -1.4 | Scherzo (+) |
| Benzophenone | 17.8 | C13H10O | 183.0805 | 183.0804 | -0.3 | PFP (+) |
| Beta-Alanine | 2.0 | C3H7NO2 | 88.0403 | 88.0404 | 1.1 | PFP (-) |
| beta-L-Fucose 1-phosphate | 9.6 | C6H13O8P | 243.0281 | 243.0275 | -2.3 | Scherzo (-) |
| | | | | | | |

| beta-Muricholic acid | 15.3 | C24H40O5 | 407.2798 | 407.2803 | 1.2 | Scherzo (-) |
|--|------|---------------|----------|----------|------|-------------|
| beta-Nicotinamide adenine dinucleotide | 3.0 | C21H27N7O14P2 | 664.1169 | 664.1164 | -0.8 | PFP (+) |
| Betaine | 2.5 | C5H11NO2 | 118.0864 | 118.0863 | -1.2 | PFP (+) |
| Bicyclo-prostaglandin E2 | 15.3 | C20H30O4 | 335.2226 | 335.2217 | -2.7 | Scherzo (+) |
| Biliverdin | 14.8 | C33H34N4O6 | 583.2556 | 583.2551 | -0.8 | Scherzo (+) |
| Biotin | 9.9 | C10H16N2O3S | 245.0962 | 245.0954 | -3.1 | Scherzo (+) |
| Blood Group A Trisaccharide | 2.7 | C20H35NO15 | 530.2093 | 530.2080 | -2.5 | Scherzo (+) |
| Butein | 2.9 | C15H12O5 | 271.0587 | 271.0612 | 9.2 | PFP (-) `´ |
| Butyric acid | 5.6 | C4H8O2 | 87.0451 | 87.0452 | 0.6 | PFP (-) |
| Butyrylcarnitine | 4.5 | C11H21NO4 | 232.1550 | 232.1543 | -2.9 | Scherzo (+) |
| Butyrylcarnitine | 5.0 | C11H21NO4 | 232.1550 | 232.1543 | -2.9 | Scherzo (+) |
| Butyrylcarnitine | 8.5 | C11H21NO4 | 232.1551 | 232.1543 | -3.3 | PFP (+) `´ |
| Caffeic acid | 10.1 | C9H8O4 | 179.0360 | 179.0350 | -5.7 | Scherzo (-) |
| Caffeic acid | 11.7 | C9H8O4 | 179.0351 | 179.0350 | -0.7 | PFP (-) |
| Capric acid | 17.9 | C10H20O2 | 171.1388 | 171.1391 | 1.5 | PFP (-) |
| Carbofuran phenol-3-ketone | 11.4 | C10H10O3 | 179.0698 | 179.0703 | 2.6 | PFP (+) |
| Carnitine | 2.0 | C7H15NO3 | 162.1126 | 162.1125 | -0.8 | PFP (+) |
| Carnitine | 2.4 | C7H15NO3 | 162.1126 | 162.1125 | -0.8 | Scherzo (+) |
| Carnosine | 1.9 | C9H14N4O3 | 227.1142 | 227.1139 | -1.5 | PFP (+) |
| Carnosine | 2.5 | C9H14N4O3 | 225.0990 | 225.0993 | 1.4 | Scherzo (-) |
| Cholic acid | 17.9 | C24H40O5 | 407.2816 | 407.2803 | -3.2 | PFP (-) |
| Chrysoeriol | 14.7 | C16H12O6 | 299.0566 | 299.0561 | -1.6 | Scherzo (-) |
| cis-Aconitate | 4.3 | C6H6O6 | 173.0096 | 173.0092 | -2.5 | PFP (-) |
| cis-cinnamic acid | 5.2 | C9H8O2 | 147.0448 | 147.0452 | 2.4 | PFP (-) |
| cis-Jasmone | 14.2 | C11H16O | 165.1275 | 165.1274 | -0.7 | Scherzo (+) |
| Citraconic acid | 4.3 | C5H6O4 | 129.0188 | 129.0193 | 4.1 | PFP (-) `´ |
| Citric acid | 2.4 | C6H8O7 | 191.0203 | 191.0197 | -3.0 | PFP (-) |
| Citric acid | 2.9 | C6H8O7 | 191.0198 | 191.0197 | -0.4 | Scherzo (-) |
| Citric acid | 3.0 | C6H8O7 | 191.0203 | 191.0197 | -3.0 | PFP (-) |
| Citric acid | 5.8 | C6H8O7 | 191.0202 | 191.0197 | -2.5 | Scherzo (-) |
| Citric acid | 7.0 | C6H8O7 | 191.0204 | 191.0197 | -3.5 | Scherzo (-) |
| Citric acid | 7.4 | C6H8O7 | 193.0339 | 193.0343 | 2.0 | Scherzo (+) |
| Citric acid | 9.1 | C6H8O7 | 191.0202 | 191.0197 | -2.5 | Scherzo (-) |
| Citrulline | 2.5 | C6H13N3O3 | 176.1031 | 176.1030 | -0.7 | Scherzo (+) |
| Citrulline | 2.5 | C6H13N3O3 | 174.0891 | 174.0884 | -3.9 | Scherzo (-) |
| Corticosterone | 13.4 | C21H30O4 | 347.2209 | 347.2217 | 2.3 | Scherzo (+) |
| Corticosterone | 14.6 | C21H30O4 | 347.2219 | 347.2217 | -0.6 | Scherzo (+) |
| Corticosterone | 14.8 | C21H30O4 | 347.2222 | 347.2217 | -1.5 | PFP (+) |
| Coumarin | 3.9 | C9H6O2 | 147.0438 | 147.0441 | 1.8 | Scherzo (+) |
| Creatine | 2.0 | C4H9N3O2 | 132.0768 | 132.0768 | -0.4 | PFP (+) |
| Creatine | 2.5 | C4H9N3O2 | 132.0768 | 132.0768 | -0.4 | Scherzo (+) |
| Creatine phosphate | 7.4 | C4H10N3O5P | 212.0431 | 212.0431 | 0.0 | Scherzo (+) |
| Creatinine | 1.9 | C4H7N3O | 114.0660 | 114.0662 | 1.7 | PFP (+) |
| Cyclic adenosine diphosphate ribose | 3.0 | C15H21N5O13P2 | 540.0529 | 540.0538 | 1.7 | PFP (-) |
| Cyclic adenosine diphosphate ribose | 5.8 | C15H21N5O13P2 | 540.0538 | 540.0538 | 0.1 | Scherzo (-) |

| Cyclic GMP | 6.0 | C10H12N5O7P | 344.0417 | 344.0402 | -4.5 | PFP (-) |
|---|------|---------------|----------|----------|------|-------------|
| Cystathionine | 2.5 | C7H14N2O4S | 223.0748 | 223.0747 | -0.4 | Scherzo (+) |
| Cysteine S-sulfate | 8.7 | C3H7NO5S2 | 199.9697 | 199.9693 | -2.1 | Scherzo (-) |
| Cysteine-glutathione disulfide | 1.9 | C13H22N4O8S2 | 425.0826 | 425.0806 | -4.6 | PFP (-) |
| Cysteine-glutathione disulfide | 3.1 | C13H22N4O8S2 | 427.0960 | 427.0952 | -1.9 | Scherzo (+) |
| Cysteine-glutathione disulfide | 3.1 | C13H22N4O8S2 | 425.0808 | 425.0806 | -0.4 | Scherzo (-) |
| Cysteine-glutathione disulfide | 6.3 | C13H22N4O8S2 | 427.0962 | 427.0952 | -2.4 | Scherzo (+) |
| Cysteine-glutathione disulfide | 1.9 | C13H22N4O8S2 | 427.0959 | 427.0952 | -1.7 | PFP (+) |
| Cytidine | 2.3 | C9H13N3O5 | 244.0931 | 244.0928 | -1.2 | Scherzo (+) |
| Cytidine | 2.6 | C9H13N3O5 | 244.0931 | 244.0928 | -1.2 | Scherzo (+) |
| Cytidine | 2.0 | C9H13N3O5 | 244.0929 | 244.0928 | -0.4 | PFP (+) |
| Cytidine 2',3'-cyclic monophosphoric acid | 3.6 | C9H12N3O7P | 306.0489 | 306.0486 | -1.1 | Scherzo (+) |
| Cytidine 2',3'-cyclic monophosphoric acid | 3.6 | C9H12N3O7P | 304.0347 | 304.0340 | -2.3 | Scherzo (-) |
| Cytidine 2',3'-cyclic monophosphoric acid | 6.2 | C9H12N3O7P | 306.0498 | 306.0486 | -4.1 | Scherzo (+) |
| Cytidine 3'-monophosphate | 2.0 | C9H14N3O8P | 322.0461 | 322.0446 | -4.7 | PFP (-) |
| Cytidine 3'-monophosphate | 2.8 | C9H14N3O8P | 322.0450 | 322.0446 | -1.3 | Scherzo (-) |
| Cytidine 3'-monophosphate | 3.6 | C9H14N3O8P | 322.0451 | 322.0446 | -1.6 | Scherzo (-) |
| Cytidine 5'-diphosphate ethanolamine | 3.1 | C11H20N4O11P2 | 445.0537 | 445.0531 | -1.3 | Scherzo (-) |
| Cytidine 5'-diphosphocholine | 2.9 | C14H26N4O11P2 | 489.1152 | 489.1146 | -1.2 | Scherzo (+) |
| Cytidine 5'-diphosphocholine | 3.5 | C14H26N4O11P2 | 489.1145 | 489.1146 | 0.2 | Scherzo (+) |
| Cytidine 5'-diphosphocholine | 2.9 | C14H26N4O11P2 | 489.1152 | 489.1146 | -1.2 | PFP (+) |
| Cytidine monophosphate | 2.0 | C9H14N3O8P | 324.0598 | 324.0591 | -2.1 | PFP (+) |
| Cytidine monophosphate | 2.3 | C9H14N3O8P | 324.0598 | 324.0591 | -2.1 | PFP (+) |
| Cytidine monophosphate | 3.2 | C9H14N3O8P | 324.0600 | 324.0591 | -2.7 | Scherzo (+) |
| Cytidine monophosphate | 3.6 | C9H14N3O8P | 324.0600 | 324.0591 | -2.7 | Scherzo (+) |
| Cytidine monophosphate | 6.6 | C9H14N3O8P | 324.0603 | 324.0591 | -3.6 | Scherzo (+) |
| Cytidine monophosphate | 6.7 | C9H14N3O8P | 324.0586 | 324.0591 | 1.6 | Scherzo (+) |
| Cytidine-5'-monophospho-N-acetylneuraminic acid | 6.5 | C20H31N4O16P | 613.1409 | 613.1400 | -1.5 | Scherzo (-) |
| Cytosine | 2.0 | C4H5N3O | 112.0506 | 112.0505 | -0.5 | PFP (+) |
| Cytosine | 3.0 | C4H5N3O | 112.0503 | 112.0505 | 2.1 | PFP (+) |
| Cytosine | 7.1 | C4H5N3O | 112.0509 | 112.0505 | -3.2 | PFP (+) |
| Daidzein | 13.1 | C15H10O4 | 253.0514 | 253.0506 | -3.0 | Scherzo (-) |
| Daidzein | 13.2 | C15H10O4 | 255.0661 | 255.0652 | -3.6 | Scherzo (+) |
| Daidzein | 16.3 | C15H10O4 | 255.0656 | 255.0652 | -1.6 | PFP (+) |
| Daidzein | 16.3 | C15H10O4 | 253.0514 | 253.0506 | -3.0 | PFP (-) |
| Daidzein 4'-sulfate | 16.3 | C15H10O7S | 333.0078 | 333.0075 | -1.1 | PFP (-) |
| Daidzin | 10.3 | C21H20O9 | 417.1188 | 417.1180 | -1.9 | Scherzo (+) |
| Daidzin | 12.9 | C21H20O9 | 417.1189 | 417.1180 | -2.1 | PFP (+) |
| Decamethylcyclopentasiloxane | 1.8 | C10H30O5Si5 | 371.1006 | 371.1012 | 1.7 | Scherzo (+) |
| Dehydroascorbic acid | 2.4 | C6H6O6 | 173.0094 | 173.0092 | -1.4 | PFP (-) |
| Dehydroascorbic acid | 2.7 | C6H6O6 | 173.0093 | 173.0092 | -0.8 | PFP (-) |
| Dehydroascorbic acid | 4.7 | C6H6O6 | 173.0103 | 173.0092 | -6.6 | Scherzo (-) |
| Delta-Hexanolactone | 8.8 | C6H10O2 | 115.0754 | 115.0754 | -0.3 | PFP (+) |
| DELTA17-6-Ketoprostaglandin F1alpha | 12.3 | C20H32O6 | 367.2131 | 367.2126 | -1.3 | Scherzo (-) |
| Deoxyadenosine | 4.4 | C10H13N5O3 | 252.1096 | 252.1091 | -1.9 | Scherzo (+) |

| Deoxyguanosine | 6.2 | C10H13N5O4 | 268.1033 | 268.1040 | 2.7 | PFP (+) |
|------------------------|------|---------------|----------|----------|------|-------------|
| Deoxyguanosine | 6.2 | C10H13N5O4 | 266.0904 | 266.0895 | -3.5 | PFP (-) |
| Deoxyguanosine | 6.6 | C10H13N5O4 | 268.1047 | 268.1040 | -2.5 | Scherzo (+) |
| Deoxyguanosine | 6.7 | C10H13N5O4 | 266.0904 | 266.0895 | -3.5 | Scherzo (-) |
| Deoxyinosine | 6.2 | C10H12N4O4 | 251.0796 | 251.0786 | -4.1 | PFP (-) |
| Deoxyinosine | 6.7 | C10H12N4O4 | 251.0795 | 251.0786 | -3.7 | Scherzo (-) |
| Deoxyuridine | 4.3 | C9H12N2O5 | 227.0673 | 227.0674 | 0.2 | PFP (-) |
| Deoxyuridine | 5.3 | C9H12N2O5 | 227.0669 | 227.0674 | 2.0 | Scherzo (-) |
| Diethyl phthalate | 16.0 | C12H14O4 | 223.0960 | 223.0965 | 2.2 | Scherzo (+) |
| Diethyltoluamide | 15.2 | C12H17NO | 192.1380 | 192.1383 | 1.5 | Scherzo (+) |
| Dihydrodaidzein | 13.0 | C15H12O4 | 257.0810 | 257.0808 | -0.6 | Scherzo (+) |
| Dihydrodaidzein | 13.1 | C15H12O4 | 255.0669 | 255.0663 | -2.4 | Scherzo (-) |
| Dihydrodaidzein | 15.7 | C15H12O4 | 255.0672 | 255.0663 | -3.6 | PFP (-) |
| Dihydrodaidzein | 15.6 | C15H12O4 | 257.0812 | 257.0808 | -1.4 | PFP (+) |
| Dihydrofolic acid | 9.7 | C19H21N7O6 | 442.1480 | 442.1481 | 0.1 | Scherzo (-) |
| Dihydrofolic acid | 11.4 | C19H21N7O6 | 442.1510 | 442.1481 | -6.6 | PFP (-) |
| Dihydroisoferulic acid | 13.5 | C10H12O4 | 195.0666 | 195.0663 | -1.6 | PFP (-) |
| Dimethyl arginine | 2.0 | C8H18N4O2 | 203.1504 | 203.1503 | -0.7 | PFP (+) |
| Dimethyl arginine | 2.4 | C8H18N4O2 | 203.1498 | 203.1503 | 2.2 | Scherzo (+) |
| Dimethylaminopurine | 4.5 | C7H9N5 | 164.0926 | 164.0931 | 2.9 | Scherzo (+) |
| Dimethylaminopurine | 6.3 | C7H9N5 | 164.0929 | 164.0931 | 1.0 | PFP (+) |
| Dimethylglycine | 1.9 | C4H9NO2 | 102.0555 | 102.0561 | 5.4 | PFP (-) |
| Dimethylmalonic acid | 7.1 | C5H8O4 | 131.0350 | 131.0350 | -0.2 | Scherzo (-) |
| Diosmetin | 14.7 | C16H12O6 | 301.0710 | 301.0707 | -1.1 | Scherzo (+) |
| Dodecanedioic acid | 14.7 | C12H22O4 | 229.1452 | 229.1445 | -2.9 | Scherzo (-) |
| Dodecanedioic acid | 17.5 | C12H22O4 | 229.1451 | 229.1445 | -2.5 | PFP (-) |
| Dodecyl sulfate | 17.6 | C12H26O4S | 265.1484 | 265.1479 | -1.9 | PFP (-) |
| Emodin | 15.5 | C15H10O5 | 269.0457 | 269.0456 | -0.6 | PFP (-) |
| Enterolactone | 11.7 | C18H18O4 | 299.1281 | 299.1278 | -1.0 | Scherzo (+) |
| Enterolactone | 14.3 | C18H18O4 | 299.1283 | 299.1278 | -1.7 | Scherzo (+) |
| Enterolactone | 16.5 | C18H18O4 | 299.1282 | 299.1278 | -1.4 | PFP (+) |
| Equol | 14.3 | C15H14O3 | 243.1023 | 243.1016 | -3.0 | Scherzo (+) |
| Equol | 17.0 | C15H14O3 | 241.0871 | 241.0870 | -0.3 | PFP (-) |
| Equol | 17.0 | C15H14O3 | 243.1021 | 243.1016 | -2.2 | PFP (+) |
| Ergothioneine | 2.9 | C9H15N3O2S | 230.0961 | 230.0958 | -1.4 | Scherzo (+) |
| Ergothioneine | 7.0 | C9H15N3O2S | 230.0962 | 230.0958 | -1.8 | Scherzo (+) |
| Ergothioneine | 2.5 | C9H15N3O2S | 230.0966 | 230.0958 | -3.6 | PFP (+) |
| Ergothioneine | 8.4 | C9H15N3O2S | 230.0962 | 230.0958 | -1.8 | PFP (+) |
| Ergothioneine | 8.9 | C9H15N3O2S | 230.0955 | 230.0958 | 1.2 | PFP (+) |
| FAD | 12.7 | C27H33N9O15P2 | 784.1556 | 784.1499 | -7.3 | PFP (-) |
| FAD | 12.8 | C27H33N9O15P2 | 786.1661 | 786.1644 | -2.1 | PFP (+) |
| Flavin Mononucleotide | 12.3 | C17H21N4O9P | 457.1129 | 457.1119 | -2.2 | PFP (+) |
| Flavin Mononucleotide | 12.4 | C17H21N4O9P | 455.0994 | 455.0973 | -4.5 | PFP (-) |
| Flavin Mononucleotide | 13.5 | C17H21N4O9P | 457.1120 | 457.1119 | -0.2 | Scherzo (+) |
| Flavin Mononucleotide | 13.9 | C17H21N4O9P | 455.0974 | 455.0973 | -0.1 | Scherzo (-) |

| Folate | 9.8 | C19H19N7O6 | 440.1316 | 440.1324 | 1.8 | Scherzo (-) |
|----------------------------|------|-------------|----------|----------|------|-------------|
| Folate | 11.4 | C19H19N7O6 | 440.1347 | 440.1324 | -5.2 | PFP (-) |
| Galactonic acid | 2.8 | C6H12O7 | 195.0521 | 195.0510 | -5.5 | Scherzo (-) |
| Galactonic acid | 3.3 | C6H12O7 | 195.0522 | 195.0510 | -6.0 | Scherzo (-) |
| Galactonic acid - lactone | 3.3 | C6H10O6 | 179.0541 | 179.0550 | 5.1 | Scherzo (+) |
| gamma-Glu-Cys | 4.4 | C8H14N2O5S | 251.0699 | 251.0696 | -1.1 | Scherzo (+) |
| gamma-Glutamyglutamic acid | 2.0 | C10H16N2O7 | 275.0896 | 275.0885 | -4.1 | PFP (-) |
| gamma-Glutamyglutamic acid | 2.9 | C10H16N2O7 | 277.1040 | 277.1030 | -3.5 | Scherzo (+) |
| gamma-Glutamyglutamic acid | 2.9 | C10H16N2O7 | 275.0896 | 275.0885 | -4.1 | Scherzo (-) |
| gamma-Glutamyglutamic acid | 3.7 | C10H16N2O7 | 277.1038 | 277.1030 | -2.8 | Scherzo (+) |
| gamma-Glutamyglutamic acid | 3.8 | C10H16N2O7 | 275.0896 | 275.0885 | -4.1 | Scherzo (-) |
| gamma-Glutamyglutamic acid | 2.1 | C10H16N2O7 | 277.1037 | 277.1030 | -2.4 | PFP (+) |
| gamma-Muricholic acid | 16.4 | C24H40O5 | 407.2784 | 407.2803 | 4.7 | Scherzo (-) |
| Genistein | 12.2 | C15H10O5 | 271.0606 | 271.0601 | -1.8 | Scherzo (+) |
| Genistein | 14.5 | C15H10O5 | 271.0605 | 271.0601 | -1.5 | Scherzo (+) |
| Genistein | 14.5 | C15H10O5 | 269.0460 | 269.0456 | -1.7 | Scherzo (-) |
| Genistein | 17.6 | C15H10O5 | 271.0601 | 271.0601 | 0.0 | PFP (+) |
| Genistein | 17.6 | C15H10O5 | 269.0468 | 269.0456 | -4.6 | PFP (-) |
| Genkwanin | 13.3 | C16H12O5 | 283.0620 | 283.0612 | -2.8 | Scherzo (-) |
| Genkwanin | 16.6 | C16H12O5 | 283.0606 | 283.0612 | 2.1 | Scherzo (-) |
| Genkwanin | 16.7 | C16H12O5 | 283.0617 | 283.0612 | -1.8 | PFP (-) |
| Gentisic acid | 11.0 | C7H6O4 | 153.0195 | 153.0193 | -1.1 | PFP (-) |
| Gentisic acid | 14.7 | C7H6O4 | 153.0200 | 153.0193 | -4.4 | Scherzo (-) |
| Glu-Gly-Arg | 2.5 | C13H24N6O6 | 361.1826 | 361.1830 | 1.1 | Scherzo (+) |
| Glu-Ile-Arg | 6.5 | C17H32N6O6 | 417.2457 | 417.2456 | -0.2 | Scherzo (+) |
| Glu-Leu-Arg | 7.7 | C17H32N6O6 | 417.2466 | 417.2456 | -2.4 | PFP (+) |
| Glu-Met | 6.8 | C10H18N2O5S | 279.1014 | 279.1009 | -1.7 | Scherzo (+) |
| Glu-Phe-Arg | 7.4 | C20H30N6O6 | 451.2342 | 451.2300 | -9.4 | Scherzo (+) |
| Glu-Ser | 3.2 | C8H14N2O6 | 235.0928 | 235.0925 | -1.4 | Scherzo (+) |
| Glu-Val-Phe | 11.9 | C19H27N3O6 | 394.1979 | 394.1973 | -1.6 | PFP (+) |
| Glucoheptonic acid | 3.3 | C7H14O8 | 225.0623 | 225.0616 | -3.2 | Scherzo (-) |
| Glucosamine 6-phosphate | 2.5 | C6H14NO8P | 258.0385 | 258.0384 | -0.3 | Scherzo (-) |
| Glucosamine-6-phosphate | 2.5 | C6H14NO8P | 260.0527 | 260.0530 | 1.1 | Scherzo (+) |
| Glucose 6-Phosphate | 2.2 | C6H13O9P | 261.0378 | 261.0370 | -3.1 | PFP (+) |
| Glucose 6-Phosphate | 8.3 | C6H13O9P | 261.0372 | 261.0370 | -0.8 | Scherzo (+) |
| Glutamate | 1.9 | C5H9NO4 | 148.0607 | 148.0604 | -1.8 | PFP (+) |
| Glutamate | 1.9 | C5H9NO4 | 146.0461 | 146.0459 | -1.5 | PFP (-) |
| Glutamate | 2.6 | C5H9NO4 | 148.0606 | 148.0604 | -1.1 | Scherzo (+) |
| Glutamate | 2.6 | C5H9NO4 | 146.0467 | 146.0459 | -5.6 | Scherzo (-) |
| Glutamate | 5.0 | C5H9NO4 | 146.0467 | 146.0459 | -5.6 | Scherzo (-) |
| Glutamine | 2.5 | C5H10N2O3 | 147.0765 | 147.0764 | -0.5 | Scherzo (+) |
| Glutamine | 2.5 | C5H10N2O3 | 145.0618 | 145.0619 | 0.5 | Scherzo (-) |
| Glutaric acid | 4.7 | C5H8O4 | 131.0347 | 131.0350 | 2.1 | PFP (-) |
| Glutaric acid | 5.6 | C5H8O4 | 131.0346 | 131.0350 | 2.9 | PFP (-) |
| Glutaric acid | 6.2 | C5H8O4 | 131.0348 | 131.0350 | 1.4 | Scherzo (-) |

| Glutathione | 3.8 | C10H17N3O6S | 306.0775 | 306.0765 | -3.2 | Scherzo (-) |
|--|------|---------------|----------|----------|------|-------------|
| Glutathione oxidized | 2.1 | C20H32N6O12S2 | 611.1486 | 611.1447 | -6.4 | PFP (-) |
| Glutathione oxidized | 2.8 | C20H32N6O12S2 | 613.1601 | 613.1592 | -1.4 | PFP (+) |
| Glutathione oxidized | 2.9 | C20H32N6O12S2 | 613.1597 | 613.1592 | -0.8 | Scherzo (+) |
| Glutathione oxidized | 2.9 | C20H32N6O12S2 | 611.1449 | 611.1447 | -0.3 | Scherzo (-) |
| Glutathione oxidized | 2.9 | C20H32N6O12S2 | 611.1481 | 611.1447 | -5.6 | PFP (-) |
| Glutathione oxidized | 3.5 | C20H32N6O12S2 | 611.1406 | 611.1447 | 6.7 | Scherzo (-) |
| Glutathione oxidized | 5.2 | C20H32N6O12S2 | 613.1612 | 613.1592 | -3.2 | Scherzo (+) |
| Glutathione oxidized | 5.3 | C20H32N6O12S2 | 611.1452 | 611.1447 | -0.8 | Scherzo (-) |
| Glutathione, reduced | 3.8 | C10H17N3O6S | 308.0920 | 308.0911 | -3.0 | Scherzo (+) |
| Gly-Leu | 4.2 | C8H16N2O3 | 189.1229 | 189.1234 | 2.5 | Scherzo (+) |
| Gly-Leu | 5.7 | C8H16N2O3 | 189.1237 | 189.1234 | -1.7 | PFP (+) |
| Gly-Phe | 6.6 | C11H14N2O3 | 223.1079 | 223.1077 | -0.8 | Scherzo (+) |
| Gly-Phe | 7.7 | C11H14N2O3 | 223.1080 | 223.1077 | -1.3 | PFP (+) |
| Gly-Tyr | 4.1 | C11H14N2O4 | 239.1035 | 239.1026 | -3.6 | Scherzo (+) |
| Gly-Tyr | 4.9 | C11H14N2O4 | 239.1028 | 239.1026 | -0.7 | PFP (+) |
| Glyceraldehyde, 3-(dihydrogen phosphate) | 9.5 | C3H7O6P | 168.9912 | 168.9908 | -2.7 | Scherzo (-) |
| Glyceric acid | 1.9 | C3H6O4 | 105.0192 | 105.0193 | 1.2 | PFP (-) |
| Glycerol 3-phosphate | 6.1 | C3H9O6P | 171.0072 | 171.0064 | -4.7 | Scherzo (-) |
| Glycerol 3-phosphate | 6.5 | C3H9O6P | 171.0068 | 171.0064 | -2.3 | Scherzo (-) |
| Glycerolphosphate | 2.2 | C3H9O6P | 173.0205 | 173.0210 | 2.6 | PFP (+) |
| Glycerolphosphate | 6.5 | C3H9O6P | 173.0206 | 173.0210 | 2.0 | Scherzo (+) |
| Glycerolphosphate | 9.1 | C3H9O6P | 171.0066 | 171.0064 | -1.2 | Scherzo (-) |
| Glycerophosphocholine | 2.5 | C8H20NO6P | 258.1108 | 258.1101 | -2.7 | PFP (+) |
| Glycerophosphocholine | 2.8 | C8H20NO6P | 258.1109 | 258.1101 | -3.1 | Scherzo (+) |
| Glycyl-L-leucine | 5.6 | C8H16N2O3 | 187.1088 | 187.1088 | 0.1 | PFP (-) |
| Guanidinoethyl sulfonate | 2.7 | C3H9N3O3S | 166.0292 | 166.0292 | -0.1 | Scherzo (-) |
| Guanine | 2.4 | C5H5N5O | 152.0556 | 152.0567 | 7.2 | PFP (+) |
| Guanine | 2.8 | C5H5N5O | 152.0565 | 152.0567 | 1.2 | Scherzo (+) |
| Guanine | 3.1 | C5H5N5O | 150.0412 | 150.0421 | 6.2 | Scherzo (-) |
| Guanine | 5.0 | C5H5N5O | 152.0570 | 152.0567 | -2.0 | PFP (+) |
| Guanine | 5.4 | C5H5N5O | 152.0572 | 152.0567 | -3.4 | PFP (+) |
| Guanine | 5.4 | C5H5N5O | 150.0422 | 150.0421 | -0.5 | PFP (-) |
| Guanine | 6.6 | C5H5N5O | 152.0569 | 152.0567 | -1.4 | Scherzo (+) |
| Guanine | 7.3 | C5H5N5O | 152.0568 | 152.0567 | -0.7 | PFP (+) |
| Guanine | 8.0 | C5H5N5O | 152.0570 | 152.0567 | -2.0 | PFP (+) |
| Guanine | 8.4 | C5H5N5O | 152.0564 | 152.0567 | 1.9 | Scherzo (+) |
| Guanine | 8.5 | C5H5N5O | 152.0567 | 152.0567 | -0.1 | PFP (+) |
| Guanine | 13.1 | C5H5N5O | 152.0562 | 152.0567 | 3.2 | Scherzo (+) |
| Guanine | 6.2 | C5H5N5O | 152.0565 | 152.0567 | 1.2 | PFP (+) |
| Guanosine | 5.4 | C10H13N5O5 | 284.0996 | 284.0990 | -2.3 | PFP (+) |
| Guanosine | 5.4 | C10H13N5O5 | 282.0858 | 282.0844 | -5.0 | PFP (-) |
| Guanosine | 6.2 | C10H13N5O5 | 284.1001 | 284.0990 | -4.0 | Scherzo (+) |
| Guanosine | 6.3 | C10H13N5O5 | 282.0857 | 282.0844 | -4.6 | Scherzo (-) |
| Guanosine monophosphate | 2.5 | C10H14N5O8P | 364.0650 | 364.0653 | 0.8 | PFP (+) |

| Guanosine monophosphate | 3.0 | C10H14N5O8P | 362.0524 | 362.0507 | -4.6 | PFP (-) |
|---------------------------|------|-------------|----------|----------|------|-------------|
| Guanosine monophosphate | 3.1 | C10H14N5O8P | 364.0659 | 364.0653 | -1.7 | PFP (+) |
| Guanosine monophosphate | 3.9 | C10H14N5O8P | 362.0521 | 362.0507 | -3.8 | PFP (-) |
| Guanosine monophosphate | 4.8 | C10H14N5O8P | 362.0512 | 362.0507 | -1.3 | PFP (-) |
| Guanosine monophosphate | 6.6 | C10H14N5O8P | 364.0656 | 364.0653 | -0.9 | PFP (+) |
| Guanosine monophosphate | 6.6 | C10H14N5O8P | 362.0523 | 362.0507 | -4.4 | PFP (-) |
| Guanosine monophosphate | 9.1 | C10H14N5O8P | 364.0665 | 364.0653 | -3.4 | Scherzo (+) |
| Guanosine monophosphate | 9.3 | C10H14N5O8P | 362.0513 | 362.0507 | -1.6 | Scherzo (-) |
| Guanosine monophosphate | 10.0 | C10H14N5O8P | 364.0658 | 364.0653 | -1.4 | Scherzo (+) |
| Hexadecanedioic acid | 18.0 | C16H30O4 | 285.2071 | 285.2071 | 0.1 | PFP (-) |
| Hexaethylene glycol | 10.0 | C12H26O7 | 283.1759 | 283.1751 | -2.7 | PFP (+) |
| Hexanoyl-L-carnitine | 8.9 | C13H25NO4 | 260.1865 | 260.1856 | -3.3 | Scherzo (+) |
| Hexanoyl-L-carnitine | 12.6 | C13H25NO4 | 260.1862 | 260.1856 | -2.2 | PFP (+) |
| Hippuric acid | 9.5 | C9H9NO3 | 178.0509 | 178.0510 | 0.4 | PFP (-) |
| Histidine | 1.9 | C6H9N3O2 | 156.0769 | 156.0768 | -1.0 | PFP (+) |
| Histidine | 1.9 | C6H9N3O2 | 154.0620 | 154.0622 | 1.3 | PFP (-) |
| Histidine | 2.1 | C6H9N3O2 | 154.0619 | 154.0622 | 1.9 | Scherzo (-) |
| Histidine | 2.1 | C6H9N3O2 | 156.0770 | 156.0768 | -1.6 | Scherzo (+) |
| Histidine | 2.4 | C6H9N3O2 | 156.0763 | 156.0768 | 2.9 | PFP (+) |
| Homoeriodictyol | 14.0 | C16H14O6 | 301.0717 | 301.0718 | 0.2 | Scherzo (-) |
| Homovanillic acid sulfate | 9.9 | C9H10O7S | 261.0070 | 261.0075 | 1.7 | PFP (-) |
| Homovanillic acid sulfate | 10.8 | C9H10O7S | 261.0080 | 261.0075 | -2.1 | PFP (-) |
| Hydroferulic acid | 12.7 | C10H12O4 | 195.0668 | 195.0663 | -2.7 | PFP (-) |
| Hydroxybutyric acid | 2.9 | C4H8O3 | 103.0399 | 103.0401 | 1.6 | PFP (-) |
| Hydroxyphenyllactic acid | 8.7 | C9H10O4 | 181.0511 | 181.0506 | -2.6 | PFP (-) |
| Hypoxanthine | 4.2 | C5H4N4O | 137.0458 | 137.0458 | -0.1 | Scherzo (+) |
| Hypoxanthine | 5.2 | C5H4N4O | 137.0455 | 137.0458 | 2.1 | PFP (+) |
| Hypoxanthine | 6.1 | C5H4N4O | 137.0448 | 137.0458 | 7.2 | Scherzo (+) |
| Hypoxanthine | 6.2 | C5H4N4O | 137.0458 | 137.0458 | -0.1 | PFP (+) |
| Hypoxanthine | 6.7 | C5H4N4O | 137.0454 | 137.0458 | 2.8 | Scherzo (+) |
| Hypoxanthine | 3.3 | C5H4N4O | 137.0457 | 137.0458 | 0.7 | PFP (+) |
| lle-Arg | 7.8 | C12H25N5O3 | 288.2036 | 288.2030 | -2.0 | PFP (+) |
| lle-Leu | 10.6 | C12H24N2O3 | 245.1862 | 245.1860 | -0.9 | PFP (+) |
| lle-Pro-lle | 8.4 | C17H31N3O4 | 342.2389 | 342.2387 | -0.5 | Scherzo (+) |
| lle-Tyr | 8.9 | C15H22N2O4 | 295.1657 | 295.1652 | -1.6 | PFP (+) |
| lle-Val | 6.8 | C11H22N2O3 | 231.1699 | 231.1703 | 1.8 | PFP (+) |
| Indole | 9.4 | C8H7N | 118.0652 | 118.0651 | -0.6 | PFP (+) |
| Indole-3-lactic acid | 12.2 | C11H11NO3 | 206.0811 | 206.0812 | 0.3 | Scherzo (+) |
| Indole-3-lactic acid | 12.2 | C11H11NO3 | 204.0675 | 204.0666 | -4.3 | Scherzo (-) |
| Indole-3-lactic acid | 13.4 | C11H11NO3 | 204.0670 | 204.0666 | -1.9 | PFP (-) |
| Indole-3-lactic acid | 13.4 | C11H11NO3 | 206.0811 | 206.0812 | 0.3 | PFP (+) |
| Indole-6-carboxaldehyde | 12.3 | C9H7NO | 144.0461 | 144.0455 | -4.2 | Scherzo (-) |
| Indole-6-carboxaldehyde | 14.4 | C9H7NO | 144.0458 | 144.0455 | -2.2 | PFP (-) |
| Indole-6-carboxaldehyde | 9.4 | C9H7NO | 146.0601 | 146.0600 | -0.4 | PFP (+) |
| Indole-6-carboxaldehyde | 14.4 | C9H7NO | 146.0601 | 146.0600 | -0.4 | PFP (+) |

| Indoleacrylic acid | 13.4 | C11H9NO2 | 186.0567 | 186.0561 | -3.5 | Scherzo (-) |
|----------------------------|------|-------------|----------|----------|------|-------------|
| Indoleacrylic acid | 16.1 | C11H9NO2 | 186.0561 | 186.0561 | -0.3 | PFP (-) |
| Indoxyl sulfate | 10.7 | C8H7NO4S | 212.0029 | 212.0023 | -2.8 | PFP (-) |
| Inosine | 4.3 | C10H12N4O5 | 267.0744 | 267.0735 | -3.4 | PFP (-) |
| Inosine | 4.6 | C10H12N4O5 | 269.0888 | 269.0881 | -2.8 | PFP (+) |
| Inosine | 5.2 | C10H12N4O5 | 269.0882 | 269.0881 | -0.6 | PFP (+) |
| Inosine | 6.1 | C10H12N4O5 | 269.0890 | 269.0881 | -3.5 | Scherzo (+) |
| Inosine | 6.3 | C10H12N4O5 | 267.0736 | 267.0735 | -0.4 | Scherzo (-) |
| Inosinic acid | 3.0 | C10H13N4O8P | 347.0398 | 347.0398 | 0.1 | PFP (-) |
| Isocitric acid lactone | 5.8 | C6H6O6 | 173.0090 | 173.0092 | 0.9 | Scherzo (-) |
| Isoferulic acid | 16.3 | C10H10O4 | 193.0502 | 193.0506 | 2.2 | PFP (-) |
| Isoleucine | 3.5 | C6H13NO2 | 132.1016 | 132.1019 | 2.3 | Scherzo (+) |
| Isoleucine | 3.5 | C6H13NO2 | 130.0877 | 130.0874 | -2.7 | Scherzo (-) |
| Isopentenyladenine | 12.6 | C10H13N5 | 204.1240 | 204.1244 | 1.8 | PFP (+) |
| Isosteviol | 14.8 | C20H30O3 | 317.2123 | 317.2122 | -0.3 | Scherzo (-) |
| Itaconic acid | 9.0 | C5H6O4 | 129.0181 | 129.0193 | 9.5 | Scherzo (-) |
| Jasmonic acid | 11.2 | C12H18O3 | 211.1334 | 211.1329 | -2.5 | PFP (+) |
| Kaempferol | 14.7 | C15H10O6 | 285.0409 | 285.0405 | -1.5 | Scherzo (-) |
| Kynurenic acid | 9.4 | C10H7NO3 | 190.0497 | 190.0499 | 0.9 | Scherzo (+) |
| Kynurenic acid | 17.2 | C10H7NO3 | 190.0499 | 190.0499 | -0.2 | Scherzo (+) |
| Kynurenic acid | 10.2 | C10H7NO3 | 190.0503 | 190.0499 | -2.3 | PFP (+) |
| Kynurenic acid | 10.6 | C10H7NO3 | 190.0501 | 190.0499 | -1.2 | PFP (+) |
| Kynurenic acid | 11.8 | C10H7NO3 | 190.0499 | 190.0499 | -0.2 | PFP (+) |
| Kynurenine | 5.7 | C10H12N2O3 | 209.0923 | 209.0921 | -1.1 | PFP (+) |
| Kynurenine | 5.7 | C10H12N2O3 | 207.0774 | 207.0775 | 0.6 | PFP (-) |
| Kynurenine | 5.9 | C10H12N2O3 | 209.0917 | 209.0921 | 1.8 | Scherzo (+) |
| Lactate | 2.1 | C3H6O3 | 89.0248 | 89.0244 | -4.3 | PFP (-) |
| Lauric acid diethanolamide | 18.0 | C16H33NO3 | 288.2541 | 288.2533 | -2.7 | Scherzo (+) |
| Lauric acid diethanolamide | 17.9 | C16H33NO3 | 288.2536 | 288.2533 | -1.0 | PFP (+) |
| Lauroyl-L-carnitine | 13.6 | C19H37NO4 | 344.2800 | 344.2795 | -1.3 | Scherzo (+) |
| Lauroyl-L-carnitine | 17.7 | C19H37NO4 | 344.2788 | 344.2795 | 2.1 | PFP (+) |
| Leu-Leu | 11.2 | C12H24N2O3 | 245.1865 | 245.1860 | -2.2 | PFP (+) |
| Leu-Pro-Arg | 6.7 | C17H32N6O4 | 385.2555 | 385.2558 | 0.7 | PFP (+) |
| Leu-Val | 7.8 | C11H22N2O3 | 231.1708 | 231.1703 | -2.1 | PFP (+) |
| Leucine | 2.7 | C6H13NO2 | 130.0873 | 130.0874 | 0.4 | PFP (-) |
| Leukotriene E4 | 15.5 | C23H37NO5S | 438.2295 | 438.2320 | 5.6 | Scherzo (-) |
| Linoleoylcarnitine | 17.8 | C25H45NO4 | 424.3422 | 424.3421 | -0.1 | PFP (+) |
| Lumichrome | 12.0 | C12H10N4O2 | 243.0880 | 243.0877 | -1.4 | Scherzo (+) |
| Lumichrome | 15.1 | C12H10N4O2 | 241.0735 | 241.0731 | -1.7 | PFP (-) |
| Lumichrome | 15.1 | C12H10N4O2 | 243.0878 | 243.0877 | -0.6 | PFP (+) |
| Luteolin | 17.6 | C15H10O6 | 285.0408 | 285.0405 | -1.2 | PFP (-) |
| Lysine | 2.0 | C6H14N2O2 | 147.1129 | 147.1128 | -0.7 | Scherzo (+) |
| Maleic acid | 2.0 | C4H4O4 | 115.0035 | 115.0037 | 1.6 | PFP (-) |
| Maleic acid | 3.0 | C4H4O4 | 115.0037 | 115.0037 | -0.2 | PFP (-) |
| Malic acid | 2.0 | C4H6O5 | 133.0146 | 133.0143 | -2.6 | PFP (-) |

| Malic acid | 4.5 | C4H6O5 | 133.0150 | 133.0143 | -5.6 | Scherzo (-) |
|------------------------------------|------|------------|----------|----------|------|-------------|
| Maltol | 7.7 | C6H6O3 | 127.0384 | 127.0390 | 4.5 | PFP (+) |
| Mandelic acid | 9.5 | C8H8O3 | 151.0401 | 151.0401 | -0.2 | Scherzo (-) |
| Matairesinol | 11.9 | C20H22O6 | 359.1484 | 359.1489 | 1.4 | Scherzo (+) |
| Matairesinol | 13.9 | C20H22O6 | 359.1501 | 359.1489 | -3.3 | Scherzo (+) |
| Methionine | 2.3 | C5H11NO2S | 150.0584 | 150.0583 | -0.5 | PFP (+) |
| Methionine | 2.8 | C5H11NO2S | 148.0445 | 148.0438 | -4.9 | Scherzo (-) |
| Methionine | 2.9 | C5H11NO2S | 150.0587 | 150.0583 | -2.5 | Scherzo (+) |
| Methionine | 9.2 | C5H11NO2S | 150.0583 | 150.0583 | 0.2 | Scherzo (+) |
| Methionine sulfoxide | 2.6 | C5H11NO3S | 166.0529 | 166.0532 | 2.0 | Scherzo (+) |
| Methyl trans-cinnamate | 12.7 | C10H10O2 | 163.0752 | 163.0754 | 1.0 | Scherzo (+) |
| Methylsuccinic acid | 10.5 | C5H8O4 | 131.0358 | 131.0350 | -6.3 | Scherzo (-) |
| Monobutyl phthalate | 17.2 | C12H14O4 | 221.0827 | 221.0819 | -3.5 | PFP (-) |
| myo-Inositol-1,2-diphosphate | 8.3 | C6H14O12P2 | 338.9885 | 338.9888 | 0.8 | Scherzo (-) |
| Myristoleic acid | 17.9 | C14H26O2 | 227.2010 | 227.2006 | -1.9 | PFP (+) |
| N-(4-Aminobenzoyl)-L-glutamic acid | 6.3 | C12H14N2O5 | 265.0840 | 265.0830 | -3.8 | PFP (-) |
| N-(4-Aminobenzoyl)-L-glutamic acid | 7.4 | C12H14N2O5 | 267.0990 | 267.0976 | -5.4 | Scherzo (+) |
| N-(4-Aminobenzoyl)-L-glutamic acid | 7.6 | C12H14N2O5 | 265.0843 | 265.0830 | -4.9 | Scherzo (-) |
| N-(4-Aminobenzoyl)-L-glutamic acid | 6.3 | C12H14N2O5 | 267.0979 | 267.0976 | -1.3 | PFP (+) |
| N-Acetyl galactosamine | 2.7 | C8H15NO6 | 222.0982 | 222.0972 | -4.5 | Scherzo (+) |
| N-Acetyl galactosamine | 2.7 | C8H15NO6 | 220.0831 | 220.0827 | -2.0 | Scherzo (-) |
| N-acetyl glutamic acid | 2.8 | C7H11NO5 | 190.0710 | 190.0710 | 0.0 | PFP (+) |
| N-acetyl glutamic acid | 2.8 | C7H11NO5 | 188.0569 | 188.0565 | -2.4 | PFP (-) |
| N-acetyl glutamic acid | 3.0 | C7H11NO5 | 188.0567 | 188.0565 | -1.3 | PFP (-) |
| N-acetyl glutamic acid | 5.7 | C7H11NO5 | 190.0709 | 190.0710 | 0.5 | Scherzo (+) |
| N-acetyl glutamic acid | 5.7 | C7H11NO5 | 188.0569 | 188.0565 | -2.4 | Scherzo (-) |
| N-Acetyl-D-glucosamine 6-phosphate | 1.9 | C8H16NO9P | 300.0485 | 300.0490 | 1.6 | PFP (-) |
| N-Acetyl-D-glucosamine 6-phosphate | 2.3 | C8H16NO9P | 300.0486 | 300.0490 | 1.3 | PFP (-) |
| N-Acetyl-D-glucosamine 6-phosphate | 6.6 | C8H16NO9P | 300.0498 | 300.0490 | -2.7 | Scherzo (-) |
| N-Acetyl-D-glucosamine 6-phosphate | 8.6 | C8H16NO9P | 300.0481 | 300.0490 | 3.0 | Scherzo (-) |
| N-Acetyl-D-glucosamine 6-phosphate | 9.3 | C8H16NO9P | 300.0495 | 300.0490 | -1.7 | Scherzo (-) |
| N-Acetyl-D-norleucine | 11.1 | C8H15NO3 | 172.0981 | 172.0979 | -1.0 | PFP (-) |
| N-Acetyl-DL-valine | 6.6 | C7H13NO3 | 158.0824 | 158.0823 | -0.8 | PFP (-) |
| N-Acetyl-DL-valine | 7.2 | C7H13NO3 | 158.0825 | 158.0823 | -1.5 | Scherzo (-) |
| N-Acetyl-DL-valine | 7.8 | C7H13NO3 | 158.0823 | 158.0823 | -0.2 | PFP (-) |
| N-Acetyl-DL-valine | 8.7 | C7H13NO3 | 158.0828 | 158.0823 | -3.4 | Scherzo (-) |
| N-Acetyl-L-alanine | 2.8 | C5H9NO3 | 130.0511 | 130.0510 | -1.0 | PFP (-) |
| N-Acetyl-L-alanine | 5.1 | C5H9NO3 | 130.0513 | 130.0510 | -2.5 | Scherzo (-) |
| N-Acetyl-L-alanine | 5.7 | C5H9NO3 | 130.0514 | 130.0510 | -3.3 | Scherzo (-) |
| N-Acetyl-L-Aspartate | 5.7 | C6H9NO5 | 174.0415 | 174.0408 | -4.0 | Scherzo (-) |
| N-Acetyl-L-Glutamine | 4.4 | C7H12N2O4 | 189.0869 | 189.0870 | 0.4 | Scherzo (+) |
| N-Acetyl-L-Glutamine | 4.5 | C7H12N2O4 | 187.0725 | 187.0724 | -0.4 | Scherzo (-) |
| N-Acetyl-L-Leucine | 10.6 | C8H15NO3 | 174.1118 | 174.1125 | 3.8 | Scherzo (+) |
| N-Acetyl-L-Leucine | 11.1 | C8H15NO3 | 174.1128 | 174.1125 | -1.9 | PFP (+) |
| N-Acetyl-L-methionine | 8.1 | C7H13NO3S | 192.0683 | 192.0689 | 3.1 | PFP (+) |

| N-Acetyl-L-Methionine | 8.1 | C7H13NO3S | 190.0548 | 190.0543 | -2.4 | PFP (-) |
|--|------|---------------|----------|----------|------|-------------|
| N-Acetyl-L-methionine | 9.2 | C7H13NO3S | 192.0684 | 192.0689 | 2.6 | Scherzo (+) |
| N-Acetyl-L-Methionine | 9.3 | C7H13NO3S | 190.0550 | 190.0543 | -3.5 | Scherzo (-) |
| N-Acetyl-L-Phenylalanine | 12.0 | C11H13NO3 | 208.0975 | 208.0968 | -3.3 | Scherzo (+) |
| N-Acetyl-L-phenylalanine | 12.3 | C11H13NO3 | 206.0828 | 206.0823 | -2.6 | PFP (-) |
| N-Acetyl-L-Phenylalanine | 12.4 | C11H13NO3 | 208.0973 | 208.0968 | -2.3 | PFP (+) |
| N-Acetyl-L-tyrosine | 9.4 | C11H13NO4 | 222.0779 | 222.0772 | -3.2 | PFP (-) |
| N-Acetylaspartylglutamic acid | 7.1 | C11H16N2O8 | 303.0839 | 303.0834 | -1.7 | Scherzo (-) |
| N-Acetylaspartylglutamic acid | 7.2 | C11H16N2O8 | 305.0973 | 305.0979 | 2.1 | Scherzo (+) |
| N-Alpha-acetyllysine | 1.9 | C8H16N2O3 | 189.1242 | 189.1234 | -4.4 | PFP (+) |
| N-Alpha-acetyllysine | 2.6 | C8H16N2O3 | 189.1233 | 189.1234 | 0.4 | Scherzo (+) |
| N-Formyl-L-methionine | 7.3 | C6H11NO3S | 176.0384 | 176.0387 | 1.6 | PFP (-) |
| N-Formyl-L-methionine | 9.3 | C6H11NO3S | 176.0383 | 176.0387 | 2.2 | Scherzo (-) |
| N-Glycolylneuraminic acid | 2.1 | C11H19NO10 | 324.0939 | 324.0936 | -0.9 | PFP (-) |
| N-Glycolylneuraminic acid | 4.9 | C11H19NO10 | 324.0949 | 324.0936 | -3.9 | Scherzo (-) |
| N-Glycolylneuraminic acid | 5.2 | C11H19NO10 | 324.0945 | 324.0936 | -2.7 | Scherzo (-) |
| N-Glycolylneuraminic acid | 5.3 | C11H19NO10 | 326.1088 | 326.1082 | -1.9 | Scherzo (+) |
| N-Succinyl-5-aminoimidazole-4-carboxamide ribose | 6.1 | C13H18N4O9 | 375.1146 | 375.1147 | 0.1 | PFP (+) |
| N,N-Dimethylaniline | 3.6 | C8H11N | 122.0966 | 122.0964 | -1.4 | Scherzo (+) |
| N,N-Dimethylaniline | 8.2 | C8H11N | 122.0966 | 122.0964 | -1.4 | PFP (+) |
| N,N-Dimethylguanosine | 7.4 | C12H17N5O5 | 312.1311 | 312.1303 | -2.7 | Scherzo (+) |
| N,N-Dimethylguanosine | 8.3 | C12H17N5O5 | 312.1312 | 312.1303 | -3.0 | PFP (+) |
| N.epsilonAcetyl-L-lysine | 2.8 | C8H16N2O3 | 189.1233 | 189.1234 | 0.4 | Scherzo (+) |
| N.epsilonAcetyl-L-lysine | 2.4 | C8H16N2O3 | 189.1236 | 189.1234 | -1.2 | PFP (+) |
| NAD | 3.5 | C21H27N7O14P2 | 664.1184 | 664.1164 | -3.0 | PFP (+) |
| NAD | 5.9 | C21H27N7O14P2 | 664.1167 | 664.1164 | -0.5 | Scherzo (+) |
| NAD | 5.9 | C21H27N7O14P2 | 662.1042 | 662.1019 | -3.5 | Scherzo (-) |
| Nandrolone | 14.1 | C18H26O2 | 275.2005 | 275.2006 | 0.2 | Scherzo (+) |
| Naringenin | 14.2 | C15H12O5 | 273.0762 | 273.0758 | -1.6 | Scherzo (+) |
| Naringenin | 17.5 | C15H12O5 | 271.0621 | 271.0612 | -3.3 | PFP (-) |
| Naringenin | 17.5 | C15H12O5 | 273.0761 | 273.0758 | -1.3 | PFP (+) |
| Naringenin-4'-ObetaD-glucuronide | 14.1 | C21H20O11 | 447.0929 | 447.0933 | 0.9 | Scherzo (-) |
| Naringenin-4'-ObetaD-glucuronide | 14.7 | C21H20O11 | 447.0949 | 447.0933 | -3.6 | PFP (-) |
| Niacinamide | 2.7 | C6H6N2O | 123.0556 | 123.0553 | -2.5 | PFP (+) |
| Nicotinamide | 3.5 | C6H6N2O | 123.0555 | 123.0553 | -1.7 | Scherzo (+) |
| Nicotinate | 2.6 | C6H5NO2 | 124.0395 | 124.0393 | -1.6 | PFP (+) |
| Nicotinate | 2.6 | C6H5NO2 | 122.0248 | 122.0248 | -0.4 | PFP (-) |
| Nicotinate | 2.9 | C6H5NO2 | 124.0395 | 124.0393 | -1.6 | Scherzo (+) |
| Nicotinate | 3.6 | C6H5NO2 | 124.0395 | 124.0393 | -1.6 | Scherzo (+) |
| Nicotinate | 3.6 | C6H5NO2 | 122.0254 | 122.0248 | -5.3 | Scherzo (-) |
| Nicotinic acid mononucleotide | 8.6 | C11H14NO9P | 336.0484 | 336.0479 | -1.5 | Scherzo (+) |
| Nutriacholic acid | 15.7 | C24H38O4 | 391.2853 | 391.2843 | -2.6 | Scherzo (+) |
| Nutriacholic acid | 17.8 | C24H38O4 | 391.2849 | 391.2843 | -1.6 | PFP (+) |
| O-Phospho-L-Serine | 6.8 | C3H8NO6P | 184.0015 | 184.0017 | 0.8 | Scherzo (-) |
| O-Phospho-L-Serine | 6.9 | C3H8NO6P | 186.0155 | 186.0162 | 3.8 | Scherzo (+) |

| O-phosphoryl-ethanolamine | 1.9 | C2H8NO4P | 140.0117 | 140.0118 | 0.9 | PFP (-) |
|--------------------------------------|------|-------------|----------|----------|------|-------------|
| O-phosphoryl-ethanolamine | 2.5 | C2H8NO4P | 140.0123 | 140.0118 | -3.4 | Scherzo (-) |
| O-phosphoryl-ethanolamine | 2.6 | C2H8NO4P | 142.0260 | 142.0264 | 2.6 | Scherzo (+) |
| Octadecanedioic acid | 16.4 | C18H34O4 | 313.2390 | 313.2384 | -1.8 | Scherzo (-) |
| Octanoylcarnitine | 11.0 | C15H29NO4 | 288.2175 | 288.2169 | -1.9 | Scherzo (+) |
| Octanoylcarnitine | 15.9 | C15H29NO4 | 288.2174 | 288.2169 | -1.6 | PFP (+) |
| Oleoyl-L-carnitine | 16.8 | C25H47NO4 | 426.3586 | 426.3578 | -1.9 | Scherzo (+) |
| Oleoyl-L-carnitine | 17.9 | C25H47NO4 | 426.3569 | 426.3578 | 2.1 | PFP (+) |
| omega-Benzoyloxyphloracetophenone | 12.9 | C15H12O6 | 287.0565 | 287.0561 | -1.4 | Scherzo (-) |
| Ophtalmic acid | 3.8 | C11H19N3O6 | 290.1351 | 290.1347 | -1.5 | Scherzo (+) |
| Orotic acid | 2.9 | C5H4N2O4 | 155.0098 | 155.0098 | 0.2 | PFP (-) |
| Oxypurinol | 3.5 | C5H4N4O2 | 151.0267 | 151.0262 | -3.6 | PFP (-) |
| Oxypurinol | 5.0 | C5H4N4O2 | 151.0273 | 151.0262 | -7.6 | Scherzo (-) |
| p-Acetamidophenyl .betaD-glucuronide | 9.7 | C14H17NO8 | 326.0877 | 326.0881 | 1.3 | PFP (-) |
| p-Acetamidophenyl .betaD-glucuronide | 10.8 | C14H17NO8 | 328.1028 | 328.1027 | -0.3 | Scherzo (+) |
| p-Acetamidophenyl .betaD-glucuronide | 11.0 | C14H17NO8 | 326.0879 | 326.0881 | 0.7 | Scherzo (-) |
| p-Acetaminobenzoic acid | 10.1 | C9H9NO3 | 180.0654 | 180.0655 | 0.7 | Scherzo (+) |
| p-Acetaminobenzoic acid | 10.2 | C9H9NO3 | 178.0515 | 178.0510 | -3.0 | Scherzo (-) |
| p-Acetaminobenzoic acid | 11.7 | C9H9NO3 | 178.0513 | 178.0510 | -1.9 | PFP (-) |
| p-Acetaminobenzoic acid | 11.7 | C9H9NO3 | 180.0656 | 180.0655 | -0.4 | PFP (+) |
| p-Hydroxyphenyllactic acid | 9.0 | C9H10O4 | 181.0512 | 181.0506 | -3.1 | Scherzo (-) |
| p-tert-Butylcatechol | 16.4 | C10H14O2 | 165.0921 | 165.0921 | 0.0 | PFP (-) |
| Palmitic acid alkyne | 14.9 | C16H28O2 | 253.2160 | 253.2162 | 0.8 | Scherzo (+) |
| Palmitoyl sphingomyelin | 17.9 | C39H79N2O6P | 703.5747 | 703.5749 | 0.2 | PFP (+) |
| Palmitoylcarnitine | 16.6 | C23H45NO4 | 400.3434 | 400.3421 | -3.1 | Scherzo (+) |
| Palmitoylcarnitine | 17.9 | C23H45NO4 | 400.3428 | 400.3421 | -1.6 | PFP (+) |
| Pantothenate | 6.4 | C9H17NO5 | 220.1182 | 220.1180 | -1.1 | PFP (+) |
| Pantothenate | 7.0 | C9H17NO5 | 220.1184 | 220.1180 | -2.0 | Scherzo (+) |
| Pantothenic acid | 6.4 | C9H17NO5 | 218.1042 | 218.1034 | -3.7 | PFP (-) |
| Pantothenic acid | 7.1 | C9H17NO5 | 218.1044 | 218.1034 | -4.6 | Scherzo (-) |
| Pentaethylene glycol | 7.6 | C10H22O6 | 239.1475 | 239.1489 | 5.9 | Scherzo (+) |
| Pentaethylene glycol | 8.9 | C10H22O6 | 239.1484 | 239.1489 | 2.2 | PFP (+) |
| Phe-Asp | 4.4 | C13H16N2O5 | 281.1131 | 281.1132 | 0.4 | Scherzo (+) |
| Phe-Glu | 4.9 | C14H18N2O5 | 295.1287 | 295.1289 | 0.5 | Scherzo (+) |
| Phe-Glu | 6.5 | C14H18N2O5 | 295.1293 | 295.1289 | -1.5 | PFP (+) |
| Phe-Gly | 5.4 | C11H14N2O3 | 223.1080 | 223.1077 | -1.3 | Scherzo (+) |
| Phe-Gly | 6.8 | C11H14N2O3 | 223.1079 | 223.1077 | -0.8 | PFP (+) |
| Phe-Leu | 12.6 | C15H22N2O3 | 279.1712 | 279.1703 | -3.2 | PFP (+) |
| Phe-Pro | 8.6 | C14H18N2O3 | 263.1388 | 263.1390 | 0.8 | Scherzo (+) |
| Phe-Val | 9.8 | C14H20N2O3 | 265.1544 | 265.1547 | 1.0 | PFP (+) |
| Phenaceturic acid | 11.2 | C10H11NO3 | 194.0813 | 194.0812 | -0.7 | Scherzo (+) |
| Phenaceturic acid | 10.2 | C10H11NO3 | 194.0813 | 194.0812 | -0.7 | PFP (+) |
| Phenyl glucuronide | 8.2 | C12H14O7 | 269.0675 | 269.0667 | -3.0 | PFP (-) |
| Phenyl glucuronide | 11.0 | C12H14O7 | 269.0667 | 269.0667 | -0.1 | Scherzo (-) |
| Phenylacetaldehyde | 3.9 | C8H8O | 121.0650 | 121.0648 | -1.7 | Scherzo (+) |

| Phenylacetaldehyde | 11.0 | C8H8O | 121.0648 | 121.0648 | -0.1 | Scherzo (+) |
|---------------------|------|------------|----------|----------|------|-------------|
| Phenylacetaldehyde | 12.4 | C8H8O | 121.0649 | 121.0648 | -0.9 | PFP (+) |
| Phenylacetylglycine | 10.2 | C10H11NO3 | 192.0670 | 192.0666 | -2.0 | PFP (-) |
| Phenylacetylglycine | 11.3 | C10H11NO3 | 192.0674 | 192.0666 | -4.1 | Scherzo (-) |
| Phenylalanine | 4.8 | C9H11NO2 | 166.0867 | 166.0863 | -2.6 | PFP (+) |
| Phenylalanine | 5.2 | C9H11NO2 | 164.0722 | 164.0717 | -3.0 | PFP (-) |
| Phenylalanine | 5.7 | C9H11NO2 | 166.0864 | 166.0863 | -0.8 | Scherzo (+) |
| Phenylalanine | 5.8 | C9H11NO2 | 164.0725 | 164.0717 | -4.9 | Scherzo (-) |
| Phenylalanine | 9.0 | C9H11NO2 | 166.0859 | 166.0863 | 2.2 | Scherzo (+) |
| Phenylalanine | 9.1 | C9H11NO2 | 166.0862 | 166.0863 | 0.4 | Scherzo (+) |
| Phenylalanine | 12.0 | C9H11NO2 | 166.0859 | 166.0863 | 2.2 | Scherzo (+) |
| Phenylalanine | 12.3 | C9H11NO2 | 166.0862 | 166.0863 | 0.4 | PFP (+) |
| Phenylalanine | 14.0 | C9H11NO2 | 166.0858 | 166.0863 | 2.8 | Scherzo (+) |
| Phenylalanine | 9.6 | C9H11NO2 | 166.0859 | 166.0863 | 2.2 | PFP (+) |
| Phosphocreatine | 7.3 | C4H10N3O5P | 210.0293 | 210.0285 | -3.7 | Scherzo (-) |
| Phosphorylcholine | 2.5 | C5H14NO4P | 184.0736 | 184.0733 | -1.5 | PFP (+) |
| Phosphorylcholine | 2.8 | C5H14NO4P | 184.0737 | 184.0733 | -2.1 | Scherzo (+) |
| Phthalic anhydride | 16.0 | C8H4O3 | 149.0233 | 149.0233 | 0.1 | Scherzo (+) |
| Phthalic anhydride | 17.2 | C8H4O3 | 149.0233 | 149.0233 | 0.1 | PFP (+) |
| Phytosphingosine | 14.4 | C18H39NO3 | 318.3007 | 318.3003 | -1.4 | Scherzo (+) |
| Pimelic acid | 9.3 | C7H12O4 | 159.0667 | 159.0663 | -2.6 | Scherzo (-) |
| Pimelic acid | 10.2 | C7H12O4 | 159.0666 | 159.0663 | -2.0 | PFP (-) |
| Pipecolic acid | 2.8 | C6H11NO2 | 130.0861 | 130.0863 | 1.2 | Scherzo (+) |
| Pipecolinic acid | 2.0 | C6H11NO2 | 130.0862 | 130.0863 | 0.5 | Scherzo (+) |
| Pipecolinic acid | 2.4 | C6H11NO2 | 130.0860 | 130.0863 | 2.0 | PFP (+) |
| Pro-Arg | 5.2 | C11H21N5O3 | 272.1709 | 272.1717 | 3.0 | Scherzo (+) |
| Pro-Arg | 8.1 | C11H21N5O3 | 272.1721 | 272.1717 | -1.4 | PFP (+) |
| Pro-Asp | 2.0 | C9H14N2O5 | 231.0974 | 231.0976 | 0.6 | PFP (+) |
| Pro-Gly | 2.4 | C7H12N2O3 | 173.0920 | 173.0921 | 0.4 | Scherzo (+) |
| Pro-Ile | 5.0 | C11H20N2O3 | 229.1550 | 229.1547 | -1.4 | Scherzo (+) |
| Pro-Phe | 9.6 | C14H18N2O3 | 263.1394 | 263.1390 | -1.4 | PFP (+) |
| Pro-Val | 3.5 | C10H18N2O3 | 215.1390 | 215.1390 | 0.1 | Scherzo (+) |
| Proline | 2.1 | C5H9NO2 | 116.0707 | 116.0706 | -0.8 | PFP (+) |
| Propionylcarnitine | 2.9 | C10H19NO4 | 218.1393 | 218.1387 | -2.8 | Scherzo (+) |
| Propionylcarnitine | 3.5 | C10H19NO4 | 218.1393 | 218.1387 | -2.8 | Scherzo (+) |
| Propionylcarnitine | 6.4 | C10H19NO4 | 218.1391 | 218.1387 | -1.9 | PFP (+) |
| Prostaglandin A1 | 16.4 | C20H32O4 | 335.2233 | 335.2228 | -1.6 | Scherzo (-) |
| Prostaglandin A2 | 14.6 | C20H30O4 | 333.2075 | 333.2071 | -1.1 | Scherzo (-) |
| Prostaglandin A2 | 16.1 | C20H30O4 | 333.2079 | 333.2071 | -2.3 | Scherzo (-) |
| Prostaglandin A2 | 17.8 | C20H30O4 | 333.2085 | 333.2071 | -4.1 | PFP (-) |
| Prostaglandin B1 | 15.6 | C20H32O4 | 335.2231 | 335.2228 | -1.0 | Scherzo (-) |
| Prostaglandin D1 | 17.7 | C20H34O5 | 353.2338 | 353.2334 | -1.3 | PFP (-) |
| Prostaglandin E1 | 14.8 | C20H34O5 | 353.2338 | 353.2334 | -1.3 | Scherzo (-) |
| Prostaglandin H2 | 14.6 | C20H32O5 | 351.2180 | 351.2177 | -0.9 | Scherzo (-) |
| Prostaglandin H2 | 17.6 | C20H32O5 | 351.2195 | 351.2177 | -5.1 | PFP (-) |

| Prostaglandin I2 | 12.8 | C20H32O5 | 353.2329 | 353.2323 | -1.8 | Scherzo (+) |
|------------------------------|------|-------------|----------|----------|------|-------------|
| Prostaglandin I2 | 13.0 | C20H32O5 | 353.2334 | 353.2323 | -3.3 | Scherzo (+) |
| Prostaglandin I2 | 13.8 | C20H32O5 | 353.2333 | 353.2323 | -3.0 | Scherzo (+) |
| Prostaglandin I2 | 17.4 | C20H32O5 | 353.2329 | 353.2323 | -1.8 | PFP (+) |
| Purine | 4.2 | C5H4N4 | 121.0508 | 121.0509 | 0.6 | PFP (+) |
| Purine | 4.2 | C5H4N4 | 119.0365 | 119.0363 | -1.5 | PFP (-) |
| Purine | 4.6 | C5H4N4 | 121.0509 | 121.0509 | -0.2 | Scherzo (+) |
| Pyridoxal 5-phosphate | 6.7 | C8H10NO6P | 248.0324 | 248.0319 | -2.2 | Scherzo (+) |
| Pyridoxal 5-phosphate | 6.7 | C8H10NO6P | 246.0177 | 246.0173 | -1.6 | Scherzo (-) |
| PyroGlu-Phe | 11.8 | C14H16N2O4 | 277.1189 | 277.1183 | -2.2 | Scherzo (+) |
| PyroGlu-Phe | 12.2 | C14H16N2O4 | 277.1184 | 277.1183 | -0.4 | PFP (+) |
| PyroGlu-Pro | 7.7 | C10H14N2O4 | 227.1026 | 227.1026 | 0.1 | Scherzo (+) |
| PyroGlu-Pro | 7.0 | C10H14N2O4 | 227.1029 | 227.1026 | -1.2 | PFP (+) |
| PyroGlu-Pro | 7.4 | C10H14N2O4 | 227.1026 | 227.1026 | 0.1 | PFP (+) |
| PyroGlu-Tyr | 9.6 | C14H16N2O5 | 293.1132 | 293.1132 | 0.0 | Scherzo (+) |
| Pyroglutamic acid | 1.9 | C5H7NO3 | 130.0503 | 130.0499 | -3.3 | PFP (+) |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 128.0356 | 128.0353 | -2.2 | PFP (-) |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 128.0354 | 128.0353 | -0.6 | Scherzo (-) |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 130.0499 | 130.0499 | -0.2 | Scherzo (+) |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 130.0493 | 130.0499 | 4.4 | PFP (+) |
| Pyroglutamic acid | 5.6 | C5H7NO3 | 128.0359 | 128.0353 | -4.5 | Scherzo (-) |
| Pyroglutamic acid | 5.6 | C5H7NO3 | 130.0498 | 130.0499 | 0.5 | Scherzo (+) |
| Pyroglutamic acid | 6.3 | C5H7NO3 | 130.0497 | 130.0499 | 1.3 | Scherzo (+) |
| Quinolin-2-ol | 10.6 | C9H7NO | 144.0454 | 144.0455 | 0.6 | PFP (-) |
| Quinolin-2-ol | 11.3 | C9H7NO | 144.0451 | 144.0455 | 2.7 | PFP (-) |
| Quinolin-3-ol | 10.5 | C9H7NO | 146.0598 | 146.0600 | 1.6 | Scherzo (+) |
| Quinolin-3-ol | 17.1 | C9H7NO | 144.0460 | 144.0455 | -3.5 | Scherzo (-) |
| Quinoline-2,8-diol | 10.7 | C9H7NO2 | 160.0406 | 160.0404 | -1.2 | PFP (-) |
| Resorcinol | 8.6 | C6H6O2 | 109.0289 | 109.0295 | 5.5 | PFP (-) |
| Riboflavin | 9.6 | C17H20N4O6 | 377.1466 | 377.1456 | -2.8 | Scherzo (+) |
| Riboflavin | 9.6 | C17H20N4O6 | 375.1316 | 375.1310 | -1.6 | Scherzo (-) |
| Riboflavin | 11.7 | C17H20N4O6 | 377.1467 | 377.1456 | -3.0 | PFP (+) |
| Riboflavin | 11.7 | C17H20N4O6 | 375.1331 | 375.1310 | -5.6 | PFP (-) |
| Ribonolactone | 6.5 | C5H8O5 | 147.0305 | 147.0299 | -4.1 | Scherzo (-) |
| Ribose 1-phosphate | 2.2 | C5H11O8P | 229.0113 | 229.0119 | 2.5 | PFP (-) |
| Ribose 1-phosphate | 9.2 | C5H11O8P | 229.0128 | 229.0119 | -4.0 | Scherzo (-) |
| (5'-Adenosyl)-L-homocysteine | 3.5 | C14H20N6O5S | 385.1301 | 385.1289 | -3.2 | Scherzo (+) |
| Adenosyl-L-methionine | 2.5 | C15H22N6O5S | 399.1452 | 399.1445 | -1.7 | Scherzo (+) |
| Adenosyl-L-methionine | 2.3 | C15H22N6O5S | 399.1450 | 399.1445 | -1.2 | PFP (+) |
| Lactoylglutathione | 5.1 | C13H21N3O8S | 380.1131 | 380.1122 | -2.3 | Scherzo (+) |
| Saccharic acid | 5.1 | C6H10O8 | 209.0309 | 209.0303 | -2.9 | Scherzo (-) |
| Sarcosine | 2.0 | C3H7NO2 | 90.0551 | 90.0550 | -1.6 | PFP (+) |
| Schaftoside | 10.0 | C26H28O14 | 565.1569 | 565.1552 | -3.0 | Scherzo (+) |
| Schaftoside | 10.0 | C26H28O14 | 563.1425 | 563.1406 | -3.3 | Scherzo (-) |
| Schaftoside | 13.1 | C26H28O14 | 563.1442 | 563.1406 | -6.3 | PFP (-) |

| Schaftoside | 13.5 | C26H28O14 | 563.1439 | 563.1406 | -5.8 | PFP (-) |
|-------------------------|------|---------------|----------|----------|------|-------------|
| Schaftoside | 13.1 | C26H28O14 | 565.1560 | 565.1552 | -1.5 | PFP (+) |
| Schaftoside | 13.5 | C26H28O14 | 565.1560 | 565.1552 | -1.5 | PFP (+) |
| Sebacic acid | 15.4 | C10H18O4 | 201.1137 | 201.1132 | -2.3 | PFP (-) |
| Ser-Leu | 4.7 | C9H18N2O4 | 219.1339 | 219.1339 | 0.1 | PFP (+) |
| Serotonin | 4.1 | C10H12N2O | 177.1015 | 177.1022 | 4.2 | Scherzo (+) |
| sn-Glycerol 3-phosphate | 2.2 | C3H9O6P | 171.0066 | 171.0064 | -1.2 | PFP (-) |
| sn-Glycerol 3-phosphate | 9.3 | C3H9O6P | 173.0210 | 173.0210 | -0.3 | Scherzo (+) |
| sn-Glycerol 3-phosphate | 9.4 | C3H9O6P | 171.0073 | 171.0064 | -5.3 | Scherzo (-) |
| Spermidine | 2.2 | C7H19N3 | 146.1649 | 146.1652 | 1.8 | Scherzo (+) |
| Spermine | 1.9 | C10H26N4 | 203.2232 | 203.2230 | -0.9 | Scherzo (+) |
| Sphinganine | 14.3 | C18H39NO2 | 302.3061 | 302.3054 | -2.4 | Scherzo (+) |
| Sphinganine | 17.7 | C18H39NO2 | 302.3057 | 302.3054 | -1.1 | PFP (+) `´ |
| Stachydrine | 2.9 | C7H13NO2 | 144.1020 | 144.1019 | -0.6 | PFP (+) |
| Stachydrine | 3.7 | C7H13NO2 | 144.1019 | 144.1019 | 0.1 | PFP (+) |
| Stearidonic acid | 16.1 | C18H28O2 | 277.2161 | 277.2162 | 0.4 | Scherzo (+) |
| Stearoyl-L-carnitine | 17.9 | C25H49NO4 | 428.3744 | 428.3734 | -2.2 | Scherzo (+) |
| Stearoyl-L-carnitine | 17.9 | C25H49NO4 | 428.3738 | 428.3734 | -0.8 | PFP (+) `´ |
| Suberic acid | 10.7 | C8H14O4 | 173.0825 | 173.0819 | -3.3 | Scherzo (-) |
| Suberic acid | 12.5 | C8H14O4 | 173.0821 | 173.0819 | -1.0 | PFP (-) |
| Succinic acid | 2.9 | C4H6O4 | 117.0196 | 117.0193 | -2.3 | PFP (-) |
| Syringic acid | 10.1 | C9H10O5 | 199.0602 | 199.0601 | -0.5 | Scherzo (+) |
| Syringic acid | 10.1 | C9H10O5 | 197.0460 | 197.0456 | -2.3 | Scherzo (-) |
| Syringic acid | 12.4 | C9H10O5 | 197.0457 | 197.0456 | -0.8 | PFP (-) |
| Syringic acid | 12.4 | C9H10O5 | 199.0605 | 199.0601 | -2.0 | PFP (+) |
| Taurine | 1.9 | C2H7NO3S | 126.0222 | 126.0219 | -2.1 | PFP (+) |
| Taurine | 1.9 | C2H7NO3S | 124.0076 | 124.0074 | -1.7 | PFP (-) |
| Taurine | 2.6 | C2H7NO3S | 126.0218 | 126.0219 | 1.1 | Scherzo (+) |
| Taurine | 2.6 | C2H7NO3S | 124.0075 | 124.0074 | -0.9 | Scherzo (-) |
| Taurocholic acid | 15.0 | C26H45NO7S | 514.2873 | 514.2844 | -5.6 | PFP (-) |
| Taurocholic acid | 17.7 | C26H45NO7S | 516.3002 | 516.2990 | -2.4 | PFP (+) |
| Taurodeoxycholic acid | 17.2 | C26H45NO6S | 498.2900 | 498.2895 | -1.0 | PFP (-) |
| Tetradecanedioic acid | 16.3 | C14H26O4 | 257.1753 | 257.1758 | 2.1 | Scherzo (-) |
| Tetradecanedioic acid | 17.9 | C14H26O4 | 257.1759 | 257.1758 | -0.3 | PFP (-) |
| Tetraethylene glycol | 6.8 | C8H18O5 | 195.1224 | 195.1227 | 1.5 | Scherzo (+) |
| Tetraethylene glycol | 7.4 | C8H18O5 | 195.1228 | 195.1227 | -0.5 | PFP (+) |
| Thiamine | 2.2 | C12H16N4OS | 263.0979 | 263.0972 | -2.6 | Scherzo (-) |
| Thiamine | 2.6 | C12H16N4OS | 265.1123 | 265.1118 | -2.0 | PFP (+) |
| Thiamine monophosphate | 2.4 | C12H17N4O4PS | 345.0790 | 345.0781 | -2.6 | PFP (+) |
| Thiamine pyrophosphate | 3.5 | C12H18N4O7P2S | 425.0451 | 425.0444 | -1.6 | Scherzo (+) |
| Threonic acid | 1.9 | C4H8O5 | 135.0300 | 135.0299 | -0.7 | PFP (-) |
| Threonic acid | 2.9 | C4H8O5 | 135.0302 | 135.0299 | -2.2 | Scherzo (-) |
| Threonic acid | 3.4 | C4H8O5 | 135.0307 | 135.0299 | -5.9 | Scherzo (-) |
| Threonine | 2.5 | C4H9NO3 | 120.0655 | 120.0655 | 0.2 | Scherzo (+) |
| Threonine | 4.6 | C4H9NO3 | 120.0653 | 120.0655 | 1.8 | Scherzo (+) |

| Thromboxane B2 | 16.8 | C20H34O6 | 369.2289 | 369.2283 | -1.7 | PFP (-) |
|-------------------------------|------|-------------|----------|----------|------|-------------|
| Thromboxane B2 | 17.4 | C20H34O6 | 369.2285 | 369.2283 | -0.7 | PFP (-) |
| Thymidine | 6.7 | C10H14N2O5 | 243.0976 | 243.0976 | -0.2 | PFP (+) |
| Thymidine | 6.7 | C10H14N2O5 | 241.0825 | 241.0830 | 2.1 | PFP (-) |
| Thymidine | 7.0 | C10H14N2O5 | 243.0979 | 243.0976 | -1.4 | Scherzo (+) |
| Thymidine | 7.1 | C10H14N2O5 | 241.0839 | 241.0830 | -3.7 | Scherzo (-) |
| Thymine | 4.0 | C5H6N2O2 | 127.0501 | 127.0502 | 0.8 | PFP (+) |
| Thymine | 4.0 | C5H6N2O2 | 125.0360 | 125.0357 | -2.8 | PFP (-) |
| Thymine | 5.3 | C5H6N2O2 | 127.0499 | 127.0502 | 2.4 | Scherzo (+) |
| Thymine | 5.4 | C5H6N2O2 | 125.0363 | 125.0357 | -5.2 | Scherzo (-) |
| Thymine | 6.2 | C5H6N2O2 | 127.0505 | 127.0502 | -2.4 | Scherzo (+) |
| Thymine | 6.7 | C5H6N2O2 | 127.0500 | 127.0502 | 1.6 | PFP (+) |
| Thymine | 7.0 | C5H6N2O2 | 127.0503 | 127.0502 | -0.8 | Scherzo (+) |
| trans-2-Hydroxycinnamic acid | 3.0 | C9H8O3 | 165.0541 | 165.0546 | 3.2 | Scherzo (+) |
| trans-2-Hydroxycinnamic acid | 3.9 | C9H8O3 | 165.0548 | 165.0546 | -1.1 | Scherzo (+) |
| trans-2-Hydroxycinnamic acid | 11.2 | C9H8O3 | 163.0407 | 163.0401 | -3.9 | Scherzo (-) |
| trans-2-Hydroxycinnamic acid | 13.2 | C9H8O3 | 163.0400 | 163.0401 | 0.4 | PFP (-) |
| trans-2-Hydroxycinnamic acid | 3.0 | C9H8O3 | 165.0550 | 165.0546 | -2.3 | PFP (+) |
| trans-Ferulic acid | 11.5 | C10H10O4 | 193.0507 | 193.0506 | -0.4 | Scherzo (-) |
| trans-Traumatic acid | 16.3 | C12H20O4 | 227.1288 | 227.1289 | 0.4 | PFP (-) |
| trans-Traumatic acid | 17.0 | C12H20O4 | 227.1291 | 227.1289 | -1.0 | PFP (-) |
| Tri(3-chloropropyl) phosphate | 16.5 | C9H18Cl3O4P | 327.0084 | 327.0081 | -0.9 | Scherzo (+) |
| Tri(3-chloropropyl) phosphate | 17.8 | C9H18Cl3O4P | 327.0077 | 327.0081 | 1.3 | PFP (+) |
| Tributylamine | 16.2 | C12H27N | 186.2216 | 186.2216 | 0.2 | PFP (+) |
| Tricin | 14.6 | C17H14O7 | 331.0818 | 331.0812 | -1.7 | Scherzo (+) |
| Trigonelline | 2.8 | C7H7NO2 | 138.0549 | 138.0550 | 0.4 | Scherzo (+) |
| Trihydroxycholestanoic acid | 17.7 | C27H46O5 | 449.3259 | 449.3273 | 3.0 | Scherzo (-) |
| Trp-Glu | 8.9 | C16H19N3O5 | 334.1378 | 334.1398 | 5.8 | PFP (+) |
| Tryptophan | 7.8 | C11H12N2O2 | 205.0971 | 205.0972 | 0.2 | Scherzo (+) |
| Tryptophan | 7.9 | C11H12N2O2 | 203.0830 | 203.0826 | -2.0 | Scherzo (-) |
| Tryptophan | 9.3 | C11H12N2O2 | 203.0825 | 203.0826 | 0.5 | PFP (-) |
| Tryptophan | 9.4 | C11H12N2O2 | 205.0978 | 205.0972 | -3.2 | PFP (+) |
| Tryptophol | 12.5 | C10H11NO | 162.0908 | 162.0913 | 3.3 | Scherzo (+) |
| Tyr-Gly | 3.6 | C11H14N2O4 | 239.1018 | 239.1026 | 3.5 | Scherzo (+) |
| Tyr-Gly | 3.9 | C11H14N2O4 | 239.1028 | 239.1026 | -0.7 | PFP (+) |
| Tyr-Leu | 10.2 | C15H22N2O4 | 295.1661 | 295.1652 | -2.9 | PFP (+) |
| Tyrosine | 3.0 | C9H11NO3 | 182.0807 | 182.0812 | 2.6 | Scherzo (+) |
| Tyrosine | 3.0 | C9H11NO3 | 182.0816 | 182.0812 | -2.4 | PFP (+) |
| Tyrosine | 3.3 | C9H11NO3 | 180.0669 | 180.0666 | -1.6 | PFP (-) |
| Tyrosine | 3.6 | C9H11NO3 | 182.0815 | 182.0812 | -1.8 | PFP (+) |
| Tyrosine | 3.7 | C9H11NO3 | 180.0665 | 180.0666 | 0.7 | PFP (-) |
| Tyrosine | 3.9 | C9H11NO3 | 182.0811 | 182.0812 | 0.4 | Scherzo (+) |
| Tyrosine | 3.9 | C9H11NO3 | 180.0668 | 180.0666 | -1.0 | Scherzo (-) |
| Undecanedioic acid | 14.1 | C11H20O4 | 215.1302 | 215.1289 | -6.1 | Scherzo (-) |
| Undecanedioic acid | 16.9 | C11H20O4 | 215.1296 | 215.1289 | -3.3 | PFP (-) |

| Uracil | 2.4 | C4H4N2O2 | 113.0346 | 113.0346 | -0.4 | PFP (+) |
|--------------------------|------|------------|----------|----------|------|-------------|
| Uracil | 2.5 | C4H4N2O2 | 111.0201 | 111.0200 | -0.9 | PFP (-) |
| Uracil | 5.9 | C4H4N2O2 | 113.0343 | 113.0346 | 2.2 | PFP (+) |
| Urate | 2.6 | C5H4N4O3 | 167.0215 | 167.0211 | -2.6 | PFP (-) |
| Urate | 2.8 | C5H4N4O3 | 169.0357 | 169.0356 | -0.5 | PFP (+) |
| Urate | 4.1 | C5H4N4O3 | 169.0357 | 169.0356 | -0.5 | Scherzo (+) |
| Urate | 4.2 | C5H4N4O3 | 167.0219 | 167.0211 | -5.0 | Scherzo (-) |
| Uridine | 2.6 | C9H12N2O6 | 243.0634 | 243.0623 | -4.7 | PFP (-) |
| Uridine | 2.8 | C9H12N2O6 | 245.0771 | 245.0768 | -1.2 | PFP (+) |
| Uridine | 3.0 | C9H12N2O6 | 243.0633 | 243.0623 | -4.3 | PFP (-) |
| Uridine | 3.8 | C9H12N2O6 | 245.0768 | 245.0768 | 0.0 | Scherzo (+) |
| Uridine | 3.9 | C9H12N2O6 | 243.0630 | 243.0623 | -3.0 | Scherzo (-) |
| Uridine | 4.3 | C9H12N2O6 | 243.0622 | 243.0623 | 0.2 | Scherzo (-) |
| Uridine 5'-monophosphate | 10.4 | C9H13N2O9P | 325.0439 | 325.0432 | -2.3 | Scherzo (+) |
| Urobilin | 11.0 | C33H42N4O6 | 591.3178 | 591.3177 | -0.2 | Scherzo (+) |
| Urobilin | 17.0 | C33H42N4O6 | 591.3182 | 591.3177 | -0.8 | PFP (+) |
| Urocanate | 2.5 | C6H6N2O2 | 139.0503 | 139.0502 | -0.7 | Scherzo (+) |
| Val-Leu | 7.2 | C11H22N2O3 | 231.1703 | 231.1703 | 0.1 | PFP (+) |
| Val-Leu | 8.6 | C11H22N2O3 | 231.1703 | 231.1703 | 0.1 | PFP (+) |
| Val-Val | 4.1 | C10H20N2O3 | 217.1549 | 217.1547 | -1.1 | PFP (+) |
| Vitamin C | 2.0 | C6H8O6 | 175.0252 | 175.0248 | -2.2 | PFP (-) |
| Vitamin C | 3.4 | C6H8O6 | 177.0397 | 177.0394 | -1.9 | Scherzo (+) |
| Vitamin C | 3.5 | C6H8O6 | 175.0257 | 175.0248 | -5.1 | Scherzo (-) |
| Xanthine | 3.6 | C5H4N4O2 | 153.0409 | 153.0407 | -1.3 | PFP (+) |
| Xanthine | 4.5 | C5H4N4O2 | 153.0408 | 153.0407 | -0.7 | Scherzo (+) |
| Xanthine | 6.5 | C5H4N4O2 | 153.0411 | 153.0407 | -2.6 | PFP (+) |
| Xanthine | 7.0 | C5H4N4O2 | 153.0406 | 153.0407 | 0.7 | Scherzo (+) |
| Xanthosine | 6.5 | C10H12N4O6 | 283.0687 | 283.0684 | -1.0 | Scherzo (-) |
| Xanthosine | 6.5 | C10H12N4O6 | 285.0837 | 285.0830 | -2.6 | PFP (+) |
| Xanthosine | 6.8 | C10H12N4O6 | 285.0836 | 285.0830 | -2.2 | PFP (+) |
| Xanthosine | 6.8 | C10H12N4O6 | 283.0690 | 283.0684 | -2.1 | PFP (-) |
| Xanthosine | 7.0 | C10H12N4O6 | 285.0838 | 285.0830 | -2.9 | Scherzo (+) |
| Xanthosine | 7.1 | C10H12N4O6 | 283.0694 | 283.0684 | -3.5 | Scherzo (-) |
| Xanthurenic acid | 10.7 | C10H7NO4 | 204.0307 | 204.0302 | -2.3 | PFP (-) |
| Xanthurenic acid | 12.2 | C10H7NO4 | 204.0308 | 204.0302 | -2.8 | PFP (-) |
| Xylose | 3.7 | C5H10O5 | 149.0455 | 149.0456 | 0.3 | Scherzo (-) |

Table 2.9 Putative Fecal Metabolite Identifications Compiled from Four Untargeted Metabolomic Datasets

| Putative ID | Retention | Chemical | Found at | Exact Mass | Mass Error | Column (+/-) |
|--|-----------|---------------|---------------------|----------------|------------|--------------|
| | Time | Formula | Mass (<i>m/z</i>) | (<i>m/z</i>) | (ppm) | · · · |
| | (min) | | . , | | | |
| alpha-Hydroxybutyric acid | 2.9 | C4H8O3 | 103.0399 | 103.0401 | 1.6 | PFP (-) |
| alpha-L-Glu-L-Tyr | 4.5 | C14H18N2O6 | 311.1261 | 311.1238 | -7.5 | Scherzo (+) |
| alpha-L-Glu-L-Tyr | 7.6 | C14H18N2O6 | 311.1255 | 311.1238 | -5.6 | Scherzo (+) |
| alpha-L-Glu-L-Tyr | 5.8 | C14H18N2O6 | 311.1253 | 311.1238 | -4.9 | PFP (+) |
| alpha-L-Glu-L-Tyr | 7.3 | C14H18N2O6 | 311.1246 | 311.1238 | -2.7 | PFP (+) |
| alpha,alpha'-Trehalose 6-phosphate | 9.6 | C12H23O14P | 421.0747 | 421.0753 | 1.4 | Scherzo (-) |
| beta-Nicotinamide adenine dinucleotide | 5.9 | C21H27N7O14P2 | 664.1158 | 664.1164 | 0.9 | Scherzo (+) |
| gamma-Muricholic acid | 17.4 | C24H40O5 | 407.2803 | 407.2803 | 0.0 | PFP (-) |
| gamma-Muricholic acid | 15.3 | C24H40O5 | 407.2810 | 407.2803 | -1.7 | Scherzo (-) |
| gamma-Muricholic acid | 15.7 | C24H40O5 | 407.2803 | 407.2803 | 0.0 | Scherzo (-) |
| gamma-Nonalactone | 12.1 | C9H16O2 | 157.1228 | 157.1223 | -3.1 | Scherzo (+) |
| omega-Benzoyloxyphloracetophenone | 15.7 | C15H12O6 | 287.0563 | 287.0561 | -0.7 | PFP (-) |
| omega-Benzoyloxyphloracetophenone | 12.9 | C15H12O6 | 287.0564 | 287.0561 | -1.0 | Scherzo (-) |
| (-)-Catechin | 10.6 | C15H14O6 | 289.0713 | 289.0718 | 1.6 | PFP (-) |
| (-)-Catechin | 9.3 | C15H14O6 | 289.0731 | 289.0718 | -4.6 | Scherzo (-) |
| (-)-Homoeriodictyol | 14.2 | C16H14O6 | 303.0874 | 303.0863 | -3.6 | Scherzo (+) |
| (-)-Hydroxycitric acid lactone | 2.4 | C6H6O7 | 189.0045 | 189.0041 | -2.2 | PFP (-) |
| (-)-N-Acetylneuraminic acid | 2.1 | C11H19NO9 | 308.1000 | 308.0987 | -4.2 | PFP (-) |
| (-)-N-Acetylneuraminic acid | 5.6 | C11H19NO9 | 308.1000 | 308.0987 | -4.2 | Scherzo (-) |
| (-)-N-Acetylneuraminic acid | 5.6 | C11H19NO9 | 310.1143 | 310.1133 | -3.4 | Scherzo (+) |
| (-)-N-Acetylneuraminic acid | 6.3 | C11H19NO9 | 310.1154 | 310.1133 | -6.9 | Scherzo (+) |
| (-)-N-Acetylneuraminic acid | 1.9 | C11H19NO9 | 310.1150 | 310.1133 | -5.6 | PFP (+) |
| (-)-N-Acetylneuraminic acid | 2.1 | C11H19NO9 | 310.1146 | 310.1133 | -4.3 | PFP (+) |
| (-)-Quinic acid | 1.9 | C7H12O6 | 191.0565 | 191.0561 | -2.0 | PFP (-) |
| (-)-Quinic acid | 3.6 | C7H12O6 | 191.0569 | 191.0561 | -4.1 | Scherzo (-) |
| (-)-Quinic acid | 3.6 | C7H12O6 | 193.0706 | 193.0707 | 0.3 | Scherzo (+) |
| (+-)-2-Hydroxyisocaproic acid | 9.4 | C6H12O3 | 131.0711 | 131.0714 | 2.1 | PFP (-) |
| (+-)-2-Hydroxyisocaproic acid | 10.1 | C6H12O3 | 131.0715 | 131.0714 | -1.0 | Scherzo (-) |
| (+-)7-epi-Jasmonic acid | 9.6 | C12H18O3 | 211.1333 | 211.1329 | -2.0 | Scherzo (+) |
| (+-)7-epi-Jasmonic acid | 10.3 | C12H18O3 | 211.1333 | 211.1329 | -2.0 | Scherzo (+) |
| (+-)7-epi-Jasmonic acid | 11.2 | C12H18O3 | 211.1333 | 211.1329 | -2.0 | PFP (+) |
| (+-)7-epi-Jasmonic acid | 12.3 | C12H18O3 | 211.1325 | 211.1329 | 1.8 | PFP (+) |
| (+)-2-Hydroxyisocaproic acid | 9.9 | C6H12O3 | 131.0714 | 131.0714 | -0.2 | PFP (-) |
| Butyrylcarnitine | 4.5 | C11H21NO4 | 232.1550 | 232.1543 | -2.9 | Scherzo (+) |
| Butyrylcarnitine | 5.0 | C11H21NO4 | 232.1564 | 232.1543 | -8.9 | Scherzo (+) |
| Butyrylcarnitine | 8.5 | C11H21NO4 | 232.1551 | 232.1543 | -3.3 | PFP (+) |

| (+)-2-Hydroxy-3-methylbutyric acid | 5.7 | C5H10O3 | 117.0557 | 117.0557 | 0.2 | PFP (-) |
|--|------|--------------|----------|----------|------|----------------|
| Lactate | 2.1 | C3H6O3 | 89.0245 | 89.0244 | -0.9 | PFP (-) |
| 1-beta-D-Arabinofuranosyluracil 5'- monophosphate | 2.5 | C9H13N2O9P | 323.0291 | 323.0286 | -1.6 | PFP (-) |
| 1-beta-D-Arabinofuranosyluracil 5'- monophosphate | 13.0 | C9H13N2O9P | 323.0288 | 323.0286 | -0.7 | Scherzo (-) |
| 1-(10Z-Heptadecenoyl)-sn-glycero-3- | 17.8 | C23H45O9P | 495.2735 | 495.2729 | -1.3 | PFP (-) |
| 1-(1Z-Octadecenyl)-sn-glycero-3- | 12.7 | C26H54NO6P | 508.3745 | 508.3762 | 3.2 | Scherzo (+) |
| 1-Ethyl-3-piperidinamine | 34 | C7H16N2 | 129 1385 | 129 1386 | 10 | Scherzo (+) |
| 1-Ethyl-3-piperidinamine | 5.5 | C7H16N2 | 129 1389 | 129 1386 | -2.1 | PFP (+) |
| 1-Hexadecanovl-2-octadecadienovl-sn- | 15.6 | C42H80NO8P | 758 5673 | 758 5694 | 2.8 | Scherzo (+) |
| alvcero-3-phosphocholine | 1010 | 012110011001 | 100.0010 | 10010001 | 2.0 | 00110120() |
| 1-Methyladenosine | 2.6 | C11H15N5O4 | 282.1202 | 282.1197 | -1.8 | Scherzo (+) |
| 1-Methyladenosine | 6.7 | C11H15N5O4 | 282,1185 | 282,1197 | 4.2 | Scherzo (+) |
| 1-Methyladenosine | 6.8 | C11H15N5O4 | 282.1197 | 282.1197 | -0.1 | PFP (+) |
| 1-Methyluric acid | 7.0 | C6H6N4O3 | 181.0373 | 181.0367 | -3.3 | Scherzo (-) |
| 1-Methyluric acid | 6.9 | C6H6N4O3 | 183.0513 | 183.0513 | -0.2 | Scherzo (+) |
| 1-Methylxanthine | 7.4 | C6H6N4O2 | 167.0569 | 167.0564 | -3.3 | Scherzo (+) |
| 1-Methylxanthine | 7.1 | C6H6N4O2 | 167.0565 | 167.0564 | -0.9 | PFP (+) `´ |
| 1-Myristoyl-2-hydroxy-sn-glycero-3- phosphoethanolamine | 16.2 | C19H40NO7P | 424.2482 | 424.2470 | -2.9 | Scherzo (-) |
| 1-Myristoyl-2-hydroxy-sn-glycero-3- | 15.3 | C19H40NO7P | 426.2631 | 426.2615 | -3.7 | Scherzo (+) |
| 1-Myristoyl-2-hydroxy-sn-glycero-3- phosphoethanolamine | 16.1 | C19H40NO7P | 426.2623 | 426.2615 | -1.8 | Scherzo (+) |
| 1-Myristoyl-sn-glycero-3-phosphocholine | 16.6 | C22H46NO7P | 468.3097 | 468.3085 | -2.6 | Scherzo (+) |
| 1-Oleoyl-2-myristoyl-sn-glycero-3- | 15.7 | C40H78NO8P | 732.5532 | 732.5538 | 0.8 | Scherzo (+) |
| phosphocholine | | | | | 0.0 | $O_{ab} = (1)$ |
| 1-Oleoyi-sn-giycero-3-phosphocholine | 14.4 | | 522.3559 | 522.3554 | -0.9 | Scherzo (+) |
| 1-Oleoyi-sn-giycero-3-phosphocholine | 18.0 | | 0ZZ.30Z3 | 322.3334 | 6.0 | PPP(+) |
| phosphoethanolamine | 16.3 | C23H46NU7P | 478.2942 | 478.2939 | -0.6 | Scherzo (-) |
| 1-Palmitoyl-2-hydroxy-sn-glycero-3- phospho-(1'-rac-glycerol) | 17.5 | C22H45O9P | 483.2751 | 483.2729 | -4.7 | Scherzo (-) |
| 1-Palmitoyl-2-hydroxy-sn-glycero-3- phosphoethanolamine | 15.2 | C21H44NO7P | 452.2798 | 452.2783 | -3.4 | Scherzo (-) |
| 1-Palmitoyl-2-hydroxy-sn-glycero-3- phosphoethanolamine | 17.4 | C21H44NO7P | 452.2781 | 452.2783 | 0.4 | Scherzo (-) |

| 1-Palmitoyl-2-hydroxy-sn-glycero-3- | 15.0 | C21H44NO7P | 454.2933 | 454.2928 | -1.1 | Scherzo (+) |
|--------------------------------------|------|------------|----------|----------|------|---------------|
| | 15.0 | 0041140070 | 407 0075 | 407.0674 | 0.2 | |
| I-Stearoyi-Z-nydroxy-Sn-glycero-3- | 15.3 | 621H4307P | 437.2075 | 437.2074 | -0.3 | Scherzo (-) |
| phosphate | 47.0 | 0041140070 | 407 0075 | 407 0074 | 0.0 | |
| 1-Stearoyi-2-nydroxy-sn-giycero-3- | 17.3 | C21H43O7P | 437.2075 | 437.2074 | -0.3 | Scherzo (-) |
| phosphate | 47.0 | 040110404 | 040 4500 | 040 4000 | 1.0 | |
| 1,11-Undecanedicarboxylic acid | 17.8 | C13H24O4 | 243.1599 | 243.1602 | 1.2 | |
| 1,11-Undecanedicarboxylic acid | 15.9 | C13H24O4 | 243.1606 | 243.1602 | -1./ | Scherzo (-) |
| 1,2-Benzenedicarboxylic acid | 10.4 | C8H6O4 | 165.0197 | 165.0193 | -2.2 | PFP (-) |
| 1,2-dioleoyl-sn-glycero-3- | 15.7 | C44H84NO8P | 786.6001 | 786.6007 | 0.8 | Scherzo (+) |
| phosphatidylcholine | | | | | | |
| 1,2-Dipentadecanoyl-sn-glycero-3- | 15.6 | C38H76NO8P | 706.5374 | 706.5381 | 1.0 | Scherzo (+) |
| phosphocholine | | | | | | |
| 1,2,3-Benzenetriol | 7.7 | C6H6O3 | 127.0387 | 127.0390 | 2.1 | PFP (+) |
| 1,3-Cyclohexanedicarboxylic acid | 9.5 | C8H12O4 | 171.0664 | 171.0663 | -0.7 | PFP (-) |
| 1,3-Cyclohexanedicarboxylic acid | 12.4 | C8H12O4 | 171.0662 | 171.0663 | 0.5 | PFP (-) |
| 1,3-Cyclohexanedicarboxylic acid | 9.0 | C8H12O4 | 171.0663 | 171.0663 | -0.1 | Scherzo (-) |
| 1,3-Dicyclohexylurea | 16.4 | C13H24N2O | 225.1961 | 225.1961 | 0.2 | Scherzo (+) |
| 1,5-Diaminonaphthalene | 7.8 | C10H10N2 | 159.0920 | 159.0917 | -2.1 | Scherzo (+) |
| 1,5-Diaminonaphthalene | 9.4 | C10H10N2 | 159.0918 | 159.0917 | -0.8 | PFP (+) `´ |
| 1.5-Isoquinolinediol | 4.8 | C9H7NO2 | 160.0405 | 160.0404 | -0.6 | PFP (-) |
| 1,5-Isoquinolinediol | 10.1 | C9H7NO2 | 160.0397 | 160.0404 | 4.4 | PFP (-) |
| 1,5-Isoquinolinediol | 7.0 | C9H7NO2 | 160.0413 | 160.0404 | -5.6 | Scherzo (-) |
| 1.5-Isoquinolinediol | 9.4 | C9H7NO2 | 160.0411 | 160.0404 | -4.4 | Scherzo (-) |
| 1.5-Isoquinolinediol | 7.0 | C9H7NO2 | 162.0552 | 162.0550 | -1.5 | Scherzo (+) |
| 1,5-Isoquinolinediol | 9.4 | C9H7NO2 | 162.0553 | 162.0550 | -2.1 | Scherzo (+) |
| 1.5-Isoquinolinediol | 4.8 | C9H7NO2 | 162.0550 | 162.0550 | -0.2 | PFP (+) `´ |
| 1.5-Isoquinolinediol | 10.2 | C9H7NO2 | 162.0552 | 162.0550 | -1.5 | PFP (+) |
| 1.5-Isoquinolinediol | 12.5 | C9H7NO2 | 162 0554 | 162 0550 | -27 | PFP (+) |
| 10-Formyl-7.8-dihydrofolic acid | 10.1 | C20H21N7O7 | 470,1450 | 470.1430 | -4.3 | PFP (-) |
| 10-Formyl-7 8-dihydrofolic acid | 94 | C20H21N7O7 | 470 1447 | 470 1430 | -37 | Scherzo (-) |
| 10-Formyl-7 8-dihydrofolic acid | 9.3 | C20H21N7O7 | 472 1591 | 472 1575 | -3.3 | Scherzo (+) |
| 10-Formyl-7.8-dihydrofolic acid | 10.1 | C20H21N7O7 | 472 1575 | 472 1575 | 0.0 | PFP (+) |
| 10F 127-octadecadienoic acid | 16.6 | C18H32O2 | 281 2484 | 281 2475 | -3.2 | Scherzo $(+)$ |
| 10E 12Z-octadecadienoic acid | 17.8 | C18H32O2 | 281 2482 | 281 2475 | -2.5 | PFP (+) |
| 11 alpha -Hydroxyprogesterone | 11.5 | C21H30O3 | 331 2273 | 331 2268 | -1.6 | Scherzo $(+)$ |
| 12 13-Dibydroxy-97-octadecenoic acid | 17.0 | C18H34O4 | 313 2378 | 313 2384 | 2.0 | PFP (_) |
| 12 13-Dihydroxy-97-octadecenoic acid | 14.3 | C18H34O4 | 315 2530 | 315 2530 | 2.0 | Scherzo $(+)$ |
| 12 13-Dihydroxy-97-octadecenoic acid | 17.1 | C18H34O4 | 315 2541 | 315 2530 | -3.5 | Scherzo $(+)$ |
| 12(13) Enovy 07-octadecensic acid | 17.1 | C18H32O3 | 207 2/2/ | 207 2424 | -3.3 | Scherzo $(+)$ |
| | 17.4 | 010113203 | 231.2434 | 231.2424 | -5.5 | |

| 16-Hydroxyhexadecanoic acid | 18.0 | C16H32O3 | 271.2285 | 271.2279 | -2.3 | PFP (-) |
|-------------------------------------|------|------------|----------|----------|------|-------------|
| 16.alphaHydroxypregnenolone | 15.8 | C21H32O3 | 333.2426 | 333.2424 | -0.5 | Scherzo (+) |
| 16.alphaHydroxypregnenolone | 15.3 | C21H32O3 | 333.2431 | 333.2424 | -2.0 | PFP (+) |
| 17.alphaNandrolone | 17.5 | C18H26O2 | 275.2003 | 275.2006 | 0.9 | PFP (+) |
| 1H-Indole-3-propanoic acid | 13.6 | C11H11NO2 | 190.0867 | 190.0863 | -2.3 | Scherzo (+) |
| 1H-Indole-3-propanoic acid | 15.8 | C11H11NO2 | 190.0868 | 190.0863 | -2.8 | PFP (+) |
| 1H-Indole-3-propanoic acid | 16.5 | C11H11NO2 | 190.0866 | 190.0863 | -1.8 | PFP (+) |
| 1H-Indole-4-carboxaldehyde | 7.8 | C9H7NO | 146.0598 | 146.0600 | 1.6 | Scherzo (+) |
| 1H-Indole-4-carboxaldehyde | 12.3 | C9H7NO | 146.0598 | 146.0600 | 1.6 | Scherzo (+) |
| 1H-Indole-4-carboxaldehyde | 9.4 | C9H7NO | 146.0595 | 146.0600 | 3.7 | PFP (+) |
| 1H-Indole-4-carboxaldehyde | 14.4 | C9H7NO | 146.0601 | 146.0600 | -0.4 | PFP (+) |
| 2-(N-Morpholino)ethanesulfonic acid | 4.0 | C6H13NO4S | 194.0499 | 194.0493 | -3.3 | PFP (-) |
| 2-(N-Morpholino)ethanesulfonic acid | 4.8 | C6H13NO4S | 194.0501 | 194.0493 | -4.4 | PFP (-) |
| 2-(N-Morpholino)ethanesulfonic acid | 6.5 | C6H13NO4S | 194.0496 | 194.0493 | -1.8 | Scherzo (-) |
| 2-Acetylpyrazine | 2.3 | C6H6N2O | 123.0553 | 123.0553 | -0.1 | Scherzo (+) |
| 2-Acetylpyrazine | 2.0 | C6H6N2O | 123.0555 | 123.0553 | -1.7 | PFP (+) |
| 2-Amino-1-naphthol | 6.1 | C10H9NO | 160.0755 | 160.0757 | 1.2 | PFP (+) |
| 2-Dimethylamino-6-hydroxypurine | 5.0 | C7H9N5O | 180.0882 | 180.0880 | -1.2 | Scherzo (+) |
| 2-Dimethylamino-6-hydroxypurine | 7.4 | C7H9N5O | 180.0874 | 180.0880 | 3.3 | Scherzo (+) |
| 2-Dimethylamino-6-hydroxypurine | 5.9 | C7H9N5O | 180.0883 | 180.0880 | -1.7 | PFP (+) |
| 2-Hydroxy-3-methoxybenzoic acid | 11.6 | C8H8O4 | 167.0351 | 167.0350 | -0.7 | PFP (-) |
| 2-Hydroxy-3-methoxybenzoic acid | 10.0 | C8H8O4 | 167.0361 | 167.0350 | -6.7 | Scherzo (-) |
| 2-Hydroxyibuprofen | 17.3 | C13H18O3 | 221.1187 | 221.1183 | -1.7 | PFP (-) |
| 2-Isopropylmalic acid | 8.4 | C7H12O5 | 175.0613 | 175.0612 | -0.6 | PFP (-) |
| 2-Isopropylmalic acid | 10.2 | C7H12O5 | 175.0618 | 175.0612 | -3.4 | Scherzo (-) |
| 2-Keto-3-deoxyoctonic acid | 1.9 | C8H14O8 | 237.0623 | 237.0616 | -3.0 | PFP (-) |
| 2-Keto-3-deoxyoctonic acid | 4.6 | C8H14O8 | 237.0625 | 237.0616 | -3.8 | Scherzo (-) |
| 2-Keto-3-deoxyoctonic acid | 5.2 | C8H14O8 | 237.0624 | 237.0616 | -3.4 | Scherzo (-) |
| 2-Ketohexanoic acid | 8.3 | C6H10O3 | 129.0551 | 129.0557 | 4.8 | PFP (-) |
| 2-Methoxybenzoic acid | 10.1 | C8H8O3 | 151.0403 | 151.0401 | -1.5 | PFP (-) |
| 2-Methoxycinnamic acid | 11.4 | C10H10O3 | 177.0560 | 177.0557 | -1.6 | PFP (-) |
| 2-Methyl-1,4-benzoquinone | 14.3 | C7H6O2 | 123.0442 | 123.0441 | -1.1 | Scherzo (+) |
| 2-Methyl-1,4-benzoquinone | 17.0 | C7H6O2 | 123.0437 | 123.0441 | 2.9 | PFP (+) |
| 2-Methyl-3-ketovaleric acid | 9.2 | C6H10O3 | 129.0556 | 129.0557 | 0.9 | PFP (-) |
| 2-Methyl-3-ketovaleric acid | 16.8 | C6H10O3 | 129.0561 | 129.0557 | -2.9 | Scherzo (-) |
| 2-Methylbutyryl-L-carnitine | 7.3 | C12H23NO4 | 246.1699 | 246.1700 | 0.3 | Scherzo (+) |
| 2-Methylbutyryl-L-carnitine | 10.3 | C12H23NO4 | 246.1708 | 246.1700 | -3.3 | PFP (+) |
| 2-Methylquinolin-8-ol | 12.2 | C10H9NO | 160.0760 | 160.0757 | -1.9 | Scherzo (+) |
| 2-Oleoyl-1-palmitoyl-sn-glycero-3- | 15.6 | C42H82NO8P | 760.5844 | 760.5851 | 0.9 | Scherzo (+) |
| phosphocholine | | | | | | |

| 2-Phenylacetamide | 3.8 | C8H9NO | 136.0759 | 136.0757 | -1.5 | Scherzo (+) |
|-------------------------------------|------|------------|----------|----------|------|-------------|
| 2-Phenylacetamide | 3.0 | C8H9NO | 136.0757 | 136.0757 | -0.1 | PFP (+) |
| 2-Phenylbutyric acid | 10.5 | C10H12O2 | 165.0912 | 165.0910 | -1.2 | Scherzo (+) |
| 2-Piperidinone | 6.6 | C5H9NO | 100.0757 | 100.0757 | -0.1 | PFP (+) |
| 2,2-Dimethylglutaric acid | 11.2 | C7H12O4 | 159.0661 | 159.0663 | 1.1 | PFP (-) |
| 2,2-Dimethylglutaric acid | 10.4 | C7H12O4 | 159.0666 | 159.0663 | -2.0 | Scherzo (-) |
| 2,3-Dihydroxy-4-methoxybenzoic acid | 8.8 | C8H8O5 | 183.0296 | 183.0299 | 1.6 | Scherzo (-) |
| 2,3-Dihydroxybenzoic acid | 8.6 | C7H6O4 | 153.0194 | 153.0193 | -0.5 | Scherzo (-) |
| 2,3,5-Trimethylpyrazine | 11.2 | C7H10N2 | 123.0917 | 123.0917 | -0.2 | PFP (+) |
| 2,4-Dimethylphenol | 12.4 | C8H10O | 121.0659 | 121.0659 | -0.1 | PFP (-) |
| 2,4(3H,5H)-Furandione | 2.9 | C4H4O3 | 101.0233 | 101.0233 | 0.2 | PFP (+) |
| 2,6-Dihydroxybenzoic acid | 14.1 | C7H6O4 | 153.0203 | 153.0193 | -6.3 | PFP (-) |
| 2,6-Dimethoxyphenol | 10.1 | C8H10O3 | 155.0706 | 155.0703 | -2.1 | Scherzo (+) |
| 2,6-Dimethoxyphenol | 12.4 | C8H10O3 | 155.0696 | 155.0703 | 4.3 | PFP (+) |
| 2,6-Xylidine | 8.2 | C8H11N | 122.0960 | 122.0964 | 3.5 | PFP (+) |
| 2'-Deoxyadenosine | 4.7 | C10H13N5O3 | 252.1086 | 252.1091 | 2.1 | PFP (+) |
| 2'-Deoxycytidine | 2.4 | C9H13N3O4 | 228.0979 | 228.0979 | -0.1 | Scherzo (+) |
| 2'-Deoxycytidine | 2.3 | C9H13N3O4 | 228.0973 | 228.0979 | 2.5 | PFP (+) |
| 2'-Deoxyinosine | 6.7 | C10H12N4O4 | 253.0943 | 253.0931 | -4.6 | Scherzo (+) |
| 2'-Deoxyinosine | 6.2 | C10H12N4O4 | 253.0936 | 253.0931 | -1.9 | PFP (+) |
| 2'-O-Methyladenosine | 6.2 | C11H15N5O4 | 282.1204 | 282.1197 | -2.6 | Scherzo (+) |
| 2S-Amino-4E-octadecene-1,3S-diol | 14.8 | C18H37NO2 | 300.2910 | 300.2897 | -4.3 | Scherzo (+) |
| 2S-Amino-4E-octadecene-1,3S-diol | 17.8 | C18H37NO2 | 300.2894 | 300.2897 | 1.0 | PFP (+) |
| 3-(2-Ethylhexoxy)propan-1-amine | 11.2 | C11H25NO | 188.2014 | 188.2009 | -2.7 | Scherzo (+) |
| 3-(2-Ethylhexoxy)propan-1-amine | 17.1 | C11H25NO | 188.2010 | 188.2009 | -0.6 | PFP (+) |
| 3-(2-Hydroxyphenyl)propionic acid | 12.4 | C9H10O3 | 165.0561 | 165.0557 | -2.3 | PFP (-) |
| 3-(2-Hydroxyphenyl)propionic acid | 11.0 | C9H10O3 | 165.0567 | 165.0557 | -5.9 | Scherzo (-) |
| 3-(4-Hydroxyphenyl)propionic acid | 10.5 | C9H10O3 | 165.0565 | 165.0557 | -4.7 | Scherzo (-) |
| 3-Acetamidophenol | 9.7 | C8H9NO2 | 150.0557 | 150.0561 | 2.3 | PFP (-) |
| 3-Acetamidophenol | 9.5 | C8H9NO2 | 152.0701 | 152.0706 | 3.4 | Scherzo (+) |
| 3-Acetamidophenol | 9.7 | C8H9NO2 | 152.0702 | 152.0706 | 2.7 | PFP (+) |
| 3-Acetoxypyridine | 2.8 | C7H7NO2 | 138.0543 | 138.0550 | 4.8 | Scherzo (+) |
| 3-Aminobenzoic acid | 6.6 | C7H7NO2 | 138.0545 | 138.0550 | 3.3 | PFP (+) |
| 3-Aminohexanoic acid | 2.7 | C6H13NO2 | 130.0873 | 130.0874 | 0.4 | PFP (-) |
| 3-Aminopentanoic acid | 2.0 | C5H11NO2 | 116.0719 | 116.0717 | -1.7 | PFP (-) |
| 3-Coumaric acid | 11.3 | C9H8O3 | 165.0543 | 165.0546 | 1.9 | Scherzo (+) |
| 3-Cyclohexyl-1,1-dimethylurea | 12.8 | C9H18N2O | 171.1491 | 171.1492 | 0.5 | Scherzo (+) |
| 3-Cyclohexyl-1,1-dimethylurea | 13.9 | C9H18N2O | 171.1492 | 171.1492 | -0.1 | PFP (+) |
| 3-Dehydroshikimic acid | 6.1 | C7H8O5 | 171.0304 | 171.0299 | -2.9 | Scherzo (-) |
| 3-Ethylphenol | 11.0 | C8H10O | 121.0664 | 121.0659 | -4.2 | Scherzo (-) |

| 3-Hydroxy-3-methylglutaric acid | 3.0 | C6H10O5 | 161.0459 | 161.0456 | -2.2 | PFP (-) |
|----------------------------------|------|-----------|----------|----------|------|-------------|
| 3-Hydroxy-3-methylglutaric acid | 3.5 | C6H10O5 | 161.0459 | 161.0456 | -2.2 | PFP (-) |
| 3-Hydroxy-3-methylglutaric acid | 5.2 | C6H10O5 | 161.0460 | 161.0456 | -2.8 | Scherzo (-) |
| 3-Hydroxy-4-methoxybenzaldehyde | 8.8 | C8H8O3 | 151.0407 | 151.0401 | -4.2 | PFP (-) |
| 3-Hydroxy-4-methoxybenzaldehyde | 10.5 | C8H8O3 | 151.0407 | 151.0401 | -4.2 | Scherzo (-) |
| 3-Hydroxy-4-methoxybenzaldehyde | 10.8 | C8H8O3 | 153.0548 | 153.0546 | -1.2 | Scherzo (+) |
| 3-Hydroxy-4-methoxybenzoic acid | 10.0 | C8H8O4 | 169.0496 | 169.0495 | -0.4 | Scherzo (+) |
| 3-Hydroxy-4-methoxybenzoic acid | 11.6 | C8H8O4 | 169.0495 | 169.0495 | 0.2 | PFP (+) |
| 3-Hydroxy-4-methoxycinnamic acid | 13.1 | C10H10O4 | 193.0512 | 193.0506 | -3.0 | PFP (-) |
| 3-Hydroxy-4-methoxycinnamic acid | 14.7 | C10H10O4 | 193.0504 | 193.0506 | 1.2 | PFP (-) |
| 3-Hydroxy-4-methoxycinnamic acid | 16.3 | C10H10O4 | 193.0501 | 193.0506 | 2.7 | PFP (-) |
| 3-Hydroxy-4-methoxycinnamic acid | 14.0 | C10H10O4 | 193.0509 | 193.0506 | -1.4 | Scherzo (-) |
| 3-Hydroxy-4-methoxycinnamic acid | 11.5 | C10H10O4 | 195.0657 | 195.0652 | -2.6 | Scherzo (+) |
| 3-Hydroxy-4-methoxycinnamic acid | 13.8 | C10H10O4 | 195.0655 | 195.0652 | -1.6 | PFP (+) |
| 3-Hydroxyanthranilic acid | 4.3 | C7H7NO3 | 152.0351 | 152.0353 | 1.4 | Scherzo (-) |
| 3-Hydroxybenzaldehyde | 10.1 | C7H6O2 | 121.0292 | 121.0295 | 2.5 | PFP (-) |
| 3-Hydroxybenzaldehyde | 11.2 | C7H6O2 | 121.0294 | 121.0295 | 0.8 | PFP (-) |
| 3-Hydroxybenzaldehyde | 10.4 | C7H6O2 | 121.0304 | 121.0295 | -7.4 | Scherzo (-) |
| 3-Hydroxybenzoic acid | 9.7 | C7H6O3 | 137.0240 | 137.0244 | 3.1 | Scherzo (-) |
| 3-Hydroxybutyrylcarnitine | 4.2 | C11H21NO5 | 248.1488 | 248.1493 | 1.8 | PFP (+) |
| 3-Hydroxyoleylcarnitine | 17.7 | C25H47NO5 | 442.3525 | 442.3527 | 0.5 | PFP (+) |
| 3-Hydroxypicolinic acid | 2.9 | C6H5NO3 | 138.0196 | 138.0197 | 0.5 | PFP (-) |
| 3-Hydroxypicolinic acid | 7.0 | C6H5NO3 | 138.0198 | 138.0197 | -0.9 | Scherzo (-) |
| 3-Indoleacetic acid | 14.4 | C10H9NO2 | 176.0710 | 176.0706 | -2.2 | PFP (+) |
| 3-Indoleacetic acid | 12.5 | C10H9NO2 | 174.0561 | 174.0561 | -0.3 | Scherzo (-) |
| 3-Indoleacetic acid | 10.8 | C10H9NO2 | 176.0708 | 176.0706 | -1.1 | Scherzo (+) |
| 3-Indoleacetic acid | 12.5 | C10H9NO2 | 176.0709 | 176.0706 | -1.6 | Scherzo (+) |
| 3-Indoleacrylic acid | 7.8 | C11H9NO2 | 188.0713 | 188.0706 | -3.7 | Scherzo (+) |
| 3-Indoleacrylic acid | 10.0 | C11H9NO2 | 188.0709 | 188.0706 | -1.5 | Scherzo (+) |
| 3-Indoleacrylic acid | 12.2 | C11H9NO2 | 188.0710 | 188.0706 | -2.1 | Scherzo (+) |
| 3-Indoleacrylic acid | 13.0 | C11H9NO2 | 188.0701 | 188.0706 | 2.7 | Scherzo (+) |
| 3-Indoleacrylic acid | 9.4 | C11H9NO2 | 188.0710 | 188.0706 | -2.1 | PFP (+) |
| 3-Indoleacrylic acid | 10.7 | C11H9NO2 | 188.0706 | 188.0706 | 0.1 | PFP (+) |
| 3-Indolepropionic acid | 15.8 | C11H11NO2 | 188.0724 | 188.0717 | -3.7 | PFP (-) |
| 3-Methyladipic acid | 9.3 | C7H12O4 | 159.0667 | 159.0663 | -2.6 | Scherzo (-) |
| 3-Methylindole | 7.9 | C9H9N | 132.0808 | 132.0808 | -0.2 | Scherzo (+) |
| 3-Methylindole | 9.4 | C9H9N | 132.0806 | 132.0808 | 1.4 | PFP (+) |
| 3-O-Methylgallic acid | 9.8 | C8H8O5 | 183.0302 | 183.0299 | -1.6 | PFP (-) |
| 3-Oxocholic acid | 17.7 | C24H38O5 | 405.2663 | 405.2647 | -4.1 | PFP (-) |
| 3-Oxocholic acid | 14.5 | C24H38O5 | 405.2652 | 405.2647 | -1.4 | Scherzo (-) |

| 3-Oxocholic acid | 15.1 | C24H38O5 | 405.2663 | 405.2647 | -4.1 | Scherzo (-) |
|--|------|-----------|----------|----------|------|-------------|
| 3-Oxocholic acid | 16.1 | C24H38O5 | 405.2656 | 405.2647 | -2.3 | Scherzo (-) |
| 3-tert-Butylphenol | 14.7 | C10H14O | 149.0971 | 149.0972 | 0.6 | PFP (-) |
| 3-tert-Butylphenol | 13.8 | C10H14O | 149.0979 | 149.0972 | -4.8 | Scherzo (-) |
| 3-Ureidopropionic acid | 3.5 | C4H8N2O3 | 131.0455 | 131.0462 | 5.5 | Scherzo (-) |
| 3,3-Dimethylacrylic acid | 1.9 | C5H8O2 | 101.0599 | 101.0597 | -1.9 | PFP (+) |
| 3,4-Dihydro-6-hydroxyalpha.,2,5,7,8- | 17.1 | C19H28O4 | 321.2069 | 321.2060 | -2.7 | Scherzo (+) |
| pentamethyl-2H-1-benzopyran-2- | | | | | | . , |
| pentanoic acid | | | | | | |
| 3,4-Dihydrocoumarin | 5.7 | C9H8O2 | 149.0595 | 149.0597 | 1.4 | Scherzo (+) |
| 3,4-Dihydrocoumarin | 11.0 | C9H8O2 | 149.0601 | 149.0597 | -2.6 | Scherzo (+) |
| 3,4-Dihydrocoumarin | 5.2 | C9H8O2 | 149.0589 | 149.0597 | 5.4 | PFP (+) |
| 3,4-Dihydrocoumarin | 12.4 | C9H8O2 | 149.0600 | 149.0597 | -1.9 | PFP (+) |
| 3,4-Dihydroxy-L-phenylalanine | 3.9 | C9H11NO4 | 196.0619 | 196.0615 | -1.9 | Scherzo (-) |
| 3,4-Dihydroxyacetophenone | 9.5 | C8H8O3 | 151.0407 | 151.0401 | -4.2 | Scherzo (-) |
| 3,4-Dihydroxybenzoic acid | 8.6 | C7H6O4 | 155.0338 | 155.0339 | 0.6 | Scherzo (+) |
| 3,4-Dimethylbenzoic acid | 12.6 | C9H10O2 | 151.0755 | 151.0754 | -0.9 | Scherzo (+) |
| 3,4,2',4',6'-Pentahydroxychalcone | 16.7 | C15H12O6 | 287.0562 | 287.0561 | -0.3 | PFP (-) |
| 3,4,2',4',6'-Pentahydroxychalcone | 16.6 | C15H12O6 | 289.0711 | 289.0707 | -1.5 | PFP (+) |
| 3,4'-Dimethoxy-5,7,3'-trihydroxyflavone | 17.9 | C17H14O7 | 329.0673 | 329.0667 | -1.9 | PFP (-) |
| 3,4'-Dimethoxy-5,7,3'-trihydroxyflavone | 14.6 | C17H14O7 | 329.0680 | 329.0667 | -4.0 | Scherzo (-) |
| 3,5-Dihydroxybenzoic acid | 8.6 | C7H6O4 | 153.0195 | 153.0193 | -1.1 | PFP (-) |
| 3,5-Dihydroxybenzoic acid | 8.5 | C7H6O4 | 155.0337 | 155.0339 | 1.2 | PFP (+) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 14.2 | C11H12O5 | 223.0616 | 223.0612 | -1.8 | PFP (-) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 11.4 | C11H12O5 | 223.0624 | 223.0612 | -5.4 | Scherzo (-) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 11.4 | C11H12O5 | 225.0763 | 225.0758 | -2.4 | Scherzo (+) |
| 3,5-Dimethoxy-4-hydroxycinnamic acid | 14.2 | C11H12O5 | 225.0762 | 225.0758 | -2.0 | PFP (+) |
| 3,6,4'-Trihydroxyflavone | 12.3 | C15H10O5 | 269.0467 | 269.0456 | -4.3 | Scherzo (-) |
| 3alpha-Hydroxy-7-oxo-5beta-cholanic acid | 14.6 | C24H38O4 | 391.2835 | 391.2843 | 2.0 | Scherzo (+) |
| 3alpha-Hydroxy-7-oxo-5beta-cholanic acid | 15.1 | C24H38O4 | 391.2844 | 391.2843 | -0.3 | Scherzo (+) |
| 3alpha-Hydroxy-7-oxo-5beta-cholanic acid | 16.4 | C24H38O4 | 391.2845 | 391.2843 | -0.5 | Scherzo (+) |
| 3',4',5,7-Tetrahydroxy-3-methoxyflavone | 14.8 | C16H12O7 | 317.0662 | 317.0656 | -2.0 | Scherzo (+) |
| 4-Aminobenzoic acid | 8.0 | C7H7NO2 | 138.0548 | 138.0550 | 1.2 | Scherzo (+) |
| 4-Ethoxybenzoic acid | 14.1 | C9H10O3 | 167.0704 | 167.0703 | -0.8 | Scherzo (+) |
| 4-Ethoxybenzoic acid | 17.6 | C9H10O3 | 167.0705 | 167.0703 | -1.4 | Scherzo (+) |
| 4-Guanidinobutanoic acid | 2.3 | C5H11N3O2 | 146.0924 | 146.0924 | 0.0 | Scherzo (+) |
| 4-Hydroxy-L-glutamic acid | 3.2 | C5H9NO5 | 164.0558 | 164.0554 | -2.7 | Scherzo (+) |
| 4-Hydroxybenzaldehyde | 4.0 | C7H6O2 | 123.0444 | 123.0441 | -2.8 | Scherzo (+) |
| 4-Hydroxybenzaldehyde | 3.0 | C7H6O2 | 123.0444 | 123.0441 | -2.8 | PFP (+) |
| 4-Hydroxybenzoic acid | 10.3 | C7H6O3 | 137.0246 | 137.0244 | -1.3 | PFP (-) |

| 4-Hydroxybenzoic acid | 14.8 | C7H6O3 | 137.0244 | 137.0244 | 0.1 | PFP (-) |
|--|------|-------------|----------|----------|------|-------------|
| 4-Hydroxybenzoic acid | 10.2 | C7H6O3 | 139.0386 | 139.0390 | 2.7 | PFP (+) |
| 4-Hydroxybenzoic acid | 9.6 | C7H6O3 | 139.0389 | 139.0390 | 0.5 | Scherzo (+) |
| 4-Hydroxyisophthalic acid | 9.2 | C8H6O5 | 181.0141 | 181.0143 | 0.8 | PFP (-) |
| 4-Hydroxyisophthalic acid | 14.1 | C8H6O5 | 181.0144 | 181.0143 | -0.8 | PFP (-) |
| 4-Hydroxyquinoline-2-carbaldehyde | 11.3 | C10H7NO2 | 172.0405 | 172.0404 | -0.6 | PFP (-) |
| 4-Imidazoleacrylic acid | 2.5 | C6H6N2O2 | 139.0502 | 139.0502 | 0.0 | Scherzo (+) |
| 4-Imidazoleacrylic acid | 2.4 | C6H6N2O2 | 139.0500 | 139.0502 | 1.4 | PFP (+) |
| 4-Methylguinolin-2-ol | 13.4 | C10H9NO | 158.0609 | 158.0611 | 1.5 | PFP (-) |
| 4-Pyridoxic acid | 4.7 | C8H9NO4 | 182.0460 | 182.0459 | -0.7 | PFP (-) |
| 4-Pyridoxic acid | 6.0 | C8H9NO4 | 182.0463 | 182.0459 | -2.3 | PFP (-) |
| 4-Pyridoxic acid | 4.3 | C8H9NO4 | 182.0469 | 182.0459 | -5.6 | Scherzo (-) |
| 4-Pyridoxic acid | 6.7 | C8H9NO4 | 182.0465 | 182.0459 | -3.4 | Scherzo (-) |
| 4-Pyridoxic acid | 6.6 | C8H9NO4 | 184.0607 | 184.0604 | -1.5 | Scherzo (+) |
| 4-Pyridoxic acid | 6.0 | C8H9NO4 | 184.0608 | 184.0604 | -2.0 | PFP (+) |
| 5-(2-Hydroxyethyl)-4-methylthiazole | 4.5 | C6H9NOS | 144.0477 | 144.0478 | 0.4 | Scherzo (+) |
| 5-(2-Hydroxyethyl)-4-methylthiazole | 2.5 | C6H9NOS | 144.0475 | 144.0478 | 1.8 | PFP (+) |
| 5-(2-Hydroxyethyl)-4-methylthiazole | 4.6 | C6H9NOS | 144.0473 | 144.0478 | 3.2 | PFP (+) |
| 5-Amino-1-naphthol | 3.9 | C10H9NO | 160.0753 | 160.0757 | 2.4 | Scherzo (+) |
| 5-Aminovaleric acid | 1.9 | C5H11NO2 | 118.0864 | 118.0863 | -1.2 | PFP (+) |
| 5-Hydroxyindole | 10.2 | C8H7NO | 134.0602 | 134.0600 | -1.2 | PFP (+) |
| 5-Hydroxyindole-3-acetic acid | 10.7 | C10H9NO3 | 190.0502 | 190.0510 | 4.1 | PFP (-) |
| 5-Hydroxyindole-3-acetic acid | 11.3 | C10H9NO3 | 190.0517 | 190.0510 | -3.8 | PFP (-) |
| 5-Hydroxyindole-3-acetic acid | 10.5 | C10H9NO3 | 192.0660 | 192.0655 | -2.5 | Scherzo (+) |
| 5-Hydroxyindole-3-acetic acid | 10.6 | C10H9NO3 | 192.0658 | 192.0655 | -1.5 | PFP (+) |
| 5-Hydroxyindole-3-acetic acid | 11.3 | C10H9NO3 | 192.0660 | 192.0655 | -2.5 | PFP (+) |
| 5-Hydroxyindole-3-acetic acid | 11.7 | C10H9NO3 | 192.0656 | 192.0655 | -0.4 | PFP (+) |
| 5-Hydroxyindoleacetic acid | 9.6 | C10H9NO3 | 192.0659 | 192.0655 | -2.0 | Scherzo (+) |
| 5-Hydroxyisovanillic acid | 9.9 | C8H8O5 | 183.0305 | 183.0299 | -3.3 | PFP (-) |
| 5-Hydroxytryptophol | 9.9 | C10H11NO2 | 178.0858 | 178.0863 | 2.6 | PFP (+) |
| 5-Keto-D-gluconic acid | 1.9 | C6H10O7 | 193.0351 | 193.0354 | 1.5 | PFP (-) |
| 5-Keto-D-gluconic acid | 4.0 | C6H10O7 | 193.0361 | 193.0354 | -3.7 | Scherzo (-) |
| 5-Methyl-2'-deoxycytidine | 2.9 | C10H15N3O4 | 242.1130 | 242.1135 | 2.2 | PFP (+) |
| 5-Methyl-5,6-Dihydrouracil | 4.5 | C5H8N2O2 | 129.0660 | 129.0659 | -1.2 | Scherzo (+) |
| 5-Thymidylic acid | 4.0 | C10H15N2O8P | 321.0499 | 321.0493 | -1.8 | PFP (-) |
| 5-Thymidylic acid | 4.7 | C10H15N2O8P | 321.0498 | 321.0493 | -1.5 | PFP (-) |
| 5,7,3',4',5'-Pentahydroxyflavone | 16.9 | C15H10O7 | 301.0355 | 301.0354 | -0.4 | PFP (-) |
| 5.alphaPregnan-3.alpha.,17-diol-20-one | 15.6 | C21H34O6S | 413.2002 | 413.2003 | 0.3 | PFP (-) |
| 3-sulfate | | | | | | |

| 5.alphaPregnan-3.alpha.,17-diol-20-one | 16.6 | C21H34O6S | 413.2001 | 413.2003 | 0.6 | PFP (-) |
|--|------------|-------------|----------|----------|------|--|
| 5-Sullate | 75 | C11H15N5O3S | 208 0076 | 208 0068 | -2.5 | Scherzo (+) |
| 6-Dimethylaminopurine | 63 | C7H9N5 | 16/ 0030 | 16/ 0931 | -2.5 | PEP(+) |
| 6-Dimethylaminopurine | 15 | | 164 0028 | 16/ 0031 | 1.6 | Scherzo $(+)$ |
| 6-Hydroxynicotinic acid | 4.5 6 Q | C6H5NO3 | 1/0 03/0 | 1/0 03/2 | 1.0 | Scherzo $(+)$ |
| 6-Methyladenine | 3.4 | C6H7N5 | 150 0772 | 150 0774 | 1.0 | PEP(+) |
| 6-Methyladenine | 73 | | 150.0772 | 150.0774 | 5.5 | DED(+) |
| 6-Methyladenine | 6.0 | CONTING | 150.0700 | 150.0774 | 0.0 | $\frac{1}{2} \sum_{i=1}^{n} \frac{1}{2} \sum_{i=1}^{n} \frac{1}$ |
| 6.7 1'-Tribydroxyisoflayone | 12.2 | | 271 0600 | 271 0601 | 0.0 | Scherzo $(+)$ |
| 6.7 <i>1</i> '-Tribydroxyisoflayone | 12.2 | C15H10O5 | 271.0000 | 271.0001 | -0.7 | PEP(+) |
| 6alpha-Mannohiose | 2.6 | C12H22O11 | 2/1.0003 | 3/1 1089 | -0.7 | Scherzo $(-)$ |
| 6"-O-Acetylaenistin | 12.0 | C23H22O11 | 475 1261 | 475 1225 | -4.0 | Scherzo $(+)$ |
| 6"-O-Acetylgenistin | 12.4 | C23H22O11 | 475 1257 | 475 1235 | -3.6 | Scherzo $(+)$ |
| 7-Hydroxy-3-(1-methoxynbenyl)coumarin | 15.3 | C16H12O4 | 267 0667 | 267 0663 | -5.0 | Scherzo $(-)$ |
| 7-Hydroxy-4-(methoxymethyl)coumarin | 10.0 | C11H10O4 | 207.0007 | 207.0000 | -1.0 | DED (+) |
| 7-Hydroxy-4-(methoxymethyl)coumarin | 16.7 | C11H10O4 | 207.0040 | 207.0052 | 2.0 | PFP(r) |
| 7-Hydroxy-4-(methoxyflayone | 10.7 | C16H12O4 | 260 0813 | 207.0032 | _1 7 | $\frac{\Gamma}{\Gamma} = \left(\frac{1}{2} \right)$ |
| 7-Keto-3 alpha, 12- alpha - | 13.3 | C2/H38O5 | 107 2708 | 209.0000 | -1.7 | Scherzo $(+)$ |
| dibydroxycholanic acid | 15.5 | 024113003 | 407.2790 | 407.2732 | -1.5 | Scherzo (1) |
| 7-Keto-3 alpha, 12- alpha - | 1/1 | C2/H38O5 | 107 2706 | 107 2702 | -1.0 | Schorzo (+) |
| dihydroxycholanic acid | 14.1 | 024113003 | 407.2790 | 407.2792 | -1.0 | Scheizo (+) |
| 7-Keto-3.alpha12alpha | 14.6 | C24H38O5 | 407.2803 | 407.2792 | -2.7 | Scherzo (+) |
| dihydroxycholanic acid | | | | | | () |
| 7-Methylguanine | 2.8 | C6H7N5O | 164.0583 | 164.0578 | -3.2 | PFP (-) |
| 7-Methylguanine | 2.9 | C6H7N5O | 166.0720 | 166.0723 | 2.0 | PFP (+) |
| 7-Methylguanine | 3.5 | C6H7N5O | 166.0727 | 166.0723 | -2.2 | Scherzo (+) |
| 7-Methylguanosine | 7.1 | C11H15N5O5 | 298.1157 | 298.1146 | -3.7 | PFP (+) `´ |
| 7,8-Dehydropregnenolone | 12.3 | C21H30O2 | 315.2325 | 315.2319 | -2.0 | Scherzo (+) |
| 7,8-Dehydropregnenolone | 12.9 | C21H30O2 | 315.2312 | 315.2319 | 2.1 | Scherzo (+) |
| 7,8-Dehydropregnenolone | 15.3 | C21H30O2 | 315.2321 | 315.2319 | -0.8 | PFP (+) |
| 7,8-Dimethoxycoumarin | 11.4 | C11H10O4 | 207.0656 | 207.0652 | -2.0 | Scherzo (+) |
| 7,8-Dimethoxycoumarin | 14.2 | C11H10O4 | 207.0652 | 207.0652 | 0.0 | PFP (+) |
| 7,8,4'-Trihydroxyisoflavone | 11.4 | C15H10O5 | 271.0604 | 271.0601 | -1.1 | Scherzo (+) |
| 8-Hydroxyquinoline-2-carbaldehyde | 10.5 | C10H7NO2 | 172.0409 | 172.0404 | -2.9 | Scherzo (-) |
| 8-Hydroxyquinoline-5-carboxylic acid | 10.6 | C10H7NO3 | 188.0357 | 188.0353 | -2.0 | PFP (-) |
| 8-Hydroxyquinoline-5-carboxylic acid | 11.8 | C10H7NO3 | 188.0355 | 188.0353 | -1.0 | PFP (-) |
| 8-Hydroxyquinoline-5-carboxylic acid | 17.1 | C10H7NO3 | 188.0358 | 188.0353 | -2.6 | Scherzo (-) |
| 9,10-Dihydroxy-12Z-octadecenoic acid | 16.9 | C18H34O4 | 315.2545 | 315.2530 | -4.8 | Scherzo (+) |
| 9,10-Dihydroxy-12Z-octadecenoic acid | 17.9 | C18H34O4 | 315.2539 | 315.2530 | -2.9 | PFP (+) |

| 9(10)-Epoxy-12Z-octadecenoic acid | 14.3 | C18H32O3 | 297.2435 | 297.2424 | -3.6 | Scherzo (+) |
|-----------------------------------|------|--------------|----------|----------|------|-------------|
| 9(10)-Epoxy-12Z-octadecenoic acid | 15.7 | C18H32O3 | 297.2425 | 297.2424 | -0.3 | Scherzo (+) |
| 9(10)-Epoxy-12Z-octadecenoic acid | 16.9 | C18H32O3 | 297.2437 | 297.2424 | -4.3 | Scherzo (+) |
| 9(10)-Epoxy-12Z-octadecenoic acid | 17.9 | C18H32O3 | 297.2433 | 297.2424 | -3.0 | PFP (+) |
| Acetyl-L-carnitine | 2.5 | C9H17NO4 | 204.1235 | 204.1230 | -2.3 | Scherzo (+) |
| Acetyl-L-carnitine | 2.6 | C9H17NO4 | 204.1235 | 204.1230 | -2.3 | Scherzo (+) |
| Acetyl-L-carnitine | 3.8 | C9H17NO4 | 204.1236 | 204.1230 | -2.8 | PFP (+) |
| Acetyl-L-Threonine | 2.5 | C6H11NO4 | 160.0619 | 160.0615 | -2.3 | PFP (-) |
| Acetyl-L-Threonine | 4.6 | C6H11NO4 | 160.0621 | 160.0615 | -3.6 | Scherzo (-) |
| Acetyl-L-Threonine | 4.7 | C6H11NO4 | 162.0761 | 162.0761 | -0.1 | Scherzo (+) |
| Acetylcysteine | 14.2 | C5H9NO3S | 162.0226 | 162.0230 | 2.7 | PFP (-) |
| Acetylcysteine | 17.7 | C5H9NO3S | 162.0227 | 162.0230 | 2.1 | PFP (-) |
| Acetylglycine | 2.3 | C4H7NO3 | 116.0355 | 116.0353 | -1.6 | PFP (-) |
| Adenine | 2.3 | C5H5N5 | 134.0473 | 134.0472 | -0.6 | PFP (-) |
| Adenine | 4.0 | C5H5N5 | 134.0473 | 134.0472 | -0.6 | PFP (-) |
| Adenine | 2.3 | C5H5N5 | 136.0620 | 136.0618 | -1.7 | PFP (+) |
| Adenine | 4.0 | C5H5N5 | 136.0615 | 136.0618 | 2.0 | PFP (+) |
| Adenine | 4.7 | C5H5N5 | 136.0618 | 136.0618 | -0.2 | PFP (+) |
| Adenine | 2.5 | C5H5N5 | 136.0622 | 136.0618 | -3.2 | Scherzo (+) |
| Adenine | 4.5 | C5H5N5 | 136.0615 | 136.0618 | 2.0 | Scherzo (+) |
| Adenosine | 4.0 | C10H13N5O4 | 266.0892 | 266.0895 | 1.1 | PFP (-) |
| Adenosine | 2.4 | C10H13N5O4 | 268.1037 | 268.1040 | 1.2 | PFP (+) |
| Adenosine | 4.0 | C10H13N5O4 | 268.1049 | 268.1040 | -3.2 | PFP (+) |
| Adenosine | 4.1 | C10H13N5O4 | 268.1054 | 268.1040 | -5.1 | Scherzo (+) |
| Adenosine 5-monophosphate | 5.2 | C10H14N5O7P | 346.0567 | 346.0558 | -2.6 | Scherzo (-) |
| Adenosine 5-monophosphate | 5.1 | C10H14N5O7P | 348.0710 | 348.0704 | -1.8 | Scherzo (+) |
| Adenylyl(3'-5')cytidine | 7.1 | C19H25N8O11P | 571.1327 | 571.1308 | -3.4 | PFP (-) |
| Adenylyl(3'-5')cytidine | 6.8 | C19H25N8O11P | 571.1324 | 571.1308 | -2.9 | Scherzo (-) |
| Adenylyl(3'-5')cytidine | 6.7 | C19H25N8O11P | 573.1456 | 573.1453 | -0.5 | Scherzo (+) |
| Adenylyl(3'-5')cytidine | 7.1 | C19H25N8O11P | 573.1455 | 573.1453 | -0.3 | PFP (+) |
| Adipic acid | 7.5 | C6H10O4 | 145.0511 | 145.0506 | -3.2 | PFP (-) |
| Agmatine | 2.2 | C5H14N4 | 131.1291 | 131.1291 | 0.2 | Scherzo (+) |
| Ala-Ile | 3.6 | C9H18N2O3 | 203.1389 | 203.1390 | 0.6 | Scherzo (+) |
| Ala-Ile-Arg | 2.9 | C15H30N6O4 | 359.2396 | 359.2401 | 1.5 | PFP (+) |
| Ala-Ile-Lys | 2.2 | C15H30N4O4 | 331.2340 | 331.2340 | -0.1 | Scherzo (+) |
| Ala-Leu | 4.0 | C9H18N2O3 | 203.1396 | 203.1390 | -2.9 | Scherzo (+) |
| Ala-Leu | 5.4 | C9H18N2O3 | 203.1401 | 203.1390 | -5.3 | PFP (+) |
| Ala-Met | 2.8 | C8H16N2O3S | 221.0956 | 221.0954 | -0.7 | PFP (+) |
| Ala-Phe | 6.6 | C12H16N2O3 | 237.1245 | 237.1234 | -4.8 | Scherzo (+) |
| Ala-Phe | 8.0 | C12H16N2O3 | 237.1235 | 237.1234 | -0.5 | PFP (+) |
| Ala-Ser | 2.2 | C6H12N2O4 | 177.0866 | 177.0870 | 2.1 | Scherzo (+) |
|-----------------------|------|------------|----------|----------|------|-------------|
| Ala-Thr | 2.2 | C7H14N2O4 | 191.1033 | 191.1026 | -3.5 | Scherzo (+) |
| Ala-Tyr | 4.0 | C12H16N2O4 | 253.1191 | 253.1183 | -3.2 | Scherzo (+) |
| Ala-Val | 2.6 | C8H16N2O3 | 189.1237 | 189.1234 | -1.7 | Scherzo (+) |
| Ala-Val | 2.4 | C8H16N2O3 | 189.1240 | 189.1234 | -3.3 | PFP (+) |
| Ala-Val-Arg | 3.2 | C14H28N6O4 | 345.2241 | 345.2245 | 1.1 | PFP (+) |
| Albizziin | 3.8 | C4H9N3O3 | 146.0573 | 146.0571 | -1.3 | Scherzo (-) |
| Alpha-D-Glucose | 1.9 | C6H12O6 | 179.0559 | 179.0561 | 1.2 | PFP (-) |
| Alpha-Linolenic acid | 17.9 | C18H30O2 | 279.2327 | 279.2319 | -3.0 | PFP (+) |
| Alpha-Linolenic acid | 14.3 | C18H30O2 | 279.2324 | 279.2319 | -1.9 | Scherzo (+) |
| Alpha-Linolenic acid | 15.6 | C18H30O2 | 279.2321 | 279.2319 | -0.9 | Scherzo (+) |
| Alpha-Linolenic acid | 16.9 | C18H30O2 | 279.2330 | 279.2319 | -4.1 | Scherzo (+) |
| Amino caproic acid | 5.7 | C6H13NO2 | 132.1020 | 132.1019 | -0.7 | PFP (+) |
| Aminocaproic acid | 3.5 | C6H13NO2 | 130.0880 | 130.0874 | -5.0 | Scherzo (-) |
| Apigenin 7-glucoside | 14.5 | C21H20O10 | 431.0999 | 431.0984 | -3.5 | PFP (-) |
| Apigenin 7-glucoside | 11.3 | C21H20O10 | 431.0997 | 431.0984 | -3.1 | Scherzo (-) |
| Apigenin 7-glucoside | 11.3 | C21H20O10 | 433.1143 | 433.1129 | -3.2 | Scherzo (+) |
| Apigenin 7-glucoside | 14.5 | C21H20O10 | 433.1131 | 433.1129 | -0.4 | PFP (+) |
| Apiin | 10.9 | C26H28O14 | 565.1570 | 565.1552 | -3.2 | Scherzo (+) |
| Arg-lle | 4.0 | C12H25N5O3 | 288.2034 | 288.2030 | -1.3 | PFP (+) |
| Arg-Phe | 6.5 | C15H23N5O3 | 322.1872 | 322.1874 | 0.5 | PFP (+) |
| Arg-Tyr | 2.6 | C15H23N5O4 | 338.1821 | 338.1823 | 0.5 | Scherzo (+) |
| Arg-Tyr | 4.0 | C15H23N5O4 | 338.1825 | 338.1823 | -0.7 | PFP (+) |
| Argininosuccinic acid | 2.5 | C10H18N4O6 | 291.1309 | 291.1299 | -3.4 | Scherzo (+) |
| Asiatic acid | 17.6 | C30H48O5 | 487.3425 | 487.3429 | 0.8 | Scherzo (-) |
| Asn-Ile-Arg | 2.4 | C16H31N7O5 | 402.2471 | 402.2459 | -2.9 | Scherzo (+) |
| Asn-Ile-Lys | 2.2 | C16H31N5O5 | 374.2415 | 374.2398 | -4.5 | Scherzo (+) |
| Asn-Ile-Lys | 2.3 | C16H31N5O5 | 374.2411 | 374.2398 | -3.5 | PFP (+) |
| Asn-Phe | 6.5 | C13H17N3O4 | 280.1303 | 280.1292 | -4.0 | Scherzo (+) |
| Asn-Phe | 7.5 | C13H17N3O4 | 280.1301 | 280.1292 | -3.3 | PFP (+) |
| Asn-Phe-Lys | 3.9 | C19H29N5O5 | 408.2237 | 408.2242 | 1.1 | PFP (+) |
| Asn-Tyr | 4.0 | C13H17N3O5 | 296.1241 | 296.1241 | 0.0 | Scherzo (+) |
| Asn-Tyr | 5.0 | C13H17N3O5 | 296.1241 | 296.1241 | 0.0 | PFP (+) |
| Asp-Ile-Arg | 3.5 | C16H30N6O6 | 403.2309 | 403.2300 | -2.3 | Scherzo (+) |
| Asp-Ile-Arg | 3.5 | C16H30N6O6 | 403.2305 | 403.2300 | -1.3 | PFP (+) |
| Asp-Ile-Arg | 4.2 | C16H30N6O6 | 403.2304 | 403.2300 | -1.1 | PFP (+) |
| Asp-Ile-Lys | 2.5 | C16H30N4O6 | 375.2251 | 375.2238 | -3.4 | Scherzo (+) |
| Asp-Ile-Lys | 2.4 | C16H30N4O6 | 375.2250 | 375.2238 | -3.2 | PFP (+) |
| Asp-Leu | 5.2 | C10H18N2O5 | 247.1294 | 247.1289 | -2.2 | Scherzo (+) |
| Asp-Leu | 5.7 | C10H18N2O5 | 247.1293 | 247.1289 | -1.8 | Scherzo (+) |

| Asp-Leu | 4.7 | C10H18N2O5 | 247.1297 | 247.1289 | -3.4 | PFP (+) |
|----------------------------|------|-------------|----------|----------|------|-------------|
| Asp-Leu | 5.7 | C10H18N2O5 | 247.1297 | 247.1289 | -3.4 | PFP (+) |
| Asp-Pro | 3.1 | C9H14N2O5 | 231.0981 | 231.0976 | -2.4 | Scherzo (+) |
| Asp-Pro | 2.4 | C9H14N2O5 | 231.0982 | 231.0976 | -2.8 | PFP (+) |
| Asp-Tyr | 6.0 | C13H16N2O6 | 297.1090 | 297.1081 | -3.0 | Scherzo (+) |
| Asp-Tyr | 5.6 | C13H16N2O6 | 297.1090 | 297.1081 | -3.0 | PFP (+) |
| Asparagine | 2.4 | C4H8N2O3 | 131.0467 | 131.0462 | -3.7 | Scherzo (-) |
| Aspartic acid | 2.7 | C4H7NO4 | 134.0454 | 134.0448 | -4.6 | Scherzo (+) |
| Aspartic acid | 3.2 | C4H7NO4 | 134.0449 | 134.0448 | -0.9 | Scherzo (+) |
| Azelaic acid | 14.3 | C9H16O4 | 187.0981 | 187.0976 | -2.8 | PFP (-) |
| Azelaic acid | 14.3 | C9H16O4 | 189.1119 | 189.1121 | 1.3 | PFP (+) |
| Azelaic acid | 11.9 | C9H16O4 | 187.0986 | 187.0976 | -5.5 | Scherzo (-) |
| Azelaic acid | 11.9 | C9H16O4 | 189.1132 | 189.1121 | -5.6 | Scherzo (+) |
| B6 pyridoxine | 2.5 | C8H11NO3 | 170.0812 | 170.0812 | -0.2 | PFP (+) |
| B6 pyridoxine | 2.4 | C8H11NO3 | 170.0809 | 170.0812 | 1.6 | Scherzo (+) |
| Baicalin | 13.9 | C21H18O11 | 447.0934 | 447.0922 | -2.7 | Scherzo (+) |
| Benzoic acid ethyl ester | 15.0 | C9H10O2 | 151.0761 | 151.0754 | -4.9 | Scherzo (+) |
| Benzoic acid ethyl ester | 16.6 | C9H10O2 | 151.0752 | 151.0754 | 1.1 | PFP (+) |
| Benzophenone | 17.3 | C13H10O | 183.0803 | 183.0804 | 0.8 | Scherzo (+) |
| Beta-N-Acetylglucosamine | 2.7 | C8H15NO6 | 220.0828 | 220.0827 | -0.6 | Scherzo (-) |
| Betaine | 2.5 | C5H11NO2 | 118.0865 | 118.0863 | -2.0 | PFP (+) |
| Biliverdin | 14.8 | C33H34N4O6 | 583.2568 | 583.2551 | -2.9 | Scherzo (+) |
| Biliverdin | 17.7 | C33H34N4O6 | 583.2546 | 583.2551 | 0.9 | PFP (+) |
| Biocytin | 8.2 | C16H28N4O4S | 373.1917 | 373.1904 | -3.5 | PFP (+) |
| Biotin | 9.9 | C10H16N2O3S | 245.0962 | 245.0954 | -3.1 | Scherzo (+) |
| Butyric acid | 5.6 | C4H8O2 | 87.0453 | 87.0452 | -1.7 | PFP (-) |
| Caffeic acid | 11.7 | C9H8O4 | 179.0352 | 179.0350 | -1.2 | PFP (-) |
| Caffeic acid | 10.1 | C9H8O4 | 179.0365 | 179.0350 | -8.5 | Scherzo (-) |
| Caffeic acid | 10.1 | C9H8O4 | 181.0498 | 181.0495 | -1.4 | Scherzo (+) |
| Capric acid | 17.9 | C10H20O2 | 171.1389 | 171.1391 | 0.9 | PFP (-) |
| Carbofuran phenol-3-ketone | 11.4 | C10H10O3 | 179.0698 | 179.0703 | 2.6 | PFP (+) |
| Chenodeoxycholic acid | 16.8 | C24H40O4 | 391.2853 | 391.2854 | 0.2 | Scherzo (-) |
| Chenodeoxycholic acid | 17.8 | C24H40O4 | 391.2852 | 391.2854 | 0.5 | Scherzo (-) |
| Cholic acid | 17.9 | C24H40O5 | 407.2814 | 407.2803 | -2.7 | PFP (-) |
| Cholic acid | 16.4 | C24H40O5 | 407.2817 | 407.2803 | -3.4 | Scherzo (-) |
| Chrysoeriol | 14.7 | C16H12O6 | 299.0567 | 299.0561 | -2.0 | Scherzo (-) |
| Chrysoeriol | 14.7 | C16H12O6 | 301.0712 | 301.0707 | -1.8 | Scherzo (+) |
| cis-Jasmone | 14.2 | C11H16O | 165.1275 | 165.1274 | -0.7 | Scherzo (+) |
| Citraconic acid | 2.3 | C5H6O4 | 129.0189 | 129.0193 | 3.3 | PFP (-) |
| Citraconic acid | 4.4 | C5H6O4 | 129.0198 | 129.0193 | -3.6 | Scherzo (-) |

| Citraconic acid | 4.5 | C5H6O4 | 131.0337 | 131.0339 | 1.5 | Scherzo (+) |
|-------------------------------------|------|---------------|----------|----------|------|-------------|
| Citric acid | 2.4 | C6H8O7 | 191.0203 | 191.0197 | -3.0 | PFP (-) |
| Citric acid | 3.0 | C6H8O7 | 191.0201 | 191.0197 | -1.9 | PFP (-) |
| Citric acid | 2.9 | C6H8O7 | 191.0202 | 191.0197 | -2.5 | Scherzo (-) |
| Citric acid | 4.8 | C6H8O7 | 191.0206 | 191.0197 | -4.6 | Scherzo (-) |
| Citrulline | 1.9 | C6H13N3O3 | 174.0889 | 174.0884 | -2.8 | PFP (-) |
| Citrulline | 1.9 | C6H13N3O3 | 176.1028 | 176.1030 | 1.0 | PFP (+) |
| Citrulline | 2.5 | C6H13N3O3 | 174.0893 | 174.0884 | -5.1 | Scherzo (-) |
| Citrulline | 2.5 | C6H13N3O3 | 176.1035 | 176.1030 | -3.0 | Scherzo (+) |
| Coproporphyrin I | 17.2 | C36H38N4O8 | 655.2761 | 655.2762 | 0.2 | Scherzo (+) |
| Corticosterone | 14.8 | C21H30O4 | 347.2219 | 347.2217 | -0.6 | PFP (+) |
| Corticosterone | 11.6 | C21H30O4 | 347.2224 | 347.2217 | -2.0 | Scherzo (+) |
| Cortisol | 16.9 | C21H30O5 | 363.2169 | 363.2166 | -0.8 | PFP (+) |
| Cortisol | 14.4 | C21H30O5 | 363.2175 | 363.2166 | -2.5 | Scherzo (+) |
| Creatine | 2.0 | C4H9N3O2 | 132.0771 | 132.0768 | -2.6 | PFP (+) |
| Creatine | 2.5 | C4H9N3O2 | 132.0771 | 132.0768 | -2.6 | Scherzo (+) |
| Creatinine | 1.9 | C4H7N3O | 114.0663 | 114.0662 | -1.0 | PFP (+) |
| Cuminaldehyde | 11.8 | C10H12O | 149.0958 | 149.0961 | 1.9 | PFP (+) |
| Cyclic adenosine diphosphate ribose | 3.0 | C15H21N5O13P2 | 540.0552 | 540.0538 | -2.5 | PFP (-) |
| Cyclic adenosine diphosphate ribose | 5.8 | C15H21N5O13P2 | 540.0537 | 540.0538 | 0.3 | Scherzo (-) |
| Cytidine | 2.3 | C9H13N3O5 | 244.0937 | 244.0928 | -3.7 | Scherzo (+) |
| Cytidine | 2.0 | C9H13N3O5 | 244.0935 | 244.0928 | -2.9 | PFP (+) |
| Cytidine-5'-monophospho-N- | 6.5 | C20H31N4O16P | 613.1416 | 613.1400 | -2.6 | Scherzo (-) |
| acetylneuraminic acid | | | | | | |
| Cytosine | 2.0 | C4H5N3O | 112.0506 | 112.0505 | -0.5 | PFP (+) |
| Cytosine | 7.1 | C4H5N3O | 112.0506 | 112.0505 | -0.5 | PFP (+) |
| (-)-Citramalic acid | 5.6 | C5H8O5 | 147.0301 | 147.0299 | -1.4 | Scherzo (-) |
| Arabinonic acid | 1.9 | C5H10O6 | 165.0412 | 165.0405 | -4.5 | PFP (-) |
| Arabinonic acid | 2.8 | C5H10O6 | 165.0414 | 165.0405 | -5.7 | Scherzo (-) |
| Arabitol | 2.7 | C5H12O5 | 151.0621 | 151.0612 | -6.0 | Scherzo (-) |
| Aspartic acid | 1.9 | C4H7NO4 | 132.0301 | 132.0302 | 1.0 | PFP (-) |
| Aspartic acid | 2.8 | C4H7NO4 | 132.0309 | 132.0302 | -5.1 | Scherzo (-) |
| erythro-Sphinganine | 15.2 | C18H39NO2 | 302.3061 | 302.3054 | -2.4 | Scherzo (+) |
| Fructose 1,6-bisphosphate | 3.3 | C6H14O12P2 | 338.9892 | 338.9888 | -1.2 | Scherzo (-) |
| Gluconic acid | 3.3 | C6H12O7 | 195.0517 | 195.0510 | -3.4 | Scherzo (-) |
| Gluconic acid, .deltalactone | 3.3 | C6H10O6 | 179.0550 | 179.0550 | 0.1 | Scherzo (+) |
| Glucosamine, 6-sulfate | 2.5 | C6H13NO8S | 258.0302 | 258.0289 | -5.0 | Scherzo (-) |
| Glucose | 2.6 | C6H12O6 | 179.0567 | 179.0561 | -3.3 | Scherzo (-) |
| myo-Inositol-4-phosphate | 8.6 | C6H13O9P | 259.0228 | 259.0224 | -1.4 | Scherzo (-) |
| Pipecolinic acid | 2.0 | C6H11NO2 | 130.0864 | 130.0863 | -1.1 | Scherzo (+) |

| Pipecolinic acid | 2.8 | C6H11NO2 | 130.0861 | 130.0863 | 1.2 | Scherzo (+) |
|------------------------------|------|-------------|----------|----------|------|-------------|
| Pipecolinic acid | 2.4 | C6H11NO2 | 130.0861 | 130.0863 | 1.2 | PFP (+) `´ |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 128.0355 | 128.0353 | -1.4 | PFP (-) |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 128.0357 | 128.0353 | -3.0 | Scherzo (-) |
| Pyroglutamic acid | 5.6 | C5H7NO3 | 128.0360 | 128.0353 | -5.3 | Scherzo (-) |
| Quinovose | 2.8 | C6H12O5 | 163.0615 | 163.0612 | -1.8 | Scherzo (-) |
| Saccharic acid | 5.1 | C6H10O8 | 209.0311 | 209.0303 | -3.9 | Scherzo (-) |
| Xylose | 1.9 | C5H10O5 | 149.0451 | 149.0456 | 3.0 | PFP (-) |
| Xylose | 3.7 | C5H10O5 | 149.0462 | 149.0456 | -4.4 | Scherzo (-) |
| Daidzein | 16.3 | C15H10O4 | 253.0510 | 253.0506 | -1.5 | PFP (-) |
| Daidzein | 16.3 | C15H10O4 | 255.0658 | 255.0652 | -2.4 | PFP (+) |
| Daidzein | 13.1 | C15H10O4 | 253.0512 | 253.0506 | -2.3 | Scherzo (-) |
| Daidzein | 13.2 | C15H10O4 | 255.0664 | 255.0652 | -4.7 | Scherzo (+) |
| Daidzein 4'-sulfate | 16.3 | C15H10O7S | 333.0076 | 333.0075 | -0.5 | PFP (-) |
| Daidzin | 10.3 | C21H20O9 | 417.1199 | 417.1180 | -4.5 | Scherzo (+) |
| Daidzin | 12.9 | C21H20O9 | 417.1190 | 417.1180 | -2.4 | PFP (+) |
| Datiscin | 14.4 | C27H30O15 | 593.1541 | 593.1512 | -4.9 | PFP (-) |
| Deoxyadenosine | 4.4 | C10H13N5O3 | 252.1101 | 252.1091 | -3.9 | Scherzo (+) |
| Deoxyadenosine monophosphate | 6.5 | C10H14N5O6P | 330.0621 | 330.0609 | -3.6 | Scherzo (-) |
| Deoxyadenosine monophosphate | 6.5 | C10H14N5O6P | 332.0754 | 332.0755 | 0.2 | Scherzo (+) |
| Deoxycytidine | 2.5 | C9H13N3O4 | 226.0838 | 226.0833 | -2.1 | Scherzo (-) |
| Deoxyguanosine | 6.2 | C10H13N5O4 | 266.0904 | 266.0895 | -3.5 | PFP (-) |
| Deoxyguanosine | 6.2 | C10H13N5O4 | 268.1047 | 268.1040 | -2.5 | PFP (+) |
| Deoxyguanosine | 6.7 | C10H13N5O4 | 266.0908 | 266.0895 | -5.0 | Scherzo (-) |
| Deoxyguanosine | 6.6 | C10H13N5O4 | 268.1051 | 268.1040 | -4.0 | Scherzo (+) |
| Deoxyinosine | 6.2 | C10H12N4O4 | 251.0795 | 251.0786 | -3.7 | PFP (-) |
| Deoxyinosine | 6.7 | C10H12N4O4 | 251.0798 | 251.0786 | -4.9 | Scherzo (-) |
| Deoxyuridine | 4.3 | C9H12N2O5 | 227.0679 | 227.0674 | -2.4 | PFP (-) |
| Deoxyuridine | 5.3 | C9H12N2O5 | 227.0683 | 227.0674 | -4.2 | Scherzo (-) |
| Deoxyuridine | 5.2 | C9H12N2O5 | 229.0821 | 229.0819 | -0.9 | Scherzo (+) |
| Diethyl phthalate | 16.0 | C12H14O4 | 223.0963 | 223.0965 | 0.9 | Scherzo (+) |
| Diethyltoluamide | 15.2 | C12H17NO | 192.1378 | 192.1383 | 2.6 | Scherzo (+) |
| Dihydrodaidzein | 15.7 | C15H12O4 | 255.0668 | 255.0663 | -2.0 | PFP (-) |
| Dihydrodaidzein | 13.1 | C15H12O4 | 255.0670 | 255.0663 | -2.8 | Scherzo (-) |
| Dihydrodaidzein | 13.0 | C15H12O4 | 257.0817 | 257.0808 | -3.3 | Scherzo (+) |
| Dihydrodaidzein | 15.6 | C15H12O4 | 257.0814 | 257.0808 | -2.2 | PFP (+) |
| Dihydroisoferulic acid | 13.5 | C10H12O4 | 195.0666 | 195.0663 | -1.6 | PFP (-) |
| Dihydroisoferulic acid | 11.4 | C10H12O4 | 195.0664 | 195.0663 | -0.6 | Scherzo (-) |
| Dimethyl arginine | 2.0 | C8H18N4O2 | 203.1501 | 203.1503 | 0.7 | PFP (+) |
| Dimethyl arginine | 2.4 | C8H18N4O2 | 203.1505 | 203.1503 | -1.2 | Scherzo (+) |

| Diosmetin | 12.3 | C16H12O6 | 301.0720 | 301.0707 | -4.5 | Scherzo (+) |
|------------------------|------|------------|----------|----------|------|-------------|
| Diosmetin | 15.7 | C16H12O6 | 301.0699 | 301.0707 | 2.5 | PFP (+) |
| 3-Phenyllactic acid | 11.6 | C9H10O3 | 165.0563 | 165.0557 | -3.5 | PFP (-) |
| 3-Phenyllactic acid | 10.9 | C9H10O3 | 167.0706 | 167.0703 | -2.0 | Scherzo (+) |
| Arginine | 2.2 | C6H14N4O2 | 175.1193 | 175.1190 | -2.0 | Scherzo (+) |
| Arginine | 2.0 | C6H14N4O2 | 175.1192 | 175.1190 | -1.4 | PFP (+) `´ |
| Indole-3-lactic acid | 13.4 | C11H11NO3 | 204.0671 | 204.0666 | -2.4 | PFP (-) |
| Indole-3-lactic acid | 12.2 | C11H11NO3 | 204.0677 | 204.0666 | -5.3 | Scherzo (-) |
| Indole-3-lactic acid | 12.2 | C11H11NO3 | 206.0817 | 206.0812 | -2.6 | Scherzo (+) |
| Indole-3-lactic acid | 13.4 | C11H11NO3 | 206.0813 | 206.0812 | -0.6 | PFP (+) `´ |
| Isocitric acid lactone | 2.4 | C6H6O6 | 173.0095 | 173.0092 | -2.0 | PFP (-) |
| Isocitric acid lactone | 2.7 | C6H6O6 | 173.0094 | 173.0092 | -1.4 | PFP (-) |
| Leu-Val | 6.8 | C11H22N2O3 | 229.1564 | 229.1558 | -2.7 | PFP (-) |
| Leu-Val | 7.8 | C11H22N2O3 | 229.1564 | 229.1558 | -2.7 | PFP (-) |
| Leu-Val | 4.3 | C11H22N2O3 | 229.1564 | 229.1558 | -2.7 | Scherzo (-) |
| Leu-Val | 5.1 | C11H22N2O3 | 229.1564 | 229.1558 | -2.7 | Scherzo (-) |
| Leu-Val | 6.1 | C11H22N2O3 | 231.1697 | 231.1703 | 2.7 | Scherzo (+) |
| Leu-Val | 7.8 | C11H22N2O3 | 231.1710 | 231.1703 | -2.9 | PFP (+) |
| Malic acid | 2.0 | C4H6O5 | 133.0145 | 133.0143 | -1.9 | PFP (-) |
| Malic acid | 4.5 | C4H6O5 | 133.0148 | 133.0143 | -4.1 | Scherzo (-) |
| Phenylalanine | 12.0 | C9H11NO2 | 166.0859 | 166.0863 | 2.2 | Scherzo (+) |
| Phenylalanine | 13.7 | C9H11NO2 | 166.0862 | 166.0863 | 0.4 | PFP (+) |
| Dodecanedioic acid | 17.5 | C12H22O4 | 229.1450 | 229.1445 | -2.1 | PFP (-) |
| Dodecanedioic acid | 14.7 | C12H22O4 | 229.1456 | 229.1445 | -4.7 | Scherzo (-) |
| Dodecanedioic acid | 14.7 | C12H22O4 | 231.1594 | 231.1591 | -1.3 | Scherzo (+) |
| Dodecyl sulfate | 17.6 | C12H26O4S | 265.1482 | 265.1479 | -1.1 | PFP (-) |
| Emodin | 14.4 | C15H10O5 | 269.0461 | 269.0456 | -2.0 | PFP (-) |
| Emodin | 15.5 | C15H10O5 | 269.0462 | 269.0456 | -2.4 | PFP (-) |
| Enterolactone | 11.7 | C18H18O4 | 299.1286 | 299.1278 | -2.7 | Scherzo (+) |
| Enterolactone | 12.6 | C18H18O4 | 299.1283 | 299.1278 | -1.7 | Scherzo (+) |
| Enterolactone | 14.3 | C18H18O4 | 299.1287 | 299.1278 | -3.0 | Scherzo (+) |
| Enterolactone | 14.2 | C18H18O4 | 299.1279 | 299.1278 | -0.4 | PFP (+) |
| Enterolactone | 15.4 | C18H18O4 | 299.1287 | 299.1278 | -3.0 | PFP (+) |
| Enterolactone | 16.5 | C18H18O4 | 299.1283 | 299.1278 | -1.7 | PFP (+) |
| Equol | 17.0 | C15H14O3 | 241.0874 | 241.0870 | -1.6 | PFP (-) |
| Equol | 14.3 | C15H14O3 | 243.1026 | 243.1016 | -4.2 | Scherzo (+) |
| Equol | 17.0 | C15H14O3 | 243.1022 | 243.1016 | -2.6 | PFP (+) |
| Ethoxyquin | 11.6 | C14H19NO | 218.1544 | 218.1539 | -2.1 | Scherzo (+) |
| Ethylmalonic acid | 5.6 | C5H8O4 | 131.0350 | 131.0350 | -0.2 | PFP (-) |
| Ethylmalonic acid | 7.1 | C5H8O4 | 131.0349 | 131.0350 | 0.6 | Scherzo (-) |

| FAD | 12.7 | C27H33N9O15P2 | 784.1515 | 784.1499 | -2.1 | PFP (-) |
|---------------------------|------|---------------|----------|----------|------|-------------|
| Ferulic acid ethyl ester | 15.0 | C12H14O4 | 223.0970 | 223.0965 | -2.3 | Scherzo (+) |
| Ferulic acid ethyl ester | 17.5 | C12H14O4 | 223.0960 | 223.0965 | 2.2 | PFP (+) |
| Ferulic acid methyl ester | 16.5 | C11H12O4 | 207.0668 | 207.0663 | -2.5 | PFP (-) |
| Ferulic acid methyl ester | 13.8 | C11H12O4 | 209.0805 | 209.0808 | 1.6 | PFP (+) |
| Flavin Mononucleotide | 12.4 | C17H21N4O9P | 455.0971 | 455.0973 | 0.5 | PFP (-) |
| Flavin Mononucleotide | 12.3 | C17H21N4O9P | 457.1111 | 457.1119 | 1.7 | PFP (+) |
| Folate | 11.4 | C19H19N7O6 | 440.1318 | 440.1324 | 1.4 | PFP (-) |
| Folate | 11.4 | C19H19N7O6 | 442.1476 | 442.1470 | -1.4 | PFP (+) |
| Folate | 9.8 | C19H19N7O6 | 440.1339 | 440.1324 | -3.4 | Scherzo (-) |
| Fumaric acid | 2.0 | C4H4O4 | 115.0035 | 115.0037 | 1.6 | PFP (-) |
| Galactonic acid | 1.9 | C6H12O7 | 195.0518 | 195.0510 | -3.9 | PFP (-) |
| Galactonic acid | 2.8 | C6H12O7 | 195.0522 | 195.0510 | -6.0 | Scherzo (-) |
| Galactonic acid | 3.3 | C6H12O7 | 197.0652 | 197.0656 | 1.9 | Scherzo (+) |
| Genistein | 17.6 | C15H10O5 | 269.0458 | 269.0456 | -0.9 | PFP (-) |
| Genistein | 14.4 | C15H10O5 | 271.0597 | 271.0601 | 1.5 | PFP (+) |
| Genistein | 17.6 | C15H10O5 | 271.0604 | 271.0601 | -1.1 | PFP (+) |
| Genistein | 13.2 | C15H10O5 | 269.0467 | 269.0456 | -4.3 | Scherzo (-) |
| Genistein | 14.5 | C15H10O5 | 269.0466 | 269.0456 | -3.9 | Scherzo (-) |
| Genistein | 14.5 | C15H10O5 | 271.0607 | 271.0601 | -2.2 | Scherzo (+) |
| Genkwanin | 16.7 | C16H12O5 | 283.0618 | 283.0612 | -2.1 | PFP (-) |
| Genkwanin | 13.3 | C16H12O5 | 283.0615 | 283.0612 | -1.1 | Scherzo (-) |
| Genkwanin | 16.6 | C16H12O5 | 283.0623 | 283.0612 | -3.9 | Scherzo (-) |
| Gentisic acid | 11.0 | C7H6O4 | 153.0195 | 153.0193 | -1.1 | PFP (-) |
| Gentisic acid | 14.7 | C7H6O4 | 153.0200 | 153.0193 | -4.4 | Scherzo (-) |
| GIn-Leu-Arg | 2.4 | C17H33N7O5 | 416.2615 | 416.2616 | 0.2 | Scherzo (+) |
| Glu-Gly-Arg | 2.5 | C13H24N6O6 | 361.1821 | 361.1830 | 2.5 | Scherzo (+) |
| Glu-Ile-Arg | 2.4 | C17H32N6O6 | 417.2466 | 417.2456 | -2.4 | Scherzo (+) |
| Glu-Ile-Arg | 6.5 | C17H32N6O6 | 417.2454 | 417.2456 | 0.5 | Scherzo (+) |
| Glu-Ile-Arg | 3.2 | C17H32N6O6 | 417.2465 | 417.2456 | -2.1 | PFP (+) |
| Glu-Ile-Arg | 7.7 | C17H32N6O6 | 417.2458 | 417.2456 | -0.5 | PFP (+) |
| Glu-Ile-Lys | 2.2 | C17H32N4O6 | 389.2413 | 389.2395 | -4.7 | Scherzo (+) |
| Glu-Ile-Lys | 2.4 | C17H32N4O6 | 389.2409 | 389.2395 | -3.7 | PFP (+) |
| Glu-Phe | 7.0 | C14H18N2O5 | 295.1303 | 295.1289 | -4.9 | Scherzo (+) |
| Glu-Phe | 8.5 | C14H18N2O5 | 295.1301 | 295.1289 | -4.2 | PFP (+) |
| Glu-Val | 2.8 | C10H18N2O5 | 247.1293 | 247.1289 | -1.8 | Scherzo (+) |
| Glu-Val | 2.5 | C10H18N2O5 | 247.1290 | 247.1289 | -0.6 | PFP (+) |
| Glucoheptonic acid | 3.3 | C7H14O8 | 225.0615 | 225.0616 | 0.4 | Scherzo (-) |
| Glucosaminic acid | 2.4 | C6H13NO6 | 194.0667 | 194.0670 | 1.6 | Scherzo (-) |
| Glucose 1-phosphate | 2.2 | C6H13O9P | 259.0218 | 259.0224 | 2.5 | PFP (-) |

| Glutamine | 2.5 | C5H10N2O3 | 147.0769 | 147.0764 | -3.3 | Scherzo (+) |
|-----------------------|------|------------|----------|----------|------|-------------|
| Glutaric acid | 4.7 | C5H8O4 | 131.0351 | 131.0350 | -0.9 | PFP (-) |
| Glutaric acid | 6.2 | C5H8O4 | 131.0350 | 131.0350 | -0.2 | Scherzo (-) |
| Gly-lle | 4.7 | C8H16N2O3 | 189.1234 | 189.1234 | -0.2 | PFP (+) |
| Gly-lle-Arg | 3.1 | C14H28N6O4 | 345.2235 | 345.2245 | 2.8 | PFP (+) |
| Gly-Leu | 4.2 | C8H16N2O3 | 189.1239 | 189.1234 | -2.8 | Scherzo (+) |
| Gly-Leu | 5.7 | C8H16N2O3 | 189.1241 | 189.1234 | -3.9 | PFP (+) |
| Gly-Leu-Arg | 2.4 | C14H28N6O4 | 345.2258 | 345.2245 | -3.8 | Scherzo (+) |
| Gly-Leu-Lys | 2.2 | C14H28N4O4 | 317.2183 | 317.2183 | 0.1 | Scherzo (+) |
| Gly-Lys | 2.0 | C8H17N3O3 | 204.1344 | 204.1343 | -0.6 | Scherzo (+) |
| Gly-Met | 2.8 | C7H14N2O3S | 207.0799 | 207.0798 | -0.5 | Scherzo (+) |
| Gly-Met | 3.5 | C7H14N2O3S | 207.0804 | 207.0798 | -2.9 | Scherzo (+) |
| Gly-Met | 2.8 | C7H14N2O3S | 207.0802 | 207.0798 | -2.0 | PFP (+) |
| Gly-Phe | 6.6 | C11H14N2O3 | 223.1084 | 223.1077 | -3.0 | Scherzo (+) |
| Gly-Phe | 7.7 | C11H14N2O3 | 223.1084 | 223.1077 | -3.0 | PFP (+) |
| Gly-Tyr | 4.1 | C11H14N2O4 | 239.1034 | 239.1026 | -3.2 | Scherzo (+) |
| Gly-Tyr | 4.9 | C11H14N2O4 | 239.1033 | 239.1026 | -2.8 | PFP (+) |
| Glyceric acid | 1.9 | C3H6O4 | 105.0194 | 105.0193 | -0.7 | PFP (-) |
| Glycerolphosphate | 6.5 | C3H9O6P | 171.0071 | 171.0064 | -4.1 | Scherzo (-) |
| Glycerophosphocholine | 2.5 | C8H20NO6P | 258.1104 | 258.1101 | -1.2 | PFP (+) |
| Glycerophosphocholine | 2.8 | C8H20NO6P | 258.1111 | 258.1101 | -3.9 | Scherzo (+) |
| Glycyl-L-leucine | 4.6 | C8H16N2O3 | 187.1093 | 187.1088 | -2.6 | PFP (-) |
| Glycyl-L-leucine | 5.6 | C8H16N2O3 | 187.1093 | 187.1088 | -2.6 | PFP (-) |
| Glycyl-L-leucine | 3.9 | C8H16N2O3 | 187.1091 | 187.1088 | -1.5 | Scherzo (-) |
| Guanine | 2.3 | C5H5N5O | 150.0421 | 150.0421 | 0.2 | PFP (-) |
| Guanine | 5.4 | C5H5N5O | 150.0416 | 150.0421 | 3.5 | PFP (-) |
| Guanine | 2.4 | C5H5N5O | 152.0567 | 152.0567 | -0.1 | PFP (+) |
| Guanine | 5.0 | C5H5N5O | 152.0572 | 152.0567 | -3.4 | PFP (+) |
| Guanine | 5.4 | C5H5N5O | 152.0572 | 152.0567 | -3.4 | PFP (+) |
| Guanine | 6.2 | C5H5N5O | 152.0570 | 152.0567 | -2.0 | PFP (+) |
| Guanine | 7.3 | C5H5N5O | 152.0566 | 152.0567 | 0.6 | PFP (+) |
| Guanine | 8.7 | C5H5N5O | 152.0567 | 152.0567 | -0.1 | PFP (+) |
| Guanine | 3.1 | C5H5N5O | 150.0427 | 150.0421 | -3.8 | Scherzo (-) |
| Guanine | 2.8 | C5H5N5O | 152.0569 | 152.0567 | -1.4 | Scherzo (+) |
| Guanine | 6.6 | C5H5N5O | 152.0572 | 152.0567 | -3.4 | Scherzo (+) |
| Guanosine | 5.4 | C10H13N5O5 | 282.0852 | 282.0844 | -2.9 | PFP (-) |
| Guanosine | 5.4 | C10H13N5O5 | 284.0999 | 284.0990 | -3.3 | PFP (+) |
| Guanosine | 6.3 | C10H13N5O5 | 282.0858 | 282.0844 | -5.0 | Scherzo (-) |
| Guanosine | 6.2 | C10H13N5O5 | 284.1004 | 284.0990 | -5.1 | Scherzo (+) |
| Hematoporphyrin IX | 16.5 | C34H38N4O6 | 597.2743 | 597.2719 | -4.1 | PFP (-) |

| Heptadecasphinganine | 14.4 | C17H37NO2 | 288.2898 | 288.2897 | -0.3 | Scherzo (+) |
|--------------------------|------|------------|----------|----------|------|-------------|
| Hexadecanedioic acid | 18.0 | C16H30O4 | 285.2075 | 285.2071 | -1.3 | PFP (-) `´ |
| Hexanoyl-L-carnitine | 8.9 | C13H25NO4 | 260.1866 | 260.1856 | -3.7 | Scherzo (+) |
| Hexanoyl-L-carnitine | 12.6 | C13H25NO4 | 260.1856 | 260.1856 | 0.2 | PFP (+) |
| Hippuric acid | 9.5 | C9H9NO3 | 178.0508 | 178.0510 | 1.0 | PFP (-) |
| His-Ile | 2.4 | C12H20N4O3 | 269.1619 | 269.1608 | -4.0 | Scherzo (+) |
| His-Ile | 2.8 | C12H20N4O3 | 269.1618 | 269.1608 | -3.6 | PFP (+) |
| His-Lys | 2.4 | C12H21N5O3 | 284.1712 | 284.1717 | 1.8 | PFP (+) |
| His-Phe | 3.5 | C15H18N4O3 | 303.1474 | 303.1452 | -7.4 | Scherzo (+) |
| His-Phe | 4.8 | C15H18N4O3 | 303.1461 | 303.1452 | -3.1 | PFP (+) `´ |
| His-Pro | 2.1 | C11H16N4O3 | 253.1297 | 253.1295 | -0.7 | Scherzo (+) |
| His-Pro | 1.9 | C11H16N4O3 | 253.1300 | 253.1295 | -1.9 | PFP (+) |
| His-Trp | 5.5 | C17H19N5O3 | 342.1578 | 342.1561 | -5.1 | Scherzo (+) |
| His-Trp | 8.4 | C17H19N5O3 | 342.1575 | 342.1561 | -4.2 | PFP (+) `´ |
| His-Tyr | 2.4 | C15H18N4O4 | 319.1420 | 319.1401 | -6.0 | Scherzo (+) |
| His-Tyr | 3.0 | C15H18N4O4 | 319.1387 | 319.1401 | 4.3 | PFP (+) |
| His-Val | 2.1 | C11H18N4O3 | 255.1445 | 255.1452 | 2.6 | Scherzo (+) |
| His-Val | 1.9 | C11H18N4O3 | 255.1459 | 255.1452 | -2.9 | PFP (+) `´ |
| Histidine | 7.6 | C6H9N3O2 | 156.0763 | 156.0768 | 2.9 | PFP (+) |
| Histidine | 2.1 | C6H9N3O2 | 154.0625 | 154.0622 | -1.9 | Scherzo (-) |
| Histidine | 2.1 | C6H9N3O2 | 156.0763 | 156.0768 | 2.9 | Scherzo (+) |
| Homovanillic acid | 10.4 | C9H10O4 | 181.0509 | 181.0506 | -1.5 | Scherzo (-) |
| Hydroferulic acid | 12.7 | C10H12O4 | 195.0668 | 195.0663 | -2.7 | PFP (-) |
| Hydroferulic acid | 10.8 | C10H12O4 | 195.0673 | 195.0663 | -5.2 | Scherzo (-) |
| Hydroxyphenylacetic acid | 10.0 | C8H8O3 | 153.0548 | 153.0546 | -1.2 | PFP (+) |
| Hydroxyphenyllactic acid | 8.7 | C9H10O4 | 181.0514 | 181.0506 | -4.3 | PFP (-) |
| Hydroxyphenyllactic acid | 9.0 | C9H10O4 | 181.0514 | 181.0506 | -4.3 | Scherzo (-) |
| Hypoxanthine | 3.3 | C5H4N4O | 137.0459 | 137.0458 | -0.8 | PFP (+) |
| Hypoxanthine | 5.2 | C5H4N4O | 137.0453 | 137.0458 | 3.6 | PFP (+) |
| Hypoxanthine | 6.2 | C5H4N4O | 137.0459 | 137.0458 | -0.8 | PFP (+) |
| Hypoxanthine | 4.2 | C5H4N4O | 137.0461 | 137.0458 | -2.3 | Scherzo (+) |
| Hypoxanthine | 6.1 | C5H4N4O | 137.0460 | 137.0458 | -1.5 | Scherzo (+) |
| Hypoxanthine | 6.7 | C5H4N4O | 137.0460 | 137.0458 | -1.5 | Scherzo (+) |
| lle-Ala | 2.7 | C9H18N2O3 | 203.1394 | 203.1390 | -1.9 | Scherzo (+) |
| Ile-Ala | 2.9 | C9H18N2O3 | 203.1395 | 203.1390 | -2.4 | PFP (+) |
| lle-Arg | 2.2 | C12H25N5O3 | 288.2041 | 288.2030 | -3.7 | Scherzo (+) |
| lle-Arg | 2.5 | C12H25N5O3 | 288.2038 | 288.2030 | -2.7 | Scherzo (+) |
| lle-Arg | 2.4 | C12H25N5O3 | 288.2043 | 288.2030 | -4.4 | PFP (+) |
| lle-Arg | 7.8 | C12H25N5O3 | 288.2028 | 288.2030 | 0.8 | PFP (+) |
| lle-Asp | 3.1 | C10H18N2O5 | 247.1300 | 247.1289 | -4.7 | Scherzo (+) |

| lle-Asp | 3.5 | C10H18N2O5 | 247.1275 | 247.1289 | 5.5 | Scherzo (+) |
|-------------|------|-------------|----------|----------|------|-------------|
| lle-Glu | 2.8 | C11H20N2O5 | 261.1452 | 261.1445 | -2.7 | Scherzo (+) |
| lle-Glu | 3.5 | C11H20N2O5 | 261.1454 | 261.1445 | -3.4 | Scherzo (+) |
| lle-Glu | 2.9 | C11H20N2O5 | 261.1451 | 261.1445 | -2.3 | PFP (+) |
| lle-Gly | 3.5 | C8H16N2O3 | 189.1238 | 189.1234 | -2.3 | Scherzo (+) |
| lle-His | 2.0 | C12H20N4O3 | 269.1605 | 269.1608 | 1.2 | PFP (+) |
| lle-His | 7.0 | C12H20N4O3 | 269.1596 | 269.1608 | 4.5 | PFP (+) |
| lle-lle-Arg | 3.5 | C18H36N6O4 | 401.2871 | 401.2871 | 0.0 | Scherzo (+) |
| lle-lle-Arg | 6.4 | C18H36N6O4 | 401.2884 | 401.2871 | -3.3 | PFP (+) |
| lle-lle-Arg | 7.0 | C18H36N6O4 | 401.2872 | 401.2871 | -0.3 | PFP (+) |
| lle-lle-Arg | 7.8 | C18H36N6O4 | 401.2867 | 401.2871 | 0.9 | PFP (+) |
| lle-Leu | 6.9 | C12H24N2O3 | 245.1867 | 245.1860 | -3.0 | Scherzo (+) |
| lle-Leu | 7.3 | C12H24N2O3 | 245.1870 | 245.1860 | -4.2 | Scherzo (+) |
| lle-Leu | 9.8 | C12H24N2O3 | 245.1866 | 245.1860 | -2.6 | PFP (+) `´ |
| lle-Leu | 10.6 | C12H24N2O3 | 245.1865 | 245.1860 | -2.2 | PFP (+) |
| lle-Leu-Lys | 3.5 | C18H36N4O4 | 373.2813 | 373.2809 | -1.0 | Scherzo (+) |
| lle-Leu-Lys | 10.0 | C18H36N4O4 | 373.2809 | 373.2809 | 0.1 | PFP (+) |
| lle-Lys | 2.3 | C12H25N3O3 | 260.1975 | 260.1969 | -2.4 | Scherzo (+) |
| lle-Lys | 1.9 | C12H25N3O3 | 260.1973 | 260.1969 | -1.7 | PFP (+) |
| lle-Lys | 6.3 | C12H25N3O3 | 260.1971 | 260.1969 | -0.9 | PFP (+) |
| lle-Lys | 6.9 | C12H25N3O3 | 260.1972 | 260.1969 | -1.3 | PFP (+) |
| lle-Met | 6.3 | C11H22N2O3S | 263.1436 | 263.1424 | -4.6 | Scherzo (+) |
| lle-Met | 6.7 | C11H22N2O3S | 263.1433 | 263.1424 | -3.5 | Scherzo (+) |
| lle-Met | 8.4 | C11H22N2O3S | 263.1436 | 263.1424 | -4.6 | PFP (+) |
| lle-Met | 9.1 | C11H22N2O3S | 263.1430 | 263.1424 | -2.3 | PFP (+) |
| lle-Phe | 8.3 | C15H22N2O3 | 279.1711 | 279.1703 | -2.8 | Scherzo (+) |
| lle-Phe | 8.7 | C15H22N2O3 | 279.1685 | 279.1703 | 6.5 | Scherzo (+) |
| lle-Phe | 12.1 | C15H22N2O3 | 279.1710 | 279.1703 | -2.4 | PFP (+) |
| lle-Pro | 6.6 | C11H20N2O3 | 229.1551 | 229.1547 | -1.9 | Scherzo (+) |
| lle-Pro-lle | 8.1 | C17H31N3O4 | 342.2387 | 342.2387 | 0.1 | Scherzo (+) |
| lle-Pro-lle | 8.4 | C17H31N3O4 | 342.2400 | 342.2387 | -3.7 | Scherzo (+) |
| lle-Pro-lle | 12.2 | C17H31N3O4 | 342.2396 | 342.2387 | -2.5 | PFP (+) |
| lle-Pro-lle | 12.8 | C17H31N3O4 | 342.2390 | 342.2387 | -0.8 | PFP (+) |
| lle-Ser | 2.6 | C9H18N2O4 | 219.1341 | 219.1339 | -0.8 | Scherzo (+) |
| lle-Ser | 2.4 | C9H18N2O4 | 219.1340 | 219.1339 | -0.3 | PFP (+) |
| lle-Thr | 2.6 | C10H20N2O4 | 233.1501 | 233.1496 | -2.2 | Scherzo (+) |
| lle-Thr | 2.5 | C10H20N2O4 | 233.1503 | 233.1496 | -3.1 | PFP (+) |
| lle-Trp | 12.9 | C17H23N3O3 | 318.1819 | 318.1812 | -2.1 | PFP (+) |
| lle-Tyr | 8.9 | C15H22N2O4 | 295.1663 | 295.1652 | -3.6 | PFP (+) |
| lle-Tyr | 9.3 | C15H22N2O4 | 295.1658 | 295.1652 | -1.9 | PFP (+) |

| lle-Val | 4.3 | C11H22N2O3 | 231.1711 | 231.1703 | -3.4 | Scherzo (+) |
|---------------------------------|------|------------|----------|----------|------|-------------|
| lle-Val | 6.8 | C11H22N2O3 | 231.1710 | 231.1703 | -2.9 | PFP (+) |
| lle-Val-Arg | 4.3 | C17H34N6O4 | 387.2717 | 387.2714 | -0.7 | PFP (+) |
| lle-Val-Lys | 7.0 | C17H34N4O4 | 359.2658 | 359.2653 | -1.4 | PFP (+) |
| Indole | 9.4 | C8H7N | 118.0650 | 118.0651 | 1.1 | PFP (+) |
| Indole-2-carboxylic acid | 13.9 | C9H7NO2 | 160.0398 | 160.0404 | 3.7 | PFP (-) |
| Indole-3-carboxylic acid | 12.1 | C9H7NO2 | 160.0410 | 160.0404 | -3.7 | Scherzo (-) |
| Indole-6-carboxaldehyde | 11.8 | C9H7NO | 144.0453 | 144.0455 | 1.3 | PFP (-) |
| Indole-6-carboxaldehyde | 14.4 | C9H7NO | 144.0460 | 144.0455 | -3.5 | PFP (-) |
| Indole-6-carboxaldehyde | 12.3 | C9H7NO | 144.0460 | 144.0455 | -3.5 | Scherzo (-) |
| Indoleacrylic acid | 16.1 | C11H9NO2 | 186.0558 | 186.0561 | 1.3 | PFP (-) |
| Indoleacrylic acid | 13.4 | C11H9NO2 | 186.0564 | 186.0561 | -1.9 | Scherzo (-) |
| Indoxyl sulfate | 10.7 | C8H7NO4S | 212.0020 | 212.0023 | 1.4 | PFP (-) |
| Inosine | 4.3 | C10H12N4O5 | 267.0738 | 267.0735 | -1.2 | PFP (-) |
| Inosine | 5.2 | C10H12N4O5 | 267.0745 | 267.0735 | -3.8 | PFP (-) |
| Inosine | 4.6 | C10H12N4O5 | 269.0884 | 269.0881 | -1.3 | PFP (+) |
| Inosine | 5.2 | C10H12N4O5 | 269.0889 | 269.0881 | -3.2 | PFP (+) |
| Inosine | 6.3 | C10H12N4O5 | 267.0750 | 267.0735 | -5.7 | Scherzo (-) |
| Inosine | 6.1 | C10H12N4O5 | 269.0891 | 269.0881 | -3.9 | Scherzo (+) |
| Isopentenyladenine | 9.2 | C10H13N5 | 204.1248 | 204.1244 | -2.1 | Scherzo (+) |
| Isopentenyladenine | 12.6 | C10H13N5 | 204.1244 | 204.1244 | -0.1 | PFP (+) |
| Isosakuranetin | 15.9 | C16H14O5 | 285.0776 | 285.0769 | -2.6 | Scherzo (-) |
| Jasmonic acid | 12.0 | C12H18O3 | 211.1329 | 211.1329 | -0.1 | PFP (+) |
| Kaempferol | 17.6 | C15H10O6 | 287.0551 | 287.0550 | -0.3 | PFP (+) |
| Kaempferol | 14.7 | C15H10O6 | 285.0402 | 285.0405 | 0.9 | Scherzo (-) |
| Kaempferol | 14.7 | C15H10O6 | 287.0556 | 287.0550 | -2.1 | Scherzo (+) |
| Kaempferol-7-O-neohesperidoside | 14.4 | C27H30O15 | 595.1668 | 595.1658 | -1.8 | PFP (+) |
| Kynurenic acid | 9.4 | C10H7NO3 | 190.0505 | 190.0499 | -3.3 | Scherzo (+) |
| Kynurenic acid | 17.2 | C10H7NO3 | 190.0504 | 190.0499 | -2.8 | Scherzo (+) |
| Kynurenic acid | 10.2 | C10H7NO3 | 190.0501 | 190.0499 | -1.2 | PFP (+) |
| Kynurenic acid | 10.6 | C10H7NO3 | 190.0498 | 190.0499 | 0.4 | PFP (+) |
| Kynurenic acid | 11.8 | C10H7NO3 | 190.0500 | 190.0499 | -0.7 | PFP (+) |
| Kynurenic acid | 12.5 | C10H7NO3 | 190.0501 | 190.0499 | -1.2 | PFP (+) |
| gamma-Glutamyglutamic acid | 2.0 | C10H16N2O7 | 275.0888 | 275.0885 | -1.2 | PFP (-) |
| gamma-Glutamyglutamic acid | 2.4 | C10H16N2O7 | 275.0895 | 275.0885 | -3.7 | Scherzo (-) |
| gamma-Glutamyglutamic acid | 3.8 | C10H16N2O7 | 275.0899 | 275.0885 | -5.2 | Scherzo (-) |
| gamma-Glutamyglutamic acid | 3.7 | C10H16N2O7 | 277.1045 | 277.1030 | -5.3 | Scherzo (+) |
| 2-Hydroxyglutaric acid | 2.4 | C5H8O5 | 147.0302 | 147.0299 | -2.0 | PFP (-) |
| 2-Hydroxyglutaric acid | 4.4 | C5H8O5 | 147.0304 | 147.0299 | -3.4 | Scherzo (-) |
| 3-Phenyllactic acid | 11.8 | C9H10O3 | 165.0564 | 165.0557 | -4.1 | Scherzo (-) |

| Alanynorleucine | 4.3 | C9H18N2O3 | 203.1392 | 203.1390 | -0.9 | PFP (+) |
|--------------------------------|------|--------------|----------|----------|------|-------------|
| Arginine | 2.2 | C6H14N4O2 | 173.1051 | 173.1044 | -4.0 | Scherzo (-) |
| Arginine | 1.8 | C6H14N4O2 | 175.1189 | 175.1190 | 0.3 | Scherzo (+) |
| Aspartyphenylalanine | 8.1 | C13H16N2O5 | 279.0994 | 279.0987 | -2.7 | PFP (-) |
| Aspartyphenylalanine | 8.1 | C13H16N2O5 | 281.1142 | 281.1132 | -3.6 | PFP (+) |
| Aspartyphenylalanine | 7.6 | C13H16N2O5 | 279.0999 | 279.0987 | -4.5 | Scherzo (-) |
| Aspartyphenylalanine | 7.6 | C13H16N2O5 | 281.1144 | 281.1132 | -4.3 | Scherzo (+) |
| Carnitine | 2.0 | C7H15NO3 | 162.1122 | 162.1125 | 1.7 | PFP (+) |
| Carnitine | 2.4 | C7H15NO3 | 162.1127 | 162.1125 | -1.4 | Scherzo (+) |
| Citrulline | 2.5 | C6H13N3O3 | 176.1031 | 176.1030 | -0.7 | Scherzo (+) |
| Cysteic acid | 7.5 | C3H7NO5S | 167.9978 | 167.9972 | -3.5 | Scherzo (-) |
| Cysteine S-sulfate | 2.2 | C3H7NO5S2 | 199.9691 | 199.9693 | 1.0 | PFP (-) |
| Cysteine S-sulfate | 9.6 | C3H7NO5S2 | 199.9697 | 199.9693 | -2.1 | Scherzo (-) |
| Cysteine S-sulfate | 9.7 | C3H7NO5S2 | 201.9840 | 201.9838 | -0.8 | Scherzo (+) |
| Cysteine-glutathione disulfide | 3.1 | C13H22N4O8S2 | 425.0804 | 425.0806 | 0.5 | Scherzo (-) |
| Cysteine-glutathione disulfide | 3.1 | C13H22N4O8S2 | 427.0955 | 427.0952 | -0.7 | Scherzo (+) |
| Cystine | 2.4 | C6H12N2O4S2 | 239.0170 | 239.0166 | -1.8 | Scherzo (-) |
| Cystine | 2.4 | C6H12N2O4S2 | 241.0319 | 241.0311 | -3.2 | Scherzo (+) |
| Glutamate | 1.9 | C5H9NO4 | 146.0465 | 146.0459 | -4.2 | PFP (-) |
| Glutamate | 1.9 | C5H9NO4 | 148.0610 | 148.0604 | -3.8 | PFP (+) |
| Glutamate | 2.6 | C5H9NO4 | 146.0465 | 146.0459 | -4.2 | Scherzo (-) |
| Glutamate | 2.6 | C5H9NO4 | 148.0600 | 148.0604 | 2.9 | Scherzo (+) |
| Glutamine | 2.5 | C5H10N2O3 | 145.0623 | 145.0619 | -3.0 | Scherzo (-) |
| Histidine | 1.9 | C6H9N3O2 | 156.0765 | 156.0768 | 1.6 | PFP (+) |
| Isoleucine | 3.7 | C6H13NO2 | 130.0878 | 130.0874 | -3.5 | Scherzo (-) |
| Isoleucine | 3.5 | C6H13NO2 | 132.1021 | 132.1019 | -1.4 | Scherzo (+) |
| Lysine | 2.1 | C6H14N2O2 | 145.0985 | 145.0983 | -1.7 | Scherzo (-) |
| Lysine | 2.0 | C6H14N2O2 | 147.1132 | 147.1128 | -2.7 | Scherzo (+) |
| Methionine | 2.1 | C5H11NO2S | 148.0440 | 148.0438 | -1.6 | PFP (-) |
| Methionine | 8.1 | C5H11NO2S | 148.0436 | 148.0438 | 1.1 | PFP (-) |
| Methionine | 2.3 | C5H11NO2S | 150.0587 | 150.0583 | -2.5 | PFP (+) |
| Methionine | 8.1 | C5H11NO2S | 150.0580 | 150.0583 | 2.2 | PFP (+) |
| Methionine | 2.8 | C5H11NO2S | 148.0444 | 148.0438 | -4.3 | Scherzo (-) |
| Methionine | 2.9 | C5H11NO2S | 150.0587 | 150.0583 | -2.5 | Scherzo (+) |
| Methionine | 9.2 | C5H11NO2S | 150.0592 | 150.0583 | -5.8 | Scherzo (+) |
| Methionine sulfoxide | 1.9 | C5H11NO3S | 166.0534 | 166.0532 | -1.0 | PFP (+) |
| Methionine sulfoxide | 2.6 | C5H11NO3S | 164.0389 | 164.0387 | -1.3 | Scherzo (-) |
| Methionine sulfoxide | 2.6 | C5H11NO3S | 166.0536 | 166.0532 | -2.2 | Scherzo (+) |
| Phenylalanine | 5.2 | C9H11NO2 | 164.0724 | 164.0717 | -4.3 | PFP (-) |
| Phenylalanine | 11.1 | C9H11NO2 | 164.0718 | 164.0717 | -0.6 | PFP (-) |

| Phenylalanine | 5.2 | C9H11NO2 | 166.0868 | 166.0863 | -3.3 | PFP (+) |
|---------------------|------|------------|----------|----------|------|-------------|
| Phenylalanine | 7.7 | C9H11NO2 | 166.0866 | 166.0863 | -2.0 | PFP (+) |
| Phenylalanine | 11.5 | C9H11NO2 | 166.0864 | 166.0863 | -0.8 | PFP (+) |
| Phenylalanine | 5.8 | C9H11NO2 | 164.0724 | 164.0717 | -4.3 | Scherzo (-) |
| Phenylalanine | 5.7 | C9H11NO2 | 166.0867 | 166.0863 | -2.6 | Scherzo (+) |
| Pipecolic acid | 2.6 | C6H11NO2 | 130.0863 | 130.0863 | -0.3 | PFP (+) `´ |
| Proline | 2.1 | C5H9NO2 | 116.0705 | 116.0706 | 0.9 | PFP (+) |
| Propionylcarnitine | 2.9 | C10H19NO4 | 218.1386 | 218.1387 | 0.4 | Scherzo (+) |
| Propionylcarnitine | 6.4 | C10H19NO4 | 218.1383 | 218.1387 | 1.7 | PFP (+) `´ |
| Saccharopine | 2.5 | C11H20N2O6 | 277.1403 | 277.1394 | -3.2 | Scherzo (+) |
| Threonine | 2.5 | C4H9NO3 | 120.0659 | 120.0655 | -3.2 | Scherzo (+) |
| Tryptophan | 9.3 | C11H12N2O2 | 203.0834 | 203.0826 | -3.9 | PFP (-) |
| Tryptophan | 13.6 | C11H12N2O2 | 203.0826 | 203.0826 | 0.0 | PFP (-) |
| Tryptophan | 9.4 | C11H12N2O2 | 205.0976 | 205.0972 | -2.2 | PFP (+) |
| Tryptophan | 7.9 | C11H12N2O2 | 203.0832 | 203.0826 | -3.0 | Scherzo (-) |
| Tryptophan | 7.8 | C11H12N2O2 | 205.0978 | 205.0972 | -3.2 | Scherzo (+) |
| Tyrosine | 3.3 | C9H11NO3 | 180.0673 | 180.0666 | -3.8 | PFP (-) |
| Tyrosine | 3.0 | C9H11NO3 | 182.0819 | 182.0812 | -4.0 | PFP (+) |
| Tyrosine | 3.6 | C9H11NO3 | 182.0816 | 182.0812 | -2.4 | PFP (+) |
| Tyrosine | 3.9 | C9H11NO3 | 180.0672 | 180.0666 | -3.2 | Scherzo (-) |
| Tyrosine | 3.0 | C9H11NO3 | 182.0815 | 182.0812 | -1.8 | Scherzo (+) |
| Tyrosine | 3.9 | C9H11NO3 | 182.0818 | 182.0812 | -3.5 | Scherzo (+) |
| Tyrosine | 11.2 | C9H11NO3 | 182.0808 | 182.0812 | 2.0 | Scherzo (+) |
| Tyrosine | 7.0 | C9H11NO3 | 182.0815 | 182.0812 | -1.8 | PFP (+) |
| Lauroyl-L-carnitine | 13.6 | C19H37NO4 | 344.2808 | 344.2795 | -3.7 | Scherzo (+) |
| Leu-GIn-Arg | 3.5 | C17H33N7O5 | 416.2609 | 416.2616 | 1.7 | PFP (+) |
| Leu-Gln-Arg | 15.9 | C17H33N7O5 | 416.2635 | 416.2616 | -4.6 | PFP (+) |
| Leu-Gly-Lys | 2.5 | C14H28N4O4 | 317.2198 | 317.2183 | -4.6 | PFP (+) |
| Leu-Ile-Lys | 6.9 | C18H36N4O4 | 373.2807 | 373.2809 | 0.6 | PFP (+) |
| Leu-Leu | 11.2 | C12H24N2O3 | 245.1866 | 245.1860 | -2.6 | PFP (+) |
| Leu-Leu | 14.1 | C12H24N2O3 | 245.1865 | 245.1860 | -2.2 | PFP (+) |
| Leu-Leu-Lys | 6.2 | C18H36N4O4 | 373.2819 | 373.2809 | -2.6 | PFP (+) |
| Leu-Phe | 12.6 | C15H22N2O3 | 279.1708 | 279.1703 | -1.7 | PFP (+) |
| Leu-Val-Lys | 2.3 | C17H34N4O4 | 359.2639 | 359.2653 | 3.8 | Scherzo (+) |
| Luteolin | 17.6 | C15H10O6 | 285.0404 | 285.0405 | 0.2 | PFP (-) |
| Lys-Leu | 3.1 | C12H25N3O3 | 260.1976 | 260.1969 | -2.8 | PFP (+) |
| Lys-Lys | 2.8 | C12H26N4O3 | 275.2089 | 275.2078 | -4.1 | PFP (+) |
| Lys-Trp | 5.3 | C17H24N4O3 | 333.1921 | 333.1921 | 0.1 | Scherzo (+) |
| Lys-Trp | 8.9 | C17H24N4O3 | 333.1909 | 333.1921 | 3.7 | PFP (+) |
| m-cresol | 10.1 | C7H8O | 107.0499 | 107.0502 | 3.2 | PFP (-) |

| Malonic acid | 2.3 | C3H4O4 | 103.0036 | 103.0037 | 0.8 | PFP (-) |
|------------------------------------|------|-------------|----------|----------|------|-------------|
| Maltotetraose | 2.7 | C24H42O21 | 665.2180 | 665.2146 | -5.1 | Scherzo (-) |
| Maltotriose | 2.7 | C18H32O16 | 503.1639 | 503.1618 | -4.3 | Scherzo (-) |
| Matairesinol | 11.9 | C20H22O6 | 359.1496 | 359.1489 | -1.9 | Scherzo (+) |
| Matairesinol | 13.9 | C20H22O6 | 359.1503 | 359.1489 | -3.8 | Scherzo (+) |
| Matairesinol | 15.2 | C20H22O6 | 359.1501 | 359.1489 | -3.3 | PFP (+) |
| Met-Ile | 10.0 | C11H22N2O3S | 261.1283 | 261.1278 | -1.8 | PFP (-) |
| Met-Leu | 7.1 | C11H22N2O3S | 263.1416 | 263.1424 | 3.0 | Scherzo (+) |
| Met-Leu | 10.0 | C11H22N2O3S | 263.1420 | 263.1424 | 1.5 | PFP (+) |
| Met-Val | 6.4 | C10H20N2O3S | 249.1274 | 249.1267 | -2.6 | PFP (+) |
| Methyl trans-cinnamate | 12.0 | C10H10O2 | 163.0748 | 163.0754 | 3.4 | Scherzo (+) |
| Methyl trans-cinnamate | 12.7 | C10H10O2 | 163.0753 | 163.0754 | 0.4 | Scherzo (+) |
| Mucic acid | 1.9 | C6H10O8 | 209.0302 | 209.0303 | 0.4 | PFP (-) |
| Mucic acid | 4.1 | C6H10O8 | 209.0313 | 209.0303 | -4.8 | Scherzo (-) |
| Myristoleic acid | 17.9 | C14H26O2 | 227.2004 | 227.2006 | 0.7 | PFP (+) |
| N-(4-Aminobenzoyl)-L-glutamic acid | 6.3 | C12H14N2O5 | 267.0977 | 267.0976 | -0.6 | PFP (+) |
| N-acetyl glutamic acid | 2.8 | C7H11NO5 | 188.0571 | 188.0565 | -3.5 | PFP (-) |
| N-acetyl glutamic acid | 3.0 | C7H11NO5 | 188.0566 | 188.0565 | -0.8 | PFP (-) |
| N-acetyl glutamic acid | 5.7 | C7H11NO5 | 188.0573 | 188.0565 | -4.5 | Scherzo (-) |
| N-acetyl glutamic acid | 5.7 | C7H11NO5 | 190.0708 | 190.0710 | 1.1 | Scherzo (+) |
| N-acetyl Mannosamine | 1.9 | C8H15NO6 | 222.0971 | 222.0972 | 0.5 | PFP (+) |
| N-acetyl Mannosamine | 2.7 | C8H15NO6 | 222.0981 | 222.0972 | -4.0 | Scherzo (+) |
| N-Acetyl-D-galactosamine 4-sulfate | 2.3 | C8H15NO9S | 300.0401 | 300.0395 | -2.1 | PFP (-) |
| N-Acetyl-D-glucosamine 6-phosphate | 9.3 | C8H16NO9P | 300.0499 | 300.0490 | -3.0 | Scherzo (-) |
| N-Acetyl-D-lactosamine | 2.6 | C14H25NO11 | 384.1506 | 384.1500 | -1.5 | Scherzo (+) |
| N-Acetyl-D-norleucine | 11.1 | C8H15NO3 | 172.0981 | 172.0979 | -1.0 | PFP (-) |
| N-Acetyl-D-norleucine | 10.6 | C8H15NO3 | 172.0986 | 172.0979 | -4.0 | Scherzo (-) |
| N-Acetyl-D-norleucine | 12.6 | C8H15NO3 | 172.0987 | 172.0979 | -4.5 | Scherzo (-) |
| N-Acetyl-DL-valine | 6.6 | C7H13NO3 | 158.0824 | 158.0823 | -0.8 | PFP (-) |
| N-Acetyl-DL-valine | 7.8 | C7H13NO3 | 158.0824 | 158.0823 | -0.8 | PFP (-) |
| N-Acetyl-DL-valine | 7.2 | C7H13NO3 | 158.0827 | 158.0823 | -2.7 | Scherzo (-) |
| N-Acetyl-DL-valine | 8.7 | C7H13NO3 | 158.0828 | 158.0823 | -3.4 | Scherzo (-) |
| N-Acetyl-DL-valine | 10.7 | C7H13NO3 | 158.0829 | 158.0823 | -4.0 | Scherzo (-) |
| N-Acetyl-L-alanine | 5.1 | C5H9NO3 | 130.0513 | 130.0510 | -2.5 | Scherzo (-) |
| N-Acetyl-L-alanine | 7.5 | C5H9NO3 | 130.0519 | 130.0510 | -7.2 | Scherzo (-) |
| N-Acetyl-L-alanine | 5.0 | C5H9NO3 | 132.0647 | 132.0655 | 6.2 | Scherzo (+) |
| N-Acetyl-L-Aspartate | 5.7 | C6H9NO5 | 174.0411 | 174.0408 | -1.7 | Scherzo (-) |
| N-Acetyl-L-Glutamine | 4.5 | C7H12N2O4 | 187.0730 | 187.0724 | -3.0 | Scherzo (-) |
| N-Acetyl-L-Glutamine | 4.4 | C7H12N2O4 | 189.0871 | 189.0870 | -0.6 | Scherzo (+) |
| N-Acetyl-L-Leucine | 10.2 | C8H15NO3 | 172.0981 | 172.0979 | -1.0 | PFP (-) |

| N-Acetyl-L-Leucine | 10.5 | C8H15NO3 | 174.1123 | 174.1125 | 1.0 | PFP (+) |
|---------------------------------|------|---------------|----------|----------|------|-------------|
| N-Acetyl-L-Leucine | 11.1 | C8H15NO3 | 174.1125 | 174.1125 | -0.2 | PFP (+) |
| N-Acetyl-L-Leucine | 10.6 | C8H15NO3 | 174.1124 | 174.1125 | 0.4 | Scherzo (+) |
| N-Acetyl-L-Methionine | 7.6 | C7H13NO3S | 190.0547 | 190.0543 | -1.9 | PFP (-) |
| N-Acetyl-L-Methionine | 8.1 | C7H13NO3S | 190.0548 | 190.0543 | -2.4 | PFP (-) |
| N-Acetyl-L-methionine | 8.1 | C7H13NO3S | 192.0683 | 192.0689 | 3.1 | PFP (+) |
| N-Acetyl-L-Methionine | 9.3 | C7H13NO3S | 190.0550 | 190.0543 | -3.5 | Scherzo (-) |
| N-Acetyl-L-methionine | 9.2 | C7H13NO3S | 192.0685 | 192.0689 | 2.0 | Scherzo (+) |
| N-Acetyl-L-phenylalanine | 12.3 | C11H13NO3 | 206.0821 | 206.0823 | 0.8 | PFP (-) |
| N-Acetyl-L-Phenylalanine | 12.4 | C11H13NO3 | 208.0971 | 208.0968 | -1.3 | PFP (+) |
| N-Acetyl-L-phenylalanine | 12.0 | C11H13NO3 | 206.0820 | 206.0823 | 1.3 | Scherzo (-) |
| N-Acetyl-L-Phenylalanine | 15.9 | C11H13NO3 | 206.0819 | 206.0823 | 1.8 | Scherzo (-) |
| N-Acetyl-L-Phenylalanine | 12.0 | C11H13NO3 | 208.0974 | 208.0968 | -2.8 | Scherzo (+) |
| N-Acetyl-L-tyrosine | 9.4 | C11H13NO4 | 222.0775 | 222.0772 | -1.4 | PFP (-) |
| N-Acetyl-L-tyrosine | 9.3 | C11H13NO4 | 224.0928 | 224.0917 | -4.8 | PFP (+) |
| N-Acetylglucosaminylasparagine | 2.4 | C12H21N3O8 | 336.1410 | 336.1401 | -2.6 | Scherzo (+) |
| N-Acetylglutamic acid | 2.8 | C7H11NO5 | 190.0709 | 190.0710 | 0.5 | PFP (+) |
| N-Acetylhistamine | 2.2 | C7H11N3O | 154.0974 | 154.0975 | 0.6 | Scherzo (+) |
| N-Acetylhistamine | 2.3 | C7H11N3O | 154.0973 | 154.0975 | 1.2 | PFP (+) |
| N-Acetylputrescine | 2.2 | C6H14N2O | 131.1180 | 131.1179 | -0.8 | Scherzo (+) |
| N-Caffeoyl-O-methyltyramine | 15.7 | C18H19NO4 | 312.1251 | 312.1241 | -3.1 | PFP (-) |
| N-Carboxyethylgammaaminobutyric | 2.3 | C7H13NO4 | 176.0921 | 176.0917 | -2.1 | Scherzo (+) |
| acid | | | | | | |
| N-Desmethyltramadol | 17.4 | C15H23NO2 | 250.1780 | 250.1802 | 8.6 | PFP (+) |
| N-FormyI-L-methionine | 7.3 | C6H11NO3S | 176.0389 | 176.0387 | -1.2 | PFP (-) |
| N-Formyl-L-methionine | 9.3 | C6H11NO3S | 176.0385 | 176.0387 | 1.1 | Scherzo (-) |
| N-Glycolylneuraminic acid | 5.2 | C11H19NO10 | 324.0945 | 324.0936 | -2.7 | Scherzo (-) |
| N-Glycolylneuraminic acid | 5.3 | C11H19NO10 | 326.1092 | 326.1082 | -3.2 | Scherzo (+) |
| N,N-Bis(2-hydroxyethyl)glycine | 2.6 | C6H13NO4 | 164.0915 | 164.0917 | 1.4 | Scherzo (+) |
| N,N-Dimethylguanosine | 7.4 | C12H17N5O5 | 312.1318 | 312.1303 | -5.0 | Scherzo (+) |
| N.alphaAcetyl-L-lysine | 2.4 | C8H16N2O3 | 187.1089 | 187.1088 | -0.4 | Scherzo (-) |
| N.alphaAcetyl-L-lysine | 1.9 | C8H16N2O3 | 189.1238 | 189.1234 | -2.3 | PFP (+) |
| N.epsilonAcetyl-L-lysine | 2.8 | C8H16N2O3 | 189.1230 | 189.1234 | 2.0 | Scherzo (+) |
| N6-Methyladenine | 2.3 | C6H7N5 | 150.0774 | 150.0774 | 0.1 | Scherzo (+) |
| NAD | 3.0 | C21H27N7O14P2 | 664.1155 | 664.1164 | 1.4 | PFP (+) |
| NAD | 5.9 | C21H27N7O14P2 | 662.1061 | 662.1019 | -6.4 | Scherzo (-) |
| Naringenin | 17.6 | C15H12O5 | 271.0615 | 271.0612 | -1.1 | PFP (-) |
| Naringenin | 14.2 | C15H12O5 | 273.0770 | 273.0758 | -4.6 | Scherzo (+) |
| Naringenin | 17.5 | C15H12O5 | 273.0762 | 273.0758 | -1.6 | PFP (+) |
| Nicotinate | 2.6 | C6H5NO2 | 122.0249 | 122.0248 | -1.2 | PFP (-) |

| Nicotinate | 2.6 | C6H5NO2 | 124.0395 | 124.0393 | -1.6 | PFP (+) |
|----------------------|------|-------------|----------|----------|------|-------------|
| Nicotinate | 3.6 | C6H5NO2 | 122.0253 | 122.0248 | -4.5 | Scherzo (-) |
| Nicotinate | 2.9 | C6H5NO2 | 124.0394 | 124.0393 | -0.8 | Scherzo (+) |
| Nicotinate | 3.6 | C6H5NO2 | 124.0396 | 124.0393 | -2.4 | Scherzo (+) |
| Nutriacholic acid | 17.8 | C24H38O4 | 391.2852 | 391.2843 | -2.3 | PFP (+) |
| Nutriacholic acid | 13.6 | C24H38O4 | 391.2858 | 391.2843 | -3.9 | Scherzo (+) |
| Nutriacholic acid | 15.7 | C24H38O4 | 391.2857 | 391.2843 | -3.6 | Scherzo (+) |
| Octadecanedioic acid | 15.7 | C18H34O4 | 313.2394 | 313.2384 | -3.1 | Scherzo (-) |
| Octanoylcarnitine | 15.9 | C15H29NO4 | 288.2167 | 288.2169 | 0.8 | PFP (+) |
| Oleoyl-L-carnitine | 16.8 | C25H47NO4 | 426.3589 | 426.3578 | -2.6 | Scherzo (+) |
| Ornithine | 2.5 | C5H12N2O2 | 131.0828 | 131.0826 | -1.5 | Scherzo (-) |
| Orotic acid | 14.5 | C5H4N2O4 | 155.0096 | 155.0098 | 1.5 | Scherzo (-) |
| Oxypurinol | 3.5 | C5H4N4O2 | 151.0268 | 151.0262 | -4.3 | PFP (-) |
| Oxypurinol | 5.0 | C5H4N4O2 | 151.0272 | 151.0262 | -7.0 | Scherzo (-) |
| p-tert-Butylcatechol | 16.4 | C10H14O2 | 165.0920 | 165.0921 | 0.6 | PFP (-) |
| p-tert-Butylcatechol | 14.7 | C10H14O2 | 165.0922 | 165.0921 | -0.6 | Scherzo (-) |
| Palmitic acid alkyne | 14.9 | C16H28O2 | 253.2170 | 253.2162 | -3.1 | Scherzo (+) |
| Palmitoylcarnitine | 16.6 | C23H45NO4 | 400.3434 | 400.3421 | -3.1 | Scherzo (+) |
| Palmitoylcarnitine | 17.9 | C23H45NO4 | 400.3430 | 400.3421 | -2.1 | PFP (+) |
| Pantothenate | 6.4 | C9H17NO5 | 218.1034 | 218.1034 | 0.0 | PFP (-) |
| Pantothenate | 6.4 | C9H17NO5 | 220.1183 | 220.1180 | -1.6 | PFP (+) |
| Pantothenate | 7.0 | C9H17NO5 | 220.1184 | 220.1180 | -2.0 | Scherzo (+) |
| Pantothenic acid | 7.1 | C9H17NO5 | 218.1045 | 218.1034 | -5.0 | Scherzo (-) |
| Phe-Ala | 4.5 | C12H16N2O3 | 237.1240 | 237.1234 | -2.7 | Scherzo (+) |
| Phe-Ala | 6.6 | C12H16N2O3 | 237.1239 | 237.1234 | -2.2 | PFP (+) |
| Phe-Arg | 4.4 | C15H23N5O3 | 322.1867 | 322.1874 | 2.1 | PFP (+) |
| Phe-Asn | 4.0 | C13H17N3O4 | 280.1294 | 280.1292 | -0.8 | PFP (+) |
| Phe-Asp | 4.4 | C13H16N2O5 | 281.1144 | 281.1132 | -4.3 | Scherzo (+) |
| Phe-Asp | 5.4 | C13H16N2O5 | 281.1141 | 281.1132 | -3.2 | PFP (+) |
| Phe-Asp | 7.3 | C13H16N2O5 | 281.1122 | 281.1132 | 3.6 | PFP (+) |
| Phe-Asp-Lys | 4.4 | C19H28N4O6 | 409.2083 | 409.2082 | -0.3 | PFP (+) |
| Phe-Gln | 5.1 | C14H19N3O4 | 294.1452 | 294.1448 | -1.3 | PFP (+) |
| Phe-Glu | 4.9 | C14H18N2O5 | 295.1303 | 295.1289 | -4.9 | Scherzo (+) |
| Phe-Glu | 6.5 | C14H18N2O5 | 295.1300 | 295.1289 | -3.9 | PFP (+) |
| Phe-Gly | 5.4 | C11H14N2O3 | 223.1083 | 223.1077 | -2.6 | Scherzo (+) |
| Phe-Gly | 6.8 | C11H14N2O3 | 223.1083 | 223.1077 | -2.6 | PFP (+) |
| Phe-Ile-Lys | 8.2 | C21H34N4O4 | 407.2641 | 407.2653 | 2.9 | PFP (+) |
| Phe-Met | 7.7 | C14H20N2O3S | 297.1283 | 297.1267 | -5.3 | Scherzo (+) |
| Phe-Met | 11.0 | C14H20N2O3S | 297.1275 | 297.1267 | -2.6 | PFP (+) |
| Phe-Phe | 9.0 | C18H20N2O3 | 313.1558 | 313.1547 | -3.6 | Scherzo (+) |

| Phe-Phe | 13.5 | C18H20N2O3 | 313.1554 | 313.1547 | -2.3 | PFP (+) |
|-------------------------------|------|------------|----------|----------|------|-------------|
| Phe-Pro | 8.6 | C14H18N2O3 | 263.1398 | 263.1390 | -3.0 | Scherzo (+) |
| Phe-Pro | 11.7 | C14H18N2O3 | 263.1395 | 263.1390 | -1.8 | PFP (+) |
| Phe-Ser | 4.4 | C12H16N2O4 | 253.1186 | 253.1183 | -1.3 | PFP (+) |
| Phe-Thr | 3.7 | C13H18N2O4 | 267.1350 | 267.1339 | -4.0 | Scherzo (+) |
| Phe-Thr | 5.0 | C13H18N2O4 | 267.1347 | 267.1339 | -2.9 | PFP (+) `´ |
| Phe-Trp | 9.4 | C20H21N3O3 | 352.1673 | 352.1656 | -4.9 | Scherzo (+) |
| Phe-Tyr | 7.7 | C18H20N2O4 | 329.1512 | 329.1496 | -4.9 | Scherzo (+) |
| Phe-Tyr | 10.9 | C18H20N2O4 | 329.1508 | 329.1496 | -3.7 | PFP (+) |
| Phe-Val | 6.9 | C14H20N2O3 | 265.1556 | 265.1547 | -3.5 | Scherzo (+) |
| Phe-Val | 9.8 | C14H20N2O3 | 265.1552 | 265.1547 | -2.0 | PFP (+) `´ |
| Phe-Val-Lys | 6.5 | C20H32N4O4 | 393.2501 | 393.2496 | -1.2 | PFP (+) |
| Phenylacetaldehyde | 11.6 | C8H8O | 119.0500 | 119.0502 | 2.0 | PFP (-) |
| Phenylacetaldehyde | 12.4 | C8H8O | 119.0497 | 119.0502 | 4.5 | PFP (-) |
| Phenylacetaldehyde | 13.2 | C8H8O | 119.0499 | 119.0502 | 2.9 | PFP (-) |
| Phenylacetaldehyde | 3.9 | C8H8O | 121.0650 | 121.0648 | -1.7 | Scherzo (+) |
| Phenylacetaldehyde | 11.0 | C8H8O | 121.0650 | 121.0648 | -1.7 | Scherzo (+) |
| Phenylacetaldehyde | 11.8 | C8H8O | 121.0646 | 121.0648 | 1.6 | Scherzo (+) |
| Phenylacetaldehyde | 11.6 | C8H8O | 121.0649 | 121.0648 | -0.9 | PFP (+) |
| Phenylacetaldehyde | 12.4 | C8H8O | 121.0648 | 121.0648 | -0.1 | PFP (+) |
| Phenylacetylglycine | 11.3 | C10H11NO3 | 192.0671 | 192.0666 | -2.5 | Scherzo (-) |
| Phloroglucinolcarboxylic acid | 11.1 | C7H6O5 | 169.0133 | 169.0143 | 5.6 | PFP (-) |
| Phosphorylcholine | 2.4 | C5H14NO4P | 184.0731 | 184.0733 | 1.2 | PFP (+) |
| Phosphorylcholine | 2.8 | C5H14NO4P | 184.0734 | 184.0733 | -0.4 | Scherzo (+) |
| Phthalic anhydride | 16.0 | C8H4O3 | 149.0238 | 149.0233 | -3.2 | Scherzo (+) |
| Phthalic anhydride | 17.7 | C8H4O3 | 149.0241 | 149.0233 | -5.2 | PFP (+) |
| Phytosphingosine | 14.4 | C18H39NO3 | 318.3015 | 318.3003 | -3.9 | Scherzo (+) |
| Pro-Ala | 2.3 | C8H14N2O3 | 187.1081 | 187.1077 | -2.0 | Scherzo (+) |
| Pro-Ala | 2.0 | C8H14N2O3 | 187.1077 | 187.1077 | 0.1 | PFP (+) |
| Pro-Arg | 2.4 | C11H21N5O3 | 272.1724 | 272.1717 | -2.5 | PFP (+) |
| Pro-Leu | 4.3 | C11H20N2O3 | 229.1553 | 229.1547 | -2.7 | Scherzo (+) |
| Pro-Leu | 5.0 | C11H20N2O3 | 229.1552 | 229.1547 | -2.3 | Scherzo (+) |
| Pro-Lys-Arg | 16.3 | C17H33N7O4 | 400.2685 | 400.2667 | -4.5 | PFP (+) |
| Pro-Phe | 9.6 | C14H18N2O3 | 263.1399 | 263.1390 | -3.3 | PFP (+) |
| Pro-Thr | 1.9 | C9H16N2O4 | 217.1182 | 217.1183 | 0.4 | PFP (+) |
| Pro-Trp | 11.4 | C16H19N3O3 | 302.1495 | 302.1499 | 1.4 | PFP (+) |
| Pro-Tyr | 6.5 | C14H18N2O4 | 279.1339 | 279.1339 | 0.1 | PFP (+) |
| Pro-Val | 3.2 | C10H18N2O3 | 215.1392 | 215.1390 | -0.8 | PFP (+) |
| Pro-Val | 4.3 | C10H18N2O3 | 215.1385 | 215.1390 | 2.4 | PFP (+) |
| Pygenic acid C | 16.7 | C30H48O6 | 503.3375 | 503.3378 | 0.6 | Scherzo (-) |

| PyroGlu-Met | 8.3 | C10H16N2O4S | 261.0902 | 261.0904 | 0.6 | PFP (+) |
|-------------------------|------|-------------|----------|----------|------|-------------|
| PyroGlu-Phe | 7.1 | C14H16N2O4 | 277.1193 | 277.1183 | -3.7 | Scherzo (+) |
| PyroGlu-Phe | 11.8 | C14H16N2O4 | 277.1195 | 277.1183 | -4.4 | Scherzo (+) |
| PyroGlu-Phe | 8.5 | C14H16N2O4 | 277.1189 | 277.1183 | -2.2 | PFP (+) |
| PyroGlu-Pro | 3.6 | C10H14N2O4 | 227.1030 | 227.1026 | -1.6 | Scherzo (+) |
| PyroGlu-Pro | 7.7 | C10H14N2O4 | 227.1030 | 227.1026 | -1.6 | Scherzo (+) |
| PyroGlu-Pro | 7.4 | C10H14N2O4 | 227.1025 | 227.1026 | 0.6 | PFP (+) |
| PyroGlu-Tyr | 9.6 | C14H16N2O5 | 293.1138 | 293.1132 | -2.0 | Scherzo (+) |
| PyroGlu-Tyr | 5.8 | C14H16N2O5 | 293.1127 | 293.1132 | 1.7 | PFP (+) |
| PyroGlu-Tyr | 9.5 | C14H16N2O5 | 293.1131 | 293.1132 | 0.3 | PFP (+) |
| PyroGlu-Val | 2.6 | C10H16N2O4 | 229.1184 | 229.1183 | -0.5 | PFP (+) |
| Pyroglutamic acid | 1.9 | C5H7NO3 | 130.0506 | 130.0499 | -5.6 | PFP (+) |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 130.0500 | 130.0499 | -1.0 | PFP (+) |
| Pyroglutamic acid | 2.6 | C5H7NO3 | 130.0494 | 130.0499 | 3.6 | Scherzo (+) |
| Pyroglutamic acid | 5.6 | C5H7NO3 | 130.0500 | 130.0499 | -1.0 | Scherzo (+) |
| Quinaldic acid | 11.3 | C10H7NO2 | 174.0546 | 174.0550 | 2.1 | PFP (+) |
| Quinaldic acid | 10.5 | C10H7NO2 | 174.0547 | 174.0550 | 1.5 | Scherzo (+) |
| Quinolin-2-ol | 6.7 | C9H7NO | 144.0451 | 144.0455 | 2.7 | PFP (-) |
| Quinolin-2-ol | 10.6 | C9H7NO | 144.0455 | 144.0455 | -0.1 | PFP (-) |
| Quinolin-2-ol | 11.3 | C9H7NO | 144.0450 | 144.0455 | 3.4 | PFP (-) |
| Quinolin-2-ol | 17.1 | C9H7NO | 144.0460 | 144.0455 | -3.5 | Scherzo (-) |
| Quinolin-3-ol | 9.6 | C9H7NO | 144.0461 | 144.0455 | -4.2 | Scherzo (-) |
| Quinolin-3-ol | 6.7 | C9H7NO | 146.0598 | 146.0600 | 1.6 | PFP (+) |
| Quinoline-2,4-diol | 7.0 | C9H7NO2 | 160.0401 | 160.0404 | 1.9 | PFP (-) |
| Quinoline-2,4-diol | 11.4 | C9H7NO2 | 160.0405 | 160.0404 | -0.6 | Scherzo (-) |
| Quinoline-2,4-diol | 11.4 | C9H7NO2 | 162.0551 | 162.0550 | -0.9 | Scherzo (+) |
| Quinoline-2,4-diol | 13.9 | C9H7NO2 | 162.0547 | 162.0550 | 1.6 | PFP (+) |
| Quinoline-2,8-diol | 8.2 | C9H7NO2 | 162.0550 | 162.0550 | -0.2 | PFP (+) |
| Resorcinol | 8.6 | C6H6O2 | 109.0294 | 109.0295 | 0.9 | PFP (-) |
| Resveratrol | 15.5 | C14H12O3 | 227.0723 | 227.0714 | -4.1 | PFP (-) |
| Riboflavin | 11.7 | C17H20N4O6 | 375.1321 | 375.1310 | -2.9 | PFP (-) |
| Riboflavin | 11.7 | C17H20N4O6 | 377.1462 | 377.1456 | -1.7 | PFP (+) |
| Riboflavin | 9.6 | C17H20N4O6 | 375.1315 | 375.1310 | -1.3 | Scherzo (-) |
| Riboflavin | 9.6 | C17H20N4O6 | 377.1468 | 377.1456 | -3.3 | Scherzo (+) |
| S-Adenosyl-L-methionine | 2.3 | C15H22N6O5S | 399.1443 | 399.1445 | 0.6 | PFP (+) |
| Sabinene | 16.9 | C10H16 | 137.1318 | 137.1325 | 5.0 | Scherzo (+) |
| Sarcosine | 2.0 | C3H7NO2 | 90.0552 | 90.0550 | -2.7 | PFP (+) |
| Schaftoside | 13.1 | C26H28O14 | 563.1442 | 563.1406 | -6.3 | PFP (-) |
| Schaftoside | 13.5 | C26H28O14 | 563.1440 | 563.1406 | -6.0 | PFP (-) |
| Schaftoside | 10.0 | C26H28O14 | 563.1435 | 563.1406 | -5.1 | Scherzo (-) |

| Schaftoside | 10.0 | C26H28O14 | 565.1576 | 565.1552 | -4.3 | Scherzo (+) |
|----------------------|------|------------|----------|----------|------|-------------|
| Schaftoside | 13.1 | C26H28O14 | 565.1558 | 565.1552 | -1.1 | PFP (+) |
| Schaftoside | 13.5 | C26H28O14 | 565.1562 | 565.1552 | -1.8 | PFP (+) |
| Sebacic acid | 15.4 | C10H18O4 | 201.1135 | 201.1132 | -1.3 | PFP (-) |
| Sebacic acid | 12.8 | C10H18O4 | 201.1139 | 201.1132 | -3.3 | Scherzo (-) |
| Ser-Glu | 2.3 | C8H14N2O6 | 235.0932 | 235.0925 | -3.1 | Scherzo (+) |
| Ser-Ile | 3.9 | C9H18N2O4 | 219.1335 | 219.1339 | 2.0 | PFP (+) |
| Ser-Leu | 3.8 | C9H18N2O4 | 219.1341 | 219.1339 | -0.8 | Scherzo (+) |
| Ser-Leu | 4.7 | C9H18N2O4 | 219.1343 | 219.1339 | -1.7 | PFP (+) `´ |
| Ser-Leu-Lys | 2.2 | C15H30N4O5 | 347.2300 | 347.2289 | -3.2 | Scherzo (+) |
| Ser-Leu-Lys | 2.4 | C15H30N4O5 | 347.2286 | 347.2289 | 0.9 | PFP (+) |
| Ser-Lys | 2.0 | C9H19N3O4 | 234.1452 | 234.1448 | -1.6 | Scherzo (+) |
| Ser-Met | 2.8 | C8H16N2O4S | 237.0912 | 237.0904 | -3.5 | Scherzo (+) |
| Ser-Met | 2.6 | C8H16N2O4S | 237.0915 | 237.0904 | -4.8 | PFP (+) |
| Ser-Pro | 1.9 | C8H14N2O4 | 203.1025 | 203.1026 | 0.6 | PFP (+) |
| Ser-Thr | 2.2 | C7H14N2O5 | 207.0979 | 207.0976 | -1.7 | Scherzo (+) |
| Ser-Tyr | 4.1 | C12H16N2O5 | 269.1133 | 269.1132 | -0.4 | Scherzo (+) |
| Ser-Val | 2.6 | C8H16N2O4 | 205.1184 | 205.1183 | -0.6 | Scherzo (+) |
| Ser-Val | 2.3 | C8H16N2O4 | 205.1188 | 205.1183 | -2.5 | PFP (+) |
| Serotonin | 6.1 | C10H12N2O | 177.1018 | 177.1022 | 2.5 | PFP (+) |
| Sorbitol | 2.6 | C6H14O6 | 181.0717 | 181.0718 | 0.3 | Scherzo (-) |
| Spermidine | 2.1 | C7H19N3 | 146.1652 | 146.1652 | -0.2 | Scherzo (+) |
| Spermidine | 3.4 | C7H19N3 | 146.1654 | 146.1652 | -1.6 | Scherzo (+) |
| Sphinganine | 17.7 | C18H39NO2 | 302.3061 | 302.3054 | -2.4 | PFP (+) |
| Sphinganine | 14.3 | C18H39NO2 | 302.3066 | 302.3054 | -4.1 | Scherzo (+) |
| Stachydrine | 2.9 | C7H13NO2 | 144.1020 | 144.1019 | -0.6 | PFP (+) |
| Stachydrine | 3.7 | C7H13NO2 | 144.1021 | 144.1019 | -1.3 | PFP (+) |
| Stearidonic acid | 16.6 | C18H28O2 | 277.2161 | 277.2162 | 0.4 | Scherzo (+) |
| Stearoyl-L-carnitine | 17.9 | C25H49NO4 | 428.3742 | 428.3734 | -1.8 | Scherzo (+) |
| Suberic acid | 12.5 | C8H14O4 | 173.0820 | 173.0819 | -0.4 | PFP (-) |
| Suberic acid | 10.6 | C8H14O4 | 173.0826 | 173.0819 | -3.9 | Scherzo (-) |
| Succinic acid | 2.9 | C4H6O4 | 117.0195 | 117.0193 | -1.5 | PFP (-) |
| Syringaldehyde | 15.7 | C9H10O4 | 183.0650 | 183.0652 | 1.0 | PFP (+) |
| Syringic acid | 12.4 | C9H10O5 | 197.0460 | 197.0456 | -2.3 | PFP (-) |
| Syringic acid | 13.0 | C9H10O5 | 197.0463 | 197.0456 | -3.8 | PFP (-) |
| Syringic acid | 10.1 | C9H10O5 | 197.0462 | 197.0456 | -3.3 | Scherzo (-) |
| Syringic acid | 10.1 | C9H10O5 | 199.0606 | 199.0601 | -2.5 | Scherzo (+) |
| Syringic acid | 12.4 | C9H10O5 | 199.0605 | 199.0601 | -2.0 | PFP (+) |
| Taurine | 1.9 | C2H7NO3S | 124.0075 | 124.0074 | -0.9 | PFP (-) |
| Taurine | 2.6 | C2H7NO3S | 124.0078 | 124.0074 | -3.3 | Scherzo (-) |

| Taurine | 2.6 | C2H7NO3S | 126.0217 | 126.0219 | 1.9 | Scherzo (+) |
|------------------------------|------|--------------|----------|----------|------|-------------|
| Taurochenodeoxycholic acid | 17.2 | C26H45NO6S | 498.2883 | 498.2895 | 2.4 | PFP (-) `´ |
| Taurocholic acid | 15.0 | C26H45NO7S | 514.2865 | 514.2844 | -4.1 | PFP (-) |
| Taurocholic acid | 17.8 | C26H45NO7S | 514.2864 | 514.2844 | -3.9 | PFP (-) |
| Tetradecanedioic acid | 17.9 | C14H26O4 | 257.1757 | 257.1758 | 0.5 | PFP (-) |
| Tetradecanedioic acid | 16.3 | C14H26O4 | 257.1751 | 257.1758 | 2.8 | Scherzo (-) |
| Thiamine | 2.6 | C12H16N4OS | 265.1127 | 265.1118 | -3.5 | PFP (+) |
| Thiamine | 2.2 | C12H16N4OS | 263.0979 | 263.0972 | -2.6 | Scherzo (-) |
| Thiamine | 2.1 | C12H16N4OS | 265.1127 | 265.1118 | -3.5 | Scherzo (+) |
| Thiamine monophosphate | 2.4 | C12H17N4O4PS | 345.0783 | 345.0781 | -0.6 | PFP (+) |
| Thr-Ile-Lys | 2.2 | C16H32N4O5 | 361.2455 | 361.2446 | -2.6 | Scherzo (+) |
| Thr-Leu | 3.8 | C10H20N2O4 | 233.1494 | 233.1496 | 0.8 | Scherzo (+) |
| Thr-Leu | 4.1 | C10H20N2O4 | 233.1505 | 233.1496 | -3.9 | Scherzo (+) |
| Thr-Leu | 4.6 | C10H20N2O4 | 233.1500 | 233.1496 | -1.8 | PFP (+) |
| Thr-Leu | 5.7 | C10H20N2O4 | 233.1503 | 233.1496 | -3.1 | PFP (+) |
| Thr-Lys | 2.0 | C10H21N3O4 | 248.1606 | 248.1605 | -0.5 | Scherzo (+) |
| Thr-Met | 3.4 | C9H18N2O4S | 251.1072 | 251.1060 | -4.7 | Scherzo (+) |
| Thr-Met | 2.9 | C9H18N2O4S | 251.1073 | 251.1060 | -5.1 | PFP (+) |
| Thr-Phe | 6.8 | C13H18N2O4 | 267.1351 | 267.1339 | -4.4 | Scherzo (+) |
| Thr-Thr | 2.2 | C8H16N2O5 | 221.1133 | 221.1132 | -0.5 | Scherzo (+) |
| Thr-Tyr | 4.2 | C13H18N2O5 | 283.1299 | 283.1289 | -3.7 | Scherzo (+) |
| Thr-Tyr | 4.4 | C13H18N2O5 | 283.1299 | 283.1289 | -3.7 | Scherzo (+) |
| Thr-Tyr | 5.3 | C13H18N2O5 | 283.1293 | 283.1289 | -1.6 | PFP (+) |
| Threonic acid | 1.9 | C4H8O5 | 135.0300 | 135.0299 | -0.7 | PFP (-) |
| Threonic acid | 2.9 | C4H8O5 | 135.0306 | 135.0299 | -5.2 | Scherzo (-) |
| Threonic acid | 3.4 | C4H8O5 | 135.0303 | 135.0299 | -3.0 | Scherzo (-) |
| Threonine | 4.6 | C4H9NO3 | 120.0653 | 120.0655 | 1.8 | Scherzo (+) |
| Thymidine | 6.7 | C10H14N2O5 | 241.0836 | 241.0830 | -2.5 | PFP (-) |
| Thymidine | 6.7 | C10H14N2O5 | 243.0980 | 243.0976 | -1.9 | PFP (+) |
| Thymidine | 7.1 | C10H14N2O5 | 241.0834 | 241.0830 | -1.7 | Scherzo (-) |
| Thymidine | 7.0 | C10H14N2O5 | 243.0982 | 243.0976 | -2.7 | Scherzo (+) |
| Thymine | 4.0 | C5H6N2O2 | 125.0361 | 125.0357 | -3.6 | PFP (-) |
| Thymine | 4.0 | C5H6N2O2 | 127.0501 | 127.0502 | 0.8 | PFP (+) |
| Thymine | 6.7 | C5H6N2O2 | 127.0503 | 127.0502 | -0.8 | PFP (+) |
| Thymine | 5.4 | C5H6N2O2 | 125.0359 | 125.0357 | -2.0 | Scherzo (-) |
| Thymine | 5.3 | C5H6N2O2 | 127.0501 | 127.0502 | 0.8 | Scherzo (+) |
| Thymine | 6.2 | C5H6N2O2 | 127.0496 | 127.0502 | 4.7 | Scherzo (+) |
| Thymine | 7.0 | C5H6N2O2 | 127.0506 | 127.0502 | -3.1 | Scherzo (+) |
| trans-2-Hydroxycinnamic acid | 3.3 | C9H8O3 | 163.0406 | 163.0401 | -3.3 | PFP (-) |
| trans-2-Hydroxycinnamic acid | 13.2 | C9H8O3 | 163.0403 | 163.0401 | -1.4 | PFP (-) |

| trans-2-Hydroxycinnamic acid | 11.2 | C9H8O3 | 163.0407 | 163.0401 | -3.9 | Scherzo (-) |
|-------------------------------|------|-------------|----------|----------|------|-------------|
| trans-2-Hydroxycinnamic acid | 3.0 | C9H8O3 | 165.0548 | 165.0546 | -1.1 | Scherzo (+) |
| trans-2-Hydroxycinnamic acid | 3.9 | C9H8O3 | 165.0549 | 165.0546 | -1.7 | Scherzo (+) |
| trans-2-Hydroxycinnamic acid | 3.0 | C9H8O3 | 165.0549 | 165.0546 | -1.7 | PFP (+) |
| trans-2-Hydroxycinnamic acid | 7.2 | C9H8O3 | 165.0548 | 165.0546 | -1.1 | PFP (+) |
| trans-3-Coumaric acid | 13.2 | C9H8O3 | 165.0545 | 165.0546 | 0.7 | PFP (+) |
| trans-Cinnamic acid | 5.2 | C9H8O2 | 147.0451 | 147.0452 | 0.3 | PFP (-) |
| trans-Cinnamic acid | 11.8 | C9H8O2 | 149.0597 | 149.0597 | 0.1 | Scherzo (+) |
| trans-Cinnamic acid | 15.0 | C9H8O2 | 149.0601 | 149.0597 | -2.6 | PFP (+) |
| trans-Ferulic acid | 13.9 | C10H10O4 | 193.0514 | 193.0506 | -4.0 | PFP (-) |
| trans-Ferulic acid | 11.5 | C10H10O4 | 193.0514 | 193.0506 | -4.0 | Scherzo (-) |
| trans-Ferulic acid | 10.8 | C10H10O4 | 195.0648 | 195.0652 | 2.0 | Scherzo (+) |
| trans-Traumatic acid | 17.0 | C12H20O4 | 227.1291 | 227.1289 | -1.0 | PFP (-) |
| trans-Traumatic acid | 14.2 | C12H20O4 | 227.1297 | 227.1289 | -3.6 | Scherzo (-) |
| Tri(3-chloropropyl) phosphate | 16.5 | C9H18Cl3O4P | 327.0090 | 327.0081 | -2.7 | Scherzo (+) |
| Tricin | 14.6 | C17H14O7 | 331.0822 | 331.0812 | -2.9 | Scherzo (+) |
| Tricin | 17.9 | C17H14O7 | 331.0816 | 331.0812 | -1.1 | PFP (+) |
| Trigonelline | 3.1 | C7H7NO2 | 138.0550 | 138.0550 | -0.3 | Scherzo (+) |
| Trp-Asn | 6.2 | C15H18N4O4 | 319.1412 | 319.1401 | -3.5 | Scherzo (+) |
| Trp-Asn | 7.2 | C15H18N4O4 | 319.1411 | 319.1401 | -3.2 | PFP (+) |
| Trp-Gln | 8.0 | C16H20N4O4 | 333.1565 | 333.1557 | -2.3 | PFP (+) |
| Trp-Glu | 7.1 | C16H19N3O5 | 334.1417 | 334.1398 | -5.8 | Scherzo (+) |
| Trp-Glu | 8.9 | C16H19N3O5 | 334.1405 | 334.1398 | -2.2 | PFP (+) |
| Trp-lle | 9.1 | C17H23N3O3 | 318.1828 | 318.1812 | -5.0 | Scherzo (+) |
| Trp-Ile | 13.7 | C17H23N3O3 | 318.1823 | 318.1812 | -3.4 | PFP (+) |
| Trp-Phe | 14.5 | C20H21N3O3 | 352.1664 | 352.1656 | -2.4 | PFP (+) |
| Trp-Trp | 9.9 | C22H22N4O3 | 391.1776 | 391.1765 | -2.9 | Scherzo (+) |
| Trp-Trp | 14.9 | C22H22N4O3 | 391.1769 | 391.1765 | -1.1 | PFP (+) |
| Trp-Tyr | 8.6 | C20H21N3O4 | 368.1613 | 368.1605 | -2.2 | Scherzo (+) |
| Tyr-Ala | 3.6 | C12H16N2O4 | 253.1187 | 253.1183 | -1.7 | PFP (+) |
| Tyr-Asn | 2.7 | C13H17N3O5 | 296.1249 | 296.1241 | -2.7 | Scherzo (+) |
| Tyr-Asn | 2.4 | C13H17N3O5 | 296.1242 | 296.1241 | -0.3 | PFP (+) |
| Tyr-Gln | 2.9 | C14H19N3O5 | 310.1405 | 310.1398 | -2.4 | PFP (+) |
| Tyr-Glu | 3.8 | C14H18N2O6 | 311.1239 | 311.1238 | -0.4 | PFP (+) |
| Tyr-Gly | 3.6 | C11H14N2O4 | 239.1033 | 239.1026 | -2.8 | Scherzo (+) |
| Tyr-Gly | 3.9 | C11H14N2O4 | 239.1028 | 239.1026 | -0.7 | PFP (+) |
| Tyr-Ile-Lys | 5.8 | C21H34N4O5 | 423.2604 | 423.2602 | -0.5 | PFP (+) |
| Tyr-Ile-Lys | 6.4 | C21H34N4O5 | 423.2594 | 423.2602 | 1.9 | PFP (+) |
| Tyr-Leu | 10.2 | C15H22N2O4 | 295.1661 | 295.1652 | -2.9 | PFP (+) |
| Tyr-Met | 6.8 | C14H20N2O4S | 313.1231 | 313.1217 | -4.6 | Scherzo (+) |

| Tyr-Met | 8.3 | C14H20N2O4S | 313.1231 | 313.1217 | -4.6 | PFP (+) |
|-----------------------------|------|---------------|----------|----------|------|-------------|
| Tyr-Phe | 8.2 | C18H20N2O4 | 329.1504 | 329.1496 | -2.5 | Scherzo (+) |
| Tyr-Phe | 11.5 | C18H20N2O4 | 329.1504 | 329.1496 | -2.5 | PFP (+) |
| Tyr-Pro | 6.9 | C14H18N2O4 | 279.1350 | 279.1339 | -3.8 | Scherzo (+) |
| Tyr-Pro | 7.8 | C14H18N2O4 | 279.1346 | 279.1339 | -2.4 | PFP (+) |
| Tyr-Ser | 3.4 | C12H16N2O5 | 269.1137 | 269.1132 | -1.9 | Scherzo (+) |
| Tyr-Thr | 2.8 | C13H18N2O5 | 283.1304 | 283.1289 | -5.5 | Scherzo (+) |
| Tyr-Thr | 3.5 | C13H18N2O5 | 283.1299 | 283.1289 | -3.7 | Scherzo (+) |
| Tyr-Thr | 2.8 | C13H18N2O5 | 283.1316 | 283.1289 | -9.7 | PFP (+) |
| Tyr-Tyr | 7.0 | C18H20N2O5 | 345.1462 | 345.1445 | -4.9 | Scherzo (+) |
| Tyr-Tyr | 8.9 | C18H20N2O5 | 345.1458 | 345.1445 | -3.8 | PFP (+) |
| Tyr-Val | 5.1 | C14H20N2O4 | 281.1507 | 281.1496 | -4.0 | Scherzo (+) |
| Tyr-Val-Lys | 3.6 | C20H32N4O5 | 409.2449 | 409.2446 | -0.9 | PFP (+) |
| Undecanedioic acid | 16.9 | C11H20O4 | 215.1296 | 215.1289 | -3.3 | PFP (-) |
| Undecanedioic acid | 14.1 | C11H20O4 | 215.1300 | 215.1289 | -5.2 | Scherzo (-) |
| Uracil | 2.5 | C4H4N2O2 | 111.0201 | 111.0200 | -0.9 | PFP (-) |
| Uracil | 2.4 | C4H4N2O2 | 113.0347 | 113.0346 | -1.3 | PFP (+) |
| Urate | 2.6 | C5H4N4O3 | 167.0216 | 167.0211 | -3.2 | PFP (-) |
| Urate | 2.8 | C5H4N4O3 | 169.0353 | 169.0356 | 1.9 | PFP (+) |
| Urate | 4.2 | C5H4N4O3 | 167.0218 | 167.0211 | -4.4 | Scherzo (-) |
| Urate | 4.1 | C5H4N4O3 | 169.0358 | 169.0356 | -1.1 | Scherzo (+) |
| Ureidosuccinic acid | 4.5 | C5H8N2O5 | 175.0365 | 175.0361 | -2.6 | Scherzo (-) |
| Uridine | 2.6 | C9H12N2O6 | 243.0627 | 243.0623 | -1.8 | PFP (-) |
| Uridine | 3.0 | C9H12N2O6 | 243.0630 | 243.0623 | -3.0 | PFP (-) |
| Uridine | 2.8 | C9H12N2O6 | 245.0777 | 245.0768 | -3.6 | PFP (+) |
| Uridine | 3.9 | C9H12N2O6 | 243.0630 | 243.0623 | -3.0 | Scherzo (-) |
| Uridine | 4.3 | C9H12N2O6 | 243.0633 | 243.0623 | -4.3 | Scherzo (-) |
| Uridine | 3.8 | C9H12N2O6 | 245.0764 | 245.0768 | 1.7 | Scherzo (+) |
| Uridine diphosphate glucose | 3.1 | C15H24N2O17P2 | 565.0486 | 565.0478 | -1.5 | PFP (-) |
| Urobilin | 11.0 | C33H42N4O6 | 591.3195 | 591.3177 | -3.0 | Scherzo (+) |
| Urobilin | 17.0 | C33H42N4O6 | 591.3186 | 591.3177 | -1.5 | PFP (+) |
| Val-Arg | 2.2 | C11H23N5O3 | 274.1876 | 274.1874 | -0.8 | Scherzo (+) |
| Val-Arg | 1.9 | C11H23N5O3 | 274.1875 | 274.1874 | -0.5 | PFP (+) |
| Val-Asp | 2.5 | C9H16N2O5 | 233.1141 | 233.1132 | -3.9 | Scherzo (+) |
| Val-Asp | 2.0 | C9H16N2O5 | 233.1134 | 233.1132 | -0.9 | PFP (+) |
| Val-Glu | 2.5 | C10H18N2O5 | 247.1301 | 247.1289 | -5.1 | Scherzo (+) |
| Val-Ile | 5.0 | C11H22N2O3 | 231.1711 | 231.1703 | -3.4 | Scherzo (+) |
| Val-Leu | 4.8 | C11H22N2O3 | 231.1707 | 231.1703 | -1.6 | Scherzo (+) |
| Val-Leu | 7.2 | C11H22N2O3 | 231.1710 | 231.1703 | -2.9 | PFP (+) |
| Val-Leu | 8.6 | C11H22N2O3 | 231.1712 | 231.1703 | -3.8 | PFP (+) |

| Val-Leu | 12.3 | C11H22N2O3 | 231.1706 | 231.1703 | -1.2 | PFP (+) |
|------------------|------|------------|----------|----------|------|-------------|
| Val-Leu-Lys | 3.0 | C17H34N4O4 | 359.2662 | 359.2653 | -2.6 | PFP (+) |
| Val-Leu-Lys | 3.7 | C17H34N4O4 | 359.2641 | 359.2653 | 3.3 | PFP (+) |
| Val-Phe | 7.5 | C14H20N2O3 | 265.1557 | 265.1547 | -3.9 | Scherzo (+) |
| Val-Phe | 10.5 | C14H20N2O3 | 265.1553 | 265.1547 | -2.4 | PFP (+) |
| Val-Thr | 1.9 | C9H18N2O4 | 219.1341 | 219.1339 | -0.8 | PFP (+) |
| Val-Trp | 8.2 | C16H21N3O3 | 304.1671 | 304.1656 | -5.0 | Scherzo (+) |
| Val-Trp | 11.8 | C16H21N3O3 | 304.1663 | 304.1656 | -2.4 | PFP (+) |
| Val-Tyr | 5.5 | C14H20N2O4 | 281.1507 | 281.1496 | -4.0 | Scherzo (+) |
| Val-Tyr | 7.0 | C14H20N2O4 | 281.1505 | 281.1496 | -3.3 | PFP (+) |
| Val-Val | 2.9 | C10H20N2O3 | 217.1555 | 217.1547 | -3.8 | Scherzo (+) |
| Val-Val | 3.5 | C10H20N2O3 | 217.1554 | 217.1547 | -3.4 | Scherzo (+) |
| Val-Val | 4.1 | C10H20N2O3 | 217.1555 | 217.1547 | -3.8 | PFP (+) |
| Xanthine | 3.6 | C5H4N4O2 | 153.0410 | 153.0407 | -2.0 | PFP (+) |
| Xanthine | 4.5 | C5H4N4O2 | 153.0412 | 153.0407 | -3.3 | Scherzo (+) |
| Xanthine | 7.0 | C5H4N4O2 | 153.0408 | 153.0407 | -0.7 | Scherzo (+) |
| Xanthine | 6.5 | C5H4N4O2 | 153.0404 | 153.0407 | 2.0 | PFP (+) |
| Xanthosine | 6.8 | C10H12N4O6 | 283.0695 | 283.0684 | -3.9 | PFP (-) |
| Xanthosine | 6.8 | C10H12N4O6 | 285.0836 | 285.0830 | -2.2 | PFP (+) |
| Xanthosine | 7.1 | C10H12N4O6 | 283.0683 | 283.0684 | 0.4 | Scherzo (-) |
| Xanthosine | 7.0 | C10H12N4O6 | 285.0838 | 285.0830 | -2.9 | Scherzo (+) |
| Xanthurenic acid | 12.2 | C10H7NO4 | 204.0305 | 204.0302 | -1.3 | PFP (-) |
| Xanthurenic acid | 12.8 | C10H7NO4 | 206.0450 | 206.0448 | -1.1 | Scherzo (+) |
| Xanthurenic acid | 15.3 | C10H7NO4 | 206.0449 | 206.0448 | -0.6 | Scherzo (+) |
| Xanthurenic acid | 16.9 | C10H7NO4 | 206.0456 | 206.0448 | -4.0 | Scherzo (+) |
| Xanthurenic acid | 10.1 | C10H7NO4 | 206.0457 | 206.0448 | -4.5 | PFP (+) |
| Xanthurenic acid | 12.3 | C10H7NO4 | 206.0450 | 206.0448 | -1.1 | PFP (+) |

Table 2.10 Statistically Significant Colon Metabolites

| Metabolite ID | Retention Time (min) | Chemical Formula | Fold Change DC/PC | <i>p</i> -value | Column (+/-) |
|---------------------------------|-------------------------|---------------------|----------------------|-----------------|--------------|
| 2-Amino-1-naphthol | 3.9 | C10H9NO | -37.0 | 0.017 | Scherzo (+) |
| 2-Amino-1-naphthol | 6.1 | C10H9NO | -31.9 | 0.015 | PFP (+) |
| Serotonin | 4.1 | C10H12N2O | -23.7 | 0.016 | Scherzo (+) |
| 2-Dimethylamino-6-hydroxypurine | 5.9 | C7H9N5O | -9.7 | 0.046 | PFP (+) |
| gamma-Glu-Cys | 4.4 | C8H14N2O5S | -6.5 | 0.042 | Scherzo (+) |
| Deoxyadenosine | 4.4 | C10H13N5O3 | -5.7 | 0.015 | Scherzo (+) |
| 2'-O-Methyladenosine | 6.2 | C11H15N5O4 | -4.9 | 0.043 | Scherzo (+) |
| Xanthurenic acid | 10.7 | C10H7NO4 | -4.5 | 0.005 | PFP (-) |
| Cysteine-glutathione disulfide | 6.3 | C13H22N4O8S2 | -4.0 | 0.005 | Scherzo (+) |
| Kynurenine | 5.9 | C10H12N2O3 | -3.9 | 0.032 | Scherzo (+) |
| Kynurenine | 5.7 | C10H12N2O3 | -3.8 | 0.025 | PFP (+) |
| 1H-Indole-4-carboxaldehyde | 9.6 | C9H7NO | -3.8 | 0.012 | Scherzo (+) |
| 5-Hydroxyindole-3-acetic acid | 10.7 | C10H9NO3 | -3.7 | 0.001 | PFP (-) |
| Quinoline-2,8-diol | 10.7 | C9H7NO2 | -3.7 | 0.003 | PFP (-) |
| Adenosine | 4.1 | C10H13N5O4 | -3.6 | 0.028 | Scherzo (+) |
| Nicotinate | 2.6 | C6H5NO2 | -3.6 | 0.000 | PFP (-) `´ |
| 5-Hydroxyindoleacetic acid | 9.6 | C10H9NO3 | -3.5 | 0.010 | Scherzo (+) |
| Nicotinate | 3.6 | C6H5NO2 | -3.4 | 0.001 | Scherzo (-) |
| 1H-Indole-4-carboxaldehyde | 10.6 | C9H7NO | -3.3 | 0.006 | PFP (+) |
| 5-Hydroxyindoleacetic acid | 10.6 | C10H9NO3 | -3.3 | 0.005 | PFP (+) |
| Cytidine 5'-diphosphocholine | 2.9 | C14H26N4O11P2 | -3.2 | 0.010 | PFP (+) |
| Kynurenine | 5.7 | C10H12N2O3 | -3.2 | 0.026 | PFP (-) |
| Nicotinate | 3.6 | C6H5NO2 | -3.2 | 0.000 | Scherzo (+) |
| Nicotinate | 2.6 | C6H5NO2 | -2.9 | 0.001 | PFP (+) |
| Quinolin-2-ol | 10.6 | C9H7NO | -2.8 | 0.007 | PFP (-) |
| Glutathione oxidized | 3.5 | C20H32N6O12S2 | -2.5 | 0.025 | Scherzo (-) |
| Deoxyuridine | 4.3 | C9H12N2O5 | -2.5 | 0.026 | PFP (-) |
| Orotic acid | 2.9 | C5H4N2O4 | -2.5 | 0.013 | PFP (-) |
| Glycerol 3-phosphate | 6.1 | C3H9O6P | -2.4 | 0.011 | Scherzo (-) |
| Thymine | 6.2 | C5H6N2O2 | -2.4 | 0.009 | Scherzo (+) |
| Cytidine 5'-diphosphocholine | 3.5 | C14H26N4O11P2 | -2.3 | 0.012 | Scherzo (+) |
| N-Acetyl galactosamine | 2.7 | C8H15NO6 | -2.2 | 0.015 | Scherzo (+) |
| Pro-Ile | 5.0 | C11H20N2O3 | -2.2 | 0.014 | Scherzo (+) |
| Uridine | 3.9 | C9H12N2O6 | -2.1 | 0.004 | Scherzo (-) |
| Cytidine 5'-diphosphocholine | 2.9 | C14H26N4O11P2 | -2.1 | 0.005 | Scherzo (+) |
| alpha-L-Glu-L-Tyr | 7.6 | C14H18N2O6 | -2.1 | 0.005 | Scherzo (+) |
| Phenylalanine | 9.6 | C9H11NO2 | -2.0 | 0.009 | PFP (+) |

| gamma-Glutamyglutamic acid | 2.9 | C10H16N2O7 | -2.0 | 0.007 | Scherzo (-) |
|------------------------------------|------|---------------|------|-------|-------------|
| Glu-Met | 6.8 | C10H18N2O5S | -2.0 | 0.046 | Scherzo (+) |
| Phenylalanine | 9.0 | C9H11NO2 | -2.0 | 0.011 | Scherzo (+) |
| O-Phospho-L-Serine | 6.9 | C3H8NO6P | -2.0 | 0.009 | Scherzo (+) |
| gamma-Glutamyglutamic acid | 2.9 | C10H16N2O7 | -1.9 | 0.006 | Scherzo (+) |
| alpha-L-Glu-L-Tyr | 7.3 | C14H18N2O6 | -1.9 | 0.028 | PFP (+) `´ |
| Cysteine-glutathione disulfide | 3.1 | C13H22N4O8S2 | -1.9 | 0.031 | Scherzo (+) |
| Glycerolphosphate | 6.5 | C3H9O6P | -1.9 | 0.043 | Scherzo (+) |
| Glu-Ser | 3.2 | C8H14N2O6 | -1.9 | 0.002 | Scherzo (+) |
| gamma-Glutamyglutamic acid | 3.8 | C10H16N2O7 | -1.9 | 0.000 | Scherzo (-) |
| Amino caproic acid | 8.3 | C6H13NO2 | -1.8 | 0.041 | PFP (+) |
| Gly-Tyr | 4.9 | C11H14N2O4 | -1.8 | 0.012 | PFP (+) |
| gamma-Glutamyglutamic acid | 2.1 | C10H16N2O7 | -1.8 | 0.008 | PFP (+) |
| gamma-Glutamyglutamic acid | 3.7 | C10H16N2O7 | -1.7 | 0.003 | Scherzo (+) |
| Phenylalanine | 9.1 | C9H11NO2 | -1.7 | 0.017 | Scherzo (+) |
| Glyceric acid | 1.9 | C3H6O4 | -1.6 | 0.005 | PFP (-) |
| N-Acetyl-L-methionine | 9.2 | C7H13NO3S | -1.6 | 0.041 | Scherzo (+) |
| N,N-Dimethylguanosine | 8.3 | C12H17N5O5 | -1.5 | 0.025 | PFP (+) |
| 2-Dimethylamino-6-hydroxypurine | 8.3 | C7H9N5O | -1.5 | 0.028 | PFP (+) |
| N.epsilonAcetyl-L-lysine | 2.4 | C8H16N2O3 | -1.5 | 0.003 | PFP (+) |
| NAD | 5.9 | C21H27N7O14P2 | -1.5 | 0.047 | Scherzo (+) |
| Prostaglandin E1 | 14.8 | C20H34O5 | 1.5 | 0.028 | Scherzo (-) |
| Pimelic acid | 10.2 | C7H12O4 | 1.5 | 0.024 | PFP (-) |
| Threonic acid | 1.9 | C4H8O5 | 1.5 | 0.007 | PFP (-) |
| 3-Hydroxybenzaldehyde | 11.2 | C7H6O2 | 1.5 | 0.012 | PFP (-) |
| 3-Hydroxyoctanoic acid | 14.6 | C8H16O3 | 1.5 | 0.010 | PFP (-) |
| O-phosphoryl-ethanolamine | 2.5 | C2H8NO4P | 1.5 | 0.040 | Scherzo (-) |
| 3-Hydroxybutyrylcarnitine | 2.6 | C11H21NO5 | 1.5 | 0.022 | Scherzo (+) |
| cis-Aconitate | 4.3 | C6H6O6 | 1.5 | 0.040 | PFP (-) |
| N-(4-Aminobenzoyl)-L-glutamic acid | 7.4 | C12H14N2O5 | 1.6 | 0.020 | Scherzo (+) |
| N-Acetyl-D-glucosamine 6-phosphate | 8.6 | C8H16NO9P | 1.6 | 0.007 | Scherzo (-) |
| Sarcosine | 2.0 | C3H7NO2 | 1.6 | 0.007 | PFP (+) |
| Butyrylcarnitine | 8.5 | C11H21NO4 | 1.6 | 0.023 | PFP (+) |
| Glutathione oxidized | 5.3 | C20H32N6O12S2 | 1.6 | 0.006 | Scherzo (-) |
| Glutamine | 2.5 | C5H10N2O3 | 1.6 | 0.009 | Scherzo (-) |
| Creatine | 2.5 | C4H9N3O2 | 1.6 | 0.000 | Scherzo (+) |
| Adipic acid | 7.5 | C6H10O4 | 1.6 | 0.005 | PFP (-) |
| Acetyl-L-carnitine | 2.5 | C9H17NO4 | 1.6 | 0.046 | Scherzo (+) |
| Acetyl-L-carnitine | 2.5 | C9H17NO4 | 1.6 | 0.046 | Scherzo (+) |
| Prostaglandin A1 | 16.4 | C20H32O4 | 1.6 | 0.011 | Scherzo (-) |

| Creatine | 2.0 | C4H9N3O2 | 1.6 | 0.006 | PFP (+) |
|---|------|---------------|-----|-------|-------------|
| Dihydrofolic acid | 11.4 | C19H21N7O6 | 1.7 | 0.007 | PFP (-) |
| 4-Hydroxynonenal glutathione | 12.8 | C19H33N3O8S | 1.7 | 0.019 | PFP (+) |
| Azelaic acid | 11.9 | C9H16O4 | 1.7 | 0.035 | Scherzo (+) |
| Beta-Alanine | 2.0 | C3H7NO2 | 1.7 | 0.000 | PFP (-) |
| Citric acid | 7.0 | C6H8O7 | 1.7 | 0.009 | Scherzo (-) |
| Suberic acid | 12.5 | C8H14O4 | 1.7 | 0.010 | PFP (-) |
| Pimelic acid | 9.3 | C7H12O4 | 1.7 | 0.009 | Scherzo (-) |
| Arsenic acid | 7.1 | AsH3O4 | 1.8 | 0.018 | Scherzo (-) |
| 2-Methylbutyryl-L-carnitine | 10.3 | C12H23NO4 | 1.8 | 0.016 | PFP (+) |
| 8-iso-Prostaglandin A1 | 14.8 | C20H32O4 | 1.8 | 0.002 | Scherzo (-) |
| Prostaglandin H2 | 17.6 | C20H32O5 | 1.8 | 0.001 | PFP (-) |
| Histidine | 1.9 | C6H9N3O2 | 1.8 | 0.039 | PFP (-) |
| N,N-Dimethylaniline | 3.6 | C8H11N | 1.8 | 0.006 | Scherzo (+) |
| Allantoin | 2.8 | C4H6N4O3 | 1.8 | 0.007 | Scherzo (-) |
| Biliverdin | 14.8 | C33H34N4O6 | 1.8 | 0.004 | Scherzo (+) |
| Azelaic acid | 14.3 | C9H16O4 | 1.8 | 0.030 | PFP (-) |
| Suberic acid | 10.7 | C8H14O4 | 1.9 | 0.004 | Scherzo (-) |
| Ergothioneine | 2.9 | C9H15N3O2S | 1.9 | 0.046 | Scherzo (+) |
| Glutathione oxidized | 2.8 | C20H32N6O12S2 | 1.9 | 0.009 | PFP (+) |
| Azelaic acid | 14.3 | C9H16O4 | 1.9 | 0.040 | PFP (+) |
| Butyrylcarnitine | 4.5 | C11H21NO4 | 1.9 | 0.002 | Scherzo (+) |
| Azelaic acid | 11.9 | C9H16O4 | 1.9 | 0.033 | Scherzo (-) |
| Creatinine | 1.9 | C4H7N3O | 1.9 | 0.003 | PFP (+) |
| Glutathione oxidized | 2.9 | C20H32N6O12S2 | 1.9 | 0.007 | PFP (-) |
| Lauroyl-L-carnitine | 17.7 | C19H37NO4 | 1.9 | 0.019 | PFP (+) |
| Glu-Phe-Arg | 7.4 | C20H30N6O6 | 1.9 | 0.020 | Scherzo (+) |
| Urate | 2.6 | C5H4N4O3 | 1.9 | 0.002 | PFP (-) |
| Tetraethylene glycol | 6.8 | C8H18O5 | 1.9 | 0.010 | Scherzo (+) |
| Hexanoyl-L-carnitine | 12.6 | C13H25NO4 | 2.0 | 0.034 | PFP (+) |
| N-(4-Aminobenzoyl)-L-glutamic acid | 7.6 | C12H14N2O5 | 2.0 | 0.022 | Scherzo (-) |
| Linoleoylcarnitine | 17.8 | C25H45NO4 | 2.0 | 0.012 | PFP (+) |
| Glutathione oxidized | 2.1 | C20H32N6O12S2 | 2.0 | 0.019 | PFP (-) |
| Urate | 4.2 | C5H4N4O3 | 2.0 | 0.001 | Scherzo (-) |
| 9-Oxoprosta-5Z,10,12Z,14E-tetraenoic acid | 17.8 | C20H28O3 | 2.0 | 0.000 | PFP (+) |
| Methionine sulfoxide | 2.6 | C5H11NO3S | 2.1 | 0.000 | Scherzo (+) |
| 1-Myristoyl-2-hydroxy-sn-glycero-3- | | | | | |
| phosphoethanolamine | 16.1 | C19H40NO7P | 2.1 | 0.037 | Scherzo (+) |
| Oleoyl-L-carnitine | 17.9 | C25H47NO4 | 2.1 | 0.022 | PFP (+) |
| Prostaglandin A2 | 17.8 | C20H30O4 | 2.1 | 0.000 | PFP (-) |

| N-Acetyl-L-Glutamine | 4.5 | C7H12N2O4 | 2.2 | 0.015 | Scherzo (-) |
|---|------|---------------|-----|-------|-------------|
| Prostaglandin H2 | 14.6 | C20H32O5 | 2.2 | 0.001 | Scherzo (-) |
| 1-Myristoyl-2-hydroxy-sn-glycero-3- | | | | | |
| phosphoethanolamine | 16.2 | C19H40NO7P | 2.3 | 0.036 | Scherzo (-) |
| Urate | 4.1 | C5H4N4O3 | 2.3 | 0.003 | Scherzo (+) |
| Prostaglandin A2 | 14.6 | C20H30O4 | 2.3 | 0.001 | Scherzo (-) |
| N-Acetyl-D-glucosamine 6-phosphate | 1.9 | C8H16NO9P | 2.3 | 0.020 | PFP (-) |
| Pyridoxal 5-phosphate | 6.7 | C8H10NO6P | 2.3 | 0.007 | Scherzo (+) |
| Adenosyl-L-methionine | 2.5 | C15H22N6O5S | 2.3 | 0.034 | Scherzo (+) |
| Ergothioneine | 2.5 | C9H15N3O2S | 2.3 | 0.020 | PFP (+) |
| Dodecyl sulfate | 17.6 | C12H26O4S | 2.3 | 0.033 | PFP (-) |
| Homovanillic acid sulfate | 9.9 | C9H10O7S | 2.3 | 0.009 | PFP (-) |
| Octanoylcarnitine | 15.9 | C15H29NO4 | 2.3 | 0.011 | PFP (+) |
| Threonic acid | 2.9 | C4H8O5 | 2.4 | 0.005 | Scherzo (-) |
| Hexanoyl-L-carnitine | 8.9 | C13H25NO4 | 2.4 | 0.024 | Scherzo (+) |
| 3-Hydroxyhexadecanoylcarnitine | 15.3 | C23H45NO5 | 2.5 | 0.016 | Scherzo (+) |
| 4-Hydroxybenzaldehyde | 2.8 | C7H6O2 | 2.5 | 0.008 | PFP (+) |
| 2-Deoxyribose 5-phosphate | 9.5 | C5H11O7P | 2.5 | 0.037 | Scherzo (-) |
| Urate | 2.8 | C5H4N4O3 | 2.6 | 0.003 | PFP (+) |
| 1-Myristoyl-sn-glycero-3-phosphocholine | 16.6 | C22H46NO7P | 2.6 | 0.027 | Scherzo (+) |
| Octanoylcarnitine | 11.0 | C15H29NO4 | 2.7 | 0.015 | Scherzo (+) |
| Prostaglandin A2 | 16.1 | C20H30O4 | 2.7 | 0.000 | Scherzo (-) |
| 9-Oxoprosta-5Z,10,12Z,14E-tetraenoic acid | 16.1 | C20H28O3 | 2.8 | 0.006 | Scherzo (+) |
| Nicotinamide | 3.5 | C6H6N2O | 2.8 | 0.010 | Scherzo (+) |
| 3-Hydroxyoleylcarnitine | 15.7 | C25H47NO5 | 2.9 | 0.003 | Scherzo (+) |
| 1-Oleoyl-sn-glycero-3-phosphocholine | 14.9 | C26H52NO7P | 3.0 | 0.041 | Scherzo (+) |
| 3-Hydroxyhexadecanoylcarnitine | 17.8 | C23H45NO5 | 3.0 | 0.019 | PFP (+) |
| Niacinamide | 2.7 | C6H6N2O | 3.0 | 0.005 | PFP (+) |
| N-Acetylaspartylglutamic acid | 7.2 | C11H16N2O8 | 3.0 | 0.007 | Scherzo (+) |
| 5'-S-Methyl-5'-thioadenosine | 2.4 | C11H15N5O3S | 3.1 | 0.004 | PFP (+) |
| Oleoyl-L-carnitine | 16.8 | C25H47NO4 | 3.1 | 0.031 | Scherzo (+) |
| Isosteviol | 14.8 | C20H30O3 | 3.2 | 0.000 | Scherzo (-) |
| 2-Piperidinone | 6.6 | C5H9NO | 3.2 | 0.033 | PFP (+) |
| 3,3-Dimethylacrylic acid | 1.9 | C5H8O2 | 3.4 | 0.016 | PFP (+) |
| trans-2-Hydroxycinnamic acid | 3.0 | C9H8O3 | 3.4 | 0.042 | Scherzo (+) |
| N-Acetyl-DL-valine | 6.6 | C7H13NO3 | 4.1 | 0.024 | PFP (-) |
| 1-Palmitoyl-2-hydroxy-sn-glycero-3- | | | | | |
| phosphoethanolamine | 17.4 | C21H44NO7P | 4.2 | 0.004 | Scherzo (-) |
| Glutaric acid | 4.7 | C5H8O4 | 4.4 | 0.004 | PFP (-) |
| Glutathione oxidized | 2.9 | C20H32N6O12S2 | 4.4 | 0.013 | Scherzo (-) |

| N-Acetyl-DL-valine | 7.2 | C7H13NO3 | 4.6 | 0.017 | Scherzo (-) |
|---|------|---------------|------|-------|-------------|
| Glutathione oxidized | 2.9 | C20H32N6O12S2 | 5.3 | 0.041 | Scherzo (+) |
| Glutaric acid | 6.2 | C5H8O4 | 5.4 | 0.004 | Scherzo (-) |
| 1-Oleoyl-sn-glycero-3-phosphoethanolamine | 16.3 | C23H46NO7P | 8.5 | 0.000 | Scherzo (-) |
| 1-Palmitoyl-2-hydroxy-sn-glycero-3- | | | | | |
| phosphoethanolamine | 15.2 | C21H44NO7P | 9.5 | 0.001 | Scherzo (-) |
| Adenosyl-L-methionine | 2.3 | C15H22N6O5S | 13.8 | 0.008 | PFP (+) |
| 1,2-Dimethylimidazole | 2.7 | C5H8N2 | 16.5 | 0.006 | PFP (+) |

Table 2.11 Statistically Significant Fecal Metabolites

| Metabolite ID | Retention Time (min) | Chemical Formula | Fold Change DF/PF | <i>p</i> -value | Column (+/-) |
|---|-------------------------|---------------------|----------------------|-----------------|-----------------|
| alpha-Hydroxybutyric acid | 2.9 | C4H8O3 | -1.9 | 0.012 | PFP (-) |
| Guanine | 8.7 | C5H5N5O | -3.2 | 0.017 | PFP (+) |
| Guanine (in-source fragment) | 6.2 | C5H5N5O | -2.1 | 0.006 | PFP (+) |
| Acetylcysteine | 17.7 | C5H9NO3S | -1.9 | 0.018 | PFP (-) |
| Fructose 1,6-bisphosphate | 3.3 | C6H14O12P2 | 8.7 | 0.042 | Scherzo (-) |
| N.alphaAcetyl-L-lysine | 1.9 | C8H16N2O3 | 1.7 | 0.017 | PFP (+) |
| Uridine | 4.3 | C9H12N2O6 | -2.2 | 0.033 | Scherzo (-) |
| 2'-Deoxycytidine | 2.4 | C9H13N3O4 | -1.9 | 0.045 | Scherzo (+) |
| Pro-Thr | 1.9 | C9H16N2O4 | 1.7 | 0.002 | PFP (+) |
| Quinoline-2,4-diol | 11.4 | C9H7NO2 | 2.1 | 0.020 | Scherzo (+) |
| Deoxyguanosine | 6.2 | C10H13N5O4 | -2.5 | 0.028 | PFP (-) |
| Deoxyguanosine | 6.7 | C10H13N5O4 | -2.5 | 0.045 | Scherzo (-) |
| Deoxyguanosine | 6.2 | C10H13N5O4 | -2.1 | 0.006 | PFP (+) |
| p-tert-Butylcatechol | 16.4 | C10H14O2 | -1.5 | 0.007 | PFP (-) |
| Undecanedioic acid | 16.9 | C11H20O4 | -1.7 | 0.002 | PFP (-) |
| Val-Leu | 12.3 | C11H22N2O3 | 2.7 | 0.008 | PFP (+) |
| 2-Hydroxyibuprofen | 17.3 | C13H18O3 | -1.6 | 0.001 | PFP (-) |
| 2-Amino-4E-octadecene-1,3S-diol | 17.8 | C14H20N2O3 | 1.9 | 0.036 | PFP (+) |
| Leu-Gln-Arg | 3.5 | C17H33N7O5 | -2.2 | 0.012 | PFP (+) |
| Cytidine-5'-monophospho-N-acetylneuraminic acid | 6.5 | C20H31N4O16P | -2.1 | 0.035 | Scherzo (-) |
| Stearoyl-L-carnitine | 17.9 | C25H49NO4 | 2.3 | 0.001 | Scherzo (+) |
| 1-Oleoyl-sn-glycero-3-phosphocholine | 14.4 | C26H52NO7P | -8.9 | 0.009 | Scherzo (+) |
| Coproporphyrin I | 17.2 | C36H38N4O8 | 1.7 | 0.033 | Scherzo (+) |

| Table 2 12 Complete List of | Quantified Mouse | Proteins in Colon | Samples |
|-----------------------------|------------------|-------------------|---------|
| | Quantinou mouse | | Gampies |

| Accession Number | Gene ID | Protein Name | Fold Change DC/PC | <i>p</i> -value |
|---------------------|-------------|--|----------------------|-----------------|
| P13595 | NCAM1_MOUSE | Neural cell adhesion molecule 1 | -81.0 | 0.8711 |
| Q8R2Y2 | MUC18_MOUSE | Cell surface glycoprotein MUC18 | -70.4 | 0.1244 |
| Q9CQN3 | TOM6_MOUSE | Mitochondrial import receptor subunit TOM6 homolog | -34.4 | 0.2753 |
| P49312 | ROA1_MOUSE | Heterogeneous nuclear ribonucleoprotein A1 | -27.0 | 0.9462 |
| P97816 | S100G_MOUSE | Protein S100-G | -12.9 | 0.0003* |
| P55050 | FABPI_MOUSE | Fatty acid-binding protein, intestinal | -11.3 | 0.0001* |
| Q99JX3 | GORS2_MOUSE | Golgi reassembly-stacking protein 2 | -8.5 | 0.1841 |
| Q9QZM0 | UBQL2_MOUSE | Ubiquilin-2 | -7.7 | 0.9121 |
| Q9D312 | K1C20_MOUSE | Keratin, type I cytoskeletal 20 | -7.5 | 0.0000* |
| P09528 | FRIH_MOUSE | Ferritin heavy chain | -7.4 | 0.0013* |
| P13634 | CAH1_MOUSE | Carbonic anhydrase 1 | -6.8 | 0.0001* |
| Q9D816 | CP255_MOUSE | Cytochrome P450 2C55 | -6.5 | 0.1040 |
| Q9ES28 | ARHG7_MOUSE | Rho guanine nucleotide exchange factor 7 | -5.1 | 0.0088* |
| Q9D279 | MISP_MOUSE | Mitotic interactor and substrate of PLK1 | -4.2 | 0.0001* |
| Q8VI24 | SATB2 MOUSE | DNA-binding protein SATB2 | -4.1 | 0.0035* |
| Q91VR5 | DDX1_MOUSE | ATP-dependent RNA helicase DDX1 | -4.1 | 0.0211* |
| Q6URW6 | MYH14_MOUSE | Myosin-14 | -4.1 | 0.0072* |
| P29391 | FRIL1_MOUSE | Ferritin light chain 1 | -4.1 | 0.0000* |
| P07146 | TRY2_MOUSE | Anionic trypsin-2 | -4.1 | 0.0708 |
| P20065 | TYB4_MOUSE | Thymosin beta-4 | -4.0 | 0.0007* |
| P59242 | CING_MOUSE | Cingulin | -4.0 | 0.0029* |
| P55095 | GLUC_MOUSE | Glucagon | -3.8 | 0.0001* |
| P54869 | HMCS2_MOUSE | Hydroxymethylglutaryl-CoA synthase, mitochondrial | -3.8 | 0.0245* |
| Q9JIX8 | ACINU_MOUSE | Apoptotic chromatin condensation inducer in the nucleus | -3.8 | 0.0044* |
| Q99P86 | RETNB_MOUSE | Resistin-like beta | -3.7 | 0.0821 |
| P16014 | SCG1_MOUSE | Secretogranin-1 | -3.7 | 0.0011* |
| Q8BK30 | NDUV3_MOUSE | NADH dehydrogenase [ubiquinone] flavoprotein 3, mitochondrial | -3.6 | 0.0612 |
| Q99K30 | ES8L2_MOUSE | Epidermal growth factor receptor kinase substrate 8-like protein 2 | -3.6 | 0.0005* |
| Q99K28 | ARFG2_MOUSE | ADP-ribosylation factor GTPase-activating protein 2 | -3.3 | 0.008* |
| Q60598 | SRC8_MOUSE | Src substrate cortactin | -3.2 | 0.0005* |
| Q8CHP5 | PYM1_MOUSE | Partner of Y14 and mago | -3.2 | 0.0591 |
| Q91WK0 | LRRF2_MOUSE | Leucine-rich repeat flightless-interacting protein 2 | -3.2 | 0.0143* |
| Q80Z19 | MUC2_MOUSE | Mucin-2 | -3.1 | 0.0003* |
| E9Q7G0 | NUMA1_MOUSE | Nuclear mitotic apparatus protein 1 | -3.1 | 0.0026* |
| Q62393 | TPD52_MOUSE | Tumor protein D52 | -3.0 | 0.0001* |
| Q91VW5 | GOGA4_MOUSE | Golgin subfamily A member 4 | -3.0 | 0.3107 |
| Q8VDM6 | HNRL1_MOUSE | Heterogeneous nuclear ribonucleoprotein U-like protein 1 | -3.0 | 0.0013* |

| P05784 | K1C18 MOUSE | Keratin, type I cytoskeletal 18 | -2.9 | 0.0002* |
|--------|-------------|---|------|---------|
| Q8BI84 | TGO1_MOUSE | Melanoma inhibitory activity protein 3 | -2.9 | 0.0003* |
| P63054 | PCP4 MOUSE | Purkinje cell protein 4 | -2.8 | 0.0125* |
| P97450 | ATP5J MOUSE | ATP synthase-coupling factor 6, mitochondrial | -2.8 | 0.0117* |
| P21447 | MDR1A MOUSE | Multidrug resistance protein 1A | -2.8 | 0.1481 |
| Q99PL5 | RRBP1 MOUSE | Ribosome-binding protein 1 | -2.8 | 0.0000* |
| Q62093 | SRSF2 MOUSE | Serine/arginine-rich splicing factor 2 | -2.8 | 0.0569 |
| Q99KN9 | EPN4 MOUSE | Clathrin interactor 1 | -2.8 | 0.0019* |
| Q9D1L0 | CHCH2 MOUSE | Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 | -2.8 | 0.0000* |
| Q9DCV7 | K2C7_MOUSE | Keratin, type II cytoskeletal 7 | -2.7 | 0.0000* |
| Q9D7S9 | CHMP5_MOUSE | Charged multivesicular body protein 5 | -2.7 | 0.1603 |
| Q91WG0 | EST2C_MOUSE | Acylcarnitine hydrolase | -2.7 | 0.0277* |
| Q64133 | AOFA_MOUSE | Amine oxidase [flavin-containing] A | -2.7 | 0.7291 |
| Q4VAA2 | CDV3_MOUSE | Protein CDV3 | -2.6 | 0.0012* |
| Q80W00 | PP1RA_MOUSE | Serine/threonine-protein phosphatase 1 regulatory subunit 10 | -2.6 | 0.0019* |
| O35459 | ECH1_MOUSE | Delta(3,5)-Delta(2,4)-dienoyl-CoA isomerase, mitochondrial | -2.6 | 0.2093 |
| P47212 | GALA_MOUSE | Galanin peptides | -2.6 | 0.0000* |
| P53564 | CUX1_MOUSE | Homeobox protein cut-like 1 | -2.5 | 0.4866 |
| O08784 | TCOF_MOUSE | Treacle protein | -2.5 | 0.2537 |
| P09541 | MYL4_MOUSE | Myosin light chain 4 | -2.5 | 0.0011* |
| Q9DBG5 | PLIN3_MOUSE | Perilipin-3 | -2.5 | 0.0003* |
| Q6PDG5 | SMRC2_MOUSE | SWI/SNF complex subunit SMARCC2 | -2.5 | 0.0035* |
| O88312 | AGR2_MOUSE | Anterior gradient protein 2 homolog | -2.5 | 0.0033* |
| Q9D8Y0 | EFHD2_MOUSE | EF-hand domain-containing protein D2 | -2.5 | 0.0000* |
| Q99NB9 | SF3B1_MOUSE | Splicing factor 3B subunit 1 | -2.4 | 0.0713 |
| Q921F2 | TADBP_MOUSE | TAR DNA-binding protein 43 | -2.4 | 0.1046 |
| O70400 | PDLI1_MOUSE | PDZ and LIM domain protein 1 | -2.4 | 0.0001* |
| Q80VJ2 | SRA1_MOUSE | Steroid receptor RNA activator 1 | -2.4 | 0.0037* |
| P15379 | CD44_MOUSE | CD44 antigen | -2.4 | 0.0000* |
| Q6IRU5 | CLCB_MOUSE | Clathrin light chain B | -2.4 | 0.0001* |
| P14733 | LMNB1_MOUSE | Lamin-B1 | -2.4 | 0.0000* |
| Q91WQ9 | CALL4_MOUSE | Calmodulin-like protein 4 | -2.4 | 0.0006* |
| P12787 | COX5A_MOUSE | Cytochrome c oxidase subunit 5A, mitochondrial | -2.4 | 0.0391* |
| Q9DCL8 | IPP2_MOUSE | Protein phosphatase inhibitor 2 | -2.4 | 0.5311 |
| P51125 | ICAL_MOUSE | Calpastatin | -2.4 | 0.0172* |
| Q80X50 | UBP2L_MOUSE | Ubiquitin-associated protein 2-like | -2.3 | 0.0194* |
| Q8BL66 | EEA1_MOUSE | Early endosome antigen 1 | -2.3 | 0.0307* |
| Q61699 | HS105_MOUSE | Heat shock protein 105 kDa | -2.3 | 0.0259* |
| Q9DCM0 | ETHE1_MOUSE | Persulfide dioxygenase ETHE1, mitochondrial | -2.3 | 0.0002* |
| P55012 | S12A2_MOUSE | Solute carrier family 12 member 2 | -2.3 | 0.0005* |

| Q9JLQ0 | CD2AP MOUSE | CD2-associated protein | -2.3 | 0.0000* |
|--------|-------------|--|------|---------|
| Q921M4 | GOGA2_MOUSE | Golgin subfamily A member 2 | -2.3 | 0.0369* |
| P61022 | CHP1 MOUSE | Calcineurin B homologous protein 1 | -2.3 | 0.0013* |
| P52503 | NDUS6 MOUSE | NADH dehydrogenase [ubiquinone] iron-sulfur protein 6, mitochondrial | -2.3 | 0.0003* |
| Q9QXS1 | PLEC MOUSE | Plectin | -2.3 | 0.0007* |
| P57016 | LAD1 MOUSE | Ladinin-1 | -2.3 | 0.0003* |
| O08663 | MAP2 MOUSE | Methionine aminopeptidase 2 | -2.3 | 0.0018* |
| P21107 | TPM3 MOUSE | Tropomyosin alpha-3 chain | -2.3 | 0.0039* |
| E9Q7P9 | CDHR2 MOUSE | Cadherin-related family member 2 | -2.3 | 0.0001* |
| Q8VDJ3 | VIGLN_MOUSE | Vigilin | -2.3 | 0.1032 |
| P99028 | QCR6_MOUSE | Cytochrome b-c1 complex subunit 6, mitochondrial | -2.3 | 0.0001* |
| Q8BL97 | SRSF7_MOUSE | Serine/arginine-rich splicing factor 7 | -2.3 | 0.1334 |
| Q62261 | SPTB2_MOUSE | Spectrin beta chain, non-erythrocytic 1 | -2.2 | 0.0003* |
| Q99K01 | PDXD1_MOUSE | Pyridoxal-dependent decarboxylase domain-containing protein 1 | -2.2 | 0.0112* |
| Q9ERS2 | NDUAD_MOUSE | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 13 | -2.2 | 0.5463 |
| Q61792 | LASP1_MOUSE | LIM and SH3 domain protein 1 | -2.2 | 0.0000* |
| Q02819 | NUCB1_MOUSE | Nucleobindin-1 | -2.2 | 0.0002* |
| P31428 | DPEP1_MOUSE | Dipeptidase 1 | -2.2 | 0.017* |
| P43276 | H15_MOUSE | Histone H1.5 | -2.2 | 0.0487 |
| Q9Z2I0 | LETM1_MOUSE | LETM1 and EF-hand domain-containing protein 1, mitochondrial | -2.2 | 0.0009* |
| Q61189 | ICLN_MOUSE | Methylosome subunit pICIn | -2.2 | 0.1117 |
| Q99LT0 | DPY30_MOUSE | Protein dpy-30 homolog | -2.2 | 0.0006* |
| Q9Z1D1 | EIF3G_MOUSE | Eukaryotic translation initiation factor 3 subunit G | -2.2 | 0.0036* |
| Q922Q8 | LRC59_MOUSE | Leucine-rich repeat-containing protein 59 | -2.2 | 0.0184* |
| P19536 | COX5B_MOUSE | Cytochrome c oxidase subunit 5B, mitochondrial | -2.2 | 0.0001* |
| P56391 | CX6B1_MOUSE | Cytochrome c oxidase subunit 6B1 | -2.2 | 0.0000* |
| Q8VEK3 | HNRPU_MOUSE | Heterogeneous nuclear ribonucleoprotein U | -2.2 | 0.5473 |
| Q6NZJ6 | IF4G1_MOUSE | Eukaryotic translation initiation factor 4 gamma 1 | -2.2 | 0.0002* |
| P70441 | NHRF1_MOUSE | Na(+)/H(+) exchange regulatory cofactor NHE-RF1 | -2.1 | 0.0001* |
| Q91VM9 | IPYR2_MOUSE | Inorganic pyrophosphatase 2, mitochondrial | -2.1 | 0.0141* |
| P19001 | K1C19_MOUSE | Keratin, type I cytoskeletal 19 | -2.1 | 0.0003* |
| Q8R4U7 | LUZP1_MOUSE | Leucine zipper protein 1 | -2.1 | 0.0001* |
| Q6P9R2 | OXSR1_MOUSE | Serine/threonine-protein kinase OSR1 | -2.1 | 0.0005* |
| Q91WJ8 | FUBP1_MOUSE | Far upstream element-binding protein 1 | -2.1 | 0.0000* |
| Q91V76 | CK054_MOUSE | Ester hydrolase C11orf54 homolog | -2.1 | 0.0076* |
| Q9WVA2 | TIM8A_MOUSE | Mitochondrial import inner membrane translocase subunit Tim8 A | -2.1 | 0.0000* |
| P62960 | YBOX1_MOUSE | Nuclease-sensitive element-binding protein 1 | -2.1 | 0.0001* |
| P26645 | MARCS_MOUSE | Myristoylated alanine-rich C-kinase substrate | -2.1 | 0.5655 |
| Q08331 | CALB2_MOUSE | Calretinin | -2.0 | 0.0001* |
| Q9JMD0 | ZN207_MOUSE | BUB3-interacting and GLEBS motif-containing protein ZNF207 | -2.0 | 0.0011* |

| Q9D1J3 | SARNP MOUSE | SAP domain-containing ribonucleoprotein | -2.0 | 0.3141 |
|--------|-------------|--|------|---------|
| Q61595 | KTN1 MOUSE | Kinectin | -2.0 | 0.1282 |
| Q9D8X2 | CC124 MOUSE | Coiled-coil domain-containing protein 124 | -2.0 | 0.5056 |
| Q9ERG0 | LIMA1 MOUSE | LIM domain and actin-binding protein 1 | -2.0 | 0.0007* |
| P11679 | K2C8 MOUSE | Keratin, type II cytoskeletal 8 | -2.0 | 0.0059* |
| P84089 | ERH MOUSE | Enhancer of rudimentary homolog | -2.0 | 0.0338* |
| Q64213 | SF01 MOUSE | Splicing factor 1 | -2.0 | 0.0000* |
| Q9CRB6 | TPPP3 MOUSE | Tubulin polymerization-promoting protein family member 3 | -2.0 | 0.0000* |
| P62077 | TIM8B MOUSE | Mitochondrial import inner membrane translocase subunit Tim8 B | -2.0 | 0.0028* |
| P30999 | CTND1_MOUSE | Catenin delta-1 | -2.0 | 0.4077 |
| P81117 | NUCB2_MOUSE | Nucleobindin-2 | -2.0 | 0.0001* |
| Q3UHX2 | HAP28_MOUSE | 28 kDa heat- and acid-stable phosphoprotein | -2.0 | 0.0001* |
| Q61191 | HCFC1_MOUSE | Host cell factor 1 | -2.0 | 0.0009* |
| Q148V7 | RELCH_MOUSE | LisH domain and HEAT repeat-containing protein KIAA1468 | -2.0 | 0.0001* |
| Q99L45 | IF2B_MOUSE | Eukaryotic translation initiation factor 2 subunit 2 | -2.0 | 0.0485 |
| P03995 | GFAP_MOUSE | Glial fibrillary acidic protein | -2.0 | 0.0053* |
| P16546 | SPTN1_MOUSE | Spectrin alpha chain, non-erythrocytic 1 | -2.0 | 0.0039* |
| P22005 | PENK_MOUSE | Proenkephalin-A | -2.0 | 0.1620 |
| P29341 | PABP1_MOUSE | Polyadenylate-binding protein 1 | -2.0 | 0.0468* |
| Q8BRN9 | C2D1B_MOUSE | Coiled-coil and C2 domain-containing protein 1B | -2.0 | 0.0348* |
| Q8R317 | UBQL1_MOUSE | Ubiquilin-1 | -2.0 | 0.0017* |
| Q9CR68 | UCRI_MOUSE | Cytochrome b-c1 complex subunit Rieske, mitochondrial | -2.0 | 0.2298 |
| Q64433 | CH10_MOUSE | 10 kDa heat shock protein, mitochondrial | -2.0 | 0.0004* |
| P45878 | FKBP2_MOUSE | Peptidyl-prolyl cis-trans isomerase FKBP2 | -2.0 | 0.0001* |
| Q05D44 | IF2P_MOUSE | Eukaryotic translation initiation factor 5B | -1.9 | 0.013* |
| Q9Z204 | HNRPC_MOUSE | Heterogeneous nuclear ribonucleoproteins C1/C2 | -1.9 | 0.1149 |
| Q6PDM2 | SRSF1_MOUSE | Serine/arginine-rich splicing factor 1 | -1.9 | 0.0194* |
| Q9CQX8 | RT36_MOUSE | 28S ribosomal protein S36, mitochondrial | -1.9 | 0.0033* |
| P17225 | PTBP1_MOUSE | Polypyrimidine tract-binding protein 1 | -1.9 | 0.0056* |
| Q61074 | PPM1G_MOUSE | Protein phosphatase 1G | -1.9 | 0.0222* |
| 070475 | UGDH_MOUSE | UDP-glucose 6-dehydrogenase | -1.9 | 0.3092 |
| Q8CGC7 | SYEP_MOUSE | Bifunctional glutamate/prolinetRNA ligase | -1.9 | 0.0803 |
| Q9EQS3 | MYCBP_MOUSE | C-Myc-binding protein | -1.9 | 0.0004* |
| Q921H9 | COA7_MOUSE | Cytochrome c oxidase assembly factor 7 | -1.9 | 0.0186* |
| Q61316 | HSP74_MOUSE | Heat shock 70 kDa protein 4 | -1.9 | 0.0004* |
| Q9D8S9 | BOLA1_MOUSE | BolA-like protein 1 | -1.9 | 0.0042* |
| Q03517 | SCG2_MOUSE | Secretogranin-2 | -1.9 | 0.0003* |
| O55111 | DSG2_MOUSE | Desmoglein-2 | -1.9 | 0.9939 |
| P97864 | CASP7_MOUSE | Caspase-7 | -1.9 | 0.0714 |
| P61961 | UFM1_MOUSE | Ubiquitin-fold modifier 1 | -1.9 | 0.0044* |

| Q3THE2 | ML12B MOUSE | Myosin regulatory light chain 12B | -1.9 | 0.0001* |
|--------|-------------|---|------|---------|
| Q8K183 | PDXK MOUSE | Pyridoxal kinase | -1.9 | 0.5131 |
| P0DP28 | CALM3 MOUSE | sp P0DP28 CALM3 MOUSE | -1.9 | 0.0811 |
| Q6PGH2 | JUPI2 MOUSE | Hematological and neurological expressed 1-like protein | -1.9 | 0.3907 |
| Q3U0V1 | FUBP2 MOUSE | Far upstream element-binding protein 2 | -1.9 | 0.0022* |
| Q60997 | DMBT1 MOUSE | Deleted in malignant brain tumors 1 protein | -1.9 | 0.0342* |
| Q62446 | FKBP3 MOUSE | Peptidyl-prolyl cis-trans isomerase FKBP3 | -1.9 | 0.0001* |
| P97855 | G3BP1 MOUSE | Ras GTPase-activating protein-binding protein 1 | -1.9 | 0.8099 |
| Q61545 | EWS MOUSE | RNA-binding protein EWS | -1.9 | 0.0001* |
| Q8BGD8 | COA6_MOUSE | Cytochrome c oxidase assembly factor 6 homolog | -1.9 | 0.1729 |
| Q8BMD8 | SCMC1_MOUSE | Calcium-binding mitochondrial carrier protein SCaMC-1 | -1.9 | 0.6141 |
| Q9WVE8 | PACN2_MOUSE | Protein kinase C and casein kinase substrate in neurons protein 2 | -1.9 | 0.0095* |
| P08228 | SODC_MOUSE | Superoxide dismutase [Cu-Zn] | -1.9 | 0.0019* |
| Q8VHC3 | SELM_MOUSE | Selenoprotein M | -1.9 | 0.0018* |
| P68372 | TBB4B_MOUSE | Tubulin beta-4B chain | -1.9 | 0.0203* |
| Q9ESP1 | SDF2L_MOUSE | Stromal cell-derived factor 2-like protein 1 | -1.8 | 0.8618 |
| P46656 | ADX_MOUSE | Adrenodoxin, mitochondrial | -1.8 | 0.0002* |
| Q8VDD5 | MYH9_MOUSE | Myosin-9 | -1.8 | 0.1794 |
| Q9CR98 | F136A_MOUSE | Protein FAM136A | -1.8 | 0.0000* |
| Q91W90 | TXND5_MOUSE | Thioredoxin domain-containing protein 5 | -1.8 | 0.0002* |
| Q9QY76 | VAPB_MOUSE | Vesicle-associated membrane protein-associated protein B | -1.8 | 0.0127* |
| P62075 | TIM13_MOUSE | Mitochondrial import inner membrane translocase subunit Tim13 | -1.8 | 0.0002* |
| Q6NVF9 | CPSF6_MOUSE | Cleavage and polyadenylation specificity factor subunit 6 | -1.8 | 0.0000* |
| Q99K48 | NONO_MOUSE | Non-POU domain-containing octamer-binding protein | -1.8 | 0.6999 |
| O08795 | GLU2B_MOUSE | Glucosidase 2 subunit beta | -1.8 | 0.0001* |
| Q9CQH7 | BT3L4_MOUSE | Transcription factor BTF3 homolog 4 | -1.8 | 0.0107* |
| Q62523 | ZYX_MOUSE | Zyxin | -1.8 | 0.2770 |
| P23116 | EIF3A_MOUSE | Eukaryotic translation initiation factor 3 subunit A | -1.8 | 0.3563 |
| P56959 | FUS_MOUSE | RNA-binding protein FUS | -1.8 | 0.0015* |
| Q9JKR6 | HYOU1_MOUSE | Hypoxia up-regulated protein 1 | -1.8 | 0.0007* |
| Q921W0 | CHM1A_MOUSE | Charged multivesicular body protein 1a | -1.8 | 0.0000* |
| Q9ER00 | STX12_MOUSE | Syntaxin-12 | -1.8 | 0.0002* |
| P48428 | TBCA_MOUSE | Tubulin-specific chaperone A | -1.8 | 0.0056* |
| Q9CYA0 | CREL2_MOUSE | Cysteine-rich with EGF-like domain protein 2 | -1.8 | 0.3031 |
| P62983 | RS27A_MOUSE | Ubiquitin-40S ribosomal protein S27a | -1.8 | 0.9725 |
| Q9CRB9 | MIC19_MOUSE | MICOS complex subunit Mic19 | -1.8 | 0.003* |
| P55937 | GOGA3_MOUSE | Golgin subfamily A member 3 | -1.8 | 0.2261 |
| F6ZDS4 | TPR_MOUSE | Nucleoprotein TPR | -1.8 | 0.0019* |
| Q9CQL7 | MOFA1_MOUSE | MORF4 family-associated protein 1 | -1.8 | 0.6181 |
| Q9Z1Z0 | USO1_MOUSE | General vesicular transport factor p115 | -1.8 | 0.2603 |

| Q6NZB0 | DNJC8 MOUSE | DnaJ homolog subfamily C member 8 | -1.8 | 0.0000* |
|--------|-------------|--|------|---------|
| Q8K3C3 | LZIC MOUSE | Protein LZIC | -1.8 | 0.0051* |
| Q8BGD9 | IF4B_MOUSE | Eukaryotic translation initiation factor 4B | -1.8 | 0.0097* |
| Q61207 | SAP MOUSE | Prosaposin | -1.8 | 0.0109* |
| Q6P542 | ABCF1 MOUSE | ATP-binding cassette sub-family F member 1 | -1.8 | 0.0015* |
| Q9Z2Q5 | RM40_MOUSE | 39S ribosomal protein L40, mitochondrial | -1.8 | 0.008* |
| Q64442 | DHSO_MOUSE | Sorbitol dehydrogenase | -1.8 | 0.016* |
| Q9DB15 | RM12_MOUSE | 39S ribosomal protein L12, mitochondrial | -1.8 | 0.0015* |
| Q9CWS0 | DDAH1 MOUSE | N(G),N(G)-dimethylarginine dimethylaminohydrolase 1 | -1.8 | 0.0042* |
| Q9Z1X4 | ILF3_MOUSE | Interleukin enhancer-binding factor 3 | -1.8 | 0.1819 |
| Q9Z0F7 | SYUG_MOUSE | Gamma-synuclein | -1.8 | 0.0023* |
| Q9D855 | QCR7_MOUSE | Cytochrome b-c1 complex subunit 7 | -1.7 | 0.0356* |
| Q80Y14 | GLRX5_MOUSE | Glutaredoxin-related protein 5, mitochondrial | -1.7 | 0.0001* |
| P09405 | NUCL_MOUSE | Nucleolin | -1.7 | 0.0067* |
| Q8K310 | MATR3_MOUSE | Matrin-3 | -1.7 | 0.9197 |
| Q8VIJ6 | SFPQ_MOUSE | Splicing factor, proline- and glutamine-rich | -1.7 | 0.2983 |
| E9Q557 | DESP_MOUSE | Desmoplakin | -1.7 | 0.0776 |
| Q9CQN7 | RM41_MOUSE | 39S ribosomal protein L41, mitochondrial | -1.7 | 0.0876 |
| Q8BU85 | MSRB3_MOUSE | Methionine-R-sulfoxide reductase B3, mitochondrial | -1.7 | 0.4329 |
| P61979 | HNRPK_MOUSE | Heterogeneous nuclear ribonucleoprotein K | -1.7 | 0.1405 |
| Q62241 | RU1C_MOUSE | U1 small nuclear ribonucleoprotein C | -1.7 | 0.6463 |
| Q8K5B2 | MCFD2_MOUSE | Multiple coagulation factor deficiency protein 2 homolog | -1.7 | 0.0223* |
| P29452 | CASP1_MOUSE | Caspase-1 | -1.7 | 0.0421* |
| Q9R100 | CAD17_MOUSE | Cadherin-17 | -1.7 | 0.0009* |
| P97352 | S10AD_MOUSE | Protein S100-A13 | -1.7 | 0.0008* |
| P31786 | ACBP_MOUSE | Acyl-CoA-binding protein | -1.7 | 0.0006* |
| Q66JS6 | EI3JB_MOUSE | Eukaryotic translation initiation factor 3 subunit J-B | -1.7 | 0.0000* |
| P27546 | MAP4_MOUSE | Microtubule-associated protein 4 | -1.7 | 0.0024* |
| Q62318 | TIF1B_MOUSE | Transcription intermediary factor 1-beta | -1.7 | 0.6349 |
| Q9CR21 | ACPM_MOUSE | Acyl carrier protein, mitochondrial | -1.7 | 0.0002* |
| O55023 | IMPA1_MOUSE | Inositol monophosphatase 1 | -1.7 | 0.0215* |
| Q8BUV3 | GEPH_MOUSE | Gephyrin | -1.7 | 0.0014* |
| Q9ERR7 | SEP15_MOUSE | Selenoprotein F | -1.7 | 0.6905 |
| Q9CQU0 | TXD12_MOUSE | Thioredoxin domain-containing protein 12 | -1.7 | 0.0025* |
| P26231 | CTNA1_MOUSE | Catenin alpha-1 | -1.7 | 0.0208* |
| Q69ZS7 | HBS1L_MOUSE | HBS1-like protein | -1.6 | 0.009* |
| O35143 | ATIF1_MOUSE | ATPase inhibitor, mitochondrial | -1.6 | 0.0017* |
| P62311 | LSM3_MOUSE | U6 snRNA-associated Sm-like protein LSm3 | -1.6 | 0.7105 |
| O70318 | E41L2_MOUSE | Band 4.1-like protein 2 | -1.6 | 0.0003* |
| O08583 | THOC4_MOUSE | THO complex subunit 4 | -1.6 | 0.1290 |

| Q9CQZ1 | HSBP1 MOUSE | Heat shock factor-binding protein 1 | -1.6 | 0.0002* |
|--------|-------------|---|------|---------|
| P21619 | LMNB2_MOUSE | Lamin-B2 | -1.6 | 0.2382 |
| P54728 | RD23B MOUSE | UV excision repair protein RAD23 homolog B | -1.6 | 0.0315* |
| Q9JKB3 | YBOX3 MOUSE | Y-box-binding protein 3 | -1.6 | 0.0690 |
| Q9D6J6 | NDUV2 MOUSE | NADH dehydrogenase [ubiquinone] flavoprotein 2, mitochondrial | -1.6 | 0.0126* |
| O55022 | PGRC1_MOUSE | Membrane-associated progesterone receptor component 1 | -1.6 | 0.0046* |
| Q9WVK4 | EHD1 MOUSE | EH domain-containing protein 1 | -1.6 | 0.0174* |
| P12367 | KAP2 MOUSE | cAMP-dependent protein kinase type II-alpha regulatory subunit | -1.6 | 0.0874 |
| O08539 | BIN1 MOUSE | Myc box-dependent-interacting protein 1 | -1.6 | 0.3005 |
| Q9QYR6 | MAPIA_MOUSE | Microtubule-associated protein 1A | -1.6 | 0.6640 |
| Q80WW9 | DDRGK_MOUSE | DDRGK domain-containing protein 1 | -1.6 | 0.0004* |
| Q9WUK2 | IF4H_MOUSE | Eukaryotic translation initiation factor 4H | -1.6 | 0.2464 |
| Q9EQK5 | MVP_MOUSE | Major vault protein | -1.6 | 0.0191* |
| O70251 | EF1B_MOUSE | Elongation factor 1-beta | -1.6 | 0.0922 |
| Q9EQU5 | SET_MOUSE | Protein SET | -1.6 | 0.0346* |
| Q9D6S7 | RRFM_MOUSE | Ribosome-recycling factor, mitochondrial | -1.6 | 0.3841 |
| P97792 | CXAR_MOUSE | Coxsackievirus and adenovirus receptor homolog | -1.6 | 0.9575 |
| Q9QXV0 | PCSK1_MOUSE | ProSAAS | -1.6 | 0.0346* |
| P39447 | ZO1_MOUSE | Tight junction protein ZO-1 | -1.6 | 0.6687 |
| O08585 | CLCA_MOUSE | Clathrin light chain A | -1.6 | 0.0025* |
| P31230 | AIMP1_MOUSE | Aminoacyl tRNA synthase complex-interacting multifunctional protein 1 | -1.6 | 0.5640 |
| P62073 | TIM10_MOUSE | Mitochondrial import inner membrane translocase subunit Tim10 | -1.6 | 0.003* |
| Q9D1L9 | LTOR5_MOUSE | Ragulator complex protein LAMTOR5 | -1.6 | 0.5383 |
| P60824 | CIRBP_MOUSE | Cold-inducible RNA-binding protein | -1.6 | 0.9134 |
| | — | Nascent polypeptide-associated complex subunit alpha, muscle-specific | | |
| P70670 | NACAM_MOUSE | form | -1.6 | 0.0022* |
| Q99J99 | THTM_MOUSE | 3-mercaptopyruvate sulfurtransferase | -1.6 | 0.0242* |
| Q9CXZ1 | NDUS4_MOUSE | NADH dehydrogenase [ubiquinone] iron-sulfur protein 4, mitochondrial | -1.6 | 0.0038* |
| Q60865 | CAPR1_MOUSE | Caprin-1 | -1.6 | 0.0910 |
| P17563 | SBP1_MOUSE | Selenium-binding protein 1 | -1.6 | 0.0443* |
| Q3UMT1 | PP12C_MOUSE | Protein phosphatase 1 regulatory subunit 12C | -1.6 | 0.0006* |
| P14211 | CALR_MOUSE | Calreticulin | -1.6 | 0.0907 |
| Q9CYZ2 | TPD54_MOUSE | Tumor protein D54 | -1.6 | 0.0075* |
| Q9WU28 | PFD5_MOUSE | Prefoldin subunit 5 | -1.6 | 0.0001* |
| Q8R3Q6 | CCD58_MOUSE | Coiled-coil domain-containing protein 58 | -1.6 | 0.0148* |
| P01887 | B2MG_MOUSE | Beta-2-microglobulin | -1.6 | 0.0048* |
| P26883 | FKB1A_MOUSE | Peptidyl-prolyl cis-trans isomerase FKBP1A | -1.6 | 0.8677 |
| P26369 | U2AF2_MOUSE | Splicing factor U2AF 65 kDa subunit | -1.6 | 0.0128* |
| Q9QZ23 | NFU1_MOUSE | NFU1 iron-sulfur cluster scaffold homolog, mitochondrial | -1.6 | 0.3980 |
| O88952 | LIN7C_MOUSE | Protein lin-7 homolog C | -1.6 | 0.0001* |

| P70333 | HNRH2 MOUSE | Heterogeneous nuclear ribonucleoprotein H2 | -1.6 | 0.8185 |
|--------|-------------|--|------|---------|
| O88696 | CLPP MOUSE | ATP-dependent Clp protease proteolytic subunit, mitochondrial | -1.6 | 0.2446 |
| Q64012 | RALY_MOUSE | RNA-binding protein Raly | -1.6 | 0.7938 |
| Q9CQE8 | RTRAF MOUSE | UPF0568 protein C14orf166 homolog | -1.6 | 0.0032* |
| Q8CCH2 | NHLC3 MOUSE | NHL repeat-containing protein 3 | -1.6 | 0.3497 |
| P05201 | AATC MOUSE | Aspartate aminotransferase, cytoplasmic | -1.5 | 0.6850 |
| P84104 | SRSF3 MOUSE | Serine/arginine-rich splicing factor 3 | -1.5 | 0.9251 |
| Q6P6L0 | FIL1L MOUSE | Filamin A-interacting protein 1-like | -1.5 | 0.3911 |
| Q8VE37 | RCC1 MOUSE | Regulator of chromosome condensation | -1.5 | 0.2936 |
| Q8BP92 | RCN2_MOUSE | Reticulocalbin-2 | -1.5 | 0.0113* |
| P29595 | NEDD8_MOUSE | NEDD8 | -1.5 | 0.0144* |
| Q9D8B3 | CHM4B_MOUSE | Charged multivesicular body protein 4b | -1.5 | 0.0023* |
| P99027 | RLA2_MOUSE | 60S acidic ribosomal protein P2 | -1.5 | 0.4194 |
| P61458 | PHS_MOUSE | Pterin-4-alpha-carbinolamine dehydratase | -1.5 | 0.1540 |
| Q9CPU0 | LGUL_MOUSE | Lactoylglutathione lyase | -1.5 | 0.0073* |
| P47968 | RPIA_MOUSE | Ribose-5-phosphate isomerase | -1.5 | 0.1785 |
| Q9WTR5 | CAD13_MOUSE | Cadherin-13 | -1.5 | 0.0137* |
| Q61112 | CAB45_MOUSE | 45 kDa calcium-binding protein | -1.5 | 0.6108 |
| P97300 | NPTN_MOUSE | Neuroplastin | -1.5 | 0.0001* |
| P62627 | DLRB1_MOUSE | Dynein light chain roadblock-type 1 | -1.5 | 0.1841 |
| Q91YE8 | SYNP2_MOUSE | Synaptopodin-2 | -1.5 | 0.8018 |
| P32020 | NLTP_MOUSE | Non-specific lipid-transfer protein | -1.5 | 0.1208 |
| Q99KJ8 | DCTN2_MOUSE | Dynactin subunit 2 | -1.5 | 0.0012* |
| Q9CXI5 | MANF_MOUSE | Mesencephalic astrocyte-derived neurotrophic factor | -1.5 | 0.0005* |
| Q9CR00 | PSMD9_MOUSE | 26S proteasome non-ATPase regulatory subunit 9 | -1.5 | 0.6917 |
| Q9CPQ1 | COX6C_MOUSE | Cytochrome c oxidase subunit 6C | -1.5 | 0.0195* |
| Q62418 | DBNL_MOUSE | Drebrin-like protein | -1.5 | 0.0894 |
| Q8R0F8 | FAHD1_MOUSE | Acylpyruvase FAHD1, mitochondrial | -1.5 | 0.0131* |
| Q9QX47 | SON_MOUSE | Protein SON | -1.5 | 0.1792 |
| Q8BQ47 | CNPY4_MOUSE | Protein canopy homolog 4 | -1.5 | 0.0878 |
| Q07797 | LG3BP_MOUSE | Galectin-3-binding protein | -1.5 | 0.4307 |
| Q63810 | CANB1_MOUSE | Calcineurin subunit B type 1 | -1.5 | 0.7866 |
| P61759 | PFD3_MOUSE | Prefoldin subunit 3 | -1.5 | 0.0257* |
| Q9DAU1 | CNPY3_MOUSE | Protein canopy homolog 3 | -1.5 | 0.2672 |
| P19783 | COX41_MOUSE | Cytochrome c oxidase subunit 4 isoform 1, mitochondrial | -1.5 | 0.1145 |
| P57776 | EF1D_MOUSE | Elongation factor 1-delta | -1.5 | 0.0141* |
| Q80X90 | FLNB_MOUSE | Filamin-B | -1.5 | 0.1927 |
| Q8CI51 | PDLI5_MOUSE | PDZ and LIM domain protein 5 | -1.5 | 0.9289 |
| Q8BTM8 | FLNA_MOUSE | Filamin-A | -1.5 | 0.6068 |
| Q91YQ5 | RPN1_MOUSE | Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit 1 | -1.5 | 0.7415 |
| Q3TIV5 | ZC3HF MOUSE | Zinc finger CCCH domain-containing protein 15 | -1.5 | 0.0005* |
|--------|-------------|---|------|---------|
| P34152 | FAK1 MOUSE | Focal adhesion kinase 1 | -1.5 | 0.9445 |
| O08749 | DLDH MOUSE | Dihydrolipoyl dehydrogenase, mitochondrial | -1.5 | 0.0285* |
| Q3UPL0 | SC31A MOUSE | Protein transport protein Sec31A | -1.5 | 0.0194* |
| P51859 | HDGF MOUSE | Hepatoma-derived growth factor | -1.5 | 0.0012* |
| Q9DBP5 | KCY MOUSE | UMP-CMP kinase | -1.5 | 0.0242* |
| P63254 | CRIP1 MOUSE | Cysteine-rich protein 1 | -1.5 | 0.0519 |
| Q3U9G9 | LBR MOUSE | Lamin-B receptor | -1.5 | 0.0086* |
| Q62468 | VILI MOUSE | Villin-1 | -1.5 | 0.8871 |
| Q9JL35 | HMGN5 MOUSE | High mobility group nucleosome-binding domain-containing protein 5 | -1.5 | 0.1551 |
| Q9CQ10 | CHMP3_MOUSE | Charged multivesicular body protein 3 | -1.5 | 0.0204* |
| Q61768 | KINH MOUSE | Kinesin-1 heavy chain | -1.5 | 0.0058* |
| Q64152 | BTF3 MOUSE | Transcription factor BTF3 | -1.5 | 0.1049 |
| P19467 | MUC13_MOUSE | Mucin-13 | -1.5 | 0.5582 |
| Q9D3D9 | ATPD_MOUSE | ATP synthase subunit delta, mitochondrial | -1.5 | 0.0161* |
| Q8K4L3 | SVIL_MOUSE | Supervillin | -1.5 | 0.6101 |
| P35564 | CALX_MOUSE | Calnexin | -1.5 | 0.9180 |
| Q61937 | NPM_MOUSE | Nucleophosmin | -1.5 | 0.0268* |
| Q9WTQ5 | AKA12_MOUSE | A-kinase anchor protein 12 | -1.5 | 0.0004* |
| O70209 | PDLI3_MOUSE | PDZ and LIM domain protein 3 | -1.5 | 0.9406 |
| Q9NYQ2 | HAOX2_MOUSE | Hydroxyacid oxidase 2 | -1.5 | 0.7671 |
| Q9JMG7 | HDGR3_MOUSE | Hepatoma-derived growth factor-related protein 3 | -1.4 | 0.3034 |
| P27773 | PDIA3_MOUSE | Protein disulfide-isomerase A3 | -1.4 | 0.9353 |
| Q99JF8 | PSIP1_MOUSE | PC4 and SFRS1-interacting protein | -1.4 | 0.2057 |
| Q9CZG9 | PDZ11_MOUSE | PDZ domain-containing protein 11 | -1.4 | 0.5940 |
| Q99LY9 | NDUS5_MOUSE | NADH dehydrogenase [ubiquinone] iron-sulfur protein 5 | -1.4 | 0.1366 |
| Q64299 | CCN3_MOUSE | Protein NOV homolog | -1.4 | 0.022* |
| P57759 | ERP29_MOUSE | Endoplasmic reticulum resident protein 29 | -1.4 | 0.7954 |
| Q8CBW3 | ABI1_MOUSE | Abl interactor 1 | -1.4 | 0.0842 |
| O09044 | SNP23_MOUSE | Synaptosomal-associated protein 23 | -1.4 | 0.0031* |
| Q6IRU2 | TPM4_MOUSE | Tropomyosin alpha-4 chain | -1.4 | 0.0192* |
| Q99020 | ROAA_MOUSE | Heterogeneous nuclear ribonucleoprotein A/B | -1.4 | 0.0056* |
| Q60829 | PPR1B_MOUSE | Protein phosphatase 1 regulatory subunit 1B | -1.4 | 0.0578 |
| Q9D0A3 | ARPIN_MOUSE | Arpin | -1.4 | 0.1232 |
| Q9CQ45 | NENF_MOUSE | Neudesin | -1.4 | 0.4056 |
| Q63850 | NUP62_MOUSE | Nuclear pore glycoprotein p62 | -1.4 | 0.0085* |
| Q61029 | LAP2B_MOUSE | Lamina-associated polypeptide 2, isoforms beta/delta/epsilon/gamma | -1.4 | 0.0032* |
| O70591 | PFD2_MOUSE | Prefoldin subunit 2 | -1.4 | 0.0429* |
| Q810Q5 | NMES1_MOUSE | Normal mucosa of esophagus-specific gene 1 protein | -1.4 | 0.5831 |
| Q9DBJ3 | BI2L1_MOUSE | Brain-specific angiogenesis inhibitor 1-associated protein 2-like protein 1 | -1.4 | 0.5891 |

| O35226 | PSMD4 MOUSE | 26S proteasome non-ATPase regulatory subunit 4 | -1.4 | 0.5366 |
|--------|-------------|--|------|---------|
| Q8R0W0 | EPIPL MOUSE | Epiplakin | -1.4 | 0.0697 |
| Q9CQQ8 | LSM7 MOUSE | U6 snRNA-associated Sm-like protein LSm7 | -1.4 | 0.0004* |
| Q62165 | DAG1 MOUSE | Dystroglycan | -1.4 | 0.4224 |
| P54726 | RD23A MOUSE | UV excision repair protein RAD23 homolog A | -1.4 | 0.3363 |
| P97371 | PSME1_MOUSE | Proteasome activator complex subunit 1 | -1.4 | 0.2722 |
| P20029 | BIP_MOUSE | 78 kDa glucose-regulated protein | -1.4 | 0.0115* |
| P10639 | THIO_MOUSE | Thioredoxin | -1.4 | 0.0162* |
| Q9CWM4 | PFD1_MOUSE | Prefoldin subunit 1 | -1.4 | 0.7532 |
| P56812 | PDCD5_MOUSE | Programmed cell death protein 5 | -1.4 | 0.4328 |
| P29758 | OAT_MOUSE | Ornithine aminotransferase, mitochondrial | -1.4 | 0.0264* |
| P08122 | CO4A2_MOUSE | Collagen alpha-2(IV) chain | -1.4 | 0.8406 |
| Q9Z1R2 | BAG6_MOUSE | Large proline-rich protein BAG6 | -1.4 | 0.1618 |
| Q9JHJ0 | TMOD3_MOUSE | Tropomodulin-3 | -1.4 | 0.0481* |
| P62858 | RS28_MOUSE | 40S ribosomal protein S28 | -1.4 | 0.0005* |
| Q9JLV1 | BAG3_MOUSE | BAG family molecular chaperone regulator 3 | -1.4 | 0.1657 |
| P02463 | CO4A1_MOUSE | Collagen alpha-1(IV) chain | -1.4 | 0.5855 |
| Q9CZ44 | NSF1C_MOUSE | NSFL1 cofactor p47 | -1.4 | 0.6085 |
| P62748 | HPCL1_MOUSE | Hippocalcin-like protein 1 | -1.4 | 0.6453 |
| P43277 | H13_MOUSE | Histone H1.3 | -1.4 | 0.2229 |
| O08579 | EMD_MOUSE | Emerin | -1.4 | 0.2371 |
| P56565 | S10A1_MOUSE | Protein S100-A1 | -1.4 | 0.0549 |
| Q3V0K9 | PLSI_MOUSE | Plastin-1 | -1.4 | 0.0494 |
| Q80YX1 | TENA_MOUSE | Tenascin | -1.4 | 0.1616 |
| Q02248 | CTNB1_MOUSE | Catenin beta-1 | -1.4 | 0.2880 |
| Q9CQ89 | CUTA_MOUSE | Protein CutA | -1.4 | 0.0011* |
| Q03958 | PFD6_MOUSE | Prefoldin subunit 6 | -1.4 | 0.0201* |
| O35887 | CALU_MOUSE | Calumenin | -1.4 | 0.0171* |
| Q91XA2 | GOLM1_MOUSE | Golgi membrane protein 1 | -1.4 | 0.2521 |
| Q9WV32 | ARC1B_MOUSE | Actin-related protein 2/3 complex subunit 1B | -1.4 | 0.1138 |
| Q99L47 | F10A1_MOUSE | Hsc70-interacting protein | -1.4 | 0.4360 |
| P38647 | GRP75_MOUSE | Stress-70 protein, mitochondrial | -1.4 | 0.038* |
| Q8CAQ8 | MIC60_MOUSE | MICOS complex subunit Mic60 | -1.4 | 0.0503 |
| Q7TQD2 | TPPP_MOUSE | Tubulin polymerization-promoting protein | -1.4 | 0.0059* |
| O35658 | C1QBP_MOUSE | Complement component 1 Q subcomponent-binding protein, mitochondrial | -1.4 | 0.0279* |
| P54227 | STMN1_MOUSE | Stathmin | -1.4 | 0.0644 |
| Q6ZWM4 | LSM8_MOUSE | U6 snRNA-associated Sm-like protein LSm8 | -1.4 | 0.0302* |
| O08997 | ATOX1_MOUSE | Copper transport protein ATOX1 | -1.4 | 0.0076* |
| Q60902 | EP15R_MOUSE | Epidermal growth factor receptor substrate 15-like 1 | -1.4 | 0.0013* |
| P63038 | CH60_MOUSE | 60 kDa heat shock protein, mitochondrial | -1.4 | 0.2790 |

| P21460 | CYTC_MOUSE | Cystatin-C | -1.4 | 0.7071 |
|--------|-------------|--|------|---------|
| P30681 | HMGB2 MOUSE | High mobility group protein B2 | -1.4 | 0.0196* |
| Q8R081 | HNRPL MOUSE | Heterogeneous nuclear ribonucleoprotein L | -1.4 | 0.5185 |
| Q9QXT0 | CNPY2 MOUSE | Protein canopy homolog 2 | -1.4 | 0.001* |
| P56376 | ACYP1 MOUSE | Acylphosphatase-1 | -1.4 | 0.035* |
| Q78ZA7 | NP1L4_MOUSE | Nucleosome assembly protein 1-like 4 | -1.4 | 0.7664 |
| Q9DBR7 | MYPT1 MOUSE | Protein phosphatase 1 regulatory subunit 12A | -1.4 | 0.5935 |
| Q9CY58 | PAIRB_MOUSE | Plasminogen activator inhibitor 1 RNA-binding protein | -1.4 | 0.0208* |
| O35381 | AN32A_MOUSE | Acidic leucine-rich nuclear phosphoprotein 32 family member A | -1.4 | 0.0733 |
| Q60864 | STIP1_MOUSE | Stress-induced-phosphoprotein 1 | -1.4 | 0.0169* |
| Q8VH51 | RBM39_MOUSE | RNA-binding protein 39 | -1.4 | 0.2614 |
| O89086 | RBM3_MOUSE | RNA-binding protein 3 | -1.4 | 0.6745 |
| Q8BG95 | MYPT2_MOUSE | Protein phosphatase 1 regulatory subunit 12B | -1.4 | 0.0694 |
| Q9CR41 | HYPK_MOUSE | Huntingtin-interacting protein K | -1.4 | 0.6662 |
| P34022 | RANG_MOUSE | Ran-specific GTPase-activating protein | -1.4 | 0.4402 |
| Q9DCW4 | ETFB_MOUSE | Electron transfer flavoprotein subunit beta | -1.4 | 0.4880 |
| P70372 | ELAV1_MOUSE | ELAV-like protein 1 | -1.4 | 0.5620 |
| Q9ERE7 | MESD_MOUSE | LDLR chaperone MESD | -1.4 | 0.0000* |
| Q8BJU0 | SGTA_MOUSE | Small glutamine-rich tetratricopeptide repeat-containing protein alpha | -1.4 | 0.4306 |
| Q9EPB4 | ASC_MOUSE | Apoptosis-associated speck-like protein containing a CARD | -1.4 | 0.0044* |
| Q9WV55 | VAPA_MOUSE | Vesicle-associated membrane protein-associated protein A | -1.4 | 0.3401 |
| Q9D1K2 | VATF_MOUSE | V-type proton ATPase subunit F | -1.4 | 0.8437 |
| P07724 | ALBU_MOUSE | Serum albumin | -1.4 | 0.2209 |
| Q8R3G9 | TSN8_MOUSE | Tetraspanin-8 | -1.4 | 0.6048 |
| Q99LP6 | GRPE1_MOUSE | GrpE protein homolog 1, mitochondrial | -1.4 | 0.2485 |
| Q9DBG9 | TX1B3_MOUSE | Tax1-binding protein 3 | -1.3 | 0.4945 |
| | | SWI/SNF-related matrix-associated actin-dependent regulator of chromatin | | |
| O54941 | SMCE1_MOUSE | subfamily E member 1 | -1.3 | 0.4419 |
| P48771 | CX7A2_MOUSE | Cytochrome c oxidase subunit 7A2, mitochondrial | -1.3 | 0.0407* |
| | | Dihydrolipoyllysine-residue acetyltransferase component of pyruvate | | |
| Q8BMF4 | ODP2_MOUSE | dehydrogenase complex, mitochondrial | -1.3 | 0.6639 |
| Q61581 | IBP7_MOUSE | Insulin-like growth factor-binding protein 7 | -1.3 | 0.2542 |
| P47941 | CRKL_MOUSE | Crk-like protein | -1.3 | 0.4695 |
| O09159 | MA2B1_MOUSE | Lysosomal alpha-mannosidase | -1.3 | 0.5075 |
| Q99KC8 | VMA5A_MOUSE | von Willebrand factor A domain-containing protein 5A | -1.3 | 0.6962 |
| P50543 | S10AB_MOUSE | Protein S100-A11 | -1.3 | 0.2778 |
| Q6PDN3 | MYLK_MOUSE | Myosin light chain kinase, smooth muscle | -1.3 | 0.2397 |
| 070439 | STX7_MOUSE | Syntaxin-7 | -1.3 | 0.1832 |
| Q9CQM5 | TXD17_MOUSE | Thioredoxin domain-containing protein 17 | -1.3 | 0.4929 |
| Q922Y1 | UBXN1_MOUSE | UBX domain-containing protein 1 | -1.3 | 0.0516 |

| Q8BKZ9 | ODPX MOUSE | Pyruvate dehydrogenase protein X component, mitochondrial | -1.3 | 0.031* |
|--------|-------------------------|---|------|---------|
| Q7TPW1 | NEXN_MOUSE | Nexilin | -1.3 | 0.4183 |
| Q78JW9 | UBFD1 MOUSE | Ubiguitin domain-containing protein UBFD1 | -1.3 | 0.8338 |
| P58771 | TPM1 MOUSE | Tropomyosin alpha-1 chain | -1.3 | 0.1323 |
| P10711 | TCEAT MOUSE | Transcription elongation factor A protein 1 | -1.3 | 0.0052* |
| Q03265 | ATPA MOUSE | ATP synthase subunit alpha, mitochondrial | -1.3 | 0.9476 |
| P60867 | RS20 MOUSE | 40S ribosomal protein S20 | -1.3 | 0.6138 |
| P01897 | HA1L_MOUSE | H-2 class I histocompatibility antigen, L-D alpha chain | -1.3 | 0.0323* |
| O54879 | HMGB3 MOUSE | High mobility group protein B3 | -1.3 | 0.8910 |
| P97493 | THIOM MOUSE | Thioredoxin, mitochondrial | -1.3 | 0.3207 |
| P62192 | PRS4 MOUSE | 26S protease regulatory subunit 4 | -1.3 | 0.8944 |
| Q9WTX5 | SKP1 MOUSE | S-phase kinase-associated protein 1 | -1.3 | 0.4547 |
| P18572 | BASI MOUSE | Basigin | -1.3 | 0.0549 |
| P63158 | HMGB1 MOUSE | High mobility group protein B1 | -1.3 | 0.0014* |
| P09103 | PDIA1 MOUSE | Protein disulfide-isomerase | -1.3 | 0.0259* |
| P11627 | L1CAM MOUSE | Neural cell adhesion molecule L1 | -1.3 | 0.0562 |
| Q60668 | HNRPD MOUSE | Heterogeneous nuclear ribonucleoprotein D0 | -1.3 | 0.6350 |
| P08003 | PDIA4 MOUSE | Protein disulfide-isomerase A4 | -1.3 | 0.1370 |
| Q05BC3 | EMAL ¹ MOUSE | Echinoderm microtubule-associated protein-like 1 | -1.3 | 0.9851 |
| P62774 | MTPN MOUSE | Myotrophin | -1.3 | 0.8122 |
| Q8K4G1 | LTBP4 MOUSE | Latent-transforming growth factor beta-binding protein 4 | -1.3 | 0.4485 |
| Q62048 | PEA15 MOUSE | Astrocytic phosphoprotein PEA-15 | -1.3 | 0.0596 |
| P47955 | RLA1_MOUSE | 60S acidic ribosomal protein P1 | -1.3 | 0.1581 |
| P23198 | CBX3_MOUSE | Chromobox protein homolog 3 | -1.3 | 0.2139 |
| P97822 | AN32E_MOUSE | Acidic leucine-rich nuclear phosphoprotein 32 family member E | -1.3 | 0.9885 |
| P97805 | FAM3D_MOUSE | Protein FAM3D | -1.3 | 0.4771 |
| P48024 | EIF1_MOUSE | Eukaryotic translation initiation factor 1 | -1.3 | 0.7583 |
| P60335 | PCBP1_MOUSE | Poly(rC)-binding protein 1 | -1.3 | 0.8477 |
| Q9D281 | NXP20_MOUSE | Protein Noxp20 | -1.3 | 0.5827 |
| P32261 | ANT3_MOUSE | Antithrombin-III | -1.3 | 0.1325 |
| P07309 | TTHY_MOUSE | Transthyretin | -1.3 | 0.7651 |
| P55302 | AMRP_MOUSE | Alpha-2-macroglobulin receptor-associated protein | -1.3 | 0.3499 |
| Q05186 | RCN1_MOUSE | Reticulocalbin-1 | -1.3 | 0.1123 |
| P24549 | AL1A1_MOUSE | Retinal dehydrogenase 1 | -1.3 | 0.7185 |
| Q8BJW6 | EIF2A_MOUSE | Eukaryotic translation initiation factor 2A | -1.3 | 0.7835 |
| Q9D1I5 | MCEE_MOUSE | Methylmalonyl-CoA epimerase, mitochondrial | -1.3 | 0.5342 |
| P32648 | VIP_MOUSE | VIP peptides | -1.3 | 0.8533 |
| Q9DCX2 | ATP5H_MOUSE | ATP synthase subunit d, mitochondrial | -1.3 | 0.1936 |
| P11438 | LAMP1_MOUSE | Lysosome-associated membrane glycoprotein 1 | -1.2 | 0.6630 |
| Q9D7P6 | ISCU_MOUSE | Iron-sulfur cluster assembly enzyme ISCU, mitochondrial | -1.2 | 0.0054* |

| P16045 | LEG1 MOUSE | Galectin-1 | -1.2 | 0.9251 |
|--------|-------------|---|------|---------|
| O88569 | ROA2 MOUSE | Heterogeneous nuclear ribonucleoproteins A2/B1 | -1.2 | 0.3856 |
| O35215 | DOPD MOUSE | D-dopachrome decarboxylase | -1.2 | 0.6834 |
| P00493 | HPRT_MOUSE | Hypoxanthine-guanine phosphoribosyltransferase | -1.2 | 0.7951 |
| P63323 | RS12 MOUSE | 40S ribosomal protein S12 | -1.2 | 0.0087* |
| Q5EBG8 | CA050 MOUSE | Uncharacterized protein C1orf50 homolog | -1.2 | 0.2458 |
| P58774 | TPM2 MOUSE | Tropomyosin beta chain | -1.2 | 0.0987 |
| P35278 | RAB5C MOUSE | Ras-related protein Rab-5C | -1.2 | 0.7916 |
| Q9CQK7 | RWDD1 MOUSE | RWD domain-containing protein 1 | -1.2 | 0.0087* |
| Q7TQG1 | PKHA6_MOUSE | Pleckstrin homology domain-containing family A member 6 | -1.2 | 0.7595 |
| Q9DCB8 | ISCA2_MOUSE | Iron-sulfur cluster assembly 2 homolog, mitochondrial | -1.2 | 0.1137 |
| Q91WD9 | SEGN_MOUSE | Secretagogin | -1.2 | 0.3691 |
| | _ | KH domain-containing, RNA-binding, signal transduction-associated protein | | |
| Q60749 | KHDR1_MOUSE | 1 | -1.2 | 0.2098 |
| P63242 | IF5A1_MOUSE | Eukaryotic translation initiation factor 5A-1 | -1.2 | 0.6526 |
| Q9DCT8 | CRIP2_MOUSE | Cysteine-rich protein 2 | -1.2 | 0.2515 |
| P48678 | LMNA_MOUSE | Prelamin-A/C | -1.2 | 0.5449 |
| Q9D0E1 | HNRPM_MOUSE | Heterogeneous nuclear ribonucleoprotein M | -1.2 | 0.8987 |
| | | Dihydrolipoyllysine-residue succinyltransferase component of 2- | | |
| Q9D2G2 | ODO2_MOUSE | oxoglutarate dehydrogenase complex, mitochondrial | -1.2 | 0.2694 |
| Q93092 | TALDO_MOUSE | Transaldolase | -1.2 | 0.7161 |
| Q99LC5 | ETFA_MOUSE | Electron transfer flavoprotein subunit alpha, mitochondrial | -1.2 | 0.5495 |
| O08638 | MYH11_MOUSE | Myosin-11 | -1.2 | 0.7055 |
| Q5XJY5 | COPD_MOUSE | Coatomer subunit delta | -1.2 | 0.9921 |
| Q9CQE5 | RGS10_MOUSE | Regulator of G-protein signaling 10 | -1.2 | 0.4703 |
| Q8BH64 | EHD2_MOUSE | EH domain-containing protein 2 | -1.2 | 0.8029 |
| 070570 | PIGR_MOUSE | Polymeric immunoglobulin receptor | -1.2 | 0.9420 |
| Q9WU78 | PDC6I_MOUSE | Programmed cell death 6-interacting protein | -1.2 | 0.6603 |
| Q06185 | ATP5I_MOUSE | ATP synthase subunit e, mitochondrial | -1.2 | 0.5964 |
| Q9Z0U1 | ZO2_MOUSE | Tight junction protein ZO-2 | -1.2 | 0.9698 |
| P63163 | RSMN_MOUSE | Small nuclear ribonucleoprotein-associated protein N | -1.2 | 0.7952 |
| Q78IK2 | USMG5_MOUSE | Up-regulated during skeletal muscle growth protein 5 | -1.2 | 0.9256 |
| O35685 | NUDC_MOUSE | Nuclear migration protein nudC | -1.2 | 0.4157 |
| Q9DBJ1 | PGAM1_MOUSE | Phosphoglycerate mutase 1 | -1.2 | 0.4018 |
| O55135 | IF6_MOUSE | Eukaryotic translation initiation factor 6 | -1.2 | 0.7399 |
| P09803 | CADH1_MOUSE | Cadherin-1 | -1.2 | 0.3392 |
| P20152 | VIME_MOUSE | Vimentin | -1.2 | 0.1808 |
| Q9CQR2 | RS21_MOUSE | 40S ribosomal protein S21 | -1.2 | 0.3934 |
| Q8BH97 | RCN3_MOUSE | Reticulocalbin-3 | -1.2 | 0.3656 |
| P21614 | VTDB_MOUSE | Vitamin D-binding protein | -1.2 | 0.7214 |

| Q9CY50 | SSRA MOUSE | Translocon-associated protein subunit alpha | -1.2 | 0.1270 |
|--------|-------------|---|------|--------|
| P06728 | APOA4 MOUSE | Apolipoprotein A-IV | -1.2 | 0.8529 |
| Q9JMA1 | UBP14 MOUSE | Ubiquitin carboxyl-terminal hydrolase 14 | -1.2 | 0.4826 |
| Q9CY02 | AHSP MOUSE | Alpha-hemoglobin-stabilizing protein | -1.2 | 0.8255 |
| Q9Z2I8 | SUCB2 MOUSE | SuccinateCoA ligase [GDP-forming] subunit beta, mitochondrial | -1.2 | 0.8799 |
| Q925B0 | PAWR MOUSE | PRKC apoptosis WT1 regulator protein | -1.2 | 0.3812 |
| P14206 | RSSA MOUSE | 40S ribosomal protein SA | -1.2 | 0.2888 |
| | - | Dolichyl-diphosphooligosaccharideprotein glycosyltransferase 48 kDa | | |
| O54734 | OST48 MOUSE | subunit | -1.2 | 0.8371 |
| Q91YN9 | BAG2 MOUSE | BAG family molecular chaperone regulator 2 | -1.2 | 0.7357 |
| P62320 | SMD3_MOUSE | Small nuclear ribonucleoprotein Sm D3 | -1.2 | 0.4094 |
| Q9CPT4 | MYDGF_MOUSE | Myeloid-derived growth factor | -1.2 | 0.8323 |
| P62862 | RS30 MOUSE | 40S ribosomal protein S30 | -1.2 | 0.1284 |
| Q9CR16 | PPID_MOUSE | Peptidyl-prolyl cis-trans isomerase D | -1.2 | 0.6670 |
| P49962 | SRP09_MOUSE | Signal recognition particle 9 kDa protein | -1.2 | 0.7354 |
| Q91VW3 | SH3L3_MOUSE | SH3 domain-binding glutamic acid-rich-like protein 3 | -1.2 | 0.8029 |
| Q9CQ19 | MYL9 MOUSE | Myosin regulatory light polypeptide 9 | -1.2 | 0.9167 |
| Q99MD9 | NASP_MOUSE | Nuclear autoantigenic sperm protein | -1.1 | 0.5906 |
| Q8BMK4 | CKAP4_MOUSE | Cytoskeleton-associated protein 4 | -1.1 | 0.7966 |
| Q9QYJ0 | DNJA2_MOUSE | DnaJ homolog subfamily A member 2 | -1.1 | 0.9974 |
| P56480 | ATPB_MOUSE | ATP synthase subunit beta, mitochondrial | -1.1 | 0.8938 |
| P70296 | PEBP1_MOUSE | Phosphatidylethanolamine-binding protein 1 | -1.1 | 0.8705 |
| Q60605 | MYL6_MOUSE | Myosin light polypeptide 6 | -1.1 | 0.9409 |
| P56395 | CYB5_MOUSE | Cytochrome b5 | -1.1 | 0.9548 |
| Q9CQM9 | GLRX3_MOUSE | Glutaredoxin-3 | -1.1 | 0.6913 |
| P14873 | MAP1B_MOUSE | Microtubule-associated protein 1B | -1.1 | 0.5638 |
| Q9JKB1 | UCHL3_MOUSE | Ubiquitin carboxyl-terminal hydrolase isozyme L3 | -1.1 | 0.5040 |
| O88492 | PLIN4_MOUSE | Perilipin-4 | 1.1 | 0.8072 |
| Q9D8E6 | RL4_MOUSE | 60S ribosomal protein L4 | 1.1 | 0.3381 |
| P35700 | PRDX1_MOUSE | Peroxiredoxin-1 | 1.1 | 0.9649 |
| Q9Z2W0 | DNPEP_MOUSE | Aspartyl aminopeptidase | 1.1 | 0.9140 |
| Q9Z0J0 | NPC2_MOUSE | Epididymal secretory protein E1 | 1.1 | 0.2594 |
| Q9D7M1 | GID8_MOUSE | Glucose-induced degradation protein 8 homolog | 1.2 | 0.9389 |
| Q00623 | APOA1_MOUSE | Apolipoprotein A-I | 1.2 | 0.5396 |
| P20108 | PRDX3_MOUSE | Thioredoxin-dependent peroxide reductase, mitochondrial | 1.2 | 0.3929 |
| P17751 | TPIS_MOUSE | Triosephosphate isomerase | 1.2 | 0.6175 |
| P46638 | RB11B_MOUSE | Ras-related protein Rab-11B | 1.2 | 0.6803 |
| Q99JI1 | MSTN1_MOUSE | Musculoskeletal embryonic nuclear protein 1 | 1.2 | 0.2261 |
| P23506 | PIMT_MOUSE | Protein-L-isoaspartate(D-aspartate) O-methyltransferase | 1.2 | 0.7920 |
| P97315 | CSRP1_MOUSE | Cysteine and glycine-rich protein 1 | 1.2 | 0.8949 |

| Q9EST5 | AN32B MOUSE | Acidic leucine-rich nuclear phosphoprotein 32 family member B | 1.2 | 0.9799 |
|--------|-------------|--|-----|---------|
| Q9DCS9 | NDUBA MOUSE | NADH dehydrogenase [ubiquinone] 1 beta subcomplex subunit 10 | 1.2 | 0.5223 |
| P14069 | S10A6 MOUSE | Protein S100-A6 | 1.2 | 0.4944 |
| Q61171 | PRDX2 MOUSE | Peroxiredoxin-2 | 1.2 | 0.0527 |
| P46935 | NEDD4 MOUSE | E3 ubiquitin-protein ligase NEDD4 | 1.2 | 0.7752 |
| Q99PT1 | GDIR1 MOUSE | Rho GDP-dissociation inhibitor 1 | 1.2 | 0.7711 |
| Q99LX0 | PARK7 MOUSE | Protein DJ-1 | 1.2 | 0.4826 |
| Q9D1Q6 | ERP44 MOUSE | Endoplasmic reticulum resident protein 44 | 1.2 | 0.0066* |
| Q9CQ92 | FIS1 MOUSE | Mitochondrial fission 1 protein | 1.2 | 0.5954 |
| P07214 | SPRC MOUSE | SPARC | 1.2 | 0.9385 |
| Q60631 | GRB2 MOUSE | Growth factor receptor-bound protein 2 | 1.2 | 0.5292 |
| Q9CPY7 | AMPL_MOUSE | Cytosol aminopeptidase | 1.2 | 0.9545 |
| P35385 | HSPB7 MOUSE | Heat shock protein beta-7 | 1.2 | 0.2867 |
| Q8BG05 | ROA3_MOUSE | Heterogeneous nuclear ribonucleoprotein A3 | 1.2 | 0.5977 |
| Q8BWT1 | THIM_MOUSE | 3-ketoacyl-CoA thiolase, mitochondrial | 1.2 | 0.9559 |
| P26039 | TLN1 MOUSE | Talin-1 | 1.2 | 0.8777 |
| O08677 | KNG1 MOUSE | Kininogen-1 | 1.2 | 0.9080 |
| P62137 | PP1A_MOUSE | Serine/threonine-protein phosphatase PP1-alpha catalytic subunit | 1.2 | 0.6380 |
| P17182 | ENOA_MOUSE | Alpha-enolase | 1.2 | 0.2158 |
| Q63918 | CAVN2_MOUSE | Serum deprivation-response protein | 1.2 | 0.2967 |
| P98078 | DAB2_MOUSE | Disabled homolog 2 | 1.2 | 0.2248 |
| P11031 | TCP4_MOUSE | Activated RNA polymerase II transcriptional coactivator p15 | 1.2 | 0.4558 |
| P62309 | RUXG_MOUSE | Small nuclear ribonucleoprotein G | 1.2 | 0.8696 |
| P70460 | VASP_MOUSE | Vasodilator-stimulated phosphoprotein | 1.2 | 0.5925 |
| P18242 | CATD_MOUSE | Cathepsin D | 1.2 | 0.0616 |
| Q61206 | PA1B2_MOUSE | Platelet-activating factor acetylhydrolase IB subunit beta | 1.2 | 0.1052 |
| P62889 | RL30_MOUSE | 60S ribosomal protein L30 | 1.2 | 0.8767 |
| Q9D172 | GAL3A_MOUSE | ES1 protein homolog, mitochondrial | 1.2 | 0.9564 |
| P17742 | PPIA_MOUSE | Peptidyl-prolyl cis-trans isomerase A | 1.2 | 0.0538 |
| P28656 | NP1L1_MOUSE | Nucleosome assembly protein 1-like 1 | 1.2 | 0.9128 |
| P16110 | LEG3_MOUSE | Galectin-3 | 1.2 | 0.2948 |
| Q8K0C9 | GMDS_MOUSE | GDP-mannose 4,6 dehydratase | 1.2 | 0.8202 |
| P15331 | PERI_MOUSE | Peripherin | 1.2 | 0.9283 |
| Q70IV5 | SYNEM_MOUSE | Synemin | 1.2 | 0.8723 |
| P67778 | PHB_MOUSE | Prohibitin | 1.2 | 0.2814 |
| Q62425 | NDUA4_MOUSE | Cytochrome c oxidase subunit NDUFA4 | 1.2 | 0.1410 |
| P70271 | PDLI4_MOUSE | PDZ and LIM domain protein 4 | 1.2 | 0.8497 |
| P70349 | HINT1_MOUSE | Histidine triad nucleotide-binding protein 1 | 1.2 | 0.2609 |
| Q9CPW4 | ARPC5_MOUSE | Actin-related protein 2/3 complex subunit 5 | 1.2 | 0.4986 |
| Q3URD3 | SLMAP_MOUSE | Sarcolemmal membrane-associated protein | 1.2 | 0.1692 |
| | | | | |

| P61089 | UBE2N MOUSE | Ubiguitin-conjugating enzyme E2 N | 1.2 | 0.1288 |
|--------|-------------|--|-----|---------|
| Q9Z2M7 | PMM2 MOUSE | Phosphomannomutase 2 | 1.2 | 0.7323 |
| P53994 | RAB2A MOUSE | Ras-related protein Rab-2A | 1.2 | 0.2276 |
| P70663 | SPRL1 MOUSE | SPARC-like protein 1 | 1.2 | 0.8605 |
| Q4KML4 | ABRAL MOUSE | Costars family protein ABRACL | 1.2 | 0.8630 |
| Q9Z2X1 | HNRPF_MOUSE | Heterogeneous nuclear ribonucleoprotein F | 1.3 | 0.7046 |
| Q91ZJ5 | UGPA_MOUSE | UTPglucose-1-phosphate uridylyltransferase | 1.3 | 0.1095 |
| Q60972 | RBBP4_MOUSE | Histone-binding protein RBBP4 | 1.3 | 0.0101* |
| Q9DCJ5 | NDUA8_MOUSE | NADH dehydrogenase [ubiquinone] 1 alpha subcomplex subunit 8 | 1.3 | 0.8922 |
| Q9ESY9 | GILT_MOUSE | Gamma-interferon-inducible lysosomal thiol reductase | 1.3 | 0.1838 |
| Q9DCT2 | NDUS3_MOUSE | NADH dehydrogenase [ubiquinone] iron-sulfur protein 3, mitochondrial | 1.3 | 0.1372 |
| P34884 | MIF_MOUSE | Macrophage migration inhibitory factor | 1.3 | 0.0759 |
| P80317 | TCPZ_MOUSE | T-complex protein 1 subunit zeta | 1.3 | 0.3555 |
| O08807 | PRDX4_MOUSE | Peroxiredoxin-4 | 1.3 | 0.2470 |
| P99029 | PRDX5_MOUSE | Peroxiredoxin-5, mitochondrial | 1.3 | 0.1520 |
| Q9WTP6 | KAD2_MOUSE | Adenylate kinase 2, mitochondrial | 1.3 | 0.5934 |
| P29699 | FETUA_MOUSE | Alpha-2-HS-glycoprotein | 1.3 | 0.3079 |
| Q9Z0X1 | AIFM1_MOUSE | Apoptosis-inducing factor 1, mitochondrial | 1.3 | 0.0877 |
| Q8QZT1 | THIL_MOUSE | Acetyl-CoA acetyltransferase, mitochondrial | 1.3 | 0.0950 |
| P62270 | RS18_MOUSE | 40S ribosomal protein S18 | 1.3 | 0.2514 |
| Q91VI7 | RINI_MOUSE | Ribonuclease inhibitor | 1.3 | 0.0419* |
| Q922R8 | PDIA6_MOUSE | Protein disulfide-isomerase A6 | 1.3 | 0.0670 |
| Q05793 | PGBM_MOUSE | Basement membrane-specific heparan sulfate proteoglycan core protein | 1.3 | 0.8694 |
| Q62422 | OSTF1_MOUSE | Osteoclast-stimulating factor 1 | 1.3 | 0.4510 |
| P63028 | TCTP_MOUSE | Translationally-controlled tumor protein | 1.3 | 0.7827 |
| P62264 | RS14_MOUSE | 40S ribosomal protein S14 | 1.3 | 0.2437 |
| P24369 | PPIB_MOUSE | Peptidyl-prolyl cis-trans isomerase B | 1.3 | 0.0693 |
| Q62219 | TGFI1_MOUSE | Transforming growth factor beta-1-induced transcript 1 protein | 1.3 | 0.4267 |
| Q9D1D4 | TMEDA_MOUSE | Transmembrane emp24 domain-containing protein 10 | 1.3 | 0.7751 |
| Q99JW5 | EPCAM_MOUSE | Epithelial cell adhesion molecule | 1.3 | 0.1021 |
| Q6WVG3 | KCD12_MOUSE | BTB/POZ domain-containing protein KCTD12 | 1.3 | 0.0082* |
| Q9D8S4 | ORN_MOUSE | Oligoribonuclease, mitochondrial | 1.3 | 0.8872 |
| Q62356 | FSTL1_MOUSE | Follistatin-related protein 1 | 1.3 | 0.4155 |
| P08553 | NFM_MOUSE | Neurofilament medium polypeptide | 1.3 | 0.9746 |
| P57780 | ACTN4_MOUSE | Alpha-actinin-4 | 1.3 | 0.9317 |
| O54962 | BAF_MOUSE | Barrier-to-autointegration factor | 1.3 | 0.0527 |
| P04117 | FABP4_MOUSE | Fatty acid-binding protein, adipocyte | 1.3 | 0.2109 |
| Q9CZ13 | QCR1_MOUSE | Cytochrome b-c1 complex subunit 1, mitochondrial | 1.3 | 0.9953 |
| P63017 | HSP7C_MOUSE | Heat shock cognate 71 kDa protein | 1.3 | 0.0541 |
| P97927 | LAMA4_MOUSE | Laminin subunit alpha-4 | 1.3 | 0.8016 |

| P30412 | PPIC MOUSE | Peptidyl-prolyl cis-trans isomerase C | 1.3 | 0.5472 |
|--------|-------------|--|-----|---------|
| Q8BFW7 | LPP MOUSE | Lipoma-preferred partner homolog | 1.3 | 0.4747 |
| P02469 | LAMB1 MOUSE | Laminin subunit beta-1 | 1.3 | 0.2609 |
| P62897 | CYC MOUSE | Cytochrome c, somatic | 1.3 | 0.8221 |
| Q64727 | VINC MOUSE | Vinculin | 1.3 | 0.0026* |
| Q3UTJ2 | SRBS2 MOUSE | Sorbin and SH3 domain-containing protein 2 | 1.3 | 0.3199 |
| Q8K2B3 | SDHA MOUSE | Succinate dehydrogenase [ubiguinone] flavoprotein subunit, mitochondrial | 1.3 | 0.8654 |
| Q9D7M8 | RPB4 MOUSE | DNA-directed RNA polymerase II subunit RPB4 | 1.3 | 0.4041 |
| Q08093 | CNN2 MOUSE | Calponin-2 | 1.3 | 0.1716 |
| Q9D0S9 | HINT2 MOUSE | Histidine triad nucleotide-binding protein 2, mitochondrial | 1.3 | 0.3542 |
| P26041 | MOES_MOUSE | Moesin | 1.3 | 0.6000 |
| Q64010 | CRK MOUSE | Adapter molecule crk | 1.3 | 0.7364 |
| Q9CQQ7 | AT5F1 MOUSE | ATP synthase F(0) complex subunit B1, mitochondrial | 1.4 | 0.2069 |
| P97461 | RS5 MOUSE | 40S ribosomal protein S5 | 1.4 | 0.7885 |
| P58044 | IDI1 MOUSE | Isopentenyl-diphosphate Delta-isomerase 1 | 1.4 | 0.1222 |
| P08249 | MDHM MOUSE | Malate dehydrogenase, mitochondrial | 1.4 | 0.0614 |
| Q7TMK9 | HNRPQ MOUSE | Heterogeneous nuclear ribonucleoprotein Q | 1.4 | 0.8965 |
| Q9WVA4 | TAGL2_MOUSE | Transgelin-2 | 1.4 | 0.6543 |
| Q8VC28 | AK1CD MOUSE | Aldo-keto reductase family 1 member C13 | 1.4 | 0.9440 |
| P01837 | IGKC MOUSE | Ig kappa chain C region | 1.4 | 0.2521 |
| O54724 | CAVN1 MOUSE | Polymerase I and transcript release factor | 1.4 | 0.0427* |
| Q01853 | TERA_MOUSE | Transitional endoplasmic reticulum ATPase | 1.4 | 0.005* |
| P17047 | LAMP2_MOUSE | Lysosome-associated membrane glycoprotein 2 | 1.4 | 0.6796 |
| Q60648 | SAP3_MOUSE | Ganglioside GM2 activator | 1.4 | 0.0264* |
| Q8BH95 | ECHM_MOUSE | Enoyl-CoA hydratase, mitochondrial | 1.4 | 0.2961 |
| Q60994 | ADIPO_MOUSE | Adiponectin | 1.4 | 0.1424 |
| P63276 | RS17_MOUSE | 40S ribosomal protein S17 | 1.4 | 0.5889 |
| P62141 | PP1B_MOUSE | Serine/threonine-protein phosphatase PP1-beta catalytic subunit | 1.4 | 0.1507 |
| P26638 | SYSC_MOUSE | SerinetRNA ligase, cytoplasmic | 1.4 | 0.0717 |
| Q8BHC0 | LYVE1_MOUSE | Lymphatic vessel endothelial hyaluronic acid receptor 1 | 1.4 | 0.3477 |
| O70456 | 1433S_MOUSE | 14-3-3 protein sigma | 1.4 | 0.1305 |
| Q9CXW4 | RL11_MOUSE | 60S ribosomal protein L11 | 1.4 | 0.0500 |
| Q3UM45 | PP1R7_MOUSE | Protein phosphatase 1 regulatory subunit 7 | 1.4 | 0.4307 |
| O09164 | SODE_MOUSE | Extracellular superoxide dismutase [Cu-Zn] | 1.4 | 0.1509 |
| P35279 | RAB6A_MOUSE | Ras-related protein Rab-6A | 1.4 | 0.9732 |
| Q8K3J1 | NDUS8_MOUSE | NADH dehydrogenase [ubiquinone] iron-sulfur protein 8, mitochondrial | 1.4 | 0.6083 |
| P35979 | RL12_MOUSE | 60S ribosomal protein L12 | 1.4 | 0.0812 |
| P63330 | PP2AA_MOUSE | Serine/threonine-protein phosphatase 2A catalytic subunit alpha isoform | 1.4 | 0.3680 |
| P56399 | UBP5_MOUSE | Ubiquitin carboxyl-terminal hydrolase 5 | 1.4 | 0.0588 |
| Q9D7Z6 | CLCA1_MOUSE | Calcium-activated chloride channel regulator 1 | 1.4 | 0.0625 |

| | | Serine/threonine-protein phosphatase 2A 65 kDa regulatory subunit A alpha | | |
|--------|-------------|---|-----|---------|
| Q76MZ3 | 2AAA_MOUSE | isoform | 1.4 | 0.1205 |
| Q9CZX8 | RS19_MOUSE | 40S ribosomal protein S19 | 1.4 | 0.1834 |
| Q3TTY5 | K22E MOUSE | Keratin, type II cytoskeletal 2 epidermal | 1.4 | 0.2208 |
| Q3THW5 | H2AV_MOUSE | Histone H2A.V | 1.4 | 0.1335 |
| P47962 | RL5_MOUSE | 60S ribosomal protein L5 | 1.4 | 0.5587 |
| Q9D1A2 | CNDP2_MOUSE | Cytosolic non-specific dipeptidase | 1.4 | 0.8093 |
| Q9JJU8 | SH3L1_MOUSE | SH3 domain-binding glutamic acid-rich-like protein | 1.4 | 0.003* |
| Q9QXS6 | DREB MOUSE | Drebrin | 1.4 | 0.7499 |
| P11276 | FINC_MOUSE | Fibronectin | 1.4 | 0.3941 |
| P97807 | FUMH_MOUSE | Fumarate hydratase, mitochondrial | 1.4 | 0.0523 |
| Q61233 | PLSL_MOUSE | Plastin-2 | 1.4 | 0.0778 |
| Q921I1 | TRFE_MOUSE | Serotransferrin | 1.4 | 0.8916 |
| Q9Z0M6 | CD97_MOUSE | CD97 antigen | 1.4 | 0.1485 |
| Q921U8 | SMTN_MOUSE | Smoothelin | 1.4 | 0.0308* |
| Q9D967 | MGDP1_MOUSE | Magnesium-dependent phosphatase 1 | 1.4 | 0.2777 |
| P09055 | ITB1_MOUSE | Integrin beta-1 | 1.4 | 0.1655 |
| P62082 | RS7_MOUSE | 40S ribosomal protein S7 | 1.4 | 0.0076* |
| P08113 | ENPL_MOUSE | Endoplasmin | 1.4 | 0.4721 |
| Q62465 | VAT1 MOUSE | Synaptic vesicle membrane protein VAT-1 homolog | 1.4 | 0.2884 |
| Q9DAW9 | CNN3 MOUSE | Calponin-3 | 1.4 | 0.5553 |
| P62855 | RS26_MOUSE | 40S ribosomal protein S26 | 1.4 | 0.0003* |
| P62259 | 1433E_MOUSE | 14-3-3 protein epsilon | 1.4 | 0.0088* |
| O88456 | CPNS1_MOUSE | Calpain small subunit 1 | 1.4 | 0.0034* |
| Q8CGP2 | H2B1P_MOUSE | Histone H2B type 1-P | 1.4 | 0.5368 |
| Q9CQ60 | 6PGL_MOUSE | 6-phosphogluconolactonase | 1.4 | 0.0006* |
| P42125 | ECI1_MOUSE | Enoyl-CoA delta isomerase 1, mitochondrial | 1.4 | 0.9596 |
| P01831 | THY1_MOUSE | Thy-1 membrane glycoprotein | 1.4 | 0.1433 |
| Q9CQ62 | DECR_MOUSE | 2,4-dienoyl-CoA reductase, mitochondrial | 1.4 | 0.5282 |
| Q9D0F9 | PGM1_MOUSE | Phosphoglucomutase-1 | 1.4 | 0.9155 |
| P97447 | FHL1_MOUSE | Four and a half LIM domains protein 1 | 1.4 | 0.0541 |
| Q9ET54 | PALLD_MOUSE | Palladin | 1.4 | 0.2233 |
| P97351 | RS3A_MOUSE | 40S ribosomal protein S3a | 1.4 | 0.0175* |
| P18760 | COF1_MOUSE | Cofilin-1 | 1.5 | 0.9629 |
| P54775 | PRS6B_MOUSE | 26S protease regulatory subunit 6B | 1.5 | 0.1493 |
| Q99K41 | EMIL1_MOUSE | EMILIN-1 | 1.5 | 0.6418 |
| Q99J77 | SIAS_MOUSE | Sialic acid synthase | 1.5 | 0.0554 |
| Q6P069 | SORCN_MOUSE | Sorcin | 1.5 | 0.0274* |
| P12970 | RL7A_MOUSE | 60S ribosomal protein L7a | 1.5 | 0.7572 |
| P50247 | SAHH_MOUSE | Adenosylhomocysteinase | 1.5 | 0.0503 |

| P50518 | VATE1 MOUSE | V-type proton ATPase subunit E 1 | 1.5 | 0.9336 |
|--------|-------------|---|-----|---------|
| P51150 | RAB7A_MOUSE | Ras-related protein Rab-7a | 1.5 | 0.0498 |
| P23953 | EST1C_MOUSE | Carboxylesterase 1C | 1.5 | 0.0199* |
| Q99KF1 | TMED9 MOUSE | Transmembrane emp24 domain-containing protein 9 | 1.5 | 0.6173 |
| P68037 | UB2L3 MOUSE | Ubiquitin-conjugating enzyme E2 L3 | 1.5 | 0.3984 |
| P62754 | RS6 MOUSE | 40S ribosomal protein S6 | 1.5 | 0.0236* |
| Q99LF4 | RTCB MOUSE | tRNA-splicing ligase RtcB homolog | 1.5 | 0.9456 |
| P61358 | RL27 MOUSE | 60S ribosomal protein L27 | 1.5 | 0.3692 |
| Q99KI0 | ACON_MOUSE | Aconitate hydratase, mitochondrial | 1.5 | 0.0358* |
| Q9JKF1 | IQGA1_MOUSE | Ras GTPase-activating-like protein IQGAP1 | 1.5 | 0.7695 |
| P63321 | RALA_MOUSE | Ras-related protein Ral-A | 1.5 | 0.5289 |
| P58252 | EF2_MOUSE | Elongation factor 2 | 1.5 | 0.9358 |
| P62900 | RL31_MOUSE | 60S ribosomal protein L31 | 1.5 | 0.2530 |
| P68369 | TBA1A_MOUSE | Tubulin alpha-1A chain | 1.5 | 0.3357 |
| Q91WQ3 | SYYC_MOUSE | TyrosinetRNA ligase, cytoplasmic | 1.5 | 0.9430 |
| P08121 | CO3A1_MOUSE | Collagen alpha-1(III) chain | 1.5 | 0.7411 |
| Q9Z2U1 | PSA5_MOUSE | Proteasome subunit alpha type-5 | 1.5 | 0.9163 |
| P61255 | RL26_MOUSE | 60S ribosomal protein L26 | 1.5 | 0.0114* |
| Q3TJD7 | PDLI7_MOUSE | PDZ and LIM domain protein 7 | 1.5 | 0.3047 |
| P62334 | PRS10_MOUSE | 26S protease regulatory subunit 10B | 1.5 | 0.0161* |
| Q9R0Q7 | TEBP_MOUSE | Prostaglandin E synthase 3 | 1.5 | 0.0058* |
| P47911 | RL6_MOUSE | 60S ribosomal protein L6 | 1.5 | 0.0169* |
| P70195 | PSB7_MOUSE | Proteasome subunit beta type-7 | 1.5 | 0.5072 |
| P62843 | RS15_MOUSE | 40S ribosomal protein S15 | 1.5 | 0.1550 |
| Q9QUI0 | RHOA_MOUSE | Transforming protein RhoA | 1.5 | 0.5857 |
| Q9CX86 | ROA0_MOUSE | Heterogeneous nuclear ribonucleoprotein A0 | 1.5 | 0.9007 |
| P40142 | TKT_MOUSE | Transketolase | 1.5 | 0.4940 |
| P62751 | RL23A_MOUSE | 60S ribosomal protein L23a | 1.5 | 0.5059 |
| P17918 | PCNA_MOUSE | Proliferating cell nuclear antigen | 1.5 | 0.0339* |
| Q9DBH5 | LMAN2_MOUSE | Vesicular integral-membrane protein VIP36 | 1.5 | 0.4778 |
| P00920 | CAH2_MOUSE | Carbonic anhydrase 2 | 1.5 | 0.4955 |
| P47963 | RL13_MOUSE | 60S ribosomal protein L13 | 1.5 | 0.0201* |
| Q60692 | PSB6_MOUSE | Proteasome subunit beta type-6 | 1.5 | 0.7910 |
| P60766 | CDC42_MOUSE | Cell division control protein 42 homolog | 1.5 | 0.6210 |
| P80316 | TCPE_MOUSE | T-complex protein 1 subunit epsilon | 1.5 | 0.0017* |
| P62908 | RS3_MOUSE | 40S ribosomal protein S3 | 1.5 | 0.0811 |
| P62301 | RS13_MOUSE | 40S ribosomal protein S13 | 1.5 | 0.0472* |
| P68254 | 1433T_MOUSE | 14-3-3 protein theta | 1.5 | 0.0141* |
| P67984 | RL22_MOUSE | 60S ribosomal protein L22 | 1.5 | 0.0195* |
| Q9Z2U0 | PSA7_MOUSE | Proteasome subunit alpha type-7 | 1.5 | 0.9372 |

| P08207 | S10AA MOUSE | Protein S100-A10 | 1.5 | 0.3383 |
|--------|-------------|---|-----|---------|
| Q6ZWX6 | IF2A MOUSE | Eukaryotic translation initiation factor 2 subunit 1 | 1.5 | 0.002* |
| P48036 | ANXA5 MOUSE | Annexin A5 | 1.5 | 0.0044* |
| P14131 | RS16 MOUSE | 40S ribosomal protein S16 | 1.6 | 0.0291* |
| Q62417 | SRBS1 MOUSE | Sorbin and SH3 domain-containing protein 1 | 1.6 | 0.2628 |
| Q04447 | KCRB_MOUSE | Creatine kinase B-type | 1.6 | 0.014* |
| P63101 | 1433Z_MOUSE | 14-3-3 protein zeta/delta | 1.6 | 0.0066* |
| P35980 | RL18_MOUSE | 60S ribosomal protein L18 | 1.6 | 0.7700 |
| O08553 | DPYL2_MOUSE | Dihydropyrimidinase-related protein 2 | 1.6 | 0.2031 |
| P10126 | EF1A1_MOUSE | Elongation factor 1-alpha 1 | 1.6 | 0.4514 |
| P30416 | FKBP4_MOUSE | Peptidyl-prolyl cis-trans isomerase FKBP4 | 1.6 | 0.9994 |
| Q9JII6 | AK1A1_MOUSE | Alcohol dehydrogenase [NADP(+)] | 1.6 | 0.001* |
| Q8BHN3 | GANAB_MOUSE | Neutral alpha-glucosidase AB | 1.6 | 0.0219* |
| P62196 | PRS8_MOUSE | 26S protease regulatory subunit 8 | 1.6 | 0.0039* |
| Q9CZS1 | AL1B1_MOUSE | Aldehyde dehydrogenase X, mitochondrial | 1.6 | 0.7456 |
| P53026 | RL10A_MOUSE | 60S ribosomal protein L10a | 1.6 | 0.1815 |
| P22599 | A1AT2_MOUSE | Alpha-1-antitrypsin 1-2 | 1.6 | 0.4236 |
| Q08091 | CNN1_MOUSE | Calponin-1 | 1.6 | 0.0143* |
| Q61543 | GSLG1_MOUSE | Golgi apparatus protein 1 | 1.6 | 0.0675 |
| Q9CPV4 | GLOD4_MOUSE | Glyoxalase domain-containing protein 4 | 1.6 | 0.2073 |
| Q61555 | FBN2_MOUSE | Fibrillin-2 | 1.6 | 0.8652 |
| Q91YR1 | TWF1_MOUSE | Twinfilin-1 | 1.6 | 0.1169 |
| Q9EQP2 | EHD4_MOUSE | EH domain-containing protein 4 | 1.6 | 0.3073 |
| P51410 | RL9_MOUSE | 60S ribosomal protein L9 | 1.6 | 0.5458 |
| Q8K419 | LEG4_MOUSE | Galectin-4 | 1.6 | 0.0484* |
| Q8CHP8 | PGP_MOUSE | Glycerol-3-phosphate phosphatase | 1.6 | 0.0408* |
| P02468 | LAMC1_MOUSE | Laminin subunit gamma-1 | 1.6 | 0.0094* |
| Q62186 | SSRD_MOUSE | Translocon-associated protein subunit delta | 1.6 | 0.4076 |
| Q9DBC7 | KAP0_MOUSE | cAMP-dependent protein kinase type I-alpha regulatory subunit | 1.6 | 0.0086* |
| P63325 | RS10_MOUSE | 40S ribosomal protein S10 | 1.6 | 0.6137 |
| P11352 | GPX1_MOUSE | Glutathione peroxidase 1 | 1.6 | 0.027* |
| P10518 | HEM2_MOUSE | Delta-aminolevulinic acid dehydratase | 1.6 | 0.5958 |
| P42208 | SEPT2_MOUSE | Septin-2 | 1.6 | 0.0014* |
| Q9CQA3 | SDHB_MOUSE | Succinate dehydrogenase [ubiquinone] iron-sulfur subunit, mitochondrial | 1.6 | 0.0122* |
| P62880 | GBB2_MOUSE | Guanine nucleotide-binding protein G(I)/G(S)/G(T) subunit beta-2 | 1.6 | 0.0671 |
| P97372 | PSME2_MOUSE | Proteasome activator complex subunit 2 | 1.6 | 0.0382* |
| P47791 | GSHR_MOUSE | Glutathione reductase, mitochondrial | 1.6 | 0.5202 |
| P70695 | F16P2_MOUSE | Fructose-1,6-bisphosphatase isozyme 2 | 1.6 | 0.0770 |
| Q62376 | RU17_MOUSE | U1 small nuclear ribonucleoprotein 70 kDa | 1.6 | 0.7400 |
| Q9JKA5 | GPA33_MOUSE | Cell surface A33 antigen | 1.6 | 0.1758 |

| P15947 | KLK1 MOUSE | Kallikrein-1 | 1.6 | 0.2057 |
|--------|-------------|---|-----|---------|
| Q9Z1N5 | DX39B MOUSE | Spliceosome RNA helicase Ddx39b | 1.6 | 0.1256 |
| Q61425 | HCDH MOUSE | Hydroxyacyl-coenzyme A dehydrogenase, mitochondrial | 1.6 | 0.2392 |
| P62869 | ELOB MOUSE | Elongin-B | 1.6 | 0.0259* |
| P09671 | SODM MOUSE | Superoxide dismutase [Mn], mitochondrial | 1.6 | 0.0063* |
| Q9CR57 | RL14_MOUSE | 60S ribosomal protein L14 | 1.6 | 0.5721 |
| Q9CZY3 | UB2V1 MOUSE | Ubiquitin-conjugating enzyme E2 variant 1 | 1.6 | 0.0003* |
| Q91X72 | HEMO MOUSE | Hemopexin | 1.6 | 0.1122 |
| P62849 | RS24_MOUSE | 40S ribosomal protein S24 | 1.6 | 0.8915 |
| P45591 | COF2_MOUSE | Cofilin-2 | 1.7 | 0.0089* |
| Q923D2 | BLVRB_MOUSE | Flavin reductase (NADPH) | 1.7 | 0.1716 |
| Q9CWK8 | SNX2_MOUSE | Sorting nexin-2 | 1.7 | 0.0464* |
| Q920A5 | RISC_MOUSE | Retinoid-inducible serine carboxypeptidase | 1.7 | 0.6705 |
| Q9WVJ3 | CBPQ_MOUSE | Carboxypeptidase Q | 1.7 | 0.3180 |
| P09411 | PGK1_MOUSE | Phosphoglycerate kinase 1 | 1.7 | 0.0005* |
| Q9WVH9 | FBLN5_MOUSE | Fibulin-5 | 1.7 | 0.0789 |
| P52196 | THTR_MOUSE | Thiosulfate sulfurtransferase | 1.7 | 0.7020 |
| P27601 | GNA13_MOUSE | Guanine nucleotide-binding protein subunit alpha-13 | 1.7 | 0.8643 |
| P21981 | TGM2_MOUSE | Protein-glutamine gamma-glutamyltransferase 2 | 1.7 | 0.9557 |
| P14094 | AT1B1_MOUSE | Sodium/potassium-transporting ATPase subunit beta-1 | 1.7 | 0.8264 |
| P50580 | PA2G4_MOUSE | Proliferation-associated protein 2G4 | 1.7 | 0.0002* |
| P97384 | ANX11_MOUSE | Annexin A11 | 1.7 | 0.0266* |
| Q62059 | CSPG2_MOUSE | Versican core protein | 1.7 | 0.0028* |
| O88207 | CO5A1_MOUSE | Collagen alpha-1(V) chain | 1.7 | 0.2657 |
| Q9JHU9 | INO1_MOUSE | Inositol-3-phosphate synthase 1 | 1.7 | 0.0053* |
| Q9D051 | ODPB_MOUSE | Pyruvate dehydrogenase E1 component subunit beta, mitochondrial | 1.7 | 0.1987 |
| Q9D898 | ARP5L_MOUSE | Actin-related protein 2/3 complex subunit 5-like protein | 1.7 | 0.0028* |
| Q9CWJ9 | PUR9_MOUSE | Bifunctional purine biosynthesis protein PURH | 1.7 | 0.0471* |
| Q8CDN6 | TXNL1_MOUSE | Thioredoxin-like protein 1 | 1.7 | 0.2986 |
| P14602 | HSPB1_MOUSE | Heat shock protein beta-1 | 1.7 | 0.0107* |
| P99026 | PSB4_MOUSE | Proteasome subunit beta type-4 | 1.7 | 0.0981 |
| P10922 | H10_MOUSE | Histone H1.0 | 1.7 | 0.9881 |
| O88322 | NID2_MOUSE | Nidogen-2 | 1.7 | 0.0497 |
| Q9WUM4 | COR1C_MOUSE | Coronin-1C | 1.7 | 0.0048* |
| Q9R1P1 | PSB3_MOUSE | Proteasome subunit beta type-3 | 1.7 | 0.7645 |
| P07759 | SPA3K_MOUSE | Serine protease inhibitor A3K | 1.7 | 0.0164* |
| Q9WUG6 | INSL5_MOUSE | Insulin-like peptide INSL5 | 1.7 | 0.0019* |
| P47757 | CAPZB_MOUSE | F-actin-capping protein subunit beta | 1.7 | 0.0064* |
| P26443 | DHE3_MOUSE | Glutamate dehydrogenase 1, mitochondrial | 1.7 | 0.0457* |
| P62827 | RAN_MOUSE | GTP-binding nuclear protein Ran | 1.7 | 0.1793 |

| Q9D6R2 | IDH3A MOUSE | Isocitrate dehydrogenase [NAD] subunit alpha, mitochondrial | 1.7 | 0.0294* |
|--------|-------------|--|-----|---------|
| Q9Z0S1 | BPNT1 MOUSE | 3'(2'),5'-bisphosphate nucleotidase 1 | 1.7 | 0.5375 |
| P11688 | ITA5 MOUSE | Integrin alpha-5 | 1.7 | 0.0009* |
| Q99JY0 | ECHB MOUSE | Trifunctional enzyme subunit beta, mitochondrial | 1.7 | 0.0062* |
| Q9JJI8 | RL38 MOUSE | 60S ribosomal protein L38 | 1.7 | 0.9126 |
| P10493 | NID1_MOUSE | Nidogen-1 | 1.7 | 0.8971 |
| P58021 | TM9S2 MOUSE | Transmembrane 9 superfamily member 2 | 1.7 | 0.5797 |
| P51174 | ACADL_MOUSE | Long-chain specific acyl-CoA dehydrogenase, mitochondrial | 1.7 | 0.0642 |
| P70168 | IMB1 MOUSE | Importin subunit beta-1 | 1.7 | 0.1841 |
| P26043 | RADI_MOUSE | Radixin | 1.7 | 0.2100 |
| 070423 | AOC3_MOUSE | Membrane primary amine oxidase | 1.7 | 0.8594 |
| P48758 | CBR1_MOUSE | Carbonyl reductase [NADPH] 1 | 1.7 | 0.0311* |
| O88685 | PRS6A_MOUSE | 26S protease regulatory subunit 6A | 1.7 | 0.1039 |
| P37804 | TAGL_MOUSE | Transgelin | 1.7 | 0.0051* |
| Q9QZZ6 | DERM_MOUSE | Dermatopontin | 1.7 | 0.2343 |
| P08030 | APT_MOUSE | Adenine phosphoribosyltransferase | 1.7 | 0.0212* |
| O08756 | HCD2_MOUSE | 3-hydroxyacyl-CoA dehydrogenase type-2 | 1.7 | 0.0104* |
| Q8BFY6 | PEF1_MOUSE | Peflin | 1.7 | 0.0055* |
| Q8BMS1 | ECHA_MOUSE | Trifunctional enzyme subunit alpha, mitochondrial | 1.7 | 0.0913 |
| P61982 | 1433G_MOUSE | 14-3-3 protein gamma | 1.7 | 0.0023* |
| Q62188 | DPYL3_MOUSE | Dihydropyrimidinase-related protein 3 | 1.8 | 0.0175* |
| P01027 | CO3_MOUSE | Complement C3 | 1.8 | 0.0701 |
| O35955 | PSB10_MOUSE | Proteasome subunit beta type-10 | 1.8 | 0.5139 |
| P43024 | CX6A1_MOUSE | Cytochrome c oxidase subunit 6A1, mitochondrial | 1.8 | 0.0989 |
| P62242 | RS8_MOUSE | 40S ribosomal protein S8 | 1.8 | 0.0052* |
| P82198 | BGH3_MOUSE | Transforming growth factor-beta-induced protein ig-h3 | 1.8 | 0.0000* |
| Q01768 | NDKB_MOUSE | Nucleoside diphosphate kinase B | 1.8 | 0.0214* |
| Q9DB20 | ATPO_MOUSE | ATP synthase subunit O, mitochondrial | 1.8 | 0.0117* |
| P42932 | TCPQ_MOUSE | T-complex protein 1 subunit theta | 1.8 | 0.0109* |
| P32921 | SYWC_MOUSE | TryptophantRNA ligase, cytoplasmic | 1.8 | 0.0225* |
| Q6ZWY3 | RS27L_MOUSE | 40S ribosomal protein S27-like | 1.8 | 0.0021* |
| P15532 | NDKA_MOUSE | Nucleoside diphosphate kinase A | 1.8 | 0.0305* |
| P12815 | PDCD6_MOUSE | Programmed cell death protein 6 | 1.8 | 0.3874 |
| Q6ZWN5 | RS9_MOUSE | 40S ribosomal protein S9 | 1.8 | 0.0479* |
| P68510 | 1433F_MOUSE | 14-3-3 protein eta | 1.8 | 0.0003* |
| P40124 | CAP1_MOUSE | Adenylyl cyclase-associated protein 1 | 1.8 | 0.7781 |
| P62806 | H4_MOUSE | Histone H4 | 1.8 | 0.4353 |
| P47754 | CAZA2_MOUSE | F-actin-capping protein subunit alpha-2 | 1.8 | 0.0128* |
| Q9Z0N1 | IF2G_MOUSE | Eukaryotic translation initiation factor 2 subunit 3, X-linked | 1.8 | 0.2354 |
| O89079 | COPE_MOUSE | Coatomer subunit epsilon | 1.8 | 0.0106* |

| Q62167 | DDX3X MOUSE | ATP-dependent RNA helicase DDX3X | 1.8 | 0.0374* |
|--------|-------------|--|-----|---------|
| P05202 | AATM MOUSE | Aspartate aminotransferase, mitochondrial | 1.8 | 0.0359* |
| Q9DB05 | SNAA MOUSE | Alpha-soluble NSF attachment protein | 1.8 | 0.0089* |
| P07310 | KCRM MOUSE | Creatine kinase M-type | 1.8 | 0.0655 |
| P05064 | ALDOA MOUSE | Fructose-bisphosphate aldolase A | 1.8 | 0.0031* |
| Q8VCR7 | ABHEB_MOUSE | Protein ABHD14B | 1.8 | 0.1584 |
| P54071 | IDHP_MOUSE | Isocitrate dehydrogenase [NADP], mitochondrial | 1.8 | 0.0085* |
| Q60931 | VDAC3_MOUSE | Voltage-dependent anion-selective channel protein 3 | 1.8 | 0.2564 |
| Q91V41 | RAB14_MOUSE | Ras-related protein Rab-14 | 1.8 | 0.1186 |
| P32067 | LA_MOUSE | Lupus La protein homolog | 1.8 | 0.5780 |
| P47753 | CAZA1_MOUSE | F-actin-capping protein subunit alpha-1 | 1.8 | 0.2973 |
| P19253 | RL13A_MOUSE | 60S ribosomal protein L13a | 1.8 | 0.6132 |
| Q9D819 | IPYR_MOUSE | Inorganic pyrophosphatase | 1.8 | 0.0001* |
| Q9CQE1 | NPS3B_MOUSE | Protein NipSnap homolog 3B | 1.8 | 0.0841 |
| P62281 | RS11_MOUSE | 40S ribosomal protein S11 | 1.8 | 0.2019 |
| P80314 | TCPB_MOUSE | T-complex protein 1 subunit beta | 1.8 | 0.0003* |
| O88844 | IDHC_MOUSE | Isocitrate dehydrogenase [NADP] cytoplasmic | 1.8 | 0.0061* |
| P00405 | COX2_MOUSE | Cytochrome c oxidase subunit 2 | 1.8 | 0.7867 |
| Q9CQV8 | 1433B_MOUSE | 14-3-3 protein beta/alpha | 1.8 | 0.0003* |
| P14152 | MDHC_MOUSE | Malate dehydrogenase, cytoplasmic | 1.9 | 0.0072* |
| O08547 | SC22B_MOUSE | Vesicle-trafficking protein SEC22b | 1.9 | 0.6657 |
| P07758 | A1AT1_MOUSE | Alpha-1-antitrypsin 1-1 | 1.9 | 0.9961 |
| O55060 | TPMT_MOUSE | Thiopurine S-methyltransferase | 1.9 | 0.1258 |
| P97821 | CATC_MOUSE | Dipeptidyl peptidase 1 | 1.9 | 0.0114* |
| P62267 | RS23_MOUSE | 40S ribosomal protein S23 | 1.9 | 0.0022* |
| Q9DCH4 | EIF3F_MOUSE | Eukaryotic translation initiation factor 3 subunit F | 1.9 | 0.0001* |
| P47856 | GFPT1_MOUSE | Glutaminefructose-6-phosphate aminotransferase [isomerizing] 1 | 1.9 | 0.7719 |
| Q9R0P5 | DEST_MOUSE | Destrin | 1.9 | 0.0025* |
| Q60597 | ODO1_MOUSE | 2-oxoglutarate dehydrogenase, mitochondrial | 1.9 | 0.5798 |
| P62821 | RAB1A_MOUSE | Ras-related protein Rab-1A | 1.9 | 0.6912 |
| P14869 | RLA0_MOUSE | 60S acidic ribosomal protein P0 | 1.9 | 0.0048* |
| P35762 | CD81_MOUSE | CD81 antigen | 1.9 | 0.3778 |
| Q9Z1Z2 | STRAP_MOUSE | Serine-threonine kinase receptor-associated protein | 1.9 | 0.0071* |
| P62852 | RS25_MOUSE | 40S ribosomal protein S25 | 1.9 | 0.3033 |
| P51855 | GSHB_MOUSE | Glutathione synthetase | 1.9 | 0.0005* |
| Q9JM76 | ARPC3_MOUSE | Actin-related protein 2/3 complex subunit 3 | 1.9 | 0.0015* |
| Q01730 | RSU1_MOUSE | Ras suppressor protein 1 | 1.9 | 0.0013* |
| P84099 | RL19_MOUSE | 60S ribosomal protein L19 | 1.9 | 0.4550 |
| P63001 | RAC1_MOUSE | Ras-related C3 botulinum toxin substrate 1 | 1.9 | 0.1808 |
| Q61554 | FBN1_MOUSE | Fibrillin-1 | 1.9 | 0.0197* |

| P31001 | DESM MOUSE | Desmin | 1.9 | 0.0242* |
|--------|-------------------------|--|-----|---------|
| P52480 | KPYM [_] MOUSE | Pyruvate kinase PKM | 1.9 | 0.0000* |
| P10833 | RRAS MOUSE | Ras-related protein R-Ras | 1.9 | 0.0004* |
| Q8VDN2 | AT1A1 MOUSE | Sodium/potassium-transporting ATPase subunit alpha-1 | 1.9 | 0.8932 |
| P62702 | RS4X MOUSE | 40S ribosomal protein S4, X isoform | 1.9 | 0.0829 |
| P51885 | LUM MOUSE | Lumican | 1.9 | 0.0215* |
| P19157 | GSTP1_MOUSE | Glutathione S-transferase P 1 | 2.0 | 0.0025* |
| Q91VR2 | ATPG_MOUSE | ATP synthase subunit gamma, mitochondrial | 2.0 | 0.2152 |
| P62830 | RL23_MOUSE | 60S ribosomal protein L23 | 2.0 | 0.0000* |
| P49817 | CAV1_MOUSE | Caveolin-1 | 2.0 | 0.9227 |
| Q60930 | VDAC2_MOUSE | Voltage-dependent anion-selective channel protein 2 | 2.0 | 0.1581 |
| O35206 | COFA1_MOUSE | Collagen alpha-1(XV) chain | 2.0 | 0.0566 |
| Q9R0P9 | UCHL1_MOUSE | Ubiquitin carboxyl-terminal hydrolase isozyme L1 | 2.0 | 0.6936 |
| P61750 | ARF4_MOUSE | ADP-ribosylation factor 4 | 2.0 | 0.6012 |
| P10605 | CATB_MOUSE | Cathepsin B | 2.0 | 0.0427* |
| P61161 | ARP2_MOUSE | Actin-related protein 2 | 2.0 | 0.0189* |
| Q99JI6 | RAP1B_MOUSE | Ras-related protein Rap-1b | 2.0 | 0.6902 |
| Q9DB77 | QCR2_MOUSE | Cytochrome b-c1 complex subunit 2, mitochondrial | 2.0 | 0.0327* |
| Q9D8C4 | IN35_MOUSE | Interferon-induced 35 kDa protein homolog | 2.0 | 0.9340 |
| P28654 | PGS2_MOUSE | Decorin | 2.0 | 0.0312* |
| P28653 | PGS1_MOUSE | Biglycan | 2.0 | 0.015* |
| A3KMP2 | TTC38_MOUSE | Tetratricopeptide repeat protein 38 | 2.0 | 0.0277* |
| P17710 | HXK1_MOUSE | Hexokinase-1 | 2.0 | 0.0034* |
| P46412 | GPX3_MOUSE | Glutathione peroxidase 3 | 2.0 | 0.0051* |
| P06745 | G6PI_MOUSE | Glucose-6-phosphate isomerase | 2.0 | 0.0529 |
| Q91VJ2 | CAVN3_MOUSE | Protein kinase C delta-binding protein | 2.0 | 0.0009* |
| Q91VD9 | NDUS1_MOUSE | NADH-ubiquinone oxidoreductase 75 kDa subunit, mitochondrial | 2.0 | 0.9468 |
| Q61205 | PA1B3_MOUSE | Platelet-activating factor acetylhydrolase IB subunit gamma | 2.0 | 0.0128* |
| | | Pyruvate dehydrogenase E1 component subunit alpha, somatic form, | | |
| P35486 | ODPA_MOUSE | mitochondrial | 2.0 | 0.1717 |
| P62245 | RS15A_MOUSE | 40S ribosomal protein S15a | 2.0 | 0.009* |
| P97429 | ANXA4_MOUSE | Annexin A4 | 2.0 | 0.005* |
| O35129 | PHB2_MOUSE | Prohibitin-2 | 2.0 | 0.2712 |
| Q9Z1Q5 | CLIC1_MOUSE | Chloride intracellular channel protein 1 | 2.1 | 0.0006* |
| Q60847 | COCA1_MOUSE | Collagen alpha-1(XII) chain | 2.1 | 0.0544 |
| P62838 | UB2D2_MOUSE | Ubiquitin-conjugating enzyme E2 D2 | 2.1 | 0.0015* |
| Q8VEM8 | MPCP_MOUSE | Phosphate carrier protein, mitochondrial | 2.1 | 0.6264 |
| Q9CVB6 | ARPC2_MOUSE | Actin-related protein 2/3 complex subunit 2 | 2.1 | 0.0042* |
| P25444 | RS2_MOUSE | 40S ribosomal protein S2 | 2.1 | 0.0265* |
| P23492 | PNPH_MOUSE | Purine nucleoside phosphorylase | 2.1 | 0.0028* |

| Q9R1P4 | PSA1 MOUSE | Proteasome subunit alpha type-1 | 2.1 | 0.6375 |
|--------|-------------|--|-----|---------|
| P62996 | TRA2B MOUSE | Transformer-2 protein homolog beta | 2.1 | 0.9607 |
| P62918 | RL8 MOUSE | 60S ribosomal protein L8 | 2.1 | 0.002* |
| O55143 | AT2A2 MOUSE | Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 | 2.1 | 0.2483 |
| P80313 | TCPH MOUSE | T-complex protein 1 subunit eta | 2.1 | 0.0069* |
| Q9CQI6 | COTL1 MOUSE | Coactosin-like protein | 2.1 | 0.0000* |
| P27659 | RL3 MOUSE | 60S ribosomal protein L3 | 2.1 | 0.0074* |
| P61205 | ARF3 MOUSE | ADP-ribosylation factor 3 | 2.1 | 0.6534 |
| Q64105 | SPRE MOUSE | Sepiapterin reductase | 2.1 | 0.1543 |
| Q02053 | UBA1_MOUSE | Ubiquitin-like modifier-activating enzyme 1 | 2.1 | 0.0869 |
| P80315 | TCPD_MOUSE | T-complex protein 1 subunit delta | 2.1 | 0.0246* |
| Q61702 | ITIH1_MOUSE | Inter-alpha-trypsin inhibitor heavy chain H1 | 2.1 | 0.7474 |
| Q91VC3 | IF4A3_MOUSE | Eukaryotic initiation factor 4A-III | 2.1 | 0.0352* |
| P09813 | APOA2_MOUSE | Apolipoprotein A-II | 2.1 | 0.4634 |
| Q9DBG6 | RPN2_MOUSE | Dolichyl-diphosphooligosaccharideprotein glycosyltransferase subunit 2 | 2.1 | 0.3296 |
| Q9WTP7 | KAD3_MOUSE | GTP:AMP phosphotransferase AK3, mitochondrial | 2.2 | 0.0034* |
| P10107 | ANXA1_MOUSE | Annexin A1 | 2.2 | 0.0015* |
| Q61696 | HS71A_MOUSE | Heat shock 70 kDa protein 1A | 2.2 | 0.0001* |
| P70124 | SPB5_MOUSE | Serpin B5 | 2.2 | 0.0018* |
| P68040 | RACK1_MOUSE | Receptor of activated protein C kinase 1 | 2.2 | 0.0078* |
| O09131 | GSTO1_MOUSE | Glutathione S-transferase omega-1 | 2.2 | 0.0153* |
| P07901 | HS90A_MOUSE | Heat shock protein HSP 90-alpha | 2.2 | 0.1495 |
| Q5EBG6 | HSPB6_MOUSE | Heat shock protein beta-6 | 2.2 | 0.9404 |
| Q04857 | CO6A1_MOUSE | Collagen alpha-1(VI) chain | 2.2 | 0.0151* |
| Q9R1P0 | PSA4_MOUSE | Proteasome subunit alpha type-4 | 2.2 | 0.2915 |
| P49722 | PSA2_MOUSE | Proteasome subunit alpha type-2 | 2.2 | 0.7706 |
| Q8R059 | GALE_MOUSE | UDP-glucose 4-epimerase | 2.2 | 0.0021* |
| Q922F4 | TBB6_MOUSE | Tubulin beta-6 chain | 2.3 | 0.0068* |
| Q9JMH6 | TRXR1_MOUSE | Thioredoxin reductase 1, cytoplasmic | 2.3 | 0.0408* |
| Q80X19 | COEA1_MOUSE | Collagen alpha-1(XIV) chain | 2.3 | 0.0000* |
| Q62009 | POSTN_MOUSE | Periostin | 2.3 | 0.0002* |
| Q99KP3 | CRYL1_MOUSE | Lambda-crystallin homolog | 2.3 | 0.0322* |
| Q9D0K2 | SCOT1_MOUSE | Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial | 2.3 | 0.0002* |
| P06151 | LDHA_MOUSE | L-lactate dehydrogenase A chain | 2.3 | 0.0089* |
| P11983 | TCPA_MOUSE | T-complex protein 1 subunit alpha | 2.3 | 0.0001* |
| O35643 | AP1B1_MOUSE | AP-1 complex subunit beta-1 | 2.3 | 0.4950 |
| Q9DCN2 | NB5R3_MOUSE | NADH-cytochrome b5 reductase 3 | 2.3 | 0.1310 |
| Q9JKS4 | LDB3_MOUSE | LIM domain-binding protein 3 | 2.3 | 0.0571 |
| P14148 | RL7_MOUSE | 60S ribosomal protein L7 | 2.3 | 0.3608 |
| P99024 | TBB5_MOUSE | Tubulin beta-5 chain | 2.3 | 0.7581 |

| Q61166 | MARE1 MOUSE | Microtubule-associated protein RP/EB family member 1 | 2.3 | 0.2806 |
|--------|-------------|---|-----|---------|
| Q7TPR4 | ACTN1 MOUSE | Alpha-actinin-1 | 2.4 | 0.0046* |
| Q9QUM9 | PSA6 MOUSE | Proteasome subunit alpha type-6 | 2.4 | 0.2651 |
| P26040 | EZRI MOUSE | Ezrin | 2.4 | 0.0934 |
| O09061 | PSB1 MOUSE | Proteasome subunit beta type-1 | 2.4 | 0.4024 |
| P16858 | G3P MOUSE | Glyceraldehyde-3-phosphate dehydrogenase | 2.4 | 0.0002* |
| P51881 | ADT2 MOUSE | ADP/ATP translocase 2 | 2.4 | 0.7784 |
| P16125 | LDHB MOUSE | L-lactate dehydrogenase B chain | 2.4 | 0.0042* |
| P11087 | CO1A1 MOUSE | Collagen alpha-1(I) chain | 2.4 | 0.2014 |
| O35679 | ISK4 MOUSE | Serine protease inhibitor Kazal-type 4 | 2.4 | 0.0042* |
| O55222 | ILK MOUSE | Integrin-linked protein kinase | 2.4 | 0.4624 |
| Q60932 | VDAC1 MOUSE | Voltage-dependent anion-selective channel protein 1 | 2.4 | 0.0054* |
| Q68FD5 | CLH1 MOUSE | Clathrin heavy chain 1 | 2.5 | 0.5243 |
| P01942 | HBA_MOUSE | Hemoglobin subunit alpha | 2.5 | 0.0019* |
| Q99JW2 | ACY1_MOUSE | Aminoacylase-1 | 2.5 | 0.0017* |
| P11499 | HS90B_MOUSE | Heat shock protein HSP 90-beta | 2.5 | 0.0402* |
| Q9D8N0 | EF1G_MOUSE | Elongation factor 1-gamma | 2.5 | 0.0825 |
| P14824 | ANXA6_MOUSE | Annexin A6 | 2.5 | 0.0008* |
| Q91V12 | BACH_MOUSE | Cytosolic acyl coenzyme A thioester hydrolase | 2.5 | 0.0092* |
| P24472 | GSTA4_MOUSE | Glutathione S-transferase A4 | 2.6 | 0.0167* |
| Q9QZD9 | EIF3I_MOUSE | Eukaryotic translation initiation factor 3 subunit I | 2.6 | 0.7126 |
| Q99JY9 | ARP3_MOUSE | Actin-related protein 3 | 2.6 | 0.009* |
| P80318 | TCPG_MOUSE | T-complex protein 1 subunit gamma | 2.6 | 0.0016* |
| Q8BFR5 | EFTU_MOUSE | Elongation factor Tu, mitochondrial | 2.6 | 0.5321 |
| Q8VHX6 | FLNC_MOUSE | Filamin-C | 2.6 | 0.0032* |
| Q9QZJ6 | MFAP5_MOUSE | Microfibrillar-associated protein 5 | 2.6 | 0.0087* |
| O70370 | CATS_MOUSE | Cathepsin S | 2.6 | 0.0164* |
| Q8CIB5 | FERM2_MOUSE | Fermitin family homolog 2 | 2.7 | 0.9352 |
| Q9WV54 | ASAH1_MOUSE | Acid ceramidase | 2.7 | 0.4657 |
| Q62000 | MIME_MOUSE | Mimecan | 2.7 | 0.0016* |
| P19096 | FAS_MOUSE | Fatty acid synthase | 2.7 | 0.1080 |
| O88342 | WDR1_MOUSE | WD repeat-containing protein 1 | 2.7 | 0.0018* |
| P59999 | ARPC4_MOUSE | Actin-related protein 2/3 complex subunit 4 | 2.7 | 0.0015* |
| Q91YR9 | PTGR1_MOUSE | Prostaglandin reductase 1 | 2.7 | 0.0001* |
| Q9D708 | S10AG_MOUSE | Protein S100-A16 | 2.7 | 0.0005* |
| Q9DAU7 | WFDC2_MOUSE | WAP four-disulfide core domain protein 2 | 2.7 | 0.0267* |
| Q8K0J2 | B3GN7_MOUSE | UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 7 | 2.7 | 0.0189* |
| P02089 | HBB2_MOUSE | Hemoglobin subunit beta-2 | 2.8 | 0.0032* |
| P13020 | GELS_MOUSE | Gelsolin | 2.8 | 0.0027* |
| Q9D154 | ILEUA_MOUSE | Leukocyte elastase inhibitor A | 2.8 | 0.0049* |

| Q9WUA3 | PFKAP MOUSE | ATP-dependent 6-phosphofructokinase, platelet type | 2.8 | 0.0453* |
|--------|-------------|--|-----|---------|
| O35639 | ANXA3 MOUSE | Annexin A3 | 2.8 | 0.0004* |
| P58389 | PTPA MOUSE | Serine/threonine-protein phosphatase 2A activator | 2.8 | 0.002* |
| P07356 | ANXA2 MOUSE | Annexin A2 | 2.8 | 0.0054* |
| P48962 | ADT1 MOUSE | ADP/ATP translocase 1 | 2.9 | 0.0895 |
| Q9CZM2 | RL15 MOUSE | 60S ribosomal protein L15 | 2.9 | 0.9310 |
| P19324 | SERPH MOUSE | Serpin H1 | 2.9 | 0.0005* |
| P63268 | ACTH_MOUSE | Actin, gamma-enteric smooth muscle | 2.9 | 0.0086* |
| P68368 | TBA4A_MOUSE | Tubulin alpha-4A chain | 2.9 | 0.8308 |
| Q7TMM9 | TBB2A_MOUSE | Tubulin beta-2A chain | 2.9 | 0.8720 |
| P30275 | KCRU_MOUSE | Creatine kinase U-type, mitochondrial | 2.9 | 0.0027* |
| P02088 | HBB1_MOUSE | Hemoglobin subunit beta-1 | 2.9 | 0.0029* |
| Q60854 | SPB6_MOUSE | Serpin B6 | 3.0 | 0.0016* |
| O08709 | PRDX6_MOUSE | Peroxiredoxin-6 | 3.0 | 0.0006* |
| Q8BG32 | PSD11_MOUSE | 26S proteasome non-ATPase regulatory subunit 11 | 3.0 | 0.0036* |
| Q91WL0 | ES8L3_MOUSE | Epidermal growth factor receptor kinase substrate 8-like protein 3 | 3.1 | 0.9594 |
| Q8BVA4 | LMOD1_MOUSE | Leiomodin-1 | 3.1 | 0.0247* |
| Q9JK53 | PRELP_MOUSE | Prolargin | 3.1 | 0.0008* |
| P47738 | ALDH2_MOUSE | Aldehyde dehydrogenase, mitochondrial | 3.2 | 0.0008* |
| P45376 | ALDR_MOUSE | Aldose reductase | 3.2 | 0.0001* |
| Q9JM14 | NT5C_MOUSE | 5'(3')-deoxyribonucleotidase, cytosolic type | 3.2 | 0.0000* |
| Q61598 | GDIB_MOUSE | Rab GDP dissociation inhibitor beta | 3.2 | 0.0019* |
| Q80UG5 | SEPT9_MOUSE | Septin-9 | 3.2 | 0.0008* |
| Q01149 | CO1A2_MOUSE | Collagen alpha-2(I) chain | 3.3 | 0.2946 |
| Q9DCD0 | 6PGD_MOUSE | 6-phosphogluconate dehydrogenase, decarboxylating | 3.3 | 0.1011 |
| P62962 | PROF1_MOUSE | Profilin-1 | 3.3 | 0.0001* |
| 070435 | PSA3_MOUSE | Proteasome subunit alpha type-3 | 3.3 | 0.5050 |
| P24527 | LKHA4_MOUSE | Leukotriene A-4 hydrolase | 3.3 | 0.0285* |
| P60843 | IF4A1_MOUSE | Eukaryotic initiation factor 4A-I | 3.4 | 0.0001* |
| Q8BZF8 | PGM5_MOUSE | Phosphoglucomutase-like protein 5 | 3.4 | 0.0112* |
| Q3UW53 | NIBAN_MOUSE | Protein Niban | 3.5 | 0.5502 |
| P15626 | GSTM2_MOUSE | Glutathione S-transferase Mu 2 | 3.6 | 0.0048* |
| Q99MQ4 | ASPN_MOUSE | Asporin | 3.7 | 0.0004* |
| Q9CZU6 | CISY_MOUSE | Citrate synthase, mitochondrial | 3.7 | 0.0305* |
| P10649 | GSTM1_MOUSE | Glutathione S-transferase Mu 1 | 3.7 | 0.0006* |
| Q8BP67 | RL24_MOUSE | 60S ribosomal protein L24 | 3.8 | 0.9507 |
| Q6GSS7 | H2A2A_MOUSE | Histone H2A type 2-A | 3.8 | 0.8999 |
| P68134 | ACTS_MOUSE | Actin, alpha skeletal muscle | 3.8 | 0.0002* |
| Q9R0P3 | ESTD_MOUSE | S-formylglutathione hydrolase | 3.8 | 0.0288* |
| Q91V92 | ACLY_MOUSE | ATP-citrate synthase | 3.9 | 0.0095* |

| Q02788 | CO6A2_MOUSE | Collagen alpha-2(VI) chain | 4.1 | 0.0068* |
|--------|-------------|--|------|---------|
| Q8K0C5 | ZG16_MOUSE | Zymogen granule membrane protein 16 | 4.2 | 0.0074* |
| Q9WTI7 | MYO1C_MOUSE | Unconventional myosin-Ic | 4.4 | 0.0018* |
| P84228 | H32_MOUSE | Histone H3.2 | 4.4 | 0.8648 |
| Q8CI94 | PYGB_MOUSE | Glycogen phosphorylase, brain form | 4.4 | 0.0211* |
| Q9Z0L8 | GGH_MOUSE | Gamma-glutamyl hydrolase | 4.4 | 0.0000* |
| Q9R1K9 | CETN2_MOUSE | Centrin-2 | 4.5 | 0.8196 |
| Q9D2Q8 | S10AE_MOUSE | Protein S100-A14 | 4.7 | 0.0001* |
| Q05816 | FABP5_MOUSE | Fatty acid-binding protein, epidermal | 4.8 | 0.2314 |
| P97430 | SLPI_MOUSE | Antileukoproteinase | 4.8 | 0.0001* |
| P00329 | ADH1_MOUSE | Alcohol dehydrogenase 1 | 5.2 | 0.0046* |
| P53996 | CNBP_MOUSE | Cellular nucleic acid-binding protein | 6.3 | 0.9870 |
| P11034 | MCPT1_MOUSE | Mast cell protease 1 | 6.6 | 0.8425 |
| Q8R1M8 | MPTX_MOUSE | Mucosal pentraxin | 6.6 | 0.0001* |
| Q11011 | PSA_MOUSE | Puromycin-sensitive aminopeptidase | 6.7 | 0.0194* |
| P02535 | K1C10_MOUSE | Keratin, type I cytoskeletal 10 | 6.8 | 0.2255 |
| P21550 | ENOB_MOUSE | Beta-enolase | 7.2 | 0.003* |
| Q08189 | TGM3_MOUSE | Protein-glutamine gamma-glutamyltransferase E | 7.3 | 0.0056* |
| Q9CWW6 | PIN4_MOUSE | Peptidyl-prolyl cis-trans isomerase NIMA-interacting 4 | 7.4 | 0.2584 |
| Q9R0Y5 | KAD1_MOUSE | Adenylate kinase isoenzyme 1 | 7.7 | 0.7660 |
| O54974 | LEG7_MOUSE | Galectin-7 | 8.6 | 0.2047 |
| Q5SX40 | MYH1_MOUSE | Myosin-1 | 8.6 | 0.0482* |
| P12265 | BGLR_MOUSE | Beta-glucuronidase | 8.7 | 0.2710 |
| P13412 | TNNI2_MOUSE | Troponin I, fast skeletal muscle | 9.1 | 0.1328 |
| Q91Y97 | ALDOB_MOUSE | Fructose-bisphosphate aldolase B | 9.4 | 0.2133 |
| Q8CIT9 | SBSN_MOUSE | Suprabasin | 9.9 | 0.0372* |
| Q9JM83 | CALM4_MOUSE | Calmodulin-4 | 11.0 | 0.0345* |
| Q9QZ47 | TNNT3_MOUSE | Troponin T, fast skeletal muscle | 13.3 | 0.1103 |
| Q91VC7 | PP14A_MOUSE | Protein phosphatase 1 regulatory subunit 14A | 13.7 | 0.5508 |
| P97457 | MLRS_MOUSE | Myosin regulatory light chain 2, skeletal muscle isoform | 21.0 | 0.0995 |
| P09542 | MYL3_MOUSE | Myosin light chain 3 | 32.5 | 0.1648 |
| P05977 | MYL1_MOUSE | Myosin light chain 1/3, skeletal muscle isoform | 36.1 | 0.1244 |
| P11088 | FILA_MOUSE | Filaggrin | 39.4 | 0.1585 |
| P20801 | TNNC2 MOUSE | Troponin C, skeletal muscle | 58.2 | 0.0089* |

| Accession ID | Gene ID | Protein Name | Fold Change DF/PF | <i>p</i> -value |
|-----------------|-------------|--|----------------------|-----------------|
| Q8K0C5 | ZG16 MOUSE | Zymogen granule membrane protein 16 | -41.5 | 0.8722 |
| P43137 | LIT1 MOUSE | Lithostathine-1 | -29.6 | 0.2398 |
| P16406 | AMPE_MOUSE | Glutamyl aminopeptidase | -15.0 | 0.9869 |
| Q64475 | H2B1B_MOUSE | Histone H2B type 1-B | -9.5 | 0.0955 |
| Q91XA9 | CHIA_MOUSE | Acidic mammalian chitinase | -8.5 | 0.9437 |
| P17751 | TPIS_MOUSE | Triosephosphate isomerase | -8.5 | 0.3627 |
| Q91WV7 | SLC31_MOUSE | Neutral and basic amino acid transport protein rBAT | -8.3 | 0.2913 |
| P54869 | HMCS2_MOUSE | Hydroxymethylglutaryl-CoA synthase, mitochondrial | -6.6 | 0.7390 |
| P13634 | CAH1_MOUSE | Carbonic anhydrase 1 | -4.3 | 0.1830 |
| Q9D816 | CP255_MOUSE | Cytochrome P450 2C55 | -3.4 | 0.2342 |
| Q8K419 | LEG4_MOUSE | Galectin-4 | -3.1 | 0.6688 |
| P19001 | K1C19_MOUSE | Keratin, type I cytoskeletal 19 | -3.0 | 0.7369 |
| P20029 | BIP_MOUSE | 78 kDa glucose-regulated protein | -2.6 | 0.0536 |
| P62908 | RS3_MOUSE | 40S ribosomal protein S3 | -2.4 | 0.8192 |
| Q8R1M8 | MPTX_MOUSE | Mucosal pentraxin | -2.4 | 0.3903 |
| Q8K386 | RAB15_MOUSE | Ras-related protein Rab-15 | -2.3 | 0.6168 |
| Q60997 | DMBT1_MOUSE | Deleted in malignant brain tumors 1 protein | -2.3 | 0.5446 |
| P06151 | LDHA_MOUSE | L-lactate dehydrogenase A chain | -2.2 | 0.1946 |
| Q8R1M2 | H2AJ_MOUSE | Histone H2A.J | -2.1 | 0.0383* |
| Q921I1 | TRFE_MOUSE | Serotransferrin | -2.0 | 0.5130 |
| Q9CQC2 | COL_MOUSE | Colipase | -2.0 | 0.4345 |
| P35700 | PRDX1_MOUSE | Peroxiredoxin-1 | -2.0 | 0.1534 |
| Q03265 | ATPA_MOUSE | ATP synthase subunit alpha, mitochondrial | -1.9 | 0.4065 |
| Q8VDN2 | AT1A1_MOUSE | Sodium/potassium-transporting ATPase subunit alpha-1 | -1.9 | 0.7178 |
| E9Q7P9 | CDHR2_MOUSE | Cadherin-related family member 2 | -1.9 | 0.8836 |
| P11679 | K2C8_MOUSE | Keratin, type II cytoskeletal 8 | -1.8 | 0.5118 |
| P14094 | AT1B1_MOUSE | Sodium/potassium-transporting ATPase subunit beta-1 | -1.7 | 0.0116* |
| Q91WG0 | EST2C_MOUSE | Acylcarnitine hydrolase | -1.7 | 0.0674 |
| P19467 | MUC13_MOUSE | Mucin-13 | -1.7 | 0.8498 |
| Q61847 | MEP1B_MOUSE | Meprin A subunit beta | -1.7 | 0.4119 |
| P17182 | ENOA_MOUSE | Alpha-enolase | -1.6 | 0.7469 |
| O88312 | AGR2_MOUSE | Anterior gradient protein 2 homolog | -1.6 | 0.2099 |
| P97429 | ANXA4_MOUSE | Annexin A4 | -1.6 | 0.9343 |
| P30275 | KCRU_MOUSE | Creatine kinase U-type, mitochondrial | -1.5 | 0.8891 |
| Q9CQ52 | CEL3B_MOUSE | Chymotrypsin-like elastase family member 3B | -1.5 | 0.7586 |
| P17563 | SBP1_MOUSE | Selenium-binding protein 1 | -1.5 | 0.0383* |
| P62984 | RL40_MOUSE | Ubiquitin-60S ribosomal protein L40 | -1.4 | 0.6288 |

Table 2.13 Complete List of Quantified Mouse Proteins in Feces

| Q6Q473 | CLA4A MOUSE | Calcium-activated chloride channel regulator 4A | -1.4 | 0.5389 |
|--------|-------------|--|------|---------|
| P56480 | ATPB_MOUSE | ATP synthase subunit beta, mitochondrial | -1.4 | 0.2624 |
| Q62468 | VILI_MOUSE | Villin-1 | -1.4 | 0.4644 |
| P35230 | REG3B_MOUSE | Regenerating islet-derived protein 3-beta | -1.3 | 0.7766 |
| P16858 | G3P_MOUSE | Glyceraldehyde-3-phosphate dehydrogenase | -1.2 | 0.1862 |
| P63260 | ACTG_MOUSE | Actin, cytoplasmic 2 | -1.2 | 0.8802 |
| P07356 | ANXA2_MOUSE | Annexin A2 | 1.1 | 0.4649 |
| Q80Z19 | MUC2_MOUSE | Mucin-2 | 1.3 | 0.4363 |
| P28843 | DPP4_MOUSE | Dipeptidyl peptidase 4 | 1.3 | 0.6656 |
| Q11136 | PEPD_MOUSE | Xaa-Pro dipeptidase | 1.3 | 0.3175 |
| P70412 | CUZD1_MOUSE | CUB and zona pellucida-like domain-containing protein 1 | 1.3 | 0.4442 |
| P02816 | PIP_MOUSE | Prolactin-inducible protein homolog | 1.4 | 0.1653 |
| Q60931 | VDAC3_MOUSE | Voltage-dependent anion-selective channel protein 3 | 1.4 | 0.5322 |
| P97449 | AMPN_MOUSE | Aminopeptidase N | 1.4 | 0.2856 |
| Q9CR35 | CTRB1_MOUSE | Chymotrypsinogen B | 1.4 | 0.8202 |
| P09803 | CADH1_MOUSE | Cadherin-1 | 1.4 | 0.1031 |
| P24822 | PPBI_MOUSE | Intestinal-type alkaline phosphatase | 1.4 | 0.7916 |
| Q6P8U6 | LIPP_MOUSE | Pancreatic triacylglycerol lipase | 1.5 | 0.7247 |
| P05208 | CEL2A_MOUSE | Chymotrypsin-like elastase family member 2A | 1.5 | 0.9300 |
| P24823 | PPBN_MOUSE | Alkaline phosphatase, placental-like | 1.5 | 0.5241 |
| Q60928 | GGT1_MOUSE | Gamma-glutamyltranspeptidase 1 | 1.5 | 0.0013* |
| Q9Z2W0 | DNPEP_MOUSE | Aspartyl aminopeptidase | 1.6 | 0.1142 |
| P08228 | SODC_MOUSE | Superoxide dismutase [Cu-Zn] | 1.7 | 0.7944 |
| P18761 | CAH6_MOUSE | Carbonic anhydrase 6 | 1.7 | 0.2613 |
| Q9D7Z6 | CLCA1_MOUSE | Calcium-activated chloride channel regulator 1 | 1.7 | 0.7222 |
| Q6UGQ3 | SG2B2_MOUSE | Secretoglobin family 2B member 2 | 1.8 | 0.2263 |
| P17892 | LIPR2_MOUSE | Pancreatic lipase-related protein 2 | 1.8 | 0.6553 |
| Q3SYP2 | CTRC_MOUSE | Chymotrypsin-C | 2.0 | 0.6245 |
| Q9R100 | CAD17_MOUSE | Cadherin-17 | 2.1 | 0.4024 |
| P07724 | ALBU_MOUSE | Serum albumin | 2.1 | 0.4897 |
| P15947 | KLK1_MOUSE | Kallikrein-1 | 3.4 | 0.9121 |
| Q9D733 | GP2_MOUSE | Pancreatic secretory granule membrane major glycoprotein GP2 | 3.7 | 0.9541 |
| O09049 | REG3G_MOUSE | Regenerating islet-derived protein 3-gamma | 3.8 | 0.4364 |
| P02088 | HBB1_MOUSE | Hemoglobin subunit beta-1 | 4.9 | 0.4635 |
| P62806 | H4_MOUSE | Histone H4 | 5.2 | 0.0394* |
| P07146 | TRY2_MOUSE | Anionic trypsin-2 | 6.5 | 0.2720 |
| Q8BFR5 | EFTU_MOUSE | Elongation factor Tu, mitochondrial | 6.8 | 0.4772 |
| P01942 | HBA_MOUSE | Hemoglobin subunit alpha | 7.5 | 0.5020 |

| Accession Number | Gene ID | Protein Name | Fold Change DC/PC | <i>p</i> -value |
|------------------|-------------|---|-------------------|-----------------|
| P20801 | TNNC2_MOUSE | Troponin C, skeletal muscle | 58.25 | 0.009 |
| Q08189 | TGM3_MOUSE | Protein-glutamine gamma-glutamyltransferase E | 7.29 | 0.006 |
| P21550 | ENOB_MOUSE | Beta-enolase | 7.20 | 0.003 |
| Q8R1M8 | MPTX_MOUSE | Mucosal pentraxin | 6.64 | 0.000 |
| P00329 | ADH1_MOUSE | Alcohol dehydrogenase 1 | 5.17 | 0.005 |
| P97430 | SLPI_MOUSE | Antileukoproteinase | 4.78 | 0.000 |
| Q9D2Q8 | S10AE_MOUSE | Protein S100-A14 | 4.70 | 0.000 |
| Q9Z0L8 | GGH_MOUSE | Gamma-glutamyl hydrolase | 4.44 | 0.000 |
| Q9WTI7 | MYO1C_MOUSE | Unconventional myosin-Ic | 4.36 | 0.002 |
| Q8K0C5 | ZG16_MOUSE | Zymogen granule membrane protein 16 | 4.20 | 0.007 |
| Q02788 | CO6A2_MOUSE | Collagen alpha-2(VI) chain | 4.11 | 0.007 |
| Q91V92 | ACLY_MOUSE | ATP-citrate synthase | 3.85 | 0.009 |
| P68134 | ACTS_MOUSE | Actin, alpha skeletal muscle | 3.81 | 0.000 |
| P10649 | GSTM1_MOUSE | Glutathione S-transferase Mu 1 | 3.71 | 0.001 |
| Q99MQ4 | ASPN MOUSE | Asporin | 3.68 | 0.000 |
| P15626 | GSTM2_MOUSE | Glutathione S-transferase Mu 2 | 3.62 | 0.005 |
| P60843 | IF4A1 MOUSE | Eukaryotic initiation factor 4A-I | 3.35 | 0.000 |
| P62962 | PROF1_MOUSE | Profilin-1 | 3.30 | 0.000 |
| Q80UG5 | SEPT9_MOUSE | Septin-9 | 3.24 | 0.001 |
| Q61598 | GDIB MOUSE | Rab GDP dissociation inhibitor beta | 3.19 | 0.002 |
| Q9JM14 | NT5C_MOUSE | 5'(3')-deoxyribonucleotidase, cytosolic type | 3.18 | 0.000 |
| P45376 | ALDR_MOUSE | Aldose reductase | 3.17 | 0.000 |
| P47738 | ALDH2_MOUSE | Aldehyde dehydrogenase, mitochondrial | 3.16 | 0.001 |
| Q9JK53 | PRELP MOUSE | Prolargin | 3.15 | 0.001 |
| Q8BG32 | PSD11_MOUSE | 26S proteasome non-ATPase regulatory subunit 11 | 3.05 | 0.004 |
| O08709 | PRDX6_MOUSE | Peroxiredoxin-6 | 3.00 | 0.001 |
| Q60854 | SPB6_MOUSE | Serpin B6 | 3.00 | 0.002 |
| P02088 | HBB1_MOUSE | Hemoglobin subunit beta-1 | 2.93 | 0.003 |
| P30275 | KCRU MOUSE | Creatine kinase U-type, mitochondrial | 2.93 | 0.003 |
| P63268 | ACTH_MOUSE | Actin, gamma-enteric smooth muscle | 2.87 | 0.009 |
| P19324 | SERPH_MOUSE | Serpin H1 | 2.86 | 0.001 |
| P07356 | ANXA2_MOUSE | Annexin A2 | 2.83 | 0.005 |
| P58389 | PTPA MOUSE | Serine/threonine-protein phosphatase 2A activator | 2.82 | 0.002 |
| O35639 | ANXA3 MOUSE | Annexin A3 | 2.82 | 0.000 |
| Q9D154 | ILEUA_MOUSE | Leukocyte elastase inhibitor A | 2.79 | 0.005 |
| P13020 | GELS MOUSE | Gelsolin | 2.76 | 0.003 |
| P02089 | HBB2 MOUSE | Hemoglobin subunit beta-2 | 2.76 | 0.003 |
| Q9D708 | S10AG_MOUSE | Protein S100-A16 | 2.71 | 0.000 |

Table 2.1 Statistically Significant Quantified Mouse Proteins from Colon Samples

| Q91YR9 | PTGR1 MOUSE | Prostaglandin reductase 1 | 2.70 | 0.000 |
|--------|-------------|---|------|-------|
| P59999 | ARPC4 MOUSE | Actin-related protein 2/3 complex subunit 4 | 2.69 | 0.001 |
| O88342 | WDR1 MOUSE | WD repeat-containing protein 1 | 2.68 | 0.002 |
| Q62000 | MIME MOUSE | Mimecan | 2.66 | 0.002 |
| Q9QZJ6 | MFAP5 MOUSE | Microfibrillar-associated protein 5 | 2.64 | 0.009 |
| Q8VHX6 | FLNC MOUSE | Filamin-C | 2.63 | 0.003 |
| P80318 | TCPG MOUSE | T-complex protein 1 subunit gamma | 2.61 | 0.002 |
| Q99JY9 | ARP3 MOUSE | Actin-related protein 3 | 2.59 | 0.009 |
| Q91V12 | BACH MOUSE | Cytosolic acyl coenzyme A thioester hydrolase | 2.55 | 0.009 |
| P14824 | ANXA6_MOUSE | Annexin A6 | 2.52 | 0.001 |
| Q99JW2 | ACY1_MOUSE | Aminoacylase-1 | 2.51 | 0.002 |
| P01942 | HBA_MOUSE | Hemoglobin subunit alpha | 2.51 | 0.002 |
| Q60932 | VDAC1_MOUSE | Voltage-dependent anion-selective channel protein 1 | 2.44 | 0.005 |
| O35679 | ISK4_MOUSE | Serine protease inhibitor Kazal-type 4 | 2.41 | 0.004 |
| P16125 | LDHB_MOUSE | L-lactate dehydrogenase B chain | 2.40 | 0.004 |
| P16858 | G3P_MOUSE | Glyceraldehyde-3-phosphate dehydrogenase | 2.38 | 0.000 |
| Q7TPR4 | ACTN1_MOUSE | Alpha-actinin-1 | 2.35 | 0.005 |
| P11983 | TCPA_MOUSE | T-complex protein 1 subunit alpha | 2.30 | 0.000 |
| P06151 | LDHA_MOUSE | L-lactate dehydrogenase A chain | 2.29 | 0.009 |
| Q9D0K2 | SCOT1_MOUSE | Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial | 2.29 | 0.000 |
| Q62009 | POSTN_MOUSE | Periostin | 2.27 | 0.000 |
| Q80X19 | COEA1_MOUSE | Collagen alpha-1(XIV) chain | 2.26 | 0.000 |
| Q922F4 | TBB6_MOUSE | Tubulin beta-6 chain | 2.25 | 0.007 |
| Q8R059 | GALE_MOUSE | UDP-glucose 4-epimerase | 2.25 | 0.002 |
| P68040 | RACK1_MOUSE | Receptor of activated protein C kinase 1 | 2.20 | 0.008 |
| P70124 | SPB5_MOUSE | Serpin B5 | 2.19 | 0.002 |
| Q61696 | HS71A_MOUSE | Heat shock 70 kDa protein 1A | 2.17 | 0.000 |
| P10107 | ANXA1_MOUSE | Annexin A1 | 2.17 | 0.001 |
| Q9WTP7 | KAD3_MOUSE | GTP:AMP phosphotransferase AK3, mitochondrial | 2.17 | 0.003 |
| P27659 | RL3_MOUSE | 60S ribosomal protein L3 | 2.11 | 0.007 |
| Q9CQI6 | COTL1_MOUSE | Coactosin-like protein | 2.11 | 0.000 |
| P80313 | TCPH_MOUSE | T-complex protein 1 subunit eta | 2.10 | 0.007 |
| P62918 | RL8_MOUSE | 60S ribosomal protein L8 | 2.10 | 0.002 |
| P23492 | PNPH_MOUSE | Purine nucleoside phosphorylase | 2.07 | 0.003 |
| Q9CVB6 | ARPC2_MOUSE | Actin-related protein 2/3 complex subunit 2 | 2.06 | 0.004 |
| P62838 | UB2D2_MOUSE | Ubiquitin-conjugating enzyme E2 D2 | 2.06 | 0.002 |
| Q9Z1Q5 | CLIC1_MOUSE | Chloride intracellular channel protein 1 | 2.06 | 0.001 |
| P97429 | ANXA4_MOUSE | Annexin A4 | 2.05 | 0.005 |
| P62245 | RS15A_MOUSE | 40S ribosomal protein S15a | 2.05 | 0.009 |
| Q91VJ2 | CAVN3_MOUSE | Protein kinase C delta-binding protein | 2.03 | 0.001 |

| P46412 | GPX3 MOUSE | Glutathione peroxidase 3 | 2.02 | 0.005 |
|--------|-------------------------|--|-------|-------|
| P17710 | HXK1 ⁻ MOUSE | Hexokinase-1 | 2.02 | 0.003 |
| P81117 | NUCB2 MOUSE | Nucleobindin-2 | -2.00 | 0.000 |
| P62077 | TIM8B MOUSE | Mitochondrial import inner membrane translocase subunit Tim8 B | -2.01 | 0.003 |
| Q9CRB6 | TPPP3 MOUSE | Tubulin polymerization-promoting protein family member 3 | -2.01 | 0.000 |
| Q64213 | SF01 MOUSE | Splicing factor 1 | -2.02 | 0.000 |
| P11679 | K2C8 MOUSE | Keratin, type II cytoskeletal 8 | -2.03 | 0.006 |
| Q9ERG0 | LIMAT MOUSE | LIM domain and actin-binding protein 1 | -2.03 | 0.001 |
| Q9JMD0 | ZN207 MOUSE | BUB3-interacting and GLEBS motif-containing protein ZNF207 | -2.04 | 0.001 |
| Q08331 | CALB2 MOUSE | Calretinin | -2.04 | 0.000 |
| P62960 | YBOX1 MOUSE | Nuclease-sensitive element-binding protein 1 | -2.08 | 0.000 |
| Q9WVA2 | TIM8A MOUSE | Mitochondrial import inner membrane translocase subunit Tim8 A | -2.09 | 0.000 |
| Q91V76 | CK054 MOUSE | Ester hydrolase C11orf54 homolog | -2.11 | 0.008 |
| Q91WJ8 | FUBP1 MOUSE | Far upstream element-binding protein 1 | -2.12 | 0.000 |
| Q6P9R2 | OXSR1 MOUSE | Serine/threonine-protein kinase OSR1 | -2.13 | 0.000 |
| Q8R4U7 | LUZP1 MOUSE | Leucine zipper protein 1 | -2.14 | 0.000 |
| P19001 | K1C19 MOUSE | Keratin, type I cytoskeletal 19 | -2.14 | 0.000 |
| P70441 | NHRF1 MOUSE | Na(+)/H(+) exchange regulatory cofactor NHE-RF1 | -2.15 | 0.000 |
| Q6NZJ6 | IF4G1 MOUSE | Eukaryotic translation initiation factor 4 gamma 1 | -2.15 | 0.000 |
| P56391 | CX6B1 MOUSE | Cytochrome c oxidase subunit 6B1 | -2.16 | 0.000 |
| P19536 | COX5B MOUSE | Cytochrome c oxidase subunit 5B, mitochondrial | -2.17 | 0.000 |
| Q9Z1D1 | EIF3G MOUSE | Eukaryotic translation initiation factor 3 subunit G | -2.20 | 0.004 |
| Q99LT0 | DPY30 MOUSE | Protein dpy-30 homolog | -2.20 | 0.001 |
| Q9Z2I0 | LETM1 MOUSE | LETM1 and EF-hand domain-containing protein 1, mitochondrial | -2.21 | 0.001 |
| Q02819 | NUCB1 MOUSE | Nucleobindin-1 | -2.23 | 0.000 |
| Q61792 | LASP1 MOUSE | LIM and SH3 domain protein 1 | -2.23 | 0.000 |
| Q62261 | SPTB2 MOUSE | Spectrin beta chain, non-erythrocytic 1 | -2.24 | 0.000 |
| P99028 | QCR6 MOUSE | Cytochrome b-c1 complex subunit 6, mitochondrial | -2.27 | 0.000 |
| E9Q7P9 | CDHR2 MOUSE | Cadherin-related family member 2 | -2.28 | 0.000 |
| P21107 | TPM3 MOUSE | Tropomyosin alpha-3 chain | -2.28 | 0.004 |
| O08663 | MAP2 MOUSE | Methionine aminopeptidase 2 | -2.28 | 0.002 |
| P57016 | LAD1 MOUSE | Ladinin-1 | -2.28 | 0.000 |
| Q9QXS1 | PLEC_MOUSE | Plectin | -2.30 | 0.001 |
| P52503 | NDUS6 MOUSE | NADH dehydrogenase [ubiquinone] iron-sulfur protein 6 | -2.30 | 0.000 |
| P61022 | CHP1 MOUSE | Calcineurin B homologous protein 1 | -2.31 | 0.001 |
| Q9JLQ0 | CD2AP MOUSE | CD2-associated protein | -2.34 | 0.000 |
| P55012 | S12A2 MOUSE | Solute carrier family 12 member 2 | -2.34 | 0.001 |
| Q9DCM0 | ETHE1_MOUSE | Persulfide dioxygenase ETHE1, mitochondrial | -2.34 | 0.000 |
| Q91WQ9 | CALL4_MOUSE | Calmodulin-like protein 4 | -2.39 | 0.001 |
| P14733 | LMNB1_MOUSE | Lamin-B1 | -2.39 | 0.000 |

| P15379 CD44 CD44 antigen -2.40 0.000 Q80VJ2 SRA1_MOUSE Steroir ceeptor RNA activator 1 -2.41 0.004 Q70400 PDL1_MOUSE FI-hand domain-opticin D2 -2.46 0.000 Q80812 AGR2_MOUSE FI-hand domain-containing protein D2 -2.46 0.003 Q80PD65 SIMRC2_MOUSE Anterior gradient protein 2 homolog -2.46 0.004 Q90P655 PLIN3_MOUSE Perlipin-3 -2.50 0.000 Q90P655 PLIN3_MOUSE Perlipin-3 -2.51 0.001 Q90P641 MYL4_MOUSE Serine/threonine-protein phosphatase 1 regulatory subunit 10 -2.58 0.000 Q80W00 PP1RA_MOUSE Serine/threonine-protein phosphatase 1 regulatory subunit 10 -2.57 0.000 Q90PCV7 K2C7_MOUSE Keratin, type 1 (rytoskeletal 7 -2.75 0.000 Q99KN9 EPN4_MOUSE Calarhin interactor 1 -2.75 0.000 Q99KN9 EPN4_MOUSE Keratin, type 1 (rytoskeletal 7 -2.75 0.000 Q80B14 | Q6IRU5 | CLCB MOUSE | Clathrin light chain B | -2.40 | 0.000 |
|--|--------|-------------|--|--------|-------|
| Q80VJ2 SRA1_MOUSE Steroid receptor RNA activator 1 -2.41 0.004 Q90BY0 EFHD2 MOUSE EPLand LIM domain protein 1 -2.46 0.000 Q8812 AGR2_MOUSE EF-hand domain-containing protein D2 -2.46 0.003 Q6PDG5 SMRC2_MOUSE EF-hand domain-containing protein D2 -2.46 0.003 Q6PDG5 SMRC2_MOUSE SWI/SNF complex suburit SMARCC2 -2.48 0.004 Q9DBG5 PLIN3_MOUSE Myoin light chain 4 -2.51 0.001 P47212 GALA_MOUSE Servine/Hreconine-protein phosphatase 1 regulatory subunit 10 -2.58 0.000 Q80W00 PP1RA_MOUSE Fortein CDV3 -2.64 0.001 Q9DC/7 K2C7_MOUSE Fortein CDV3 -2.75 0.000 Q9BVL0 CHCH2_MOUSE Colled-coli-helix-colled-coli-helix comain-containing protein 2 -2.75 0.000 Q9BVL4 TGO1_MOUSE Melanoma inhibitory activity protein 3 -2.88 0.000 Q99PL5 RRBP1_MOUSE Keratin, type 1 cytoskeletal 18 -2.90 0.000 <td< td=""><td>P15379</td><td>CD44_MOUSE</td><td>CD44 antigen</td><td>-2.40</td><td>0.000</td></td<> | P15379 | CD44_MOUSE | CD44 antigen | -2.40 | 0.000 |
| O70400 PDL1/I_MOUSE PDZ and LIM domain protein 1 -2.41 0.000 O9DBY0 EFHD2 MOUSE EF-Inad domain-containing protein D2 -2.46 0.003 ORDBS5 SMRC2_MOUSE Arterior gradient protein 2 homolog -2.46 0.004 O9DBG5 PLIN3_MOUSE Perilipin-3 -2.50 0.000 P09541 MYL4_MOUSE Myosin light chain 4 -2.51 0.001 P47212 GALA_MOUSE Galarin peptides -2.58 0.002 Q4VAA2 CDV3_MOUSE Protein CDV3 -2.64 0.001 Q9DCV7 K2C7_MOUSE Keratin, type II cytoskeletal 7 -2.75 0.000 Q9DKV9 EPN4_MOUSE Calitrin interractor 1 -2.75 0.002 Q9BKN9 EPN4_MOUSE Calitrin interractor 1 -2.77 0.002 Q9BKN9 EPN4_MOUSE Keratin, type I cytoskeletal 7 -2.80 0.000 Q9BKN9 EPN4_MOUSE Calitrin interractor 1 -2.75 0.002 Q9BKN9 EPN4_MOUSE Keratin, type I cytoskeletal 7 -2.80 | Q80VJ2 | SRA1_MOUSE | Steroid receptor RNA activator 1 | -2.41 | 0.004 |
| Q9D8Y0 EFHD2_MOUSE EF-hand domain-containing protein D2 -2.46 0.000 Q8D8J12 AGR2_MOUSE Anterior gradient protein 2 homolog -2.46 0.003 Q8DBG5 PLIN3_MOUSE Perilipin-3 -2.50 0.000 P09541 MVL4_MOUSE Perilipin-3 -2.51 0.001 P47212 GALA_MOUSE Galanin perildes -2.58 0.000 Q80W00 PP1RA_MOUSE Servine/Intreornine-protein phosphatase 1 regulatory subunit 10 -2.64 0.001 Q9DCV7 K2C7_MOUSE Keratin, type II cytoskeletal 7 -2.64 0.000 Q9DL0 CHCH2_MOUSE Coled-col-I-helix-coled-col-helix domain-containing protein 2 -2.75 0.000 Q99KN9 EPN4_MOUSE Cled-col-helix-coled-col-helix domain-containing protein 1 -2.88 0.000 Q89KN9 EPN4_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 Q89KN4 TGO1_MOUSE Helenoma inhibitory activity protein 3 -3.48 0.000 Q89KN4 HNRL1_MOUSE Latrin, type I cytoskeletal 18 -2.90 0.000 <td>O70400</td> <td>PDLI1 MOUSE</td> <td>PDZ and LIM domain protein 1</td> <td>-2.41</td> <td>0.000</td> | O70400 | PDLI1 MOUSE | PDZ and LIM domain protein 1 | -2.41 | 0.000 |
| 088312 AGR2_MOUSE Anterior gradient protein 2 homolog -2.46 0.003 08PD065 SMRC2_MOUSE WilkSNF complex subunit SMARC2 -2.48 0.004 09DB65 PLIN3_MOUSE Perilipin-3 -2.50 0.000 P09541 MYL4_MOUSE Galanin peptides -2.58 0.000 080W00 PP1RA_MOUSE Serine/threonine-protein phosphatase 1 regulatory subunit 10 -2.58 0.002 04VAA2 CDV3_MOUSE Protein CDV3 -2.64 0.001 09D10 CHCH2_MOUSE Keratin, type II cytoskeletal 7 -2.75 0.000 09D110 CHCH2_MOUSE Clathrin interactor 1 -2.75 0.000 039R14 R1G1_MOUSE Ribosome-binding protein 3 -2.88 0.000 04884 TG01_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 08070 DUMA1_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 080219 MUK2_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 080219 MUMA1_MOUSE Melar mitot | Q9D8Y0 | EFHD2 MOUSE | EF-hand domain-containing protein D2 | -2.46 | 0.000 |
| ORPDG5 SMRC2_MOUSE SWI/SNF complex subunit SMARC2 2.48 0.004 QBDBG5 PLIN3_MOUSE Perilipin-3 -2.50 0.000 P09541 MYL4_MOUSE Galanin pepiddes -2.51 0.001 P47212 GALA_MOUSE Galanin pepiddes -2.58 0.002 Q4VAA2 CDV3_MOUSE Frotein CDV3 -2.64 0.001 Q9D10 CHCR2_MOUSE Kerine/threonine-protein phosphatase 1 regulatory subunit 10 -2.65 0.000 Q9D10 CHCR2_MOUSE Colied-coil-helix-coiled-coil-helix domain-containing protein 2 -2.75 0.000 Q9D10 CHCR2_MOUSE Calathrin interactor 1 -2.75 0.002 Q99RN9 EPN4_MOUSE Kelosome-binding protein 1 -2.77 0.000 Q8BI84 TGO1_MOUSE Melanoma inhibitory activity protein 3 -2.88 0.001 Q8VDM6 HNR1_1_MOUSE Heterogeneous nuclear ribonucleoprotein U-like protein 1 -2.90 0.000 Q8VDM6 HNR1_1_MOUSE Mucin-2 -3.04 0.000 Q80750 NUMA1_MOUSE | O88312 | AGR2 MOUSE | Anterior gradient protein 2 homolog | -2.46 | 0.003 |
| OpDBGS PLIN3_MOUSE Pertiligin-3 2.50 0.000 P09541 MYL4_MOUSE Myosin light chain 4 -2.51 0.001 P47212 GALA_MOUSE Galanin peptides -2.58 0.000 Q80W00 PP1RA_MOUSE Serine/threonine-protein phosphatase 1 regulatory subunit 10 -2.58 0.000 Q4VAA2 CDV3_MOUSE Freine (DrV3 -2.64 0.001 Q9DC/7 K2C7_MOUSE Keratin, type II cytoskeletal 7 -2.75 0.000 Q9D1L0 CHCH2_MOUSE Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 -2.75 0.000 Q99PL5 RBP1_MOUSE Ribosome-binding protein 1 -2.77 0.000 Q88IB4 TGO1_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.001 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q80K9M6 HNRL1_MOUSE Nuclear mitotic apparatus protein 1 -3.05 0.003 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q99K28 ARF62_MOUSE Sc s | Q6PDG5 | SMRC2 MOUSE | SWI/SNF complex subunit SMARCC2 | -2.48 | 0.004 |
| P09541 MYL_MOUSE Myosin light chain 4 -2.51 0.001 P47212 GALA_MOUSE Galanin peptides -2.58 0.000 Q80W00 PP1RA_MOUSE Galanin peptides -2.58 0.002 Q4VAA2 CDV3_MOUSE Fortein CDV3 -2.64 0.001 Q9D10 CHCH2_MOUSE Colled-coil-helix-coiled-coil-helix domain-containing protein 2 -2.75 0.000 Q99H10 CHCH2_MOUSE Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 -2.75 0.000 Q99FL5 RBP1_MOUSE Clied-coil-helix-coiled-coil-helix domain-containing protein 2 -2.75 0.000 Q89KM9 EPN4_MOUSE Clied-coil-helix domain-containing protein 2 -2.75 0.000 Q89BL4 TG01_MOUSE Ribosome-binding protein 3 -2.88 0.000 Q8VDM6 HNR1_MOUSE Heterogeneous nuclear ribonucleoprotein U-like protein 1 -2.90 0.000 Q8VDM6 HNR1_MOUSE Nuclear mitotic apparatus protein 1 -3.06 0.001 Q9G760 NUMA1_MOUSE Kuclear mitotic apparatus protein 1 -3.05 | Q9DBG5 | PLIN3 MOUSE | Perilipin-3 | -2.50 | 0.000 |
| P47212 GALA_MOUSE Galanin peptides -2.58 0.000 Q80W00 PP1RA_MOUSE Serine/threenine-protein phosphatase 1 regulatory subunit 10 -2.58 0.002 Q4VAA2 CDV3 MOUSE Protein CDV3 -2.64 0.001 Q9DCV7 K2C7_MOUSE Keratin, type II cytoskeletal 7 -2.75 0.000 Q9DL0 CHCH2_MOUSE Clathrin interactor 1 -2.75 0.000 Q99PL5 RRBP1_MOUSE Clathrin interactor 1 -2.77 0.000 Q8BI84 TGO1_MOUSE Melanoma inhibitory activity protein 3 -2.88 0.000 Q8DVM6 HNRL1_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 Q8233 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q80598 SRC8_MOUSE Scr substrate cortactin -3.25 0.000 Q99K28 ARF62_MOUSE Scr substrate cortactin -3.25 0.000 Q80598 SRC8_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.56 0.001 Q99K30 <td< td=""><td>P09541</td><td>MYL4 MOUSE</td><td>Myosin light chain 4</td><td>-2.51</td><td>0.001</td></td<> | P09541 | MYL4 MOUSE | Myosin light chain 4 | -2.51 | 0.001 |
| Q80W00 PP1RĀ_MOUSE Serine/threonine-protein phosphatase 1 regulatory subunit 10 -2.58 0.002 Q4VAA2 CDV3_MOUSE Protein CDV3 -2.64 0.001 QBDCV7 K2C7_MOUSE Keratin, type II cytoskeletal 7 -2.75 0.000 Q9D1.0 CHCH2_MOUSE Colled-coil-helix-coiled-coil-helix domain-containing protein 2 -2.75 0.000 Q99N15 RRBP1_MOUSE Calathrin interactor 1 -2.77 0.000 Q8B184 TGO1_MOUSE Klearatin, type 1 cytoskeletal 18 -2.90 0.000 Q8VDM6 HNRL1_MOUSE Heterogeneous nuclear ribonucleoprotein U-like protein 1 -2.98 0.001 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q80Z19 MUC2_MOUSE Scr substrate cortactin -3.05 0.003 Q99K28 ARFG2_MOUSE Scr substrate cortactin in corteapt sprotein 2 -3.28 0.000 Q99K28 ARFG2_MOUSE ADP-ribosylation factor GTPase-activating protein 2 -3.26 0.000 Q99K28 ARFG2_MOUSE Apoptotic chromatin condensation inducer in the nucleus | P47212 | GALA_MOUSE | Galanin peptides | -2.58 | 0.000 |
| Q4VAA2 CDV3_MOUSE Protein CDV3 2-64 0.001 Q9DCV7 K2C7_MOUSE Keratin, type II cytoskeletal 7 2.75 0.000 Q9DL0 CHCH2_MOUSE Calet-coil-helix-coiled-coil-helix domain-containing protein 2 2.75 0.000 Q99PL5 RRBP1_MOUSE Clathrin interactor 1 2.775 0.000 Q8B184 TGO1_MOUSE Klasome-binding protein 1 2.775 0.000 Q8B184 TGO1_MOUSE Melanoma inhibitory activity protein 3 2.88 0.000 Q8VDM6 HNRL1_MOUSE Keratin, type I cytoskeletal 18 2.90 0.000 Q8233 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q80276 NUMA1_MOUSE Nuclear mitotic apparatus protein 1 -2.98 0.001 Q98X28 ARFG2_MOUSE Src substrate cortactin -3.07 0.000 Q99K28 ARFG2_MOUSE Src substrate cortactin cordensation inducer in the nucleus -3.76 0.001 Q99K28 ARFG2_MOUSE Secretogranin-1 -3.28 0.008 Q99K28 ARFG2_MOU | Q80W00 | PP1RA_MOUSE | Serine/threonine-protein phosphatase 1 regulatory subunit 10 | -2.58 | 0.002 |
| Q9DCV7 K2c7_MOUSE Keratin, type II cytoskeletal 7 2.75 0.000 Q9D1L0 CHCH2_MOUSE Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 2.75 0.002 Q99PL5 RRBP1_MOUSE Ciathrin interactor 1 2.77 0.000 Q89B184 TG01_MOUSE Ribosome-binding protein 1 2.77 0.000 Q8B184 TG01_MOUSE Keratin, type I cytoskeletal 18 2.90 0.000 Q8VDM6 HNR1_MOUSE Keratin, type I cytoskeletal 18 2.90 0.000 Q8201 MUK1_MOUSE Keratin type I cytoskeletal 18 2.90 0.000 Q8203 TPD52_MOUSE Tumor protein D52 3.04 0.000 Q80219 MUK2_MOUSE Muclear mitotic apparatus protein 1 -3.05 0.003 Q80219 MUC2_MOUSE Src substrate cortactin -3.07 0.000 Q99K28 ARF62_MOUSE Src substrate cortactin -3.25 0.001 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.56 0.001 Q31X8 | Q4VAA2 | CDV3_MOUSE | Protein CDV3 | -2.64 | 0.001 |
| Q9D1L0 CHCH2_MOUSE Colled-coil-helix-coiled-coil-helix domain-containing protein 2 -2.75 0.000 Q99KN9 EPN4_MOUSE Clathrin interactor 1 -2.77 0.000 Q99K15 RRBP1_MOUSE Ribosome-binding protein 1 -2.77 0.000 Q8BI84 TGO1_MOUSE Melanoma inhibitory activity protein 3 -2.88 0.000 Q8VDM6 HNRL1_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q80Z19 MUC2_MOUSE Nuclear mitotic apparatus protein 1 -3.05 0.003 Q99K28 ARFG2_MOUSE Src substrate cortactin -3.25 0.000 Q99K30 ES8L2_MOUSE Sc substrate cortactin factor receptor kinase substrate 8-like protein 2 -3.36 0.001 Q9JIX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 Q99K20 ES8L2_MOUSE Cinguin -3.86 0.001 Q99K30 ES8L2_MOUSE Sc cretogranin-1 -3.66 0.001 | Q9DCV7 | K2C7_MOUSE | Keratin, type II cytoskeletal 7 | -2.75 | 0.000 |
| Q99KN9 EPN4_MOUSE Clathrin interactor 1 -2.75 0.002 Q99PL5 RRBP1_MOUSE Ribosome-binding protein 1 -2.77 0.000 Q8BI84 TGO1_MOUSE Melanoma inhibitory activity protein 3 -2.88 0.000 Q8VDM6 HNRL1_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q80Z19 MUC2_MOUSE Tumor protein D52 -3.04 0.000 Q80Z19 MUC2_MOUSE Nuclear mitotic apparatus protein 1 -3.05 0.003 Q80X30 ES8L2_MOUSE Src substrate cortactin -3.25 0.000 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.86 0.001 Q91X8 ACINU_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.86 0.001 Q91X8 ACINU_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.86 0.001 P5095 GLUC_MOUSE Giucagon -3.82 0.004 -2.9 | Q9D1L0 | CHCH2_MOUSE | Coiled-coil-helix-coiled-coil-helix domain-containing protein 2 | -2.75 | 0.000 |
| Q99PL5 RRBF_MOUSE Ribosome-binding protein 1 -2.77 0.000 Q8B184 TGO1_MOUSE Melanoma inhibitory activity protein 3 -2.88 0.000 Q8DDM6 HNRL1_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 Q8VDM6 HNRL1_MOUSE Heterogeneous nuclear ribonucleoprotein U-like protein 1 -2.98 0.001 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q80Z19 MUC2_MOUSE Nuce mitotic apparatus protein 1 -3.05 0.003 Q80Z19 MUC2_MOUSE Mucin-2 -3.07 0.000 Q90K30 ES8L2_MOUSE Sor substrate cortactin -3.28 0.001 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.56 0.001 Q91X8 ACIN_MOUSE Secretogranin-1 -3.66 0.001 -9.5095 Q1UC_MOUSE Glucagon -3.82 0.000 -9.5095 -9.000 -9.60 -0.033 P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 | Q99KN9 | EPN4_MOUSE | Clathrin interactor 1 | -2.75 | 0.002 |
| Q8BI84 TGO1_MOUSE Melanoma inhibitory activity protein 3 -2.88 0.000 P05784 K1C18_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 Q8VDM6 HNRL1_MOUSE Keratin, type I cytoskeletal 18 -2.98 0.001 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 Q62393 TPD52_MOUSE Tumor protein D52 -3.07 0.000 Q80Z19 MUC2_MOUSE Muclear mitotic apparatus protein 1 -3.25 0.000 Q60598 SRC8_MOUSE Src substrate cortactin -3.25 0.000 Q99K28 ARFG2_MOUSE ADP-ribosylation factor GTPase-activating protein 2 -3.26 0.001 Q99K30 ES8L2_MOUSE Sccretogranin-1 -3.66 0.001 Q9JIX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 P55095 GLUC_MOUSE Glucagon -3.82 0.000 P5095 THM_MOUSE Thymosin beta-4 -4.02 0.001 P20391 FRIL1_MOUSE Ferritin | Q99PL5 | RRBP1_MOUSE | Ribosome-binding protein 1 | -2.77 | 0.000 |
| P05784 K1C18_MOUSE Keratin, type I cytoskeletal 18 -2.90 0.000 Q8VDM6 HNRL1_MOUSE Heterogeneous nuclear inbonucleoprotein U-like protein 1 -2.98 0.001 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 E9Q760 NUMA1_MOUSE Nuclear mitotic apparatus protein 1 -3.05 0.003 Q80219 MUC2_MOUSE Mucin-2 -3.07 0.000 Q60598 SRC8_MOUSE Src substrate cortactin -3.25 0.000 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.26 0.001 Q9JIX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 Q9JIX8 ACINU_MOUSE Giucagon -3.82 0.000 P55095 GLUC_MOUSE Giucagon -3.82 0.001 P29391 FRIL1_MOUSE Thymosin beta-4 -4.02 0.001 P29391 FRIL1_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE | Q8BI84 | TGO1_MOUSE | Melanoma inhibitory activity protein 3 | -2.88 | 0.000 |
| Q8VDM6 HNRL1_MOUSE Heterogeneous nuclear ribonucleoprotein U-like protein 1 -2.98 0.001 Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 E9Q7G0 NUMA1_MOUSE Nuccear mitotic apparatus protein 1 -3.05 0.003 Q80Z19 MUC2_MOUSE Mucin-2 -3.07 0.000 Q60598 SRC8_MOUSE Src substrate cortactin -3.25 0.008 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.56 0.001 Q9JK30 ES8L2_MOUSE Secretogranin-1 -3.66 0.001 Q9JX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 Q9JX8 GLUC_MOUSE Glucagon -3.82 0.000 P55095 GLUC_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 4.02 0.001 Q9B279 MISP_MOUSE DNA-binding protein SATB2 4.10 0.007 Q9ES28 ARH67_MOUSE Rho guanine nucleo | P05784 | K1C18_MOUSE | Keratin, type I cytoskeletal 18 | -2.90 | 0.000 |
| Q62393 TPD52_MOUSE Tumor protein D52 -3.04 0.000 E9Q7G0 NUMA1_MOUSE Nuclear mitotic apparatus protein 1 -3.05 0.003 Q80Z19 MUC2_MOUSE Mucin-2 -3.07 0.000 Q60598 SRC8_MOUSE Src substrate cortactin -3.25 0.000 Q99K28 ARFG2_MOUSE ADP-ribosylation factor GTPase-activating protein 2 -3.26 0.001 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.66 0.001 Q91X8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 P55095 GLUC_MOUSE Glucagon -3.82 0.000 P59242 CING_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 Q8URW6 MYH14_MOUSE Myosin-14 -4.10 0.007 Q8U244 SATB2_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE Mitotic interactor and sub | Q8VDM6 | HNRL1_MOUSE | Heterogeneous nuclear ribonucleoprotein U-like protein 1 | -2.98 | 0.001 |
| E9Q7G0 NUMA1_MOUSE Nuclear mitotic apparatus protein 1 -3.05 0.003 Q80Z19 MUC2_MOUSE Mucin-2 -3.07 0.000 Q60598 SRC8_MOUSE Src substrate cortactin -3.25 0.000 Q99K28 ARFG2_MOUSE ADP-ribosylation factor GTPase-activating protein 2 -3.28 0.008 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.66 0.001 Q9JIX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 P55095 GLUC_MOUSE Giucagon -3.82 0.000 P59242 CING_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 4.02 0.001 Q8VI24 SATB2_MOUSE DNA-binding protein SATB2 4.10 0.007 Q8V124 SATB2_MOUSE DNA-binding protein SATB2 4.12 0.004 Q9D279 MISP_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE | Q62393 | TPD52_MOUSE | Tumor protein D52 | -3.04 | 0.000 |
| Q80Z19 MUC2_MOUSE Mucin-2 -3.07 0.000 Q60598 SRC8_MOUSE Src substrate cortactin -3.25 0.000 Q99K28 ARFG2_MOUSE ADP-ribosylation factor GTPase-activating protein 2 -3.28 0.008 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.66 0.001 P16014 SCG1_MOUSE Secretogranin-1 -3.66 0.004 Q9JX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 P55095 GLUC_MOUSE Glucagon -3.82 0.000 P59242 CING_MOUSE Thymosin beta-4 -4.02 0.001 P29391 FRIL1_MOUSE Ferritin light chain 1 -4.09 0.007 Q8V124 SATB2_MOUSE DNA-binding protein SATB2 -4.10 0.007 Q8V124 SATB2_MOUSE Mitotic interactor and substrate of PLK1 -4.12 0.004 Q9D279 MISP_MOUSE Nitotic interactor and substrate of PLK1 -4.12 0.000 Q9ES28 ARHG7_M | E9Q7G0 | NUMA1_MOUSE | Nuclear mitotic apparatus protein 1 | -3.05 | 0.003 |
| Q60598 SRC8_MOUSE Src substrate cortactin -3.25 0.000 Q99K28 ARF62_MOUSE ADP-ribosylation factor GTPase-activating protein 2 -3.28 0.008 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.66 0.001 P16014 SCG1_MOUSE Secretogranin-1 -3.66 0.001 Q9JIX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 P55095 GLUC_MOUSE Glucagon -3.82 0.000 P59242 CING_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 Q6URW6 MYH14_MOUSE Ferritin light chain 1 -4.09 0.007 Q8VI24 SATB2_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE Mitotic interactor and substrate of PLK1 -4.17 0.000 Q9ES28 ARHG7_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P03634 CAHII | Q80Z19 | MUC2_MOUSE | Mucin-2 | -3.07 | 0.000 |
| Q99K28 ARFG2_MOUSE ADP-ribosylation factor GTPase-activating protein 2 -3.28 0.008 Q99K30 ES8L2_MOUSE Epidermal growth factor receptor kinase substrate 8-like protein 2 -3.56 0.001 P16014 SCG1_MOUSE Secretogranin-1 -3.66 0.001 Q9JIX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 P55095 GLUC_MOUSE Glucagon -3.82 0.000 P59242 CING_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 Q6URW6 MYH14_MOUSE Ferritin light chain 1 -4.09 0.000 Q6URW6 MYH14_MOUSE Myosin-14 -4.10 0.007 Q8VI24 SATB2_MOUSE Mitotic interactor and substrate of PLK1 -4.17 0.000 Q9ES28 ARHG7_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE | Q60598 | SRC8_MOUSE | Src substrate cortactin | -3.25 | 0.000 |
| Q99K30ES8L2_MOUSEEpidermal growth factor receptor kinase substrate 8-like protein 2-3.560.001P16014SCG1_MOUSESecretogranin-1-3.660.001Q9JIX8ACINU_MOUSEApoptotic chromatin condensation inducer in the nucleus-3.790.004P55095GLUC_MOUSEGlucagon-3.820.000P59242CING_MOUSEThymosin beta-4-4.020.001P20065TYB4_MOUSEFerritin light chain 1-4.090.000Q6URW6MYH14_MOUSEFerritin light chain 1-4.100.007Q8VI24SATB2_MOUSEDNA-binding protein SATB2-4.120.004Q9D279MISP_MOUSEMitotic interactor and substrate of PLK1-4.170.000Q9ES28ARHG7_MOUSECarbonic anhydrase 1-6.830.001P09528FRIH_MOUSEFerritin heavy chain-7.420.001Q9D312K1C20_MOUSEKeratin, type I cytoskeletal 20-7.510.000P55050FABPI_MOUSEFatty acid-binding protein, intestinal-11.290.000P97816S100G_MOUSEProtein S100-G-12.890.000 | Q99K28 | ARFG2_MOUSE | ADP-ribosylation factor GTPase-activating protein 2 | -3.28 | 0.008 |
| P16014 SCG1_MOUSE Secretogranin-1 -3.66 0.001 Q9JIX8 ACINU_MOUSE Apoptotic chromatin condensation inducer in the nucleus -3.79 0.004 P55095 GLUC_MOUSE Glucagon -3.82 0.000 P59242 CING_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 P29391 FRIL1_MOUSE Ferritin light chain 1 -4.09 0.000 Q6URW6 MYH14_MOUSE Myosin-14 -4.10 0.007 Q8VI24 SATB2_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE Mitotic interactor and substrate of PLK1 -4.17 0.000 Q9ES28 ARH67_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal | Q99K30 | ES8L2_MOUSE | Epidermal growth factor receptor kinase substrate 8-like protein 2 | -3.56 | 0.001 |
| Q9JIX8ACINU_MOUSEApoptotic chromatin condensation inducer in the nucleus-3.790.004P55095GLUC_MOUSEGlucagon-3.820.000P59242CING_MOUSECingulin-3.960.003P20065TYB4_MOUSEThymosin beta-4-4.020.001P29391FRIL1_MOUSEFerritin light chain 1-4.090.000Q6URW6MYH14_MOUSEMyosin-14-4.100.007Q8VI24SATB2_MOUSEDNA-binding protein SATB2-4.120.004Q9D279MISP_MOUSEMitotic interactor and substrate of PLK1-4.170.000Q9ES28ARHG7_MOUSERho guanine nucleotide exchange factor 7-5.070.009P13634CAH1_MOUSECarbonic anhydrase 1-6.830.000P09528FRIH_MOUSEFerritin heavy chain-7.420.001Q9D312K1C20_MOUSEKeratin, type I cytoskeletal 20-7.510.000P55050FABPI_MOUSEFatty acid-binding protein, intestinal-11.290.000P97816S100G_MOUSEProtein S100-G-12.890.000 | P16014 | SCG1_MOUSE | Secretogranin-1 | -3.66 | 0.001 |
| P55095 GLUC_MOUSE Glucagon -3.82 0.000 P59242 CING_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 P29391 FRIL1_MOUSE Ferritin light chain 1 -4.09 0.000 Q6URW6 MYH14_MOUSE Myosin-14 -4.10 0.007 Q8V124 SATB2_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE Mitotic interactor and substrate of PLK1 -4.17 0.000 Q9ES28 ARHG7_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | Q9JIX8 | ACINU_MOUSE | Apoptotic chromatin condensation inducer in the nucleus | -3.79 | 0.004 |
| P59242 CING_MOUSE Cingulin -3.96 0.003 P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 P29391 FRIL1_MOUSE Ferritin light chain 1 -4.09 0.000 Q6URW6 MYH14_MOUSE Myosin-14 -4.10 0.007 Q8VI24 SATB2_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE Mitotic interactor and substrate of PLK1 -4.17 0.000 Q9ES28 ARHG7_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE Carbonic anhydrase 1 -6.83 0.000 P09528 FRIH_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | P55095 | GLUC_MOUSE | Glucagon | -3.82 | 0.000 |
| P20065 TYB4_MOUSE Thymosin beta-4 -4.02 0.001 P29391 FRIL1_MOUSE Ferritin light chain 1 -4.09 0.000 Q6URW6 MYH14_MOUSE Myosin-14 -4.10 0.007 Q8V124 SATB2_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE Mitotic interactor and substrate of PLK1 -4.17 0.000 Q9ES28 ARHG7_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE Ferritin heavy chain -6.83 0.000 P09528 FRIH_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | P59242 | CING_MOUSE | Cingulin | -3.96 | 0.003 |
| P29391 FRIL1_MOUSE Ferritin light chain 1 -4.09 0.000 Q6URW6 MYH14_MOUSE Myosin-14 -4.10 0.007 Q8V124 SATB2_MOUSE DNA-binding protein SATB2 -4.12 0.004 Q9D279 MISP_MOUSE Mitotic interactor and substrate of PLK1 -4.17 0.000 Q9ES28 ARHG7_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE Carbonic anhydrase 1 -6.83 0.000 P09528 FRIH_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | P20065 | TYB4_MOUSE | Thymosin beta-4 | -4.02 | 0.001 |
| Q6URW6MYH14_MOUSEMyosin-14-4.100.007Q8VI24SATB2_MOUSEDNA-binding protein SATB2-4.120.004Q9D279MISP_MOUSEMitotic interactor and substrate of PLK1-4.170.000Q9ES28ARHG7_MOUSERho guanine nucleotide exchange factor 7-5.070.009P13634CAH1_MOUSECarbonic anhydrase 1-6.830.000P09528FRIH_MOUSEFerritin heavy chain-7.420.001Q9D312K1C20_MOUSEKeratin, type I cytoskeletal 20-7.510.000P55050FABPI_MOUSEFatty acid-binding protein, intestinal-11.290.000P97816S100G_MOUSEProtein S100-G-12.890.000 | P29391 | FRIL1_MOUSE | Ferritin light chain 1 | -4.09 | 0.000 |
| Q8VI24SATB2_MOUSEDNA-binding protein SATB2-4.120.004Q9D279MISP_MOUSEMitotic interactor and substrate of PLK1-4.170.000Q9ES28ARHG7_MOUSERho guanine nucleotide exchange factor 7-5.070.009P13634CAH1_MOUSECarbonic anhydrase 1-6.830.000P09528FRIH_MOUSEFerritin heavy chain-7.420.001Q9D312K1C20_MOUSEKeratin, type I cytoskeletal 20-7.510.000P55050FABPI_MOUSEFatty acid-binding protein, intestinal-11.290.000P97816S100G_MOUSEProtein S100-G-12.890.000 | Q6URW6 | MYH14_MOUSE | Myosin-14 | -4.10 | 0.007 |
| Q9D279MISP_MOUSEMitotic interactor and substrate of PLK1-4.170.000Q9ES28ARHG7_MOUSERho guanine nucleotide exchange factor 7-5.070.009P13634CAH1_MOUSECarbonic anhydrase 1-6.830.000P09528FRIH_MOUSEFerritin heavy chain-7.420.001Q9D312K1C20_MOUSEKeratin, type I cytoskeletal 20-7.510.000P55050FABPI_MOUSEFatty acid-binding protein, intestinal-11.290.000P97816S100G_MOUSEProtein S100-G-12.890.000 | Q8VI24 | SATB2_MOUSE | DNA-binding protein SATB2 | -4.12 | 0.004 |
| Q9ES28 ARHG7_MOUSE Rho guanine nucleotide exchange factor 7 -5.07 0.009 P13634 CAH1_MOUSE Carbonic anhydrase 1 -6.83 0.000 P09528 FRIH_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | Q9D279 | MISP_MOUSE | Mitotic interactor and substrate of PLK1 | -4.17 | 0.000 |
| P13634 CAH1_MOUSE Carbonic anhydrase 1 -6.83 0.000 P09528 FRIH_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | Q9ES28 | ARHG7_MOUSE | Rho guanine nucleotide exchange factor 7 | -5.07 | 0.009 |
| P09528 FRIH_MOUSE Ferritin heavy chain -7.42 0.001 Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | P13634 | CAH1_MOUSE | Carbonic anhydrase 1 | -6.83 | 0.000 |
| Q9D312 K1C20_MOUSE Keratin, type I cytoskeletal 20 -7.51 0.000 P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | P09528 | FRIH_MOUSE | Ferritin heavy chain | -7.42 | 0.001 |
| P55050 FABPI_MOUSE Fatty acid-binding protein, intestinal -11.29 0.000 P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | Q9D312 | K1C20_MOUSE | Keratin, type I cytoskeletal 20 | -7.51 | 0.000 |
| P97816 S100G_MOUSE Protein S100-G -12.89 0.000 | P55050 | FABPI_MOUSE | Fatty acid-binding protein, intestinal | -11.29 | 0.000 |
| | P97816 | S100G_MOUSE | Protein S100-G | -12.89 | 0.000 |

| Table 2.14 Species Ide | entifiied Across Distal ar | d Proximal Fecal S | Samples and their | Characteristics |
|------------------------|----------------------------|--------------------|-------------------|-----------------|
|------------------------|----------------------------|--------------------|-------------------|-----------------|

| Species Code | Species | Phylum | Class | Genus | Gram Stain | Oxygen Requirements | Pathogenicity |
|-----------------------------------|---|----------------|---------------------|-------------------|---------------|------------------------|----------------|
| ACET2 | Acetivibrio thermocellus | Bacillota | Clostridia | Acetivibrio | + | Anaerobic | Non-pathogenic |
| AGARV | Agathobacter rectalis | Bacillota | Clostridia | Agathobacter | + | Anaerobic | Non-pathogenic |
| ALISL | Aliivibrio salmonicida | Proteobacteria | Gammaproteobacteria | Allivibrio | - | Facultative | Non-pathogenic |
| ANAPI | Anaerotignum propionicum | Bacillota | Clostridia | Anaerotignum | + | Anaerobic | Pathogenic |
| BACFR | Bacteroides fragilis | Bacteroidetes | Bacteroidia | Bacteroides | - | Anaerobic | Pathogenic |
| BACLD | Bacillus licheniformis | Bacillota | Bacilli | Bacillus | + | Facultative | Non-pathogenic |
| BACME | Bacillus megaterium | Bacillota | Bacilli | Bacillus | + | Aerobic | Non-pathogenic |
| BACTN | Bacteroides thetaiotaomicron | Bacteroidetes | Bacteroidia | Bacteroides | - | Anaerobic | Non-pathogenic |
| CARHZ | Carboxydothermus hydrogenoformans | Bacillota | Clostridia | Carboxydothermus | + | Anaerobic | Non-pathogenic |
| CELJU | Cellvibrio japonicus | Proteobacteria | Gammaproteobacteria | Cellvibrio | - | Aerobic | Non-pathogenic |
| CLOAB | Clostridium acetobutylicum | Bacillota | Clostridia | Clostridium | + | Anaerobic | Non-pathogenic |
| CLOB8 | Clostridium beijerinckii | Bacillota | Clostridia | Clostridium | + | Anaerobic | Non-pathogenic |
| CLOBB | Clostridium botulinum | Bacillota | Clostridia | Clostridium | + | Anaerobic | Pathogenic |
| CLOPE/CLOP ⁻ /CLOPS | 1 Clostridium perfringens | Bacillota | Clostridia | Clostridium | + | Anaerobic | Pathogenic |
| CLOSY | Clostridium symbiosum | Bacillota | Clostridia | Lachnoclostridium | - | Anaerobic | Non-pathogenic |
| CLOTE | Clostridium tetani | Bacillota | Clostridia | Clostridium | + | Anaerobic | Pathogenic |
| CORDI | Corynebacterium diphtheriae | Actinobacteria | Actinobacteria | Corynebacterium | + | Aerobic | Pathogenic |
| COREF* | Corynebacterium | Actinobactoria | Actinohactoria | Corupobactorium | Ŧ | Focultativo | Non nothogonia |
| /CORGL* | efficiens*/glutamicum* | Actinopacteria | Actinobacteria | Corynobacterium | т | Facultative | Non-pathogenic |
| CORGL | Corynebacterium glutamicum | Actinobacteria | Actinobacteria | Corynobacterium | + | Anaerobic | Pathogenic |
| CYTH3 | Cytophaga hutchinsonii | Bacteroidetes | Cytophagia | Cytophaga | - | Aerobic | Non-pathogenic |
| DEHMC | Dehalococcoides mccartyi | Chloroflexi | Dehalococcoidetes | Dehalococcoides | + | Anaerobic | Non-pathogenic |
| DICTD | Dictyoglomus turgidum | Dictyoglomi | Dictyoglomia | Dictyoglomus | + | Anaerobic | Non-pathogenic |
| ECOLI | Escherichia coli | Proteobacteria | Gammaproteobacteria | Eschereschia | - | Facultative | Pathogenic |
| FLAJ1 | Flavobacterium johnsoniae | Bacteroidetes | Flavobacteria | Flavobacterium | - | Aerobic | Non-pathogenic |
| FUSNN | Fusobacterium nucleatum subsp. nucleatum | Fusobacteria | Fusobacteria | Fusobacterium | - | Anaerobic | Pathogenic |
| GEOUR | Geobacter uraniireducens | Proteobacteria | Deltaproteobacter | Geobacter | - | Microaerophili c | Non-pathogenic |
| LACDB | Lactobacillus delbrueckii | Bacillota | Bacilli | Lactobacillus | + | Facultative | Non-pathogenic |
| LACE2 | Lachnospira eligens | Bacillota | Clostridia | Lachnospira | + | Anaerobic | Non-pathogenic |
| LACLM | Lactococcus lactis subsp. Cremoris | Bacillota | Bacilli | Lactococcus | + | Anaerobic | Non-pathogenic |
| LACP7 | Lachnoclostridium phytofermentans | Bacillota | Clostridia | Clostridium | + | Anaerobic | Non-pathogenic |
| LEPBP | Leptospira biflexa serovar Patoc | Spirochaetota | Spirochaetia | Leptospira | - | Aerobic | Non-pathogenic |
| LEUMM* /LEUCK* | Leuconostoc mesenteroides/citreum | Bacillota | Bacilli | Leuconostoc | + | Facultative | Non-pathogenic |
| LISIN*/LISMO* | Listeria innocua/monocytogenes | Bacillota | Bacilli | Listeria | + | Anaerobic | Pathogenic |
| OCEIH | Oceanobacillus iheyensis | Bacillota | Bacilli | Oceanobacillus | + | Aerobic | Non-pathogenic |
| PARD8 | Parabacteroides distasonis | Bacteroidetes | Bacteroidia | Parabacteroides | - | Anaerobic | Pathogenic |
| PORGI* | Porphyromonas gingivalis | Bacteroidetes | Bacteroidia | Porphyromonas | - | Anaerobic | Pathogenic |

| /PORG3* | | | | | | | |
|-----------------------|-------------------------------------|----------------|---------------------|--------------------|---|-------------|----------------|
| PROM4 | Prochlorococcus marinus | Cyanobacteria | N/A | Prochlorococcus | - | Aerobic | Non-pathogenic |
| PSEAE | Pseudomonas aeruginosa | Proteobacteria | Gammaproteobacteria | Pseudomonas | - | Aerobic | Pathogenic |
| RUMCH | Ruminiclostridium cellulolyticum | Bacillota | Clostridia | Clostridium | + | Anaerobic | Non-pathogenic |
| SELRU | Selenomonas ruminantium | Bacillota | Negativicutes | Selenomonas | - | Anaerobic | Non-pathogenic |
| SHEAM* /SHELP* | Shewanella amazonensis/loihica | Proteobacteria | Gammaproteobacteria | Shewanella | - | Facultative | Non-pathogenic |
| SPITD | Spirochaeta thermophila | Spirochaetota | Spirochaetia | Spirochaeta | - | Anaerobic | Pathogenic |
| STRP6/STRP8/ STRPQ | Streptococcus pyogenes | Bacillota | Bacilli | Streptococcus | + | Facultative | Pathogenic |
| SYNJB | Synechococcus sp. | Cyanobacteria | Cyanophyceae | Synechococcus | - | Facultative | Non-pathogenic |
| SYNS3 | Synechococcus sp. | Cyanobacteria | Cyanophyceae | Synechococcus | - | Facultative | Non-pathogenic |
| SYNY3 | Synechocystis sp. | Cyanobacteria | Cyanophyceae | Synechocystis | - | Facultative | Non-pathogenic |
| THEP3 | Thermoanaerobacter pseudethanolicus | Bacillota | Clostridia | Thermoanaerobacter | + | Anaerobic | Non-pathogenic |

*Peptide quantified sourced back to two species of the same family

CHAPITRE 3 GENERAL DISCUSSION

This chapter summarizes and discusses results previously described in Chapter 2, as well as offers additional results pertaining to the metabolomic, proteomic and metaproteomic analyses of healthy mouse colon and fecal samples.

3.1 Metabolomic Analysis of Colon and Fecal Samples

Metabolomic analysis was performed to characterize the metabolome coverage from fecal and colon samples using an untargeted LC-MS/MS approach with two complementary chromatographic methods in electrospray positive and negative mode. Sample preparation was employed followed by peak picking, library searching for identification of putative metabolites and verification of peak integrations and finally, statistical analysis between distal and proximal samples. Although quantitation is employed for both metabolomic and proteomic analysis, the process is quite different between the two types of analyses. Quantitation in metabolomic analysis requires a more tedious approach to proteomics (where SWATH analysis software allows for automated quantitation) in which manual verification of metabolites is necessary to ensure quantitation and statistical analysis is accurate. Statistically significant metabolites also need to undergo extra verifications of peak integrations as these metabolites are often considered to be biomarkers in many different cases in which it is critical to ensure that peak integrations of metabolites are performed correctly. Often in metabolomic analysis, follow-up targeted analyses are required to confirm the identification and significance of metabolimes.

Untargeted metabolomics can yield useful information on observed phenotypes originating from changes at the genomic, transcriptomic, and proteomic levels. An important goal of this work was to identify distinct groups of metabolites and pathways that differ between distal and proximal colon regions in healthy mice. This study allowed us to understand baseline heterogeneity within the colon, serving for further studies when intestinal diseases are involved. The fecal metabolome was studied for the same purposes as well as to characterize how it compares to the colon metabolome in a healthy mouse model. As shown in Figure 3.1, there is a high number of metabolites that are shown to overlap between colon and fecal sample matrices, but there remains many metabolites unique to the respective sample types. With 335 common metabolites, 174 and 289 remain unique to the colon and feces respectively. Proximal and distal samples originating

from five healthy mice were subjected to homogenisation and protein precipitation followed by data processing of raw LC-MS/MS data (Figure 2.1). Although the data processing of colon and fecal samples followed the same steps, slight differences in sample preparation were employed in order to initially normalize. Higher weights (mg) of colon samples were available compared to the weights (mg) of fecal samples. The initial volume of buffer added to colon therefore corresponded to 0.5 µL of buffer per mg of tissue collected whereas 1 µL/mg was used for feces samples. Although the colon and fecal samples received are wet weights and the water content throughout the colon is unknown, normalization based on the weights of samples received was performed. Additionally, during data processing, an additional normalization step was employed after peak integration using MarkerView software where MLR normalization was employed as mentioned in Chapter 2. Although the latter step was not performed for proteomic analysis, a Bradford protein quantification was done as mentioned in Chapter 2 to normalize protein content ensuring the same conditions in all samples prior the digestion.

Another difference employed was the need for probe sonication of tissue samples for adequate homogenisation, whereas feces samples did not necessitate this step. Fecal samples were able to homogenize well with the addition of ammonium bicarbonate (ABC) buffer and 100% MeOH and vortexing, but the tissue samples being of much higher weights and the nature of whole tissue, addition of ABC buffer and MeOH with subsequent vortexing was not enough to homogenize the samples hence the necessity for probing.



Figure 3.1 Overlap of colon and fecal metabolites identified

To maximize the number of metabolites putatively identified, two chromatographic columns were employed for metabolite separation by liquid chromatography prior to mass spectrometry analysis. These were a mixed mode column with ion exchange and reverse phase stationary phase (Scherzo SM-C18) and a pentafluorophenyl (Luna PFP) column to separate compounds based on different properties and provide complementary metabolites. This was shown to be effective as shown in Figure 2.2 where, in both sample types, that there a large portion of putative metabolites identified uniquely from each column.

This work was able to putatively identify a large number of metabolites using LC-HRMS/MS from colon and fecal samples. Statistical analysis was then performed to find out which metabolites were higher in one of the colon regions. The colon dataset demonstrated important heterogeneity of 153 metabolites in the two regions, but the same pattern was not seen from the fecal samples with only 23 metabolites shown to be significant, even though a high initial number of putative metabolites were found in feces. Considering the larger number of changing metabolite levels in the colon, pathway analyses were performed to visualize which biological pathways could be playing important roles specifically in one of the regions. Although the dataset is quite complex and much more can be extracted from these results, we were able to identify two specific classes of metabolites and highlight their heterogeneity in the colon. Prostaglandins as well as tryptophan metabolites were found to increase in the distal and proximal regions, respectively. Tryptophan metabolism can be broken down into three main pathways: kynurenine pathway, serotonin pathway and the indole pathway in which the metabolites involved are largely implicated in colonic motility and gut signalling and have a large presence in the GI tract (Roth et al., 2021). More specifically, serotonin is abundant in the gut where its presence in the gut accounts for more than 90% of the body's serotonin production, although research is largely focused on serotonin in the context of neurological disorders (Appleton, 2018). Although it has been described how changing levels of serotonin in the gut can be implicated in the pathogenesis of intestinal diseases, such as IBS-C and IBS-D, its levels in the gut can also be implicated in the manifestation of neurological disorders. Literature has shown that altered levels of GI metabolites, such as serotonin, can lead to several neurological disorders, such as anxiety and depression through the gut-brain axis (Appleton, 2018; Irum et al., 2023). Serotonin is a key neurotransmitter involved in the central nervous system and in the GI tract, highlighting its potential implication in a plethora of diseases. Although several selective serotonin reuptake inhibitors (SSRIs) exist as treatment options for neurological disorders such as anxiety and depression, research has shown that certain specific bacterial species able to produce neurotransmitters, such as serotonin, populating the gut microbiome can also lead to beneficial results in this context (Potter et al., 2023). It was also found that many patients suffering from intestinal diseases from gut dysbiosis, involving tryptophan metabolism and more specifically serotonin levels, also present symptoms of neurological disorders (Potter *et al.*, 2023). The key findings that serotonin is highly upregulated in the proximal region of the colon in healthy subjects is an important result of this study. This finding indicates that monitoring serotonin levels specifically from the proximal colon could show more clear differences in the context of disease. As serotonin is much less expressed in the distal region of the colon, the proximal portion likely yields much more accurate information regarding the changing levels of serotonin in the gut. This information can be very useful to diagnose and determine the levels of serotonin needed on a patient-by-patient basis to potentially remediate symptoms of both neurological and intestinal disorders.

Several prostaglandin molecules showed increased levels in the distal portion of the colon (Table 2.2). Prostaglandins are long chain fatty acids prevalent in the gut, notably in the gut mucosa, with either anti-inflammatory or pro-inflammatory properties, making them a group of metabolites of interest in the context of GI inflammation or disease. The higher expression of several prostaglandins in the distal colon could lead to several theories about the nature of intestinal disease prognosis between the two regions of the colon, as well as the region-specific perturbations. Due to the fact that prostaglandins are heavily involved in mucosal defence, they will often be involved in the inflammatory response to resolve injury or infection in the body along with immune cells, but concurrently can also contribute to chronic inflammatory conditions by continuous recruitment of cytokines and chemokines (Aoki et Narumiya, 2012; Ricciotti et FitzGerald, 2011; Semble et Wu, 1989). Regarding CRC, the presence of several prostaglandin molecules in the distal colon could be linked to why prognosis in the proximal region of the colon is worse than in the distal region due to increase in pro-inflammatory action. In the context of CRC, prostaglandin molecules could potentially play an important role in mediating inflammation in the distal colon, whereas the same cannot be said for the proximal region. On the contrary, ulcerative colitis which is more often expressed in the distal colon could be a result of pro and chronic inflammatory action by the several prostaglandins found to be region specific in the distal portion. The findings of regional specificity of prostaglandins in healthy subjects can serve as an important baseline to further understand the prevalence, diagnosis, and treatment options for various intestinal conditions. The metabolomic analysis has demonstrated key metabolite groups that can be measured in the gut as well as which ones show regional specificity.

3.2 Proteomic Analysis of Colon Samples

Untargeted proteomics was performed on colon samples from the proximal and distal regions for protein identification and relative quantitation between the two regions studied. Proteomic analysis of colon samples was performed for identifying and quantifying mouse proteins, however, when fecal samples were analysed in the same manner, the coverage of mouse proteins was extremely low, due to most proteins being from microorganisms in feces. Therefore, a metaproteomic analysis was performed on fecal samples to identify and quantify microbial proteins as opposed to mouse proteins.

By combining both data-dependent (IDA) and data-independent (SWATH) data acquisition, a comprehensive proteomic profile was obtained for colon samples with a total of 1103 colon mouse proteins quantified. The extraction procedure previously described in Chapter 2 allows for extraction of several proteins including intracellular, membrane, and extracellular proteins. Membrane proteins are often more difficult to extract due to their lipid bilayer, notably when working with complex sample matrices but does not mean it is not possible. It is based on whether or not certain types of proteins are abundant enough in a given sample to be detected by the mass spectrometer (Lai, X., 2013; Vuckovic *et al.*, 2013). For example, highly abundant proteins are easily detected but lower abundant membrane proteins that are present in the sample are not likely to be detected. In cases like these, there are certain procedures that can be performed to enrich low abundance proteins for their detection. Procedures such a fractionation, differential centrifugation, and targeted mass spectrometry analysis can be performed to overcome high-abundant proteins to be able to detect and quantify lower abundant proteins (Sarihan *et al.*, 2023; Vuckovic *et al.*, 2013).

Performing statistical analysis revealed many changing proteins between the proximal and distal regions, with 158 proteins being differentially expressed when using strict statistical parameters (p < 0.01, *fold-change* > |2|), demonstrating high protein heterogeneity between the two regions. The online tool Reactome was used to map these proteins to specific pathways dominating in the distal and proximal colon, respectively. Proteins involved in both axon guidance and innate immune response were increased in the distal colon. On the other hand, in the proximal region, proteins involved in keratinization were increased.

Performing an analysis of the changing colon proteins using Panther, a different online software, showed additional pathways of interest, notably to the distal region of the colon. Using the list of

proteins changing by at least 50% with 281 statistically significant proteins, 129 proteins were shown have higher levels in the distal region, compared to 152 proteins for the proximal group. Although, less proteins were increased in the distal colon, these proteins were able to map more pathways, including glycolysis, integrin signalling and cytoskeletal regulation. Table 3.1 summarizes the proteins of interest from these three pathways. Although a lower fold change criteria was used for the Panther analysis, proteins changing by at least 50% with *p*-values below 0.05 are still considered to be statistically significant.

Table 3.1 Proteins with Higher Levels in Distal Colon Involved in A) Cytoskeletal Regulation, B) Integrin Signalling Pathway, and C) Glycolysis

| Cytoskeletal Regulation by Rho GTPase | | | | | |
|---------------------------------------|---|--------------------------|----------------------|--|--|
| Accession Number | Protein Name | Fold Change DC vs. PC | <i>p</i> -value | | |
| P45591 | Cofilin-2 | 1.7 | 8.9x10 ⁻³ | | |
| Q9JM76 | Actin-related protein 2/3 complex subunit 3 | 1.9 | 1.5x10 ⁻³ | | |
| Q922F4 | Tubulin beta-6 chain | 2.3 | 6.8x10 ⁻³ | | |
| P62962 | Profilin-1 | 3.3 | 1.1x10 ⁻⁴ | | |
| P59999 | Actin-related protein 2/3 complex subunit 4 | 2.7 | 1.5x10 ⁻³ | | |
| P68134 | Actin, alpha skeletal muscle | 3.8 | 1.9x10 ⁻⁴ | | |
| P63268 | Actin, gamma-enteric smooth muscle | 2.9 | 8.6x10 ⁻³ | | |
| Q9CVB6 | Actin-related protein 2/3 complex subunit 2 | 2.1 | 4.2x10 ⁻³ | | |

| Integrin Signalling Pathway | | | | | | |
|-----------------------------|--|--------------------------|----------------------|--|--|--|
| Accession Number | Protein Name | Fold Change DC vs. PC | <i>p</i> -value | | | |
| Q9JM76 | Actin-related protein 2/3 complex subunit 3 | 1.9 | 1.5x10 ⁻³ | | | |
| Q02788 | Collagen alpha-2(VI) chain | 4.1 | 6.8x10 ⁻³ | | | |
| P10833 | Ras-related protein R-Ras | 1.9 | 4.0x10 ⁻⁴ | | | |
| Q7TPR4 | Alpha-actinin-1 | 2.4 | 4.6x10 ⁻³ | | | |
| P68134 | Actin, alpha skeletal muscle | 3.8 | 1.9x10 ⁻⁴ | | | |
| P63268 | Actin, gamma-enteric smooth muscle | 2.9 | 8.6x10 ⁻³ | | | |
| P11688 | Integrin alpha-5 | 1.7 | 9.2x10 ⁻⁴ | | | |
| Q9CVB6 | Actin-related protein 2/3 complex subunit 2 | 2.1 | 4.2x10 ⁻³ | | | |
| P02468 | Laminin subunit gamma-1 | 1.6 | 9.4x10 ⁻³ | | | |
| Q80X19 | Collagen alpha-1(XIV) chain | 2.3 | 4.5x10 ⁻⁵ | | | |
| Q9D898 | Actin-related protein 2/3 complex subunit 5-like protein | 1.7 | 2.8x10 ⁻³ | | | |

| C) | | Glycolysis | | | | | | |
|----|------------------|--|--------------------------|----------------------|--|--|--|--|
| 0, | Accession Number | Protein Name | Fold Change DC vs. PC | <i>p</i> -value | | | | |
| | P17710 | Hexokinase-1 | 2.0 | 3.4x10 ⁻³ | | | | |
| | P05064 | Fructose-bisphosphate aldolase A | 1.8 | 3.1x10 ⁻³ | | | | |
| | P16858 | Glyceraldehyde-3-phosphate dehydrogenase | 2.4 | 2.4x10 ⁻⁴ | | | | |
| | P52480 | Pyruvate kinase PKM | 1.9 | 2.9x10⁻⁵ | | | | |
| | P09411 | Phosphoglycerate kinase 1 | 1.7 | 4.9x10 ⁻⁴ | | | | |

A)

164

As shown in Table 3.1, eight and eleven proteins, respectively, are implicated in cytoskeletal regulation by Rho GTPases and integrin signalling, having three proteins in common. Integrins comprise a large group of cell adhesion molecules that can bind to soluble ligands, extracellular matrix (ECM) ligands as well as cell surface ligands (Takada *et al.*, 2007). By binding to various ligands, they can participate in critical signalling by allowing interactions between cells and the ECM. This makes integrins a key component in various functions such as cell homeostasis, inflammation, cell survival and proliferation (Cooper et Giancotti, 2019). A possible explanation for the overlap between the integrin signalling and cytoskeletal regulation pathways is that integrins can allow cytoskeletal cells to bind to their targets in the ECM, a process that would involve both pathways (Ramovs *et al.*, 2017).

Although only one integrin was quantified in this dataset (integrin-alpha 5), there are several proteins that are involved in the overall binding with integrins resulting in their downstream signalling. For example, laminin is a protein that was quantified as part of the integrin signalling pathway and is implicated in the early stages of the signalling cascade. Laminins are cell adhesion glycoproteins as well and are a main target of specific integrins. The same relationship is seen with collagen proteins (which have also been quantified) in which different integrins and their subunits can bind to different ligands i.e., collagen ligands or laminin ligands depending on their binding affinities (Cooper et Giancotti, 2019). Depending on which ligands integrins will bind to, different roles can be carried out.

This analysis demonstrates that integrin and laminin binding is likely occurring more in the distal colon. Laminin and collagen proteins along with a multitude of other glycoproteins and glycosaminoglycans are found in basement membranes that are present in nearly all tissues. They are composed of thin ECM and are responsible for acting as a barrier between stroma and parenchymal cells (Mylonas et Lazaris, 2014). It has been shown that certain diseases such as cancer can alter basement membrane composition or even mutations in basement membrane proteins can be the cause of disease in tissues (Mylonas et Lazaris, 2014; Schmehl *et al.*, 2000; Spenlé *et al.*, 2014). Interestingly, Schmehl *et al.* studied the colonic tissues of patients with ulcerative colitis and found an under expression of laminin proteins combined with an overexpression of collagen type IV and V proteins. This reorganization of the basement membrane led to the possibility of loss of function of the basement membrane (Schmehl *et al.*, 2000). This is an interesting finding considering many ulcerative colitis cases are mainly found in the distal colon,
making proteins involved in integrin signalling notably, laminin and collagen proteins an area of research to consider in future studies.

Performing proteomic analysis allowed comprehensive profiling of the distinct regions of the colon, thus showing certain pathways being dominant in respective regions. Complementary pathway analyses (Panther, Reactome and MetaboAnalyst) also proved beneficial.

3.3 Metaproteomics of Fecal Samples

Metaproteomics is a growing area of research notably for the study of the gut microbiome as it allows for the identification and quantification of proteins from microbial species also offering strain specific information in certain cases (Kleiner, 2019). Although genomic approaches such as 16S rRNA analysis are widely utilized for identifying microorganism species, metaproteomics by LC-MS/MS offers advantages such as yielding information about the proteins being expressed from specific microbial species and revealing the functions that are being played out by these species allowing for a more comprehensive view of the protein network and interactions between species (Petriz et Franco, 2017). Metaproteomics also has the added advantage of higher resolution of species compared to 16S rRNA, allowing for strain specific, as well as having inherently better quantitative potential (Cortes *et al.*, 2019).

To perform metaproteomics, fecal samples undergoing protein digests directly following metabolite extraction and protein precipitation were necessary due to the high likelihood of degradation of proteins in stored fecal extracts during storage. Considering fecal matter is largely made up of microorganisms such as bacteria, the original fecal samples from five healthy female mice used for the metabolomic and proteomic analyses unfortunately did not have substantial protein amount for performing metaproteomics analysis. Considering that metabolomic sample preparation was performed prior to proteomic sample preparation and underwent subsequent storage at -80°C for several weeks, there was a considerable loss of protein in the samples. Therefore, for the purpose of a metaproteomic analysis for microorganism identification in the respective regions, additional fecal samples were used from six healthy mice, 3 females and 3 males. Upon procurement of these samples, sample preparation was performed immediately to avoid any problem associated to protein degradation in the fecal extracts. The loss of protein in the original samples was observed when protein normalization was performed using a Bradford protein assay. In the original samples about 68 μ g/ml of protein per sample was recorded whereas in the new freshly prepared samples about 1400 μ g/ml of protein per sample was recorded. When

166

the low protein concentrations were observed for the original samples that underwent protein degradation, they were discarded, and the analysis was then performed on the additional samples that were prepared immediately after metabolite extraction.

To gain a deeper understanding of proteins present in fecal samples, metaproteomics was conducted. OneOmics Software was employed for data processing, similar to the previous proteomics analysis without initial specifying a species for database searching. The primary objective of the metaproteomics analysis was to identify distinct bacterial species present in the colon and verify if any of these showed differences in abundances between the two regions. The identification of unique bacterial species was only feasible at the peptide level rather than the protein level since most proteins quantified could be attributed to at least three different bacterial species was found to be the quantified peptide, with a sequence uniquely attributed to that species. Table 2.7 summarizes the bacterial species identified, along with associated proteins and peptides from IDA acquisition in the distal and proximal regions

To conduct this analysis, pooled samples (from distal and proximal feces separately) were initially subjected to IDA acquisition for protein identification, followed by individual sample injections in SWATH mode for guantification. While IDA acquisition provided an initial impression of regional specificity, subsequent analysis of quantification data revealed that the identified peptides did not exhibit such specificity. SWATH quantification, represented in a heatmap, provided a more accurate depiction of the samples, emphasizing its superiority over IDA for quantitation. The distinction between IDA and SWATH lies in their ion selection mechanisms. IDA relies on selecting the higher intensity precursor ions for fragmentation, while SWATH utilizes small mass windows for comprehensive fragmentation. Our results underscore the advantages of SWATH in terms of quantitative measurements and reproducibility of measuring peptides throughout a sample set (Fernández-Costa et al., 2020). The complexity of fecal samples further emphasizes the need for reliable results. Subsequent work is planned to develop a targeted method for these peptides specifically for a rapid quantitative assessment of changes in the microbiome of fecal samples in the context of disease or changes in diet. Performing an MRM assay is a good way to target these peptides and confirm their presence in fecal samples. MRM is a robust analysis method and allows for lower abundant peptides/proteins to be detected. The quantitation aspect also becomes much more accurate if a targeted MRM acquisition is performed due to the higher selectivity obtained compared to SWATH, yielding better chromatographic peak shapes and thus more accurate statistical analysis to determine abundance of the proteins/peptides in each sample group (Brioschi *et al.*, 2021).

The limitations presented with IDA acquisition is also demonstrated throughout literature. Fernández-Costa et al., as well as Barkovitz et al., have both demonstrated better reproducibility between replicate samples for peptide and protein guantification when employing DIA/SWATH acquisition mode for samples due to the fact that guantification in SWATH mode utilizes MS1 (precursor ion without fragmentation) and MS2 (fragment ions) data, as opposed to only MS1 data in IDA acquisition (Barkovits et al., 2020; Fernández-Costa et al., 2020). The quantification on MS1 level employed with IDA acquisition leads to several caveats such as: loss of quantification power of low-abundant species and high interference of background signals that can also hinder peptide quantification (Willems et al., 2021). This is especially important as sample complexity increases, as is the case with fecal samples, increasing chemical noise and background signals, affecting the robustness of the data (Willems et al., 2021). Concerning bacterial peptides and proteins, Willems et al., compared identification and quantification results of different dilutions of host proteins using HeLa protein lysates and Salmonella protein lysates to assess the efficiencies of both acquisition modes. DIA/SWATH acquisition proved to be especially beneficial for Salmonella protein and peptides identifications and quantification at lower dilutions compared to IDA (Willems et al., 2021).

Although through this study was able to quantify differences, or lack thereof between proximal and distal feces, quantification relative to species amount/abundance was not able to be performed as absolute quantification is needed. That being said, there is extensive literature describing what has been quantified on the species level by metaproteomics and 16S rRNA, which is notably useful to consider for future experiments. A study performed by *Liu et al.* found that the most prevalent phyla from the fecal microbiome in control mice were *Bacteroidetes* and *Bacillota (Firmicutes)* by 16S rRNA sequencing (Liu *et al.*, 2022). Additionally, a study performed by *Qin, J et al.* reported as well that *Bacteroidetes* and *Bacillota* make up over 90% of the phyla found in the human distal colon from 16S rRNA as well (Qin *et al.*, 2010). Interestingly, *Thuy-Boun et al.* found large discrepancies between the results obtained from metaproteomic and 16S rRNA analysis on the detected levels of *Bacteroidetes* and *Bacillota (Firmicutes)* phyla from stool samples in a study comparing healthy and ulcerative colitis patients. In this study they reported 22.7% *Bacillota* composition in samples compared to 86.2% composition from 16S rRNA, along with much lower detection of *Bacteroidetes* from 16S rRNA (around 0.86%) contrary to 4.2% found

from metaproteomic analysis (Thuy-Boun *et al.*, 2022). The challenges and discrepancies shown from the study performed by *Thuy-Boun et al.* highlight the challenges and complementarity associated with two popular techniques for studying the microbiome and highlights the additional work that needs to be done to further understand and identify the gut microbiome composition.

While the study couldn't draw definitive conclusions regarding regional specificity of bacterial species, our metaproteomics via LC-HRMS/MS offered extensive microbiome coverage at the species and strain levels based on the quantified proteins and peptides monitored. This will undoubtedly serve for future projects implicating perturbations at the microbiome level. This is an exciting new area of proteomics that is applicable to many studies involving gut health and these results will serve as a starting point for our group to continue research in this field.

CONCLUSION

The GI tract, more specifically the colon has been of great interest over the last few decades due to the prevalence of intestinal diseases. Although many studies have shown how disease affects the metabolomic, proteomic, and transcriptomic profile of the colon, very few studies have shown the metabolome and proteome coverage of a healthy colon, notably with the absence of disease to further understand baseline variations in the colon prior to introduction of disease.

This work aimed to study the overall metabolomic and proteomic coverage from colon and feces of healthy mice, as well as investigate if certain of these molecules show region specificity in the colon. High overall metabolite and protein coverage was found in the colon, with many significantly changing molecules in both datasets. Regarding fecal samples, a high metabolite coverage was found, but metaproteomics was required to properly characterize the proteome of these samples. On both metabolite and protein levels, the feces did not show the same region heterogeneity as the colon samples in healthy mice. Metaproteomics revealed several advantages including the specificity of microbial species able to be quantified. Limitations encountered such as the less accurate data obtained from IDA identification regarding which species were present in the distinct regions of the colon was evident from our results.

The information revealed in this project is especially important as it has highlighted key molecular groups that can be targeted for more detailed follow-up studies involving specific diseases affecting the gut. For example, prostaglandins and tryptophan metabolites and well as keratin proteins show regional specificity in healthy subjects, where they can potentially aid in understanding the prevalence, prognosis and treatments options for intestinal diseases affecting specific regions more aggressively.

BIBLIOGRAPHIE

- Agrawal, M. et Jess, T. (2022). Implications of the changing epidemiology of inflammatory bowel disease in a changing world. *United European Gastroenterol J*, *10*(10), 1113-1120. https://doi.org/10.1002/ueg2.12317
- Ang, C. S., Rothacker, J., Patsiouras, H., Burgess, A. W. et Nice, E. C. (2010). Murine fecal proteomics: a model system for the detection of potential biomarkers for colorectal cancer. *J Chromatogr A*, 1217(19), 3330-3340. <u>https://doi.org/10.1016/j.chroma.2009.10.007</u>
- Aoki, T. et Narumiya, S. (2012). Prostaglandins and chronic inflammation. *Trends in Pharmacological Sciences*, 33(6), 304-311. https://doi.org/https://doi.org/10.1016/j.tips.2012.02.004
- Appleton, J. (2018). The Gut-Brain Axis: Influence of Microbiota on Mood and Mental Health. *Integr Med (Encinitas)*, *17*(4), 28-32.
- Armengaud, J. (2023). Metaproteomics to understand how microbiota function: The crystal ball predicts a promising future. *Environ Microbiol*, 25(1), 115-125. https://doi.org/10.1111/1462-2920.16238
- Arnold, D., Lueza, B., Douillard, J. Y., Peeters, M., Lenz, H. J., Venook, A., Heinemann, V., Van Cutsem, E., Pignon, J. P., Tabernero, J., Cervantes, A. et Ciardiello, F. (2017). Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. *Ann Oncol, 28*(8), 1713-1729. <u>https://doi.org/10.1093/annonc/mdx175</u>
- Azzouz, L. L. et Sharma, S. (2023). Physiology, Large Intestine. Dans StatPearls.
- Banerjee, S. et Mazumdar, S. (2012). Electrospray ionization mass spectrometry: a technique to access the information beyond the molecular weight of the analyte. *Int J Anal Chem*, 2012, 282574. <u>https://doi.org/10.1155/2012/282574</u>
- Baribault, H., Penner, J., Iozzo, R. V. et Wilson-Heiner, M. (1994). Colorectal hyperplasia and inflammation in keratin 8-deficient FVB/N mice. *Genes Dev*, *8*(24), 2964-2973. https://doi.org/10.1101/gad.8.24.2964
- Barkovits, K., Pacharra, S., Pfeiffer, K., Steinbach, S., Eisenacher, M., Marcus, K. et Uszkoreit, J. (2020). Reproducibility, Specificity and Accuracy of Relative Quantification Using Spectral Library-based Data-independent Acquisition. *Mol Cell Proteomics*, *19*(1), 181-197. https://doi.org/10.1074/mcp.RA119.001714
- Baxter, B. A., Parker, K. D., Nosler, M. J., Rao, S., Craig, R., Seiler, C. et Ryan, E. P. (2020). Metabolite profile comparisons between ascending and descending colon tissue in healthy adults. *World J Gastroenterol*, 26(3), 335-352. <u>https://doi.org/10.3748/wjg.v26.i3.335</u>

- Bird, I. M. (1989). High performance liquid chromatography: principles and clinical applications. *Bmj*, 299(6702), 783-787. <u>https://doi.org/10.1136/bmj.299.6702.783</u>
- Bishnupuri, K. S., Alvarado, D. M., Khouri, A. N., Shabsovich, M., Chen, B., Dieckgraefe, B. K. et Ciorba, M. A. (2019). IDO1 and Kynurenine Pathway Metabolites Activate PI3K-Akt Signaling in the Neoplastic Colon Epithelium to Promote Cancer Cell Proliferation and Inhibit Apoptosis. *Cancer Res*, 79(6), 1138-1150. <u>https://doi.org/10.1158/0008-5472.Can-18-0668</u>
- Bonetto, S., Fagoonee, S., Battaglia, E., Grassini, M., Saracco, G. M. et Pellicano, R. (2021). Recent advances in the treatment of irritable bowel syndrome. *Pol Arch Intern Med*, 131(7-8), 709-715. <u>https://doi.org/10.20452/pamw.16067</u>
- Brioschi, M., Gianazza, E., Agostoni, P., Zoanni, B., Mallia, A. et Banfi, C. (2021). Multiplexed MRM-Based Proteomics Identified Multiple Biomarkers of Disease Severity in Human Heart Failure. *Int J Mol Sci*, *22*(2). <u>https://doi.org/10.3390/ijms22020838</u>
- Busi, S. B., Lei, Z., Sumner, L. W. et Amos-Landgraf, J. M. (2023). Integrated multi-omic analyses provide insight into colon adenoma susceptibility modulation by the gut microbiota. *mSystems*, 8(4), e0015123. <u>https://doi.org/10.1128/msystems.00151-23</u>
- Chandel, N. S. (2021). Carbohydrate Metabolism. *Cold Spring Harb Perspect Biol*, 13(1). <u>https://doi.org/10.1101/cshperspect.a040568</u>
- Cheng, L. K., O'Grady, G., Du, P., Egbuji, J. U., Windsor, J. A. et Pullan, A. J. (2010). Gastrointestinal system. *Wiley Interdiscip Rev Syst Biol Med*, 2(1), 65-79. <u>https://doi.org/10.1002/wsbm.19</u>
- Cleveland, J. P. et Rose, J. R. (2013). Identification of b-/y-ions in MS/MS spectra using a two stage neural network. *Proteome Sci*, *11*(Suppl 1), S4. <u>https://doi.org/10.1186/1477-5956-11-s1-s4</u>
- Clish, C. B. (2015). Metabolomics: an emerging but powerful tool for precision medicine. *Cold Spring Harb Mol Case Stud*, *1*(1), a000588. <u>https://doi.org/10.1101/mcs.a000588</u>
- Cooper, J. et Giancotti, F. G. (2019). Integrin Signaling in Cancer: Mechanotransduction, Stemness, Epithelial Plasticity, and Therapeutic Resistance. *Cancer Cell*, *35*(3), 347-367. <u>https://doi.org/10.1016/j.ccell.2019.01.007</u>
- Corfe, B. M., Majumdar, D., Assadsangabi, A., Marsh, A. M. R., Cross, S. S., Connolly, J. B., Evans, C. A. et Lobo, A. J. (2015). Inflammation decreases keratin level in ulcerative colitis; inadequate restoration associates with increased risk of colitis-associated cancer. *BMJ Open Gastroenterology*, 2(1), e000024. <u>https://doi.org/10.1136/bmjgast-2014-000024</u>

- Cortes, L., Wopereis, H., Tartiere, A., Piquenot, J., Gouw, J. W., Tims, S., Knol, J. et Chelsky, D. (2019). Metaproteomic and 16S rRNA Gene Sequencing Analysis of the Infant Fecal Microbiome. *Int J Mol Sci*, 20(6). <u>https://doi.org/10.3390/ijms20061430</u>
- Coskun, O. (2016). Separation techniques: Chromatography. *North Clin Istanb*, *3*(2), 156-160. https://doi.org/10.14744/nci.2016.32757
- Cosnes, J., Gower-Rousseau, C., Seksik, P. et Cortot, A. (2011). Epidemiology and natural history of inflammatory bowel diseases. *Gastroenterology*, *140*(6), 1785-1794. https://doi.org/10.1053/j.gastro.2011.01.055
- Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., Tian, S., Zheng, J., Wishart, D. S., Liepinsh, E. et Schiöth, H. B. (2022). Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials. *Pharmacol Rev*, 74(3), 506-551. https://doi.org/10.1124/pharmrev.121.000408
- Deng, K., Han, P., Song, W., Wang, Z., Zhang, F., Xie, H., Zhao, W., Xu, H., Cai, Y., Rong, Z., Yu, X., Cui, B. B. et Li, K. (2018). Plasma metabolomic profiling distinguishes right-sided from left-sided colon cancer. *Clin Chim Acta*, 487, 357-362. https://doi.org/10.1016/j.cca.2018.10.010
- Deng, Y., Zhou, M., Wang, J., Yao, J., Yu, J., Liu, W., Wu, L., Wang, J. et Gao, R. (2021). Involvement of the microbiota-gut-brain axis in chronic restraint stress: disturbances of the kynurenine metabolic pathway in both the gut and brain. *Gut Microbes*, *13*(1), 1-16. <u>https://doi.org/10.1080/19490976.2020.1869501</u>
- Dent, E. W., Gupton, S. L. et Gertler, F. B. (2011, Mar 1). The growth cone cytoskeleton in axon outgrowth and guidance. *Cold Spring Harb Perspect Biol*, *3*(3). <u>https://doi.org/10.1101/cshperspect.a001800</u>
- Dettmer, K., Aronov, P. A. et Hammock, B. D. (2007). Mass spectrometry-based metabolomics. *Mass Spectrom Rev*, 26(1), 51-78. <u>https://doi.org/10.1002/mas.20108</u>
- Di Tommaso, N., Gasbarrini, A. et Ponziani, F. R. (2021). Intestinal Barrier in Human Health and Disease. *Int J Environ Res Public Health*, *18*(23). <u>https://doi.org/10.3390/ijerph182312836</u>
- Dieterich, W., Schink, M. et Zopf, Y. (2018). Microbiota in the Gastrointestinal Tract. *Med Sci* (*Basel*), 6(4). <u>https://doi.org/10.3390/medsci6040116</u>
- Dupree, E. J., Jayathirtha, M., Yorkey, H., Mihasan, M., Petre, B. A. et Darie, C. C. (2020). A Critical Review of Bottom-Up Proteomics: The Good, the Bad, and the Future of this Field. *Proteomes*, *8*(3). <u>https://doi.org/10.3390/proteomes8030014</u>
- Duraes, L. C., Steele, S. R., Valente, M. A., Lavryk, O. A., Connelly, T. M. et Kessler, H. (2022). Right colon, left colon, and rectal cancer have different oncologic and quality of life

outcomes. International Journal of Colorectal Disease, 37(4), 939-948. https://doi.org/10.1007/s00384-022-04121-x

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V., D'Eustachio, P., Stein, L. et Hermjakob, H. (2017). Reactome pathway analysis: a high-performance inmemory approach. *BMC Bioinformatics*, 18(1), 142. <u>https://doi.org/10.1186/s12859-017-1559-2</u>
- Fernández-Costa, C., Martínez-Bartolomé, S., McClatchy, D. B., Saviola, A. J., Yu, N. K. et Yates, J. R., 3rd. (2020). Impact of the Identification Strategy on the Reproducibility of the DDA and DIA Results. *J Proteome Res*, *19*(8), 3153-3161. <u>https://doi.org/10.1021/acs.jproteome.0c00153</u>
- Feuerstein, J. D., Moss, A. C. et Farraye, F. A. (2019). Ulcerative Colitis. *Mayo Clin Proc*, 94(7), 1357-1373. <u>https://doi.org/10.1016/j.mayocp.2019.01.018</u>
- Folz, J., Culver, R. N., Morales, J. M., Grembi, J., Triadafilopoulos, G., Relman, D. A., Huang, K. C., Shalon, D. et Fiehn, O. (2023). Human metabolome variation along the upper intestinal tract. *Nat Metab*, *5*(5), 777-788. <u>https://doi.org/10.1038/s42255-023-00777-z</u>
- Fouquet, G., Coman, T., Hermine, O. et Côté, F. (2019). Serotonin, hematopoiesis and stem cells. *Pharmacological Research*, *140*, 67-74. <u>https://doi.org/https://doi.org/10.1016/j.phrs.2018.08.005</u>
- Gao, J., Xiong, T., Grabauskas, G. et Owyang, C. (2022). Mucosal Serotonin Reuptake Transporter Expression in Irritable Bowel Syndrome Is Modulated by Gut Microbiota Via Mast Cell-Prostaglandin E2. *Gastroenterology*, 162(7), 1962-1974.e1966. <u>https://doi.org/10.1053/j.gastro.2022.02.016</u>
- Garg, E. et Zubair, M. (2023). Mass Spectrometer. Dans *StatPearls*. StatPearls Publishing, Copyright © 2023, StatPearls Publishing LLC.
- Geng, Z. H., Zhu, Y., Li, Q. L., Zhao, C. et Zhou, P. H. (2022). Enteric Nervous System: The Bridge Between the Gut Microbiota and Neurological Disorders. *Front Aging Neurosci*, *14*, 810483. <u>https://doi.org/10.3389/fnagi.2022.810483</u>
- Gershon, M. D. et Tack, J. (2007, 2007/01/01/). The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders. *Gastroenterology*, 132(1), 397-414. <u>https://doi.org/https://doi.org/10.1053/j.gastro.2006.11.002</u>
- Gonzalez-Covarrubias, V., Martínez-Martínez, E. et Del Bosque-Plata, L. (2022). The Potential of Metabolomics in Biomedical Applications. *Metabolites*, 12(2). https://doi.org/10.3390/metabo12020194

- Gorospe, M., Wang, X., Guyton, K. Z. et Holbrook, N. J. (1996). Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. *Mol Cell Biol*, *16*(12), 6654-6660. <u>https://doi.org/10.1128/mcb.16.12.6654</u>
- Greenwood-Van Meerveld, B., Johnson, A. C. et Grundy, D. (2017). Gastrointestinal Physiology and Function. *Handb Exp Pharmacol*, 239, 1-16. <u>https://doi.org/10.1007/164_2016_118</u>
- Gremel, G., Wanders, A., Cedernaes, J., Fagerberg, L., Hallström, B., Edlund, K., Sjöstedt, E., Uhlén, M. et Pontén, F. (2015). The human gastrointestinal tract-specific transcriptome and proteome as defined by RNA sequencing and antibody-based profiling. *J Gastroenterol*, *50*(1), 46-57. https://doi.org/10.1007/s00535-014-0958-7
- Gross, J. r. H. (2010). *Mass spectrometry : a textbook* (2nd ed.). Springer. https://doi.org/10.1007/978-3-642-10711-5
- Guijas, C., Montenegro-Burke, J. R., Warth, B., Spilker, M. E. et Siuzdak, G. (2018). Metabolomics activity screening for identifying metabolites that modulate phenotype. *Nat Biotechnol*, 36(4), 316-320. <u>https://doi.org/10.1038/nbt.4101</u>
- Haag, A. M. (2016). Mass Analyzers and Mass Spectrometers. *Adv Exp Med Biol*, 919, 157-169. https://doi.org/10.1007/978-3-319-41448-5_7
- Habtezion, A., Toivola, D. M., Butcher, E. C. et Omary, M. B. (2005). Keratin-8-deficient mice develop chronic spontaneous Th2 colitis amenable to antibiotic treatment. *J Cell Sci*, 118(Pt 9), 1971-1980. <u>https://doi.org/10.1242/jcs.02316</u>
- Hao, F., Guo, H., Zhong, J., Geng, Q., Yang, Y., Chen, B. et Guo, C. (2018). Effects of Prostaglandin E1 on Patients Undergoing Major Gastrointestinal Surgery. *Ann Surg*, 267(4), 759-765. <u>https://doi.org/10.1097/SLA.00000000002152</u>
- Hillman, E. T., Lu, H., Yao, T. et Nakatsu, C. H. (2017). Microbial Ecology along the Gastrointestinal Tract. *Microbes Environ*, 32(4), 300-313. <u>https://doi.org/10.1264/jsme2.ME17017</u>
- Ho, C. S., Lam, C. W., Chan, M. H., Cheung, R. C., Law, L. K., Lit, L. C., Ng, K. F., Suen, M. W. et Tai, H. L. (2003). Electrospray ionisation mass spectrometry: principles and clinical applications. *Clin Biochem Rev*, *24*(1), 3-12.
- Hoffmann, E. d. et Stroobant, V. (2007). *Mass spectrometry : principles and applications* (Third edition. ed.). J. Wiley.
- Holland, A. M., Bon-Frauches, A. C., Keszthelyi, D., Melotte, V. et Boesmans, W. (2021). The enteric nervous system in gastrointestinal disease etiology. *Cell Mol Life Sci*, 78(10), 4713-4733. <u>https://doi.org/10.1007/s00018-021-03812-y</u>

- Hou, K., Wu, Z. X., Chen, X. Y., Wang, J. Q., Zhang, D., Xiao, C., Zhu, D., Koya, J. B., Wei, L., Li, J. et Chen, Z. S. (2022). Microbiota in health and diseases. *Signal Transduct Target Ther*, 7(1), 135. <u>https://doi.org/10.1038/s41392-022-00974-4</u>
- Huang, Y., Duanmu, J., Liu, Y., Yan, M., Li, T. et Jiang, Q. (2021). Analysis of multi-omics differences in left-side and right-side colon cancer. *PeerJ*, *9*, e11433. <u>https://doi.org/10.7717/peerj.11433</u>
- Huang, Z., Liu, K., Ma, W., Li, D., Mo, T. et Liu, Q. (2022). The gut microbiome in human health and disease-Where are we and where are we going? A bibliometric analysis. *Front Microbiol*, *13*, 1018594. <u>https://doi.org/10.3389/fmicb.2022.1018594</u>
- Hugenholtz, F. et de Vos, W. M. (2018). Mouse models for human intestinal microbiota research: a critical evaluation. *Cell Mol Life Sci*, 75(1), 149-160. <u>https://doi.org/10.1007/s00018-017-2693-8</u>
- Imperial, R., Ahmed, Z., Toor, O. M., Erdoğan, C., Khaliq, A., Case, P., Case, J., Kennedy, K., Cummings, L. S., Melton, N., Raza, S., Diri, B., Mohammad, R., El-Rayes, B., Pluard, T., Hussain, A., Subramanian, J. et Masood, A. (2018). Comparative proteogenomic analysis of right-sided colon cancer, left-sided colon cancer and rectal cancer reveals distinct mutational profiles. *Mol Cancer*, *17*(1), 177. <u>https://doi.org/10.1186/s12943-018-0923-9</u>
- Irum, N., Afzal, T., Faraz, M. H., Aslam, Z. et Rasheed, F. (2023). The role of gut microbiota in depression: an analysis of the gut-brain axis [Review]. *Frontiers in Behavioral Neuroscience*, 17. https://doi.org/10.3389/fnbeh.2023.1185522
- James, S. L., Irving, P. M., Gearry, R. B. et Gibson, P. R. (2008). Management of distal ulcerative colitis: frequently asked questions analysis. *Intern Med J*, *38*(2), 114-119. https://doi.org/10.1111/j.1445-5994.2007.01601.x
- Jara-Gutiérrez, Á. et Baladrón, V. (2021). The Role of Prostaglandins in Different Types of Cancer. *Cells*, *10*(6). <u>https://doi.org/10.3390/cells10061487</u>
- Johnson, C. H., Ivanisevic, J. et Siuzdak, G. (2016). Metabolomics: beyond biomarkers and towards mechanisms. *Nat Rev Mol Cell Biol*, *17*(7), 451-459. <u>https://doi.org/10.1038/nrm.2016.25</u>
- Kahai, P., Mandiga, P., Wehrle, C. J. et Lobo, S. (2023). Anatomy, Abdomen and Pelvis: Large Intestine. Dans *StatPearls*.
- Karpievitch, Y. V., Polpitiya, A. D., Anderson, G. A., Smith, R. D. et Dabney, A. R. (2010). Liquid Chromatography Mass Spectrometry-Based Proteomics: Biological and Technological Aspects. Ann Appl Stat, 4(4), 1797-1823. <u>https://doi.org/10.1214/10-aoas341</u>
- Kessmann, J. (2006). Hirschsprung's disease: diagnosis and management. *Am Fam Physician*, 74(8), 1319-1322.

- Klein, M. et Varga, I. (2020). Hirschsprung's Disease-Recent Understanding of Embryonic Aspects, Etiopathogenesis and Future Treatment Avenues. *Medicina (Kaunas)*, 56(11). <u>https://doi.org/10.3390/medicina56110611</u>
- Kleiner, M. (2019). Metaproteomics: Much More than Measuring Gene Expression in Microbial Communities. *mSystems*, *4*(3). <u>https://doi.org/10.1128/mSystems.00115-19</u>
- Koutroubakis, I. E. (2010). Recent advances in the management of distal ulcerative colitis. *World J Gastrointest Pharmacol Ther*, 1(2), 43-50. <u>https://doi.org/10.4292/wjgpt.v1.i2.43</u>
- Kuipers, E. J., Grady, W. M., Lieberman, D., Seufferlein, T., Sung, J. J., Boelens, P. G., van de Velde, C. J. et Watanabe, T. (2015). Colorectal cancer. *Nat Rev Dis Primers*, *1*, 15065. <u>https://doi.org/10.1038/nrdp.2015.65</u>
- Kunkel, S. L., Thrall, R. S., Kunkel, R. G., McCormick, J. R., Ward, P. A. et Zurier, R. B. (1979, Nov). Suppression of immune complex vasculitis in rats by prostaglandin. *J Clin Invest*, 64(5), 1525-1529. <u>https://doi.org/10.1172/jci109611</u>
- Lai, L. A., Tong, Z., Chen, R. et Pan, S. (2019). Metaproteomics Study of the Gut Microbiome. *Methods Mol Biol*, *1871*, 123-132. <u>https://doi.org/10.1007/978-1-4939-8814-3_8</u>
- Lai, X. (2013). Reproducible method to enrich membrane proteins with high purity and high yield for an LC-MS/MS approach in quantitative membrane proteomics. *Electrophoresis*, *34*(6), 809-817. <u>https://doi.org/10.1002/elps.201200503</u>
- Lee, M. S., Menter, D. G. et Kopetz, S. (2017). Right Versus Left Colon Cancer Biology: Integrating the Consensus Molecular Subtypes. *J Natl Compr Canc Netw*, *15*(3), 411-419. <u>https://doi.org/10.6004/jnccn.2017.0038</u>
- Lehman, H. K. et Segal, B. H. (2020). The role of neutrophils in host defense and disease. *J Allergy Clin Immunol*, 145(6), 1535-1544. <u>https://doi.org/10.1016/j.jaci.2020.02.038</u>
- Levin, G., Duffin, K. L., Obukowicz, M. G., Hummert, S. L., Fujiwara, H., Needleman, P. et Raz, A. (2002). Differential metabolism of dihomo-gamma-linolenic acid and arachidonic acid by cyclo-oxygenase-1 and cyclo-oxygenase-2: implications for cellular synthesis of prostaglandin E1 and prostaglandin E2. *Biochem J*, 365(Pt 2), 489-496. https://doi.org/10.1042/bj20011798
- Li, J., Smith, L. S. et Zhu, H. J. (2021). Data-independent acquisition (DIA): An emerging proteomics technology for analysis of drug-metabolizing enzymes and transporters. *Drug Discov Today Technol*, 39, 49-56. <u>https://doi.org/10.1016/j.ddtec.2021.06.006</u>
- Liu, J., Qi, M., Qiu, C., Wang, F., Xie, S., Zhao, J., Wu, J. et Song, X. (2022). Integrative analysis of the mouse fecal microbiome and metabolome reveal dynamic phenotypes in the development of colorectal cancer. *Front Microbiol*, *13*, 1021325. https://doi.org/10.3389/fmicb.2022.1021325

- Livovsky, D. M., Pribic, T. et Azpiroz, F. (2020). Food, Eating, and the Gastrointestinal Tract. *Nutrients*, *12*(4). <u>https://doi.org/10.3390/nu12040986</u>
- Lotfollahzadeh, S., Taherian, M. et Anand, S. (2023). Hirschsprung Disease. Dans *StatPearls*. StatPearls Publishing, Copyright © 2023, StatPearls Publishing LLC.
- Loupakis, F., Yang, D., Yau, L., Feng, S., Cremolini, C., Zhang, W., Maus, M. K., Antoniotti, C., Langer, C., Scherer, S. J., Muller, T., Hurwitz, H. I., Saltz, L., Falcone, A. et Lenz, H. J. (2015). Primary tumor location as a prognostic factor in metastatic colorectal cancer. *J Natl Cancer Inst*, 107(3). <u>https://doi.org/10.1093/jnci/dju427</u>
- Macklin, A., Khan, S. et Kislinger, T. (2020). Recent advances in mass spectrometry based clinical proteomics: applications to cancer research. *Clin Proteomics*, *17*, *17*. <u>https://doi.org/10.1186/s12014-020-09283-w</u>
- Majumdar, D., Tiernan, J. P., Lobo, A. J., Evans, C. A. et Corfe, B. M. (2012). Keratins in colorectal epithelial function and disease. *Int J Exp Pathol*, 93(5), 305-318. https://doi.org/10.1111/j.1365-2613.2012.00830.x
- Malone, J. C., Arbor, T. C. et Shah, A. B. (2023). Embryology, Midgut. Dans *StatPearls*. StatPearls Publishing, Copyright © 2023, StatPearls Publishing LLC.
- Mandal, A. K., Zhang, Z., Kim, S. J., Tsai, P. C. et Mukherjee, A. B. (2005). Yin-yang: balancing act of prostaglandins with opposing functions to regulate inflammation. *J Immunol*, 175(10), 6271-6273. <u>https://doi.org/10.4049/jimmunol.175.10.6271</u>
- Manocha, M. et Khan, W. I. (2012). Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. *Clin Transl Gastroenterol*, *3*(4), e13. <u>https://doi.org/10.1038/ctg.2012.8</u>
- Marshall, J., Yoshino, T., Rha, S. Y., Church, D. N., Coutinho, A. K., Sampaio-Filho, C. A., Gallagher, D. J., García-Foncillas, J., Heyde, S. v. d., Juhl, H., Woodsmith, J. et Kerr, D. J. (2021). Multi-omics characterization of left-right colorectal cancer. *Journal of Clinical Oncology*, 39(15_suppl), 3542-3542. <u>https://doi.org/10.1200/JCO.2021.39.15_suppl.3542</u>
- Mason, K. L., Huffnagle, G. B., Noverr, M. C. et Kao, J. Y. (2008). Overview of gut immunology. *Adv Exp Med Biol*, 635, 1-14. <u>https://doi.org/10.1007/978-0-387-09550-9_1</u>
- Matthiesen, R. et Bunkenborg, J. (2013). Introduction to mass spectrometry-based proteomics. *Methods Mol Biol*, 1007, 1-45. <u>https://doi.org/10.1007/978-1-62703-392-3_1</u>
- Mawe, G. M. et Hoffman, J. M. (2013). Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. *Nat Rev Gastroenterol Hepatol*, *10*(8), 473-486. <u>https://doi.org/10.1038/nrgastro.2013.105</u>

- Meier, K. H. U., Trouillon, J., Li, H., Lang, M., Fuhrer, T., Zamboni, N., Sunagawa, S., Macpherson, A. J. et Sauer, U. (2023). Metabolic landscape of the male mouse gut identifies different niches determined by microbial activities. *Nat Metab*, 5(6), 968-980. <u>https://doi.org/10.1038/s42255-023-00802-1</u>
- Monteiro, M. P. et Batterham, R. L. (2017). The Importance of the Gastrointestinal Tract in Controlling Food Intake and Regulating Energy Balance. *Gastroenterology*, *152*(7), 1707-1717.e1702. <u>https://doi.org/10.1053/j.gastro.2017.01.053</u>
- Mun, J., Hur, W. et Ku, N. O. (2022). Roles of Keratins in Intestine. Int J Mol Sci, 23(14). https://doi.org/10.3390/ijms23148051
- Mylonas, C. C. et Lazaris, A. C. (2014). Colorectal cancer and basement membranes: clinicopathological correlations. *Gastroenterol Res Pract*, 2014, 580159. <u>https://doi.org/10.1155/2014/580159</u>
- Nguyen, T. L., Vieira-Silva, S., Liston, A. et Raes, J. (2015). How informative is the mouse for human gut microbiota research? *Dis Model Mech*, 8(1), 1-16. <u>https://doi.org/10.1242/dmm.017400</u>
- Ogobuiro, I., Gonzales, J., Shumway, K. R. et Tuma, F. (2023). Physiology, Gastrointestinal. Dans *StatPearls*.
- Pang, Z., Chong, J., Zhou, G., de Lima Morais, D. A., Chang, L., Barrette, M., Gauthier, C., Jacques, P.-É., Li, S. et Xia, J. (2021). MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional insights. *Nucleic Acids Research*, *49*(W1), W388-W396. https://doi.org/10.1093/nar/gkab382
- Parigi, S. M., Larsson, L., Das, S., Ramirez Flores, R. O., Frede, A., Tripathi, K. P., Diaz, O. E., Selin, K., Morales, R. A., Luo, X., Monasterio, G., Engblom, C., Gagliani, N., Saez-Rodriguez, J., Lundeberg, J. et Villablanca, E. J. (2022). The spatial transcriptomic landscape of the healing mouse intestine following damage. *Nat Commun*, *13*(1), 828. <u>https://doi.org/10.1038/s41467-022-28497-0</u>
- Petrelli, F., Tomasello, G., Borgonovo, K., Ghidini, M., Turati, L., Dallera, P., Passalacqua, R., Sgroi, G. et Barni, S. (2017). Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis. *JAMA Oncol*, *3*(2), 211-219. <u>https://doi.org/10.1001/jamaoncol.2016.4227</u>
- Petriz, B. A. et Franco, O. L. (2017). Metaproteomics as a Complementary Approach to Gut Microbiota in Health and Disease. *Front Chem*, *5*, *4*. <u>https://doi.org/10.3389/fchem.2017.00004</u>
- Potter, K., Gayle, E. J. et Deb, S. (2023, 2023/11/03). Effect of gut microbiome on serotonin metabolism: a personalized treatment approach. *Naunyn-Schmiedeberg's Archives of Pharmacology*. <u>https://doi.org/10.1007/s00210-023-02762-5</u>

- Qin, J., Li, R., Raes, J., Arumugam, M., Burgdorf, K. S., Manichanh, C., Nielsen, T., Pons, N., Levenez, F., Yamada, T., Mende, D. R., Li, J., Xu, J., Li, S., Li, D., Cao, J., Wang, B., Liang, H., Zheng, H., Xie, Y., Tap, J., Lepage, P., Bertalan, M., Batto, J. M., Hansen, T., Le Paslier, D., Linneberg, A., Nielsen, H. B., Pelletier, E., Renault, P., Sicheritz-Ponten, T., Turner, K., Zhu, H., Yu, C., Li, S., Jian, M., Zhou, Y., Li, Y., Zhang, X., Li, S., Qin, N., Yang, H., Wang, J., Brunak, S., Doré, J., Guarner, F., Kristiansen, K., Pedersen, O., Parkhill, J., Weissenbach, J., Bork, P., Ehrlich, S. D. et Wang, J. (2010). A human gut microbial gene catalogue established by metagenomic sequencing. *Nature*, 464(7285), 59-65. https://doi.org/10.1038/nature08821
- Rajakariar, R., Hilliard, M., Lawrence, T., Trivedi, S., Colville-Nash, P., Bellingan, G., Fitzgerald, D., Yaqoob, M. M. et Gilroy, D. W. (2007). Hematopoietic prostaglandin D2 synthase controls the onset and resolution of acute inflammation through PGD2 and 15deoxyDelta12 14 PGJ2. *Proc Natl Acad Sci U S A*, 104(52), 20979-20984. https://doi.org/10.1073/pnas.0707394104
- Ramovs, V., Te Molder, L. et Sonnenberg, A. (2017). The opposing roles of laminin-binding integrins in cancer. *Matrix Biol*, 57-58, 213-243. <u>https://doi.org/10.1016/j.matbio.2016.08.007</u>
- Reigstad, C. S., Salmonson, C. E., Rainey, J. F., 3rd, Szurszewski, J. H., Linden, D. R., Sonnenburg, J. L., Farrugia, G. et Kashyap, P. C. (2015). Gut microbes promote colonic serotonin production through an effect of short-chain fatty acids on enterochromaffin cells. *FASEB J*, 29(4), 1395-1403. <u>https://doi.org/10.1096/fj.14-259598</u>
- Ricciotti, E. et FitzGerald, G. A. (2011). Prostaglandins and inflammation. *Arterioscler Thromb Vasc Biol*, *31*(5), 986-1000. <u>https://doi.org/10.1161/atvbaha.110.207449</u>
- Rinninella, E., Raoul, P., Cintoni, M., Franceschi, F., Miggiano, G. A. D., Gasbarrini, A. et Mele, M. C. (2019). What is the Healthy Gut Microbiota Composition? A Changing Ecosystem across Age, Environment, Diet, and Diseases. *Microorganisms*, 7(1). <u>https://doi.org/10.3390/microorganisms7010014</u>
- Roscilli, G., Marra, E., Mori, F., Di Napoli, A., Mancini, R., Serlupi-Crescenzi, O., Virmani, A., Aurisicchio, L. et Ciliberto, G. (2013). Carnitines slow down tumor development of colon cancer in the DMH-chemical carcinogenesis mouse model. *J Cell Biochem*, *114*(7), 1665-1673. <u>https://doi.org/10.1002/jcb.24508</u>
- Rossi, A., Kapahi, P., Natoli, G., Takahashi, T., Chen, Y., Karin, M. et Santoro, M. G. (2000). Antiinflammatory cyclopentenone prostaglandins are direct inhibitors of IkappaB kinase. *Nature*, *403*(6765), 103-108. <u>https://doi.org/10.1038/47520</u>
- Roth, W., Zadeh, K., Vekariya, R., Ge, Y. et Mohamadzadeh, M. (2021). Tryptophan Metabolism and Gut-Brain Homeostasis. *Int J Mol Sci*, 22(6). <u>https://doi.org/10.3390/ijms22062973</u>
- Russell, S. A. et Bashaw, G. J. (2018). Axon guidance pathways and the control of gene expression. *Dev Dyn*, 247(4), 571-580. <u>https://doi.org/10.1002/dvdy.24609</u>

- Ryan, M. C., Stucky, M., Wakefield, C., Melott, J. M., Akbani, R., Weinstein, J. N. et Broom, B. M. (2019). Interactive Clustered Heat Map Builder: An easy web-based tool for creating sophisticated clustered heat maps. *F1000Res*, 8. <u>https://doi.org/10.12688/f1000research.20590.2</u>
- Saha, L. (2014, Jun 14). Irritable bowel syndrome: pathogenesis, diagnosis, treatment, and evidence-based medicine. *World J Gastroenterol*, 20(22), 6759-6773. https://doi.org/10.3748/wjg.v20.i22.6759
- Sarihan, M., Bal Albayrak, M. G., Kasap, M., Akpinar, G. et Kocyigit, E. (2023). An experimental workflow for enrichment of low abundant proteins from human serum for the discovery of serum biomarkers. J Biol Methods, 10, e99010001. <u>https://doi.org/10.14440/jbm.2023.394</u>
- Sasaki, H. et Fukushima, M. (1994). Prostaglandins in the treatment of cancer. *Anticancer Drugs*, 5(2), 131-138. <u>https://doi.org/10.1097/00001813-199404000-00002</u>
- Scalbert, A., Brennan, L., Fiehn, O., Hankemeier, T., Kristal, B. S., van Ommen, B., Pujos-Guillot, E., Verheij, E., Wishart, D. et Wopereis, S. (2009, Dec). Mass-spectrometry-based metabolomics: limitations and recommendations for future progress with particular focus on nutrition research. *Metabolomics*, 5(4), 435-458. <u>https://doi.org/10.1007/s11306-009-0168-0</u>
- Schmehl, K., Florian, S., Jacobasch, G., Salomon, A. et Körber, J. (2000). Deficiency of epithelial basement membrane laminin in ulcerative colitis affected human colonic mucosa. *Int J Colorectal Dis*, 15(1), 39-48. <u>https://doi.org/10.1007/s003840050006</u>
- Schröder, O., Yudina, Y., Sabirsh, A., Zahn, N., Haeggström, J. Z. et Stein, J. (2006). 15-deoxy-Delta12,14-prostaglandin J2 inhibits the expression of microsomal prostaglandin E synthase type 2 in colon cancer cells. *J Lipid Res*, *47*(5), 1071-1080. <u>https://doi.org/10.1194/jlr.M600008-JLR200</u>
- Schröder, R., Xue, L., Konya, V., Martini, L., Kampitsch, N., Whistler, J. L., Ulven, T., Heinemann, A., Pettipher, R. et Kostenis, E. (2012). PGH1, the precursor for the anti-inflammatory prostaglandins of the 1-series, is a potent activator of the pro-inflammatory receptor CRTH2/DP2. *PLoS One*, 7(3), e33329. <u>https://doi.org/10.1371/journal.pone.0033329</u>
- Semble, E. L. et Wu, W. C. (1989). Prostaglandins in the gut and their relationship to non-steroidal anti-inflammatory drugs. *Baillière's Clinical Rheumatology*, *3*(2), 247-269. https://doi.org/https://doi.org/10.1016/S0950-3579(89)80020-2
- Simon, L. S. (1999). Role and regulation of cyclooxygenase-2 during inflammation. *Am J Med*, *106*(5b), 37s-42s. <u>https://doi.org/10.1016/s0002-9343(99)00115-1</u>
- Sleno, L. (2012). The use of mass defect in modern mass spectrometry. *J Mass Spectrom*, 47(2), 226-236. <u>https://doi.org/10.1002/jms.2953</u>

- Snyder, L. R., Kirkland, J. J. et Dolan, J. W. (2010). *Introduction to modern liquid chromatography* (3rd / ed.). Wiley. <u>https://doi.org/10.1002/9780470508183</u>
- Soret, R., Schneider, S., Bernas, G., Christophers, B., Souchkova, O., Charrier, B., Righini-Grunder, F., Aspirot, A., Landry, M., Kembel, S. W., Faure, C., Heuckeroth, R. O. et Pilon, N. (2020, Nov). Glial Cell-Derived Neurotrophic Factor Induces Enteric Neurogenesis and Improves Colon Structure and Function in Mouse Models of Hirschsprung Disease. *Gastroenterology*, 159(5), 1824-1838.e1817. https://doi.org/10.1053/j.gastro.2020.07.018
- Spenlé, C., Lefebvre, O., Lacroute, J., Méchine-Neuville, A., Barreau, F., Blottière, H. M., Duclos, B., Arnold, C., Hussenet, T., Hemmerlé, J., Gullberg, D., Kedinger, M., Sorokin, L., Orend, G. et Simon-Assmann, P. (2014). The laminin response in inflammatory bowel disease: protection or malignancy? *PLoS One*, *9*(10), e111336. https://doi.org/10.1371/journal.pone.0111336
- Spiller, R. (2008, 2008/11/01/). Serotonin and GI clinical disorders. *Neuropharmacology*, 55(6), 1072-1080. <u>https://doi.org/https://doi.org/10.1016/j.neuropharm.2008.07.016</u>
- Srinivas, S. R., Prasad, P. D., Umapathy, N. S., Ganapathy, V. et Shekhawat, P. S. (2007). Transport of butyryl-L-carnitine, a potential prodrug, via the carnitine transporter OCTN2 and the amino acid transporter ATB(0,+). *Am J Physiol Gastrointest Liver Physiol*, 293(5), G1046-1053. <u>https://doi.org/10.1152/ajpgi.00233.2007</u>
- Straus, D. S. et Glass, C. K. (2001). Cyclopentenone prostaglandins: new insights on biological activities and cellular targets. *Med Res Rev*, 21(3), 185-210. https://doi.org/10.1002/med.1006
- Su, M. W., Chang, C. K., Lin, C. W., Chu, H. W., Tsai, T. N., Su, W. C., Chen, Y. C., Chang, T. K., Huang, C. W., Tsai, H. L., Wu, C. C., Chou, H. C., Shiu, B. H. et Wang, J. Y. (2022). Genomic and Metabolomic Landscape of Right-Sided and Left-Sided Colorectal Cancer: Potential Preventive Biomarkers. *Cells*, *11*(3). <u>https://doi.org/10.3390/cells11030527</u>
- Surh, Y.-J., Na, H.-K., Park, J.-M., Lee, H.-N., Kim, W., Yoon, I.-S. et Kim, D.-D. (2011). 15-Deoxy-Δ12,14-prostaglandin J2, an electrophilic lipid mediator of anti-inflammatory and proresolving signaling. *Biochemical Pharmacology*, 82(10), 1335-1351. <u>https://doi.org/https://doi.org/10.1016/j.bcp.2011.07.100</u>
- Takada, Y., Ye, X. et Simon, S. (2007). The integrins. *Genome Biol*, *8*(5), 215. <u>https://doi.org/10.1186/gb-2007-8-5-215</u>
- Taketo, M., Schroeder, A. C., Mobraaten, L. E., Gunning, K. B., Hanten, G., Fox, R. R., Roderick, T. H., Stewart, C. L., Lilly, F., Hansen, C. T. et et al. (1991). FVB/N: an inbred mouse strain preferable for transgenic analyses. *Proc Natl Acad Sci U S A*, *88*(6), 2065-2069. <u>https://doi.org/10.1073/pnas.88.6.2065</u>
- Thursby, E. et Juge, N. (2017). Introduction to the human gut microbiota. *Biochem J*, 474(11), 1823-1836. <u>https://doi.org/10.1042/bcj20160510</u>

- Thuy-Boun, P. S., Wang, A. Y., Crissien-Martinez, A., Xu, J. H., Chatterjee, S., Stupp, G. S., Su, A. I., Coyle, W. J. et Wolan, D. W. (2022). Quantitative Metaproteomics and Activity-based Protein Profiling of Patient Fecal Microbiome Identifies Host and Microbial Serine-type Endopeptidase Activity Associated With Ulcerative Colitis. *Mol Cell Proteomics*, 21(3), 100197. <u>https://doi.org/10.1016/j.mcpro.2022.100197</u>
- Tuli, L. et Ressom, H. W. (2009). LC-MS Based Detection of Differential Protein Expression. *J Proteomics Bioinform*, 2, 416-438. <u>https://doi.org/10.4172/jpb.1000102</u>
- Vadlamudi, H. C., Raju, Y. P., Yasmeen, B. R. et Vulava, J. (2012). Anatomical, biochemical and physiological considerations of the colon in design and development of novel drug delivery systems. *Curr Drug Deliv*, 9(6), 556-565. <u>https://doi.org/10.2174/156720112803529774</u>
- van der Post, S. et Hansson, G. C. (2014). Membrane protein profiling of human colon reveals distinct regional differences. *Mol Cell Proteomics*, *13*(9), 2277-2287. https://doi.org/10.1074/mcp.M114.040204
- Venkateswaran, N. et Conacci-Sorrell, M. (2020). Kynurenine: an oncometabolite in colon cancer. *Cell Stress*, 4(1), 24-26. <u>https://doi.org/10.15698/cst2020.01.210</u>
- Venkateswaran, N., Lafita-Navarro, M. C., Hao, Y. H., Kilgore, J. A., Perez-Castro, L., Braverman, J., Borenstein-Auerbach, N., Kim, M., Lesner, N. P., Mishra, P., Brabletz, T., Shay, J. W., DeBerardinis, R. J., Williams, N. S., Yilmaz, O. H. et Conacci-Sorrell, M. (2019). MYC promotes tryptophan uptake and metabolism by the kynurenine pathway in colon cancer. *Genes Dev*, 33(17-18), 1236-1251. <u>https://doi.org/10.1101/gad.327056.119</u>
- Viggiano, D., Ianiro, G., Vanella, G., Bibbò, S., Bruno, G., Simeone, G. et Mele, G. (2015). Gut barrier in health and disease: focus on childhood. *Eur Rev Med Pharmacol Sci*, *19*(6), 1077-1085.
- Vuckovic, D., Dagley, L. F., Purcell, A. W. et Emili, A. (2013). Membrane proteomics by high performance liquid chromatography-tandem mass spectrometry: Analytical approaches and challenges. *Proteomics*, *13*(3-4), 404-423. <u>https://doi.org/10.1002/pmic.201200340</u>
- Wang, B., Wu, L., Chen, J., Dong, L., Chen, C., Wen, Z., Hu, J., Fleming, I. et Wang, D. W. (2021). Metabolism pathways of arachidonic acids: mechanisms and potential therapeutic targets. *Signal Transduct Target Ther*, 6(1), 94. <u>https://doi.org/10.1038/s41392-020-00443-w</u>
- Wang, D. et DuBois, R. N. (2008). Pro-inflammatory prostaglandins and progression of colorectal cancer. *Cancer Lett*, 267(2), 197-203. <u>https://doi.org/10.1016/j.canlet.2008.03.004</u>
- Wang, S., van Schooten, F.-J., Jin, H., Jonkers, D. et Godschalk, R. (2023). The Involvement of Intestinal Tryptophan Metabolism in Inflammatory Bowel Disease Identified by a Meta-Analysis of the Transcriptome and a Systematic Review of the Metabolome. *Nutrients*, 15(13), 2886.

- Wang, W., Zhong, X. et Guo, J. (2021). Role of 2-series prostaglandins in the pathogenesis of type 2 diabetes mellitus and non-alcoholic fatty liver disease (Review). *Int J Mol Med*, 47(6). https://doi.org/10.3892/ijmm.2021.4947
- Wang, Z. et Yu, B. (2019). Chapter 15 Metabolomics, Proteomics, and Genomics: An Introduction to a Clinician. Dans V. Nambi (dir.), *Biomarkers in Cardiovascular Disease* (p. 159-170). Elsevier. <u>https://doi.org/10.1016/B978-0-323-54835-9.00015-6</u>.
- Wei, L., Singh, R., Ha, S. E., Martin, A. M., Jones, L. A., Jin, B., Jorgensen, B. G., Zogg, H., Chervo, T., Gottfried-Blackmore, A., Nguyen, L., Habtezion, A., Spencer, N. J., Keating, D. J., Sanders, K. M. et Ro, S. (2021, Jun). Serotonin Deficiency Is Associated With Delayed Gastric Emptying. *Gastroenterology*, 160(7), 2451-2466.e2419. https://doi.org/10.1053/j.gastro.2021.02.060
- Weiss, G. A. et Hennet, T. (2017). Mechanisms and consequences of intestinal dysbiosis. *Cell Mol Life Sci*, 74(16), 2959-2977. <u>https://doi.org/10.1007/s00018-017-2509-x</u>
- West, R. M. (2021). Best practice in statistics: Use the Welch t-test when testing the difference between two groups. *Annals of Clinical Biochemistry*, *58*(4), 267-269. https://doi.org/10.1177/0004563221992088
- Willems, P., Fels, U., Staes, A., Gevaert, K. et Van Damme, P. (2021). Use of Hybrid Data-Dependent and -Independent Acquisition Spectral Libraries Empowers Dual-Proteome Profiling. J Proteome Res, 20(2), 1165-1177. https://doi.org/10.1021/acs.jproteome.0c00350
- Wishart, D. S. (2008). Applications of metabolomics in drug discovery and development. *Drugs R D*, 9(5), 307-322. <u>https://doi.org/10.2165/00126839-200809050-00002</u>
- Wu, H. J. et Wu, E. (2012). The role of gut microbiota in immune homeostasis and autoimmunity. *Gut Microbes*, *3*(1), 4-14. <u>https://doi.org/10.4161/gmic.19320</u>
- Xu, X., Ocansey, D. K. W., Hang, S., Wang, B., Amoah, S., Yi, C., Zhang, X., Liu, L. et Mao, F. (2022). The gut metagenomics and metabolomics signature in patients with inflammatory bowel disease. *Gut Pathog*, *14*(1), 26. <u>https://doi.org/10.1186/s13099-022-00499-9</u>
- Zhang, X., Liu, X., Zhou, W., Du, Q., Yang, M., Ding, Y. et Hu, R. (2021). Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance. *Cell Mol Gastroenterol Hepatol*, *12*(4), 1179-1199. <u>https://doi.org/10.1016/j.jcmgh.2021.05.018</u>
- Zhang, Y., Liu, Y., Sun, J., Zhang, W., Guo, Z. et Ma, Q. (2023). Arachidonic acid metabolism in health and disease. *MedComm (2020)*, *4*(5), e363. <u>https://doi.org/10.1002/mco2.363</u>

- Zhao, Z., Bai, J., Liu, C., Wang, Y., Wang, S., Zhao, F. et Gu, Q. (2023). Metabolomics analysis of amino acid and fatty acids in colorectal cancer patients based on tandem mass spectrometry. *J Clin Biochem Nutr*, 73(2), 161-171. <u>https://doi.org/10.3164/jcbn.22-110</u>
- Zhu, X., Chen, Y. et Subramanian, R. (2014). Comparison of information-dependent acquisition, SWATH, and MS(All) techniques in metabolite identification study employing ultrahighperformance liquid chromatography-quadrupole time-of-flight mass spectrometry. *Anal Chem*, 86(2), 1202-1209. <u>https://doi.org/10.1021/ac403385y</u>
- Zwittink, R. D., van Zoeren-Grobben, D., Martin, R., van Lingen, R. A., Groot Jebbink, L. J., Boeren, S., Renes, I. B., van Elburg, R. M., Belzer, C. et Knol, J. (2017). Metaproteomics reveals functional differences in intestinal microbiota development of preterm infants. *Mol Cell Proteomics*, *16*(9), 1610-1620. <u>https://doi.org/10.1074/mcp.RA117.000102</u>